#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity
#Text=BACKGROUND:
#Text=Elevated frontal and striatal reactivity to drug cues is a transdiagnostic hallmark of substance use disorders.
1-1	0-15	Transdiagnostic	_	
1-2	16-23	Effects	_	
1-3	24-26	of	_	
1-4	27-39	Ventromedial	_	
1-5	40-50	Prefrontal	_	
1-6	51-57	Cortex	_	
1-7	58-70	Transcranial	_	
1-8	71-79	Magnetic	_	
1-9	80-91	Stimulation	_	
1-10	92-94	on	_	
1-11	95-98	Cue	_	
1-12	99-109	Reactivity	_	
1-13	110-120	BACKGROUND	_	
1-14	120-121	:	_	
1-15	122-130	Elevated	_	
1-16	131-138	frontal	_	
1-17	139-142	and	_	
1-18	143-151	striatal	_	
1-19	152-162	reactivity	_	
1-20	163-165	to	_	
1-21	166-170	drug	_	
1-22	171-175	cues	_	
1-23	176-178	is	_	
1-24	179-180	a	_	
1-25	181-196	transdiagnostic	_	
1-26	197-205	hallmark	_	
1-27	206-208	of	_	
1-28	209-218	substance	_	
1-29	219-222	use	_	
1-30	223-232	disorders	_	
1-31	232-233	.	_	

#Text=The goal of these experiments was to determine if it is possible to decrease frontal and striatal reactivity to drug cues in both cocaine users and heavy alcohol users through continuous theta burst stimulation (cTBS) to the left ventromedial prefrontal cortex (VMPFC).
2-1	234-237	The	_	
2-2	238-242	goal	_	
2-3	243-245	of	_	
2-4	246-251	these	_	
2-5	252-263	experiments	_	
2-6	264-267	was	_	
2-7	268-270	to	_	
2-8	271-280	determine	_	
2-9	281-283	if	_	
2-10	284-286	it	_	
2-11	287-289	is	_	
2-12	290-298	possible	_	
2-13	299-301	to	_	
2-14	302-310	decrease	_	
2-15	311-318	frontal	_	
2-16	319-322	and	_	
2-17	323-331	striatal	_	
2-18	332-342	reactivity	_	
2-19	343-345	to	_	
2-20	346-350	drug	_	
2-21	351-355	cues	_	
2-22	356-358	in	_	
2-23	359-363	both	_	
2-24	364-371	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
2-25	372-377	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
2-26	378-381	and	_	
2-27	382-387	heavy	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
2-28	388-395	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
2-29	396-401	users	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
2-30	402-409	through	_	
2-31	410-420	continuous	_	
2-32	421-426	theta	_	
2-33	427-432	burst	_	
2-34	433-444	stimulation	_	
2-35	445-446	(	_	
2-36	446-450	cTBS	_	
2-37	450-451	)	_	
2-38	452-454	to	_	
2-39	455-458	the	_	
2-40	459-463	left	_	
2-41	464-476	ventromedial	_	
2-42	477-487	prefrontal	_	
2-43	488-494	cortex	_	
2-44	495-496	(	_	
2-45	496-501	VMPFC	_	
2-46	501-502	)	_	
2-47	502-503	.	_	

#Text=METHODS:
#Text=Two single-blinded, within-subject, active sham–controlled experiments were performed wherein neural reactivity to drug/alcohol cues versus neutral cues was evaluated immediately before and after receiving real or sham cTBS (110% resting motor threshold, 3600 pulses, Fp1 location; N= 49: 25 cocaine users [experiment 1], 24 alcohol users [experiment 2]; 196 total functional magnetic resonance imaging scans).
3-1	504-511	METHODS	_	
3-2	511-512	:	_	
3-3	513-516	Two	_	
3-4	517-531	single-blinded	_	
3-5	531-532	,	_	
3-6	533-547	within-subject	_	
3-7	547-548	,	_	
3-8	549-555	active	_	
3-9	556-571	sham–controlled	_	
3-10	572-583	experiments	_	
3-11	584-588	were	_	
3-12	589-598	performed	_	
3-13	599-606	wherein	_	
3-14	607-613	neural	_	
3-15	614-624	reactivity	_	
3-16	625-627	to	_	
3-17	628-632	drug	_	
3-18	632-633	/	_	
3-19	633-640	alcohol	_	
3-20	641-645	cues	_	
3-21	646-652	versus	_	
3-22	653-660	neutral	_	
3-23	661-665	cues	_	
3-24	666-669	was	_	
3-25	670-679	evaluated	_	
3-26	680-691	immediately	_	
3-27	692-698	before	_	
3-28	699-702	and	_	
3-29	703-708	after	_	
3-30	709-718	receiving	_	
3-31	719-723	real	_	
3-32	724-726	or	_	
3-33	727-731	sham	_	
3-34	732-736	cTBS	_	
3-35	737-738	(	_	
3-36	738-742	110%	_	
3-37	743-750	resting	_	
3-38	751-756	motor	_	
3-39	757-766	threshold	_	
3-40	766-767	,	_	
3-41	768-772	3600	_	
3-42	773-779	pulses	_	
3-43	779-780	,	_	
3-44	781-784	Fp1	_	
3-45	785-793	location	_	
3-46	793-794	;	_	
3-47	795-796	N	_	
3-48	796-797	=	_	
3-49	798-800	49	_	
3-50	800-801	:	_	
3-51	802-804	25	_	
3-52	805-812	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]	
3-53	813-818	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]	
3-54	819-820	[	_	
3-55	820-830	experiment	_	
3-56	831-832	1	_	
3-57	832-833	]	_	
3-58	833-834	,	_	
3-59	835-837	24	_	
3-60	838-845	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse[4]	
3-61	846-851	users	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse[4]	
3-62	852-853	[	_	
3-63	853-863	experiment	_	
3-64	864-865	2	_	
3-65	865-866	]	_	
3-66	866-867	;	_	
3-67	868-871	196	_	
3-68	872-877	total	_	
3-69	878-888	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-70	889-897	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-71	898-907	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-72	908-915	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-73	916-921	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-74	921-922	)	_	
3-75	922-923	.	_	

#Text=Generalized psychophysiological interaction and three-way repeated-measures analysis of variance were used to evaluate cTBS-induced changes in drug cue-associated functional connectivity between the left VMPFC and eight regions of interest: ventral striatum, left and right caudate, left and right putamen, left and right insula, and anterior cingulate cortex.
4-1	924-935	Generalized	_	
4-2	936-955	psychophysiological	_	
4-3	956-967	interaction	_	
4-4	968-971	and	_	
4-5	972-981	three-way	_	
4-6	982-999	repeated-measures	_	
4-7	1000-1008	analysis	_	
4-8	1009-1011	of	_	
4-9	1012-1020	variance	_	
4-10	1021-1025	were	_	
4-11	1026-1030	used	_	
4-12	1031-1033	to	_	
4-13	1034-1042	evaluate	_	
4-14	1043-1055	cTBS-induced	_	
4-15	1056-1063	changes	_	
4-16	1064-1066	in	_	
4-17	1067-1071	drug	_	
4-18	1072-1086	cue-associated	_	
4-19	1087-1097	functional	_	
4-20	1098-1110	connectivity	_	
4-21	1111-1118	between	_	
4-22	1119-1122	the	_	
4-23	1123-1127	left	_	
4-24	1128-1133	VMPFC	_	
4-25	1134-1137	and	_	
4-26	1138-1143	eight	_	
4-27	1144-1151	regions	_	
4-28	1152-1154	of	_	
4-29	1155-1163	interest	_	
4-30	1163-1164	:	_	
4-31	1165-1172	ventral	_	
4-32	1173-1181	striatum	_	
4-33	1181-1182	,	_	
4-34	1183-1187	left	_	
4-35	1188-1191	and	_	
4-36	1192-1197	right	_	
4-37	1198-1205	caudate	_	
4-38	1205-1206	,	_	
4-39	1207-1211	left	_	
4-40	1212-1215	and	_	
4-41	1216-1221	right	_	
4-42	1222-1229	putamen	_	
4-43	1229-1230	,	_	
4-44	1231-1235	left	_	
4-45	1236-1239	and	_	
4-46	1240-1245	right	_	
4-47	1246-1252	insula	_	
4-48	1252-1253	,	_	
4-49	1254-1257	and	_	
4-50	1258-1266	anterior	_	
4-51	1267-1276	cingulate	_	
4-52	1277-1283	cortex	_	
4-53	1283-1284	.	_	

#Text=RESULTS:
#Text=In both experiments, there was a significant interaction between treatment (real/sham) and time (pre/post).
5-1	1285-1292	RESULTS	_	
5-2	1292-1293	:	_	
5-3	1294-1296	In	_	
5-4	1297-1301	both	_	
5-5	1302-1313	experiments	_	
5-6	1313-1314	,	_	
5-7	1315-1320	there	_	
5-8	1321-1324	was	_	
5-9	1325-1326	a	_	
5-10	1327-1338	significant	_	
5-11	1339-1350	interaction	_	
5-12	1351-1358	between	_	
5-13	1359-1368	treatment	_	
5-14	1369-1370	(	_	
5-15	1370-1374	real	_	
5-16	1374-1375	/	_	
5-17	1375-1379	sham	_	
5-18	1379-1380	)	_	
5-19	1381-1384	and	_	
5-20	1385-1389	time	_	
5-21	1390-1391	(	_	
5-22	1391-1394	pre	_	
5-23	1394-1395	/	_	
5-24	1395-1399	post	_	
5-25	1399-1400	)	_	
5-26	1400-1401	.	_	

#Text=In both experiments, cue-related functional connectivity was significantly attenuated following real cTBS versus sham cTBS.
6-1	1402-1404	In	_	
6-2	1405-1409	both	_	
6-3	1410-1421	experiments	_	
6-4	1421-1422	,	_	
6-5	1423-1434	cue-related	_	
6-6	1435-1445	functional	_	
6-7	1446-1458	connectivity	_	
6-8	1459-1462	was	_	
6-9	1463-1476	significantly	_	
6-10	1477-1487	attenuated	_	
6-11	1488-1497	following	_	
6-12	1498-1502	real	_	
6-13	1503-1507	cTBS	_	
6-14	1508-1514	versus	_	
6-15	1515-1519	sham	_	
6-16	1520-1524	cTBS	_	
6-17	1524-1525	.	_	

#Text=There was no significant interaction with region of interest for either experiment.
7-1	1526-1531	There	_	
7-2	1532-1535	was	_	
7-3	1536-1538	no	_	
7-4	1539-1550	significant	_	
7-5	1551-1562	interaction	_	
7-6	1563-1567	with	_	
7-7	1568-1574	region	_	
7-8	1575-1577	of	_	
7-9	1578-1586	interest	_	
7-10	1587-1590	for	_	
7-11	1591-1597	either	_	
7-12	1598-1608	experiment	_	
7-13	1608-1609	.	_	

#Text=CONCLUSIONS:
#Text=This is the first sham-controlled investigation to demonstrate, in two populations, that VMPFC cTBS can attenuate neural reactivity to drug and alcohol cues in frontostriatal circuits.
8-1	1610-1621	CONCLUSIONS	_	
8-2	1621-1622	:	_	
8-3	1623-1627	This	_	
8-4	1628-1630	is	_	
8-5	1631-1634	the	_	
8-6	1635-1640	first	_	
8-7	1641-1656	sham-controlled	_	
8-8	1657-1670	investigation	_	
8-9	1671-1673	to	_	
8-10	1674-1685	demonstrate	_	
8-11	1685-1686	,	_	
8-12	1687-1689	in	_	
8-13	1690-1693	two	_	
8-14	1694-1705	populations	_	
8-15	1705-1706	,	_	
8-16	1707-1711	that	_	
8-17	1712-1717	VMPFC	_	
8-18	1718-1722	cTBS	_	
8-19	1723-1726	can	_	
8-20	1727-1736	attenuate	_	
8-21	1737-1743	neural	_	
8-22	1744-1754	reactivity	_	
8-23	1755-1757	to	_	
8-24	1758-1762	drug	_	
8-25	1763-1766	and	_	
8-26	1767-1774	alcohol	_	
8-27	1775-1779	cues	_	
8-28	1780-1782	in	_	
8-29	1783-1797	frontostriatal	_	
8-30	1798-1806	circuits	_	
8-31	1806-1807	.	_	

#Text=These results provide an empirical foundation for future clinical trials that may evaluate the efficacy, durability, and clinical implications of VMPFC cTBS to treat addictions.
9-1	1808-1813	These	_	
9-2	1814-1821	results	_	
9-3	1822-1829	provide	_	
9-4	1830-1832	an	_	
9-5	1833-1842	empirical	_	
9-6	1843-1853	foundation	_	
9-7	1854-1857	for	_	
9-8	1858-1864	future	_	
9-9	1865-1873	clinical	_	
9-10	1874-1880	trials	_	
9-11	1881-1885	that	_	
9-12	1886-1889	may	_	
9-13	1890-1898	evaluate	_	
9-14	1899-1902	the	_	
9-15	1903-1911	efficacy	_	
9-16	1911-1912	,	_	
9-17	1913-1923	durability	_	
9-18	1923-1924	,	_	
9-19	1925-1928	and	_	
9-20	1929-1937	clinical	_	
9-21	1938-1950	implications	_	
9-22	1951-1953	of	_	
9-23	1954-1959	VMPFC	_	
9-24	1960-1964	cTBS	_	
9-25	1965-1967	to	_	
9-26	1968-1973	treat	_	
9-27	1974-1984	addictions	_	
9-28	1984-1985	.	_	

#Text=Elevated neural reactivity to drug cues is a common feature of substance use disorders (SUDs) and has been evaluated as a potential biomarker for predicting relapse to drug use.
10-1	1986-1994	Elevated	_	
10-2	1995-2001	neural	_	
10-3	2002-2012	reactivity	_	
10-4	2013-2015	to	_	
10-5	2016-2020	drug	_	
10-6	2021-2025	cues	_	
10-7	2026-2028	is	_	
10-8	2029-2030	a	_	
10-9	2031-2037	common	_	
10-10	2038-2045	feature	_	
10-11	2046-2048	of	_	
10-12	2049-2058	substance	_	
10-13	2059-2062	use	_	
10-14	2063-2072	disorders	_	
10-15	2073-2074	(	_	
10-16	2074-2078	SUDs	_	
10-17	2078-2079	)	_	
10-18	2080-2083	and	_	
10-19	2084-2087	has	_	
10-20	2088-2092	been	_	
10-21	2093-2102	evaluated	_	
10-22	2103-2105	as	_	
10-23	2106-2107	a	_	
10-24	2108-2117	potential	_	
10-25	2118-2127	biomarker	_	
10-26	2128-2131	for	_	
10-27	2132-2142	predicting	_	
10-28	2143-2150	relapse	_	
10-29	2151-2153	to	_	
10-30	2154-2158	drug	_	
10-31	2159-2162	use	_	
10-32	2162-2163	.	_	

#Text=Across multiple drug-using populations, cue exposure leads to elevated activity in frontostriatal and frontolimbic neural circuits involved in reward processing and salience.
11-1	2164-2170	Across	_	
11-2	2171-2179	multiple	_	
11-3	2180-2190	drug-using	_	
11-4	2191-2202	populations	_	
11-5	2202-2203	,	_	
11-6	2204-2207	cue	_	
11-7	2208-2216	exposure	_	
11-8	2217-2222	leads	_	
11-9	2223-2225	to	_	
11-10	2226-2234	elevated	_	
11-11	2235-2243	activity	_	
11-12	2244-2246	in	_	
11-13	2247-2261	frontostriatal	_	
11-14	2262-2265	and	_	
11-15	2266-2278	frontolimbic	_	
11-16	2279-2285	neural	_	
11-17	2286-2294	circuits	_	
11-18	2295-2303	involved	_	
11-19	2304-2306	in	_	
11-20	2307-2313	reward	_	
11-21	2314-2324	processing	_	
11-22	2325-2328	and	_	
11-23	2329-2337	salience	_	
11-24	2337-2338	.	_	

#Text=These regions include the ventromedial prefrontal cortex (VMPFC), ventral and dorsal striatum, anterior cingulate cortex (ACC), and anterior insula.
12-1	2339-2344	These	_	
12-2	2345-2352	regions	_	
12-3	2353-2360	include	_	
12-4	2361-2364	the	_	
12-5	2365-2377	ventromedial	_	
12-6	2378-2388	prefrontal	_	
12-7	2389-2395	cortex	_	
12-8	2396-2397	(	_	
12-9	2397-2402	VMPFC	_	
12-10	2402-2403	)	_	
12-11	2403-2404	,	_	
12-12	2405-2412	ventral	_	
12-13	2413-2416	and	_	
12-14	2417-2423	dorsal	_	
12-15	2424-2432	striatum	_	
12-16	2432-2433	,	_	
12-17	2434-2442	anterior	_	
12-18	2443-2452	cingulate	_	
12-19	2453-2459	cortex	_	
12-20	2460-2461	(	_	
12-21	2461-2464	ACC	_	
12-22	2464-2465	)	_	
12-23	2465-2466	,	_	
12-24	2467-2470	and	_	
12-25	2471-2479	anterior	_	
12-26	2480-2486	insula	_	
12-27	2486-2487	.	_	

#Text=This has been demonstrated in cocaine users, alcohol users, nicotine users, marijuana users, and opioid users.
13-1	2488-2492	This	_	
13-2	2493-2496	has	_	
13-3	2497-2501	been	_	
13-4	2502-2514	demonstrated	_	
13-5	2515-2517	in	_	
13-6	2518-2525	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
13-7	2526-2531	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
13-8	2531-2532	,	_	
13-9	2533-2540	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
13-10	2541-2546	users	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
13-11	2546-2547	,	_	
13-12	2548-2556	nicotine	_	
13-13	2557-2562	users	_	
13-14	2562-2563	,	_	
13-15	2564-2573	marijuana	_	
13-16	2574-2579	users	_	
13-17	2579-2580	,	_	
13-18	2581-2584	and	_	
13-19	2585-2591	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[8]	
13-20	2592-2597	users	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[8]	
13-21	2597-2598	.	_	

#Text=One promising new area of research in addiction treatment development has been transcranial magnetic stimulation (TMS).
14-1	2599-2602	One	_	
14-2	2603-2612	promising	_	
14-3	2613-2616	new	_	
14-4	2617-2621	area	_	
14-5	2622-2624	of	_	
14-6	2625-2633	research	_	
14-7	2634-2636	in	_	
14-8	2637-2646	addiction	_	
14-9	2647-2656	treatment	_	
14-10	2657-2668	development	_	
14-11	2669-2672	has	_	
14-12	2673-2677	been	_	
14-13	2678-2690	transcranial	_	
14-14	2691-2699	magnetic	_	
14-15	2700-2711	stimulation	_	
14-16	2712-2713	(	_	
14-17	2713-2716	TMS	_	
14-18	2716-2717	)	_	
14-19	2717-2718	.	_	

#Text=Food and Drug Administration–approved as a treatment for depression, TMS is a noninvasive brain stimulation technique that takes advantage of the ability of electromagnetic induction to induce neural activity in the cortex and, by extension, in subcortical regions through monosynaptic afferent projections.
15-1	2719-2723	Food	_	
15-2	2724-2727	and	_	
15-3	2728-2732	Drug	_	
15-4	2733-2756	Administration–approved	_	
15-5	2757-2759	as	_	
15-6	2760-2761	a	_	
15-7	2762-2771	treatment	_	
15-8	2772-2775	for	_	
15-9	2776-2786	depression	_	
15-10	2786-2787	,	_	
15-11	2788-2791	TMS	_	
15-12	2792-2794	is	_	
15-13	2795-2796	a	_	
15-14	2797-2808	noninvasive	_	
15-15	2809-2814	brain	_	
15-16	2815-2826	stimulation	_	
15-17	2827-2836	technique	_	
15-18	2837-2841	that	_	
15-19	2842-2847	takes	_	
15-20	2848-2857	advantage	_	
15-21	2858-2860	of	_	
15-22	2861-2864	the	_	
15-23	2865-2872	ability	_	
15-24	2873-2875	of	_	
15-25	2876-2891	electromagnetic	_	
15-26	2892-2901	induction	_	
15-27	2902-2904	to	_	
15-28	2905-2911	induce	_	
15-29	2912-2918	neural	_	
15-30	2919-2927	activity	_	
15-31	2928-2930	in	_	
15-32	2931-2934	the	_	
15-33	2935-2941	cortex	_	
15-34	2942-2945	and	_	
15-35	2945-2946	,	_	
15-36	2947-2949	by	_	
15-37	2950-2959	extension	_	
15-38	2959-2960	,	_	
15-39	2961-2963	in	_	
15-40	2964-2975	subcortical	_	
15-41	2976-2983	regions	_	
15-42	2984-2991	through	_	
15-43	2992-3004	monosynaptic	_	
15-44	3005-3013	afferent	_	
15-45	3014-3025	projections	_	
15-46	3025-3026	.	_	

#Text=Repetitive TMS (rTMS) produces frequency-dependent changes in neural activity, with high-frequency stimulation typically inducing long-term potentiation of cortical excitability and low-frequency stimulation inducing long-term depression of cortical excitability.
16-1	3027-3037	Repetitive	_	
16-2	3038-3041	TMS	_	
16-3	3042-3043	(	_	
16-4	3043-3047	rTMS	_	
16-5	3047-3048	)	_	
16-6	3049-3057	produces	_	
16-7	3058-3077	frequency-dependent	_	
16-8	3078-3085	changes	_	
16-9	3086-3088	in	_	
16-10	3089-3095	neural	_	
16-11	3096-3104	activity	_	
16-12	3104-3105	,	_	
16-13	3106-3110	with	_	
16-14	3111-3125	high-frequency	_	
16-15	3126-3137	stimulation	_	
16-16	3138-3147	typically	_	
16-17	3148-3156	inducing	_	
16-18	3157-3166	long-term	_	
16-19	3167-3179	potentiation	_	
16-20	3180-3182	of	_	
16-21	3183-3191	cortical	_	
16-22	3192-3204	excitability	_	
16-23	3205-3208	and	_	
16-24	3209-3222	low-frequency	_	
16-25	3223-3234	stimulation	_	
16-26	3235-3243	inducing	_	
16-27	3244-3253	long-term	_	
16-28	3254-3264	depression	_	
16-29	3265-3267	of	_	
16-30	3268-3276	cortical	_	
16-31	3277-3289	excitability	_	
16-32	3289-3290	.	_	

#Text=Theta burst stimulation (TBS), a patterned form of rTMS, is based on a rhythmic bursting pattern; it has been used to induce plasticity in preclinical preparations and can selectively increase or decrease cortical excitability in a neural circuit–specific manner in humans.
17-1	3291-3296	Theta	_	
17-2	3297-3302	burst	_	
17-3	3303-3314	stimulation	_	
17-4	3315-3316	(	_	
17-5	3316-3319	TBS	_	
17-6	3319-3320	)	_	
17-7	3320-3321	,	_	
17-8	3322-3323	a	_	
17-9	3324-3333	patterned	_	
17-10	3334-3338	form	_	
17-11	3339-3341	of	_	
17-12	3342-3346	rTMS	_	
17-13	3346-3347	,	_	
17-14	3348-3350	is	_	
17-15	3351-3356	based	_	
17-16	3357-3359	on	_	
17-17	3360-3361	a	_	
17-18	3362-3370	rhythmic	_	
17-19	3371-3379	bursting	_	
17-20	3380-3387	pattern	_	
17-21	3387-3388	;	_	
17-22	3389-3391	it	_	
17-23	3392-3395	has	_	
17-24	3396-3400	been	_	
17-25	3401-3405	used	_	
17-26	3406-3408	to	_	
17-27	3409-3415	induce	_	
17-28	3416-3426	plasticity	_	
17-29	3427-3429	in	_	
17-30	3430-3441	preclinical	_	
17-31	3442-3454	preparations	_	
17-32	3455-3458	and	_	
17-33	3459-3462	can	_	
17-34	3463-3474	selectively	_	
17-35	3475-3483	increase	_	
17-36	3484-3486	or	_	
17-37	3487-3495	decrease	_	
17-38	3496-3504	cortical	_	
17-39	3505-3517	excitability	_	
17-40	3518-3520	in	_	
17-41	3521-3522	a	_	
17-42	3523-3529	neural	_	
17-43	3530-3546	circuit–specific	_	
17-44	3547-3553	manner	_	
17-45	3554-3556	in	_	
17-46	3557-3563	humans	_	
17-47	3563-3564	.	_	

#Text=Prior studies from our lab have shown that single pulses of TMS to the left frontal pole induce a significant change in brain activity (as measured by the blood oxygen level–dependent signal) in the VMPFC and the striatum.
18-1	3565-3570	Prior	_	
18-2	3571-3578	studies	_	
18-3	3579-3583	from	_	
18-4	3584-3587	our	_	
18-5	3588-3591	lab	_	
18-6	3592-3596	have	_	
18-7	3597-3602	shown	_	
18-8	3603-3607	that	_	
18-9	3608-3614	single	_	
18-10	3615-3621	pulses	_	
18-11	3622-3624	of	_	
18-12	3625-3628	TMS	_	
18-13	3629-3631	to	_	
18-14	3632-3635	the	_	
18-15	3636-3640	left	_	
18-16	3641-3648	frontal	_	
18-17	3649-3653	pole	_	
18-18	3654-3660	induce	_	
18-19	3661-3662	a	_	
18-20	3663-3674	significant	_	
18-21	3675-3681	change	_	
18-22	3682-3684	in	_	
18-23	3685-3690	brain	_	
18-24	3691-3699	activity	_	
18-25	3700-3701	(	_	
18-26	3701-3703	as	_	
18-27	3704-3712	measured	_	
18-28	3713-3715	by	_	
18-29	3716-3719	the	_	
18-30	3720-3725	blood	_	
18-31	3726-3732	oxygen	_	
18-32	3733-3748	level–dependent	_	
18-33	3749-3755	signal	_	
18-34	3755-3756	)	_	
18-35	3757-3759	in	_	
18-36	3760-3763	the	_	
18-37	3764-3769	VMPFC	_	
18-38	3770-3773	and	_	
18-39	3774-3777	the	_	
18-40	3778-3786	striatum	_	
18-41	3786-3787	.	_	

#Text=This has been demonstrated through the use of interleaved TMS and functional magnetic resonance imaging (fMRI) in healthy, cocaine-dependent, and alcohol-dependent individuals.
19-1	3788-3792	This	_	
19-2	3793-3796	has	_	
19-3	3797-3801	been	_	
19-4	3802-3814	demonstrated	_	
19-5	3815-3822	through	_	
19-6	3823-3826	the	_	
19-7	3827-3830	use	_	
19-8	3831-3833	of	_	
19-9	3834-3845	interleaved	_	
19-10	3846-3849	TMS	_	
19-11	3850-3853	and	_	
19-12	3854-3864	functional	_	
19-13	3865-3873	magnetic	_	
19-14	3874-3883	resonance	_	
19-15	3884-3891	imaging	_	
19-16	3892-3893	(	_	
19-17	3893-3897	fMRI	_	
19-18	3897-3898	)	_	
19-19	3899-3901	in	_	
19-20	3902-3909	healthy	_	
19-21	3909-3910	,	_	
19-22	3911-3928	cocaine-dependent	_	
19-23	3928-3929	,	_	
19-24	3930-3933	and	_	
19-25	3934-3951	alcohol-dependent	_	
19-26	3952-3963	individuals	_	
19-27	3963-3964	.	_	

#Text=Furthermore, when continuous TBS (cTBS), an inhibitory form of rTMS, is applied to the VMPFC in cocaine users, there is a selective attenuation of TMS-evoked activity in the VMPFC, striatum, ACC, and insula.
20-1	3965-3976	Furthermore	_	
20-2	3976-3977	,	_	
20-3	3978-3982	when	_	
20-4	3983-3993	continuous	_	
20-5	3994-3997	TBS	_	
20-6	3998-3999	(	_	
20-7	3999-4003	cTBS	_	
20-8	4003-4004	)	_	
20-9	4004-4005	,	_	
20-10	4006-4008	an	_	
20-11	4009-4019	inhibitory	_	
20-12	4020-4024	form	_	
20-13	4025-4027	of	_	
20-14	4028-4032	rTMS	_	
20-15	4032-4033	,	_	
20-16	4034-4036	is	_	
20-17	4037-4044	applied	_	
20-18	4045-4047	to	_	
20-19	4048-4051	the	_	
20-20	4052-4057	VMPFC	_	
20-21	4058-4060	in	_	
20-22	4061-4068	cocaine	_	
20-23	4069-4074	users	_	
20-24	4074-4075	,	_	
20-25	4076-4081	there	_	
20-26	4082-4084	is	_	
20-27	4085-4086	a	_	
20-28	4087-4096	selective	_	
20-29	4097-4108	attenuation	_	
20-30	4109-4111	of	_	
20-31	4112-4122	TMS-evoked	_	
20-32	4123-4131	activity	_	
20-33	4132-4134	in	_	
20-34	4135-4138	the	_	
20-35	4139-4144	VMPFC	_	
20-36	4144-4145	,	_	
20-37	4146-4154	striatum	_	
20-38	4154-4155	,	_	
20-39	4156-4159	ACC	_	
20-40	4159-4160	,	_	
20-41	4161-4164	and	_	
20-42	4165-4171	insula	_	
20-43	4171-4172	.	_	

#Text=This paradigm was also associated with a reduction in cocaine craving.
21-1	4173-4177	This	_	
21-2	4178-4186	paradigm	_	
21-3	4187-4190	was	_	
21-4	4191-4195	also	_	
21-5	4196-4206	associated	_	
21-6	4207-4211	with	_	
21-7	4212-4213	a	_	
21-8	4214-4223	reduction	_	
21-9	4224-4226	in	_	
21-10	4227-4234	cocaine	_	
21-11	4235-4242	craving	_	
21-12	4242-4243	.	_	

#Text=When VMPFC cTBS is applied to alcohol users, there is also a significant attenuation of neural activity in these regions, suggesting that cTBS has transdiagnostic effects on frontostriatolimbic circuitry.
22-1	4244-4248	When	_	
22-2	4249-4254	VMPFC	_	
22-3	4255-4259	cTBS	_	
22-4	4260-4262	is	_	
22-5	4263-4270	applied	_	
22-6	4271-4273	to	_	
22-7	4274-4281	alcohol	_	
22-8	4282-4287	users	_	
22-9	4287-4288	,	_	
22-10	4289-4294	there	_	
22-11	4295-4297	is	_	
22-12	4298-4302	also	_	
22-13	4303-4304	a	_	
22-14	4305-4316	significant	_	
22-15	4317-4328	attenuation	_	
22-16	4329-4331	of	_	
22-17	4332-4338	neural	_	
22-18	4339-4347	activity	_	
22-19	4348-4350	in	_	
22-20	4351-4356	these	_	
22-21	4357-4364	regions	_	
22-22	4364-4365	,	_	
22-23	4366-4376	suggesting	_	
22-24	4377-4381	that	_	
22-25	4382-4386	cTBS	_	
22-26	4387-4390	has	_	
22-27	4391-4406	transdiagnostic	_	
22-28	4407-4414	effects	_	
22-29	4415-4417	on	_	
22-30	4418-4437	frontostriatolimbic	_	
22-31	4438-4447	circuitry	_	
22-32	4447-4448	.	_	

#Text=While VMPFC cTBS appears to attenuate TMS-evoked activity in craving-related circuitry, it is not yet clear, however, if these effects generalize to behaviorally relevant engagement of this circuit, such as during drug/alcohol cue exposure.
23-1	4449-4454	While	_	
23-2	4455-4460	VMPFC	_	
23-3	4461-4465	cTBS	_	
23-4	4466-4473	appears	_	
23-5	4474-4476	to	_	
23-6	4477-4486	attenuate	_	
23-7	4487-4497	TMS-evoked	_	
23-8	4498-4506	activity	_	
23-9	4507-4509	in	_	
23-10	4510-4525	craving-related	_	
23-11	4526-4535	circuitry	_	
23-12	4535-4536	,	_	
23-13	4537-4539	it	_	
23-14	4540-4542	is	_	
23-15	4543-4546	not	_	
23-16	4547-4550	yet	_	
23-17	4551-4556	clear	_	
23-18	4556-4557	,	_	
23-19	4558-4565	however	_	
23-20	4565-4566	,	_	
23-21	4567-4569	if	_	
23-22	4570-4575	these	_	
23-23	4576-4583	effects	_	
23-24	4584-4594	generalize	_	
23-25	4595-4597	to	_	
23-26	4598-4610	behaviorally	_	
23-27	4611-4619	relevant	_	
23-28	4620-4630	engagement	_	
23-29	4631-4633	of	_	
23-30	4634-4638	this	_	
23-31	4639-4646	circuit	_	
23-32	4646-4647	,	_	
23-33	4648-4652	such	_	
23-34	4653-4655	as	_	
23-35	4656-4662	during	_	
23-36	4663-4667	drug	_	
23-37	4667-4668	/	_	
23-38	4668-4675	alcohol	_	
23-39	4676-4679	cue	_	
23-40	4680-4688	exposure	_	
23-41	4688-4689	.	_	

#Text=The goal of the present study was to determine if cTBS to the VMPFC could reduce the brain response to drug cues (experiment 1) and alcohol cues (experiment 2).
24-1	4690-4693	The	_	
24-2	4694-4698	goal	_	
24-3	4699-4701	of	_	
24-4	4702-4705	the	_	
24-5	4706-4713	present	_	
24-6	4714-4719	study	_	
24-7	4720-4723	was	_	
24-8	4724-4726	to	_	
24-9	4727-4736	determine	_	
24-10	4737-4739	if	_	
24-11	4740-4744	cTBS	_	
24-12	4745-4747	to	_	
24-13	4748-4751	the	_	
24-14	4752-4757	VMPFC	_	
24-15	4758-4763	could	_	
24-16	4764-4770	reduce	_	
24-17	4771-4774	the	_	
24-18	4775-4780	brain	_	
24-19	4781-4789	response	_	
24-20	4790-4792	to	_	
24-21	4793-4797	drug	_	
24-22	4798-4802	cues	_	
24-23	4803-4804	(	_	
24-24	4804-4814	experiment	_	
24-25	4815-4816	1	_	
24-26	4816-4817	)	_	
24-27	4818-4821	and	_	
24-28	4822-4829	alcohol	_	
24-29	4830-4834	cues	_	
24-30	4835-4836	(	_	
24-31	4836-4846	experiment	_	
24-32	4847-4848	2	_	
24-33	4848-4849	)	_	
24-34	4849-4850	.	_	

#Text=Additionally, by uniting these datasets, we sought to test the hypothesis that cTBS would have similar (transdiagnostic) attenuating effects on cue reactivity in these groups.
25-1	4851-4863	Additionally	_	
25-2	4863-4864	,	_	
25-3	4865-4867	by	_	
25-4	4868-4875	uniting	_	
25-5	4876-4881	these	_	
25-6	4882-4890	datasets	_	
25-7	4890-4891	,	_	
25-8	4892-4894	we	_	
25-9	4895-4901	sought	_	
25-10	4902-4904	to	_	
25-11	4905-4909	test	_	
25-12	4910-4913	the	_	
25-13	4914-4924	hypothesis	_	
25-14	4925-4929	that	_	
25-15	4930-4934	cTBS	_	
25-16	4935-4940	would	_	
25-17	4941-4945	have	_	
25-18	4946-4953	similar	_	
25-19	4954-4955	(	_	
25-20	4955-4970	transdiagnostic	_	
25-21	4970-4971	)	_	
25-22	4972-4983	attenuating	_	
25-23	4984-4991	effects	_	
25-24	4992-4994	on	_	
25-25	4995-4998	cue	_	
25-26	4999-5009	reactivity	_	
25-27	5010-5012	in	_	
25-28	5013-5018	these	_	
25-29	5019-5025	groups	_	
25-30	5025-5026	.	_	

#Text=To achieve these goals, we performed two single-blinded, active sham–controlled brain imaging and TMS experiments wherein fMRI scans were acquired immediately before and after a session of real or sham VMPFC cTBS in a cohort of individuals with cocaine use disorder (experiment 1) and alcohol use disorder (experiment 2), respectively.
26-1	5027-5029	To	_	
26-2	5030-5037	achieve	_	
26-3	5038-5043	these	_	
26-4	5044-5049	goals	_	
26-5	5049-5050	,	_	
26-6	5051-5053	we	_	
26-7	5054-5063	performed	_	
26-8	5064-5067	two	_	
26-9	5068-5082	single-blinded	_	
26-10	5082-5083	,	_	
26-11	5084-5090	active	_	
26-12	5091-5106	sham–controlled	_	
26-13	5107-5112	brain	_	
26-14	5113-5120	imaging	_	
26-15	5121-5124	and	_	
26-16	5125-5128	TMS	_	
26-17	5129-5140	experiments	_	
26-18	5141-5148	wherein	_	
26-19	5149-5153	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
26-20	5154-5159	scans	_	
26-21	5160-5164	were	_	
26-22	5165-5173	acquired	_	
26-23	5174-5185	immediately	_	
26-24	5186-5192	before	_	
26-25	5193-5196	and	_	
26-26	5197-5202	after	_	
26-27	5203-5204	a	_	
26-28	5205-5212	session	_	
26-29	5213-5215	of	_	
26-30	5216-5220	real	_	
26-31	5221-5223	or	_	
26-32	5224-5228	sham	_	
26-33	5229-5234	VMPFC	_	
26-34	5235-5239	cTBS	_	
26-35	5240-5242	in	_	
26-36	5243-5244	a	_	
26-37	5245-5251	cohort	_	
26-38	5252-5254	of	_	
26-39	5255-5266	individuals	_	
26-40	5267-5271	with	_	
26-41	5272-5279	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
26-42	5280-5283	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
26-43	5284-5292	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
26-44	5293-5294	(	_	
26-45	5294-5304	experiment	_	
26-46	5305-5306	1	_	
26-47	5306-5307	)	_	
26-48	5308-5311	and	_	
26-49	5312-5319	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[10]	
26-50	5320-5323	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[10]	
26-51	5324-5332	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[10]	
26-52	5333-5334	(	_	
26-53	5334-5344	experiment	_	
26-54	5345-5346	2	_	
26-55	5346-5347	)	_	
26-56	5347-5348	,	_	
26-57	5349-5361	respectively	_	
26-58	5361-5362	.	_	

#Text=While 600 pulses of cTBS was the original dose observed to produce long-term depression–like effects in the primary motor cortex, for this study, 3600 pulses was chosen as our cTBS dose given that the Food and Drug Administration–approved protocol for depression treatment involves 3000 pulses/session at 10 Hz, and recent studies from our laboratory have demonstrated that 3600 pulses to the left VMPFC can decrease VMPFC connectivity to the ventral striatum, caudate, putamen, and orbitofrontal cortex in cocaine users and alcohol users.
27-1	5363-5368	While	_	
27-2	5369-5372	600	_	
27-3	5373-5379	pulses	_	
27-4	5380-5382	of	_	
27-5	5383-5387	cTBS	_	
27-6	5388-5391	was	_	
27-7	5392-5395	the	_	
27-8	5396-5404	original	_	
27-9	5405-5409	dose	_	
27-10	5410-5418	observed	_	
27-11	5419-5421	to	_	
27-12	5422-5429	produce	_	
27-13	5430-5439	long-term	_	
27-14	5440-5455	depression–like	_	
27-15	5456-5463	effects	_	
27-16	5464-5466	in	_	
27-17	5467-5470	the	_	
27-18	5471-5478	primary	_	
27-19	5479-5484	motor	_	
27-20	5485-5491	cortex	_	
27-21	5491-5492	,	_	
27-22	5493-5496	for	_	
27-23	5497-5501	this	_	
27-24	5502-5507	study	_	
27-25	5507-5508	,	_	
27-26	5509-5513	3600	_	
27-27	5514-5520	pulses	_	
27-28	5521-5524	was	_	
27-29	5525-5531	chosen	_	
27-30	5532-5534	as	_	
27-31	5535-5538	our	_	
27-32	5539-5543	cTBS	_	
27-33	5544-5548	dose	_	
27-34	5549-5554	given	_	
27-35	5555-5559	that	_	
27-36	5560-5563	the	_	
27-37	5564-5568	Food	_	
27-38	5569-5572	and	_	
27-39	5573-5577	Drug	_	
27-40	5578-5601	Administration–approved	_	
27-41	5602-5610	protocol	_	
27-42	5611-5614	for	_	
27-43	5615-5625	depression	_	
27-44	5626-5635	treatment	_	
27-45	5636-5644	involves	_	
27-46	5645-5649	3000	_	
27-47	5650-5656	pulses	_	
27-48	5656-5657	/	_	
27-49	5657-5664	session	_	
27-50	5665-5667	at	_	
27-51	5668-5670	10	_	
27-52	5671-5673	Hz	_	
27-53	5673-5674	,	_	
27-54	5675-5678	and	_	
27-55	5679-5685	recent	_	
27-56	5686-5693	studies	_	
27-57	5694-5698	from	_	
27-58	5699-5702	our	_	
27-59	5703-5713	laboratory	_	
27-60	5714-5718	have	_	
27-61	5719-5731	demonstrated	_	
27-62	5732-5736	that	_	
27-63	5737-5741	3600	_	
27-64	5742-5748	pulses	_	
27-65	5749-5751	to	_	
27-66	5752-5755	the	_	
27-67	5756-5760	left	_	
27-68	5761-5766	VMPFC	_	
27-69	5767-5770	can	_	
27-70	5771-5779	decrease	_	
27-71	5780-5785	VMPFC	_	
27-72	5786-5798	connectivity	_	
27-73	5799-5801	to	_	
27-74	5802-5805	the	_	
27-75	5806-5813	ventral	_	
27-76	5814-5822	striatum	_	
27-77	5822-5823	,	_	
27-78	5824-5831	caudate	_	
27-79	5831-5832	,	_	
27-80	5833-5840	putamen	_	
27-81	5840-5841	,	_	
27-82	5842-5845	and	_	
27-83	5846-5859	orbitofrontal	_	
27-84	5860-5866	cortex	_	
27-85	5867-5869	in	_	
27-86	5870-5877	cocaine	_	
27-87	5878-5883	users	_	
27-88	5884-5887	and	_	
27-89	5888-5895	alcohol	_	
27-90	5896-5901	users	_	
27-91	5901-5902	.	_	

#Text=All individuals received real and sham VMPFC cTBS (across two different sessions, 3600 pulses of cTBS per session; four fMRI scans per individual; 49 participants total; 196 fMRI scans total).
28-1	5903-5906	All	_	
28-2	5907-5918	individuals	_	
28-3	5919-5927	received	_	
28-4	5928-5932	real	_	
28-5	5933-5936	and	_	
28-6	5937-5941	sham	_	
28-7	5942-5947	VMPFC	_	
28-8	5948-5952	cTBS	_	
28-9	5953-5954	(	_	
28-10	5954-5960	across	_	
28-11	5961-5964	two	_	
28-12	5965-5974	different	_	
28-13	5975-5983	sessions	_	
28-14	5983-5984	,	_	
28-15	5985-5989	3600	_	
28-16	5990-5996	pulses	_	
28-17	5997-5999	of	_	
28-18	6000-6004	cTBS	_	
28-19	6005-6008	per	_	
28-20	6009-6016	session	_	
28-21	6016-6017	;	_	
28-22	6018-6022	four	_	
28-23	6023-6027	fMRI	_	
28-24	6028-6033	scans	_	
28-25	6034-6037	per	_	
28-26	6038-6048	individual	_	
28-27	6048-6049	;	_	
28-28	6050-6052	49	_	
28-29	6053-6065	participants	_	
28-30	6066-6071	total	_	
28-31	6071-6072	;	_	
28-32	6073-6076	196	_	
28-33	6077-6081	fMRI	_	
28-34	6082-6087	scans	_	
28-35	6088-6093	total	_	
28-36	6093-6094	)	_	
28-37	6094-6095	.	_	

#Text=We hypothesized that VMPFC cTBS would attenuate drug/alcohol cue–related functional connectivity (FC) within frontostriatal circuitry (VMPFC-ventral striatum, caudate, putamen), as well as nodes of the salience network (i.e., ACC, anterior insula) typically engaged by drug cues.
29-1	6096-6098	We	_	
29-2	6099-6111	hypothesized	_	
29-3	6112-6116	that	_	
29-4	6117-6122	VMPFC	_	
29-5	6123-6127	cTBS	_	
29-6	6128-6133	would	_	
29-7	6134-6143	attenuate	_	
29-8	6144-6148	drug	_	
29-9	6148-6149	/	_	
29-10	6149-6156	alcohol	_	
29-11	6157-6168	cue–related	_	
29-12	6169-6179	functional	_	
29-13	6180-6192	connectivity	_	
29-14	6193-6194	(	_	
29-15	6194-6196	FC	_	
29-16	6196-6197	)	_	
29-17	6198-6204	within	_	
29-18	6205-6219	frontostriatal	_	
29-19	6220-6229	circuitry	_	
29-20	6230-6231	(	_	
29-21	6231-6244	VMPFC-ventral	_	
29-22	6245-6253	striatum	_	
29-23	6253-6254	,	_	
29-24	6255-6262	caudate	_	
29-25	6262-6263	,	_	
29-26	6264-6271	putamen	_	
29-27	6271-6272	)	_	
29-28	6272-6273	,	_	
29-29	6274-6276	as	_	
29-30	6277-6281	well	_	
29-31	6282-6284	as	_	
29-32	6285-6290	nodes	_	
29-33	6291-6293	of	_	
29-34	6294-6297	the	_	
29-35	6298-6306	salience	_	
29-36	6307-6314	network	_	
29-37	6315-6316	(	_	
29-38	6316-6319	i.e	_	
29-39	6319-6320	.	_	
29-40	6320-6321	,	_	
29-41	6322-6325	ACC	_	
29-42	6325-6326	,	_	
29-43	6327-6335	anterior	_	
29-44	6336-6342	insula	_	
29-45	6342-6343	)	_	
29-46	6344-6353	typically	_	
29-47	6354-6361	engaged	_	
29-48	6362-6364	by	_	
29-49	6365-6369	drug	_	
29-50	6370-6374	cues	_	
29-51	6374-6375	.	_	

#Text=METHODS AND MATERIALS
#Text=Experiment 1 (Cocaine Users) and Experiment 2 (Heavy Alcohol Users)
#Text=Participants.
30-1	6376-6383	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
30-2	6384-6387	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
30-3	6388-6397	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
30-4	6398-6408	Experiment	_	
30-5	6409-6410	1	_	
30-6	6411-6412	(	_	
30-7	6412-6419	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[12]	
30-8	6420-6425	Users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[12]	
30-9	6425-6426	)	_	
30-10	6427-6430	and	_	
30-11	6431-6441	Experiment	_	
30-12	6442-6443	2	_	
30-13	6444-6445	(	_	
30-14	6445-6450	Heavy	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse[13]	
30-15	6451-6458	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse[13]	
30-16	6459-6464	Users	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse[13]	
30-17	6464-6465	)	_	
30-18	6466-6478	Participants	_	
30-19	6478-6479	.	_	

#Text=Non–treatment-seeking cocaine-dependent individuals (n = 25) and alcohol-dependent individuals (n = 24) were recruited from the Charleston, South Carolina, metropolitan area to participate in one of two single-blinded, active sham–controlled crossover studies.
31-1	6480-6501	Non–treatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[15]	
31-2	6502-6519	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[15]	
31-3	6520-6531	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[15]	
31-4	6532-6533	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-5	6533-6534	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-6	6535-6536	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-7	6537-6539	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-8	6539-6540	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-9	6541-6544	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-10	6545-6562	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
31-11	6563-6574	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
31-12	6575-6576	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-13	6576-6577	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-14	6578-6579	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-15	6580-6582	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-16	6582-6583	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-17	6584-6588	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-18	6589-6598	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-19	6599-6603	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-20	6604-6607	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-21	6608-6618	Charleston	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-22	6618-6619	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-23	6620-6625	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-24	6626-6634	Carolina	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-25	6634-6635	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-26	6636-6648	metropolitan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-27	6649-6653	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-28	6654-6656	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-29	6657-6668	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-30	6669-6671	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-31	6672-6675	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-32	6676-6678	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-33	6679-6682	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-34	6683-6697	single-blinded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-35	6697-6698	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-36	6699-6705	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-37	6706-6721	sham–controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-38	6722-6731	crossover	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-39	6732-6739	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-40	6739-6740	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=These studies were independent but were run in parallel by the same study coordinator using the same TMS equipment and facilities.
32-1	6741-6746	These	_	
32-2	6747-6754	studies	_	
32-3	6755-6759	were	_	
32-4	6760-6771	independent	_	
32-5	6772-6775	but	_	
32-6	6776-6780	were	_	
32-7	6781-6784	run	_	
32-8	6785-6787	in	_	
32-9	6788-6796	parallel	_	
32-10	6797-6799	by	_	
32-11	6800-6803	the	_	
32-12	6804-6808	same	_	
32-13	6809-6814	study	_	
32-14	6815-6826	coordinator	_	
32-15	6827-6832	using	_	
32-16	6833-6836	the	_	
32-17	6837-6841	same	_	
32-18	6842-6845	TMS	_	
32-19	6846-6855	equipment	_	
32-20	6856-6859	and	_	
32-21	6860-6870	facilities	_	
32-22	6870-6871	.	_	

#Text=Following informed consent procedures approved by the Medical University of South Carolina Institutional Review Board, participants completed screening assessments related to MRI and TMS protocol safety, mental status, and drug use to determine study eligibility (see Supplemental Methods for detailed inclusion/exclusion information).
33-1	6872-6881	Following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-2	6882-6890	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-3	6891-6898	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-4	6899-6909	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-5	6910-6918	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-6	6919-6921	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-7	6922-6925	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-8	6926-6933	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-9	6934-6944	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-10	6945-6947	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-11	6948-6953	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-12	6954-6962	Carolina	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-13	6963-6976	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-14	6977-6983	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-15	6984-6989	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-16	6989-6990	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-17	6991-7003	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-18	7004-7013	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-19	7014-7023	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-20	7024-7035	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-21	7036-7043	related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-22	7044-7046	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-23	7047-7050	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-24	7051-7054	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-25	7055-7058	TMS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-26	7059-7067	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-27	7068-7074	safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-28	7074-7075	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-29	7076-7082	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-30	7083-7089	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-31	7089-7090	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-32	7091-7094	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-33	7095-7099	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-34	7100-7103	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-35	7104-7106	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-36	7107-7116	determine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-37	7117-7122	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-38	7123-7134	eligibility	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-39	7135-7136	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-40	7136-7139	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-41	7140-7152	Supplemental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-42	7153-7160	Methods	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-43	7161-7164	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-44	7165-7173	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-45	7174-7183	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-46	7183-7184	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-47	7184-7193	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-48	7194-7205	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-49	7205-7206	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-50	7206-7207	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Eligible participants completed two MRI/rTMS visits (each ~1 hour).
34-1	7208-7216	Eligible	_	
34-2	7217-7229	participants	_	
34-3	7230-7239	completed	_	
34-4	7240-7243	two	_	
34-5	7244-7247	MRI	_	
34-6	7247-7248	/	_	
34-7	7248-7252	rTMS	_	
34-8	7253-7259	visits	_	
34-9	7260-7261	(	_	
34-10	7261-7265	each	_	
34-11	7266-7267	~	_	
34-12	7267-7268	1	_	
34-13	7269-7273	hour	_	
34-14	7273-7274	)	_	
34-15	7274-7275	.	_	

#Text=Before each study session, a multipanel urine drug screen (QuikVue 6-panel urine drug screen; Quidel, San Diego, CA) was given.
35-1	7276-7282	Before	_	
35-2	7283-7287	each	_	
35-3	7288-7293	study	_	
35-4	7294-7301	session	_	
35-5	7301-7302	,	_	
35-6	7303-7304	a	_	
35-7	7305-7315	multipanel	_	
35-8	7316-7321	urine	_	
35-9	7322-7326	drug	_	
35-10	7327-7333	screen	_	
35-11	7334-7335	(	_	
35-12	7335-7342	QuikVue	_	
35-13	7343-7344	6	_	
35-14	7344-7345	-	_	
35-15	7345-7350	panel	_	
35-16	7351-7356	urine	_	
35-17	7357-7361	drug	_	
35-18	7362-7368	screen	_	
35-19	7368-7369	;	_	
35-20	7370-7376	Quidel	_	
35-21	7376-7377	,	_	
35-22	7378-7381	San	_	
35-23	7382-7387	Diego	_	
35-24	7387-7388	,	_	
35-25	7389-7391	CA	_	
35-26	7391-7392	)	_	
35-27	7393-7396	was	_	
35-28	7397-7402	given	_	
35-29	7402-7403	.	_	

#Text=Participants were told ahead of time that if they had positive urine drug screen for (meth) amphetamine, opiates, marijuana, or benzodiazepines they would not be eligible to participate on that day and that they would have one opportunity to reschedule.
36-1	7404-7416	Participants	_	
36-2	7417-7421	were	_	
36-3	7422-7426	told	_	
36-4	7427-7432	ahead	_	
36-5	7433-7435	of	_	
36-6	7436-7440	time	_	
36-7	7441-7445	that	_	
36-8	7446-7448	if	_	
36-9	7449-7453	they	_	
36-10	7454-7457	had	_	
36-11	7458-7466	positive	_	
36-12	7467-7472	urine	_	
36-13	7473-7477	drug	_	
36-14	7478-7484	screen	_	
36-15	7485-7488	for	_	
36-16	7489-7490	(	_	
36-17	7490-7494	meth	_	
36-18	7494-7495	)	_	
36-19	7496-7507	amphetamine	_	
36-20	7507-7508	,	_	
36-21	7509-7516	opiates	_	
36-22	7516-7517	,	_	
36-23	7518-7527	marijuana	_	
36-24	7527-7528	,	_	
36-25	7529-7531	or	_	
36-26	7532-7547	benzodiazepines	_	
36-27	7548-7552	they	_	
36-28	7553-7558	would	_	
36-29	7559-7562	not	_	
36-30	7563-7565	be	_	
36-31	7566-7574	eligible	_	
36-32	7575-7577	to	_	
36-33	7578-7589	participate	_	
36-34	7590-7592	on	_	
36-35	7593-7597	that	_	
36-36	7598-7601	day	_	
36-37	7602-7605	and	_	
36-38	7606-7610	that	_	
36-39	7611-7615	they	_	
36-40	7616-7621	would	_	
36-41	7622-7626	have	_	
36-42	7627-7630	one	_	
36-43	7631-7642	opportunity	_	
36-44	7643-7645	to	_	
36-45	7646-7656	reschedule	_	
36-46	7656-7657	.	_	

#Text=In this study, none of the participants had to reschedule for a positive urine drug screen.
37-1	7658-7660	In	_	
37-2	7661-7665	this	_	
37-3	7666-7671	study	_	
37-4	7671-7672	,	_	
37-5	7673-7677	none	_	
37-6	7678-7680	of	_	
37-7	7681-7684	the	_	
37-8	7685-7697	participants	_	
37-9	7698-7701	had	_	
37-10	7702-7704	to	_	
37-11	7705-7715	reschedule	_	
37-12	7716-7719	for	_	
37-13	7720-7721	a	_	
37-14	7722-7730	positive	_	
37-15	7731-7736	urine	_	
37-16	7737-7741	drug	_	
37-17	7742-7748	screen	_	
37-18	7748-7749	.	_	

#Text=All participants received both real and sham VMPFC cTBS (one type per session) and were counterbalanced for the order in which they received stimulation (Fp1 landmark based on the International 10–20 system; 110% resting motor threshold [rMT]; six sessions of cTBS for each visit; 3600 pulses total, with a 60-second break after the first 1800 pulses).
38-1	7750-7753	All	_	
38-2	7754-7766	participants	_	
38-3	7767-7775	received	_	
38-4	7776-7780	both	_	
38-5	7781-7785	real	_	
38-6	7786-7789	and	_	
38-7	7790-7794	sham	_	
38-8	7795-7800	VMPFC	_	
38-9	7801-7805	cTBS	_	
38-10	7806-7807	(	_	
38-11	7807-7810	one	_	
38-12	7811-7815	type	_	
38-13	7816-7819	per	_	
38-14	7820-7827	session	_	
38-15	7827-7828	)	_	
38-16	7829-7832	and	_	
38-17	7833-7837	were	_	
38-18	7838-7853	counterbalanced	_	
38-19	7854-7857	for	_	
38-20	7858-7861	the	_	
38-21	7862-7867	order	_	
38-22	7868-7870	in	_	
38-23	7871-7876	which	_	
38-24	7877-7881	they	_	
38-25	7882-7890	received	_	
38-26	7891-7902	stimulation	_	
38-27	7903-7904	(	_	
38-28	7904-7907	Fp1	_	
38-29	7908-7916	landmark	_	
38-30	7917-7922	based	_	
38-31	7923-7925	on	_	
38-32	7926-7929	the	_	
38-33	7930-7943	International	_	
38-34	7944-7946	10	_	
38-35	7946-7947	–	_	
38-36	7947-7949	20	_	
38-37	7950-7956	system	_	
38-38	7956-7957	;	_	
38-39	7958-7962	110%	_	
38-40	7963-7970	resting	_	
38-41	7971-7976	motor	_	
38-42	7977-7986	threshold	_	
38-43	7987-7988	[	_	
38-44	7988-7991	rMT	_	
38-45	7991-7992	]	_	
38-46	7992-7993	;	_	
38-47	7994-7997	six	_	
38-48	7998-8006	sessions	_	
38-49	8007-8009	of	_	
38-50	8010-8014	cTBS	_	
38-51	8015-8018	for	_	
38-52	8019-8023	each	_	
38-53	8024-8029	visit	_	
38-54	8029-8030	;	_	
38-55	8031-8035	3600	_	
38-56	8036-8042	pulses	_	
38-57	8043-8048	total	_	
38-58	8048-8049	,	_	
38-59	8050-8054	with	_	
38-60	8055-8056	a	_	
38-61	8057-8059	60	_	
38-62	8059-8060	-	_	
38-63	8060-8066	second	_	
38-64	8067-8072	break	_	
38-65	8073-8078	after	_	
38-66	8079-8082	the	_	
38-67	8083-8088	first	_	
38-68	8089-8093	1800	_	
38-69	8094-8100	pulses	_	
38-70	8100-8101	)	_	
38-71	8101-8102	.	_	

#Text=Visit 2 occurred between 7 and 14 days after visit 1. fMRI drug/alcohol cue reactivity task data were collected immediately before and after cTBS stimulation (Figure 1), with the fMRI scan initiated within 20 minutes of receiving real or sham cTBS and completed no later than 40 minutes after cTBS to maximize presumed effects of cTBS on cortical activity.
39-1	8103-8108	Visit	_	
39-2	8109-8110	2	_	
39-3	8111-8119	occurred	_	
39-4	8120-8127	between	_	
39-5	8128-8129	7	_	
39-6	8130-8133	and	_	
39-7	8134-8136	14	_	
39-8	8137-8141	days	_	
39-9	8142-8147	after	_	
39-10	8148-8153	visit	_	
39-11	8154-8155	1	_	
39-12	8155-8156	.	_	
39-13	8157-8161	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
39-14	8162-8166	drug	_	
39-15	8166-8167	/	_	
39-16	8167-8174	alcohol	_	
39-17	8175-8178	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
39-18	8179-8189	reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
39-19	8190-8194	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
39-20	8195-8199	data	_	
39-21	8200-8204	were	_	
39-22	8205-8214	collected	_	
39-23	8215-8226	immediately	_	
39-24	8227-8233	before	_	
39-25	8234-8237	and	_	
39-26	8238-8243	after	_	
39-27	8244-8248	cTBS	_	
39-28	8249-8260	stimulation	_	
39-29	8261-8262	(	_	
39-30	8262-8268	Figure	_	
39-31	8269-8270	1	_	
39-32	8270-8271	)	_	
39-33	8271-8272	,	_	
39-34	8273-8277	with	_	
39-35	8278-8281	the	_	
39-36	8282-8286	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
39-37	8287-8291	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
39-38	8292-8301	initiated	_	
39-39	8302-8308	within	_	
39-40	8309-8311	20	_	
39-41	8312-8319	minutes	_	
39-42	8320-8322	of	_	
39-43	8323-8332	receiving	_	
39-44	8333-8337	real	_	
39-45	8338-8340	or	_	
39-46	8341-8345	sham	_	
39-47	8346-8350	cTBS	_	
39-48	8351-8354	and	_	
39-49	8355-8364	completed	_	
39-50	8365-8367	no	_	
39-51	8368-8373	later	_	
39-52	8374-8378	than	_	
39-53	8379-8381	40	_	
39-54	8382-8389	minutes	_	
39-55	8390-8395	after	_	
39-56	8396-8400	cTBS	_	
39-57	8401-8403	to	_	
39-58	8404-8412	maximize	_	
39-59	8413-8421	presumed	_	
39-60	8422-8429	effects	_	
39-61	8430-8432	of	_	
39-62	8433-8437	cTBS	_	
39-63	8438-8440	on	_	
39-64	8441-8449	cortical	_	
39-65	8450-8458	activity	_	
39-66	8458-8459	.	_	

#Text=Self-reported cocaine or alcohol craving (respectively) was assessed at five time points: upon visit initiation, before the baseline fMRI scan, before the cTBS session, immediately after cTBS, and after the second fMRI scan.
40-1	8460-8473	Self-reported	_	
40-2	8474-8481	cocaine	_	
40-3	8482-8484	or	_	
40-4	8485-8492	alcohol	_	
40-5	8493-8500	craving	_	
40-6	8501-8502	(	_	
40-7	8502-8514	respectively	_	
40-8	8514-8515	)	_	
40-9	8516-8519	was	_	
40-10	8520-8528	assessed	_	
40-11	8529-8531	at	_	
40-12	8532-8536	five	_	
40-13	8537-8541	time	_	
40-14	8542-8548	points	_	
40-15	8548-8549	:	_	
40-16	8550-8554	upon	_	
40-17	8555-8560	visit	_	
40-18	8561-8571	initiation	_	
40-19	8571-8572	,	_	
40-20	8573-8579	before	_	
40-21	8580-8583	the	_	
40-22	8584-8592	baseline	_	
40-23	8593-8597	fMRI	_	
40-24	8598-8602	scan	_	
40-25	8602-8603	,	_	
40-26	8604-8610	before	_	
40-27	8611-8614	the	_	
40-28	8615-8619	cTBS	_	
40-29	8620-8627	session	_	
40-30	8627-8628	,	_	
40-31	8629-8640	immediately	_	
40-32	8641-8646	after	_	
40-33	8647-8651	cTBS	_	
40-34	8651-8652	,	_	
40-35	8653-8656	and	_	
40-36	8657-8662	after	_	
40-37	8663-8666	the	_	
40-38	8667-8673	second	_	
40-39	8674-8678	fMRI	_	
40-40	8679-8683	scan	_	
40-41	8683-8684	.	_	

#Text=Procedures: Clinical Assessments.
41-1	8685-8695	Procedures	_	
41-2	8695-8696	:	_	
41-3	8697-8705	Clinical	_	
41-4	8706-8717	Assessments	_	
41-5	8717-8718	.	_	

#Text=Self-report assessments included the Structured Clinical Interview for DSM-IV, Timeline Followback [for cocaine, alcohol, marijuana, and nicotine ], Alcohol Use Disorders Identification Test, Fagerström Smoking Inventory, Beck Depression Inventory-II, and State-Trait Anxiety Inventory.
42-1	8719-8730	Self-report	_	
42-2	8731-8742	assessments	_	
42-3	8743-8751	included	_	
42-4	8752-8755	the	_	
42-5	8756-8766	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
42-6	8767-8775	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
42-7	8776-8785	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
42-8	8786-8789	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
42-9	8790-8796	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
42-10	8796-8797	,	_	
42-11	8798-8806	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-12	8807-8817	Followback	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-13	8818-8819	[	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-14	8819-8822	for	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-15	8823-8830	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-16	8830-8831	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-17	8832-8839	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-18	8839-8840	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-19	8841-8850	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-20	8850-8851	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-21	8852-8855	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-22	8856-8864	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-23	8865-8866	]	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[23]	
42-24	8866-8867	,	_	
42-25	8868-8875	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[24]	
42-26	8876-8879	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[24]	
42-27	8880-8889	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[24]	
42-28	8890-8904	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[24]	
42-29	8905-8909	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[24]	
42-30	8909-8910	,	_	
42-31	8911-8921	Fagerström	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[25]	
42-32	8922-8929	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[25]	
42-33	8930-8939	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[25]	
42-34	8939-8940	,	_	
42-35	8941-8945	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[26]	
42-36	8946-8956	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[26]	
42-37	8957-8969	Inventory-II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[26]	
42-38	8969-8970	,	_	
42-39	8971-8974	and	_	
42-40	8975-8986	State-Trait	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[27]	
42-41	8987-8994	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[27]	
42-42	8995-9004	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[27]	
42-43	9004-9005	.	_	

#Text=Timeline Followback was used to evaluate past week’s substance use at all study visits.
43-1	9006-9014	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
43-2	9015-9025	Followback	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
43-3	9026-9029	was	_	
43-4	9030-9034	used	_	
43-5	9035-9037	to	_	
43-6	9038-9046	evaluate	_	
43-7	9047-9051	past	_	
43-8	9052-9056	week	_	
43-9	9056-9057	’	_	
43-10	9057-9058	s	_	
43-11	9059-9068	substance	_	
43-12	9069-9072	use	_	
43-13	9073-9075	at	_	
43-14	9076-9079	all	_	
43-15	9080-9085	study	_	
43-16	9086-9092	visits	_	
43-17	9092-9093	.	_	

#Text=As typically done in cue-induced craving studies, study personnel ensured that craving levels were at or below baseline before participants were dismissed from each visit.
44-1	9094-9096	As	_	
44-2	9097-9106	typically	_	
44-3	9107-9111	done	_	
44-4	9112-9114	in	_	
44-5	9115-9126	cue-induced	_	
44-6	9127-9134	craving	_	
44-7	9135-9142	studies	_	
44-8	9142-9143	,	_	
44-9	9144-9149	study	_	
44-10	9150-9159	personnel	_	
44-11	9160-9167	ensured	_	
44-12	9168-9172	that	_	
44-13	9173-9180	craving	_	
44-14	9181-9187	levels	_	
44-15	9188-9192	were	_	
44-16	9193-9195	at	_	
44-17	9196-9198	or	_	
44-18	9199-9204	below	_	
44-19	9205-9213	baseline	_	
44-20	9214-9220	before	_	
44-21	9221-9233	participants	_	
44-22	9234-9238	were	_	
44-23	9239-9248	dismissed	_	
44-24	9249-9253	from	_	
44-25	9254-9258	each	_	
44-26	9259-9264	visit	_	
44-27	9264-9265	.	_	

#Text=Procedures: Drug/Alcohol Cue Reactivity fMRI Task.
45-1	9266-9276	Procedures	_	
45-2	9276-9277	:	_	
45-3	9278-9282	Drug	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]	
45-4	9282-9283	/	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]	
45-5	9283-9290	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]	
45-6	9291-9294	Cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]	
45-7	9295-9305	Reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]	
45-8	9306-9310	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
45-9	9311-9315	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]	
45-10	9315-9316	.	_	

#Text=The drug/alcohol cue reactivity task that has been used by our group in the past was administered in the MRI scanner as a block design using E-Prime 2 software (Psychology Software Tools, Inc., Sharpsburg, PA).
46-1	9317-9320	The	_	
46-2	9321-9325	drug	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
46-3	9325-9326	/	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
46-4	9326-9333	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
46-5	9334-9337	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
46-6	9338-9348	reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
46-7	9349-9353	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
46-8	9354-9358	that	_	
46-9	9359-9362	has	_	
46-10	9363-9367	been	_	
46-11	9368-9372	used	_	
46-12	9373-9375	by	_	
46-13	9376-9379	our	_	
46-14	9380-9385	group	_	
46-15	9386-9388	in	_	
46-16	9389-9392	the	_	
46-17	9393-9397	past	_	
46-18	9398-9401	was	_	
46-19	9402-9414	administered	_	
46-20	9415-9417	in	_	
46-21	9418-9421	the	_	
46-22	9422-9425	MRI	_	
46-23	9426-9433	scanner	_	
46-24	9434-9436	as	_	
46-25	9437-9438	a	_	
46-26	9439-9444	block	_	
46-27	9445-9451	design	_	
46-28	9452-9457	using	_	
46-29	9458-9465	E-Prime	_	
46-30	9466-9467	2	_	
46-31	9468-9476	software	_	
46-32	9477-9478	(	_	
46-33	9478-9488	Psychology	_	
46-34	9489-9497	Software	_	
46-35	9498-9503	Tools	_	
46-36	9503-9504	,	_	
46-37	9505-9508	Inc	_	
46-38	9508-9509	.	_	
46-39	9509-9510	,	_	
46-40	9511-9521	Sharpsburg	_	
46-41	9521-9522	,	_	
46-42	9523-9525	PA	_	
46-43	9525-9526	)	_	
46-44	9526-9527	.	_	

#Text=The total task time was 12 minutes and consisted of six 120-second epochs.
47-1	9528-9531	The	_	
47-2	9532-9537	total	_	
47-3	9538-9542	task	_	
47-4	9543-9547	time	_	
47-5	9548-9551	was	_	
47-6	9552-9554	12	_	
47-7	9555-9562	minutes	_	
47-8	9563-9566	and	_	
47-9	9567-9576	consisted	_	
47-10	9577-9579	of	_	
47-11	9580-9583	six	_	
47-12	9584-9587	120	_	
47-13	9587-9588	-	_	
47-14	9588-9594	second	_	
47-15	9595-9601	epochs	_	
47-16	9601-9602	.	_	

#Text=Each epoch included alternating 24-second blocks of four task conditions: drug, neutral, blur, and rest.
48-1	9603-9607	Each	_	
48-2	9608-9613	epoch	_	
48-3	9614-9622	included	_	
48-4	9623-9634	alternating	_	
48-5	9635-9637	24	_	
48-6	9637-9638	-	_	
48-7	9638-9644	second	_	
48-8	9645-9651	blocks	_	
48-9	9652-9654	of	_	
48-10	9655-9659	four	_	
48-11	9660-9664	task	_	
48-12	9665-9675	conditions	_	
48-13	9675-9676	:	_	
48-14	9677-9681	drug	_	
48-15	9681-9682	,	_	
48-16	9683-9690	neutral	_	
48-17	9690-9691	,	_	
48-18	9692-9696	blur	_	
48-19	9696-9697	,	_	
48-20	9698-9701	and	_	
48-21	9702-9706	rest	_	
48-22	9706-9707	.	_	

#Text=Respectively, these task conditions included images of cocaine- or alcohol-related stimuli customized for each group (e.g., crack pipe for cocaine users, liquor bottles for alcohol users), neutral stimuli (e.g., glass of water, cooking utensils, people eating dinner), blurred stimuli acting as visual controls by matching substance images in color and hue, and a fixation cross for alert rest periods.
49-1	9708-9720	Respectively	_	
49-2	9720-9721	,	_	
49-3	9722-9727	these	_	
49-4	9728-9732	task	_	
49-5	9733-9743	conditions	_	
49-6	9744-9752	included	_	
49-7	9753-9759	images	_	
49-8	9760-9762	of	_	
49-9	9763-9770	cocaine	_	
49-10	9770-9771	-	_	
49-11	9772-9774	or	_	
49-12	9775-9790	alcohol-related	_	
49-13	9791-9798	stimuli	_	
49-14	9799-9809	customized	_	
49-15	9810-9813	for	_	
49-16	9814-9818	each	_	
49-17	9819-9824	group	_	
49-18	9825-9826	(	_	
49-19	9826-9829	e.g	_	
49-20	9829-9830	.	_	
49-21	9830-9831	,	_	
49-22	9832-9837	crack	_	
49-23	9838-9842	pipe	_	
49-24	9843-9846	for	_	
49-25	9847-9854	cocaine	_	
49-26	9855-9860	users	_	
49-27	9860-9861	,	_	
49-28	9862-9868	liquor	_	
49-29	9869-9876	bottles	_	
49-30	9877-9880	for	_	
49-31	9881-9888	alcohol	_	
49-32	9889-9894	users	_	
49-33	9894-9895	)	_	
49-34	9895-9896	,	_	
49-35	9897-9904	neutral	_	
49-36	9905-9912	stimuli	_	
49-37	9913-9914	(	_	
49-38	9914-9917	e.g	_	
49-39	9917-9918	.	_	
49-40	9918-9919	,	_	
49-41	9920-9925	glass	_	
49-42	9926-9928	of	_	
49-43	9929-9934	water	_	
49-44	9934-9935	,	_	
49-45	9936-9943	cooking	_	
49-46	9944-9952	utensils	_	
49-47	9952-9953	,	_	
49-48	9954-9960	people	_	
49-49	9961-9967	eating	_	
49-50	9968-9974	dinner	_	
49-51	9974-9975	)	_	
49-52	9975-9976	,	_	
49-53	9977-9984	blurred	_	
49-54	9985-9992	stimuli	_	
49-55	9993-9999	acting	_	
49-56	10000-10002	as	_	
49-57	10003-10009	visual	_	
49-58	10010-10018	controls	_	
49-59	10019-10021	by	_	
49-60	10022-10030	matching	_	
49-61	10031-10040	substance	_	
49-62	10041-10047	images	_	
49-63	10048-10050	in	_	
49-64	10051-10056	color	_	
49-65	10057-10060	and	_	
49-66	10061-10064	hue	_	
49-67	10064-10065	,	_	
49-68	10066-10069	and	_	
49-69	10070-10071	a	_	
49-70	10072-10080	fixation	_	
49-71	10081-10086	cross	_	
49-72	10087-10090	for	_	
49-73	10091-10096	alert	_	
49-74	10097-10101	rest	_	
49-75	10102-10109	periods	_	
49-76	10109-10110	.	_	

#Text=During each task block, five images were presented (4.8 seconds).
50-1	10111-10117	During	_	
50-2	10118-10122	each	_	
50-3	10123-10127	task	_	
50-4	10128-10133	block	_	
50-5	10133-10134	,	_	
50-6	10135-10139	five	_	
50-7	10140-10146	images	_	
50-8	10147-10151	were	_	
50-9	10152-10161	presented	_	
50-10	10162-10163	(	_	
50-11	10163-10166	4.8	_	
50-12	10167-10174	seconds	_	
50-13	10174-10175	)	_	
50-14	10175-10176	.	_	

#Text=Procedures: Neuroimaging Acquisition.
51-1	10177-10187	Procedures	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[32]	
51-2	10187-10188	:	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[32]	
51-3	10189-10201	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[32]	
51-4	10202-10213	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[32]	
51-5	10213-10214	.	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[32]	

#Text=Participants were scanned using a Siemens 3.0T TIM Trio (Siemens Corp., Erlangen, Germany) MRI scanner with a 32-channel head coil.
52-1	10215-10227	Participants	_	
52-2	10228-10232	were	_	
52-3	10233-10240	scanned	_	
52-4	10241-10246	using	_	
52-5	10247-10248	a	_	
52-6	10249-10256	Siemens	_	
52-7	10257-10261	3.0T	_	
52-8	10262-10265	TIM	_	
52-9	10266-10270	Trio	_	
52-10	10271-10272	(	_	
52-11	10272-10279	Siemens	_	
52-12	10280-10284	Corp	_	
52-13	10284-10285	.	_	
52-14	10285-10286	,	_	
52-15	10287-10295	Erlangen	_	
52-16	10295-10296	,	_	
52-17	10297-10304	Germany	_	
52-18	10304-10305	)	_	
52-19	10306-10309	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[33]	
52-20	10310-10317	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[33]	
52-21	10318-10322	with	_	
52-22	10323-10324	a	_	
52-23	10325-10327	32	_	
52-24	10327-10328	-	_	
52-25	10328-10335	channel	_	
52-26	10336-10340	head	_	
52-27	10341-10345	coil	_	
52-28	10345-10346	.	_	

#Text=High-resolution T1-weighted structural images were acquired using a magnetization prepared rapid acquisition gradient-echo sequence (repetition time/echo time = 1900 ms/2.34 ms; field of view = 220 mm; matrix = 256 × 256 voxels; 192 slices; slice thickness = 1.0 mm with no gap; final resolution = 1-mm3 voxels).
53-1	10347-10362	High-resolution	_	
53-2	10363-10365	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
53-3	10365-10366	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
53-4	10366-10374	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
53-5	10375-10385	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
53-6	10386-10392	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
53-7	10393-10397	were	_	
53-8	10398-10406	acquired	_	
53-9	10407-10412	using	_	
53-10	10413-10414	a	_	
53-11	10415-10428	magnetization	_	
53-12	10429-10437	prepared	_	
53-13	10438-10443	rapid	_	
53-14	10444-10455	acquisition	_	
53-15	10456-10469	gradient-echo	_	
53-16	10470-10478	sequence	_	
53-17	10479-10480	(	_	
53-18	10480-10490	repetition	_	
53-19	10491-10495	time	_	
53-20	10495-10496	/	_	
53-21	10496-10500	echo	_	
53-22	10501-10505	time	_	
53-23	10506-10507	=	_	
53-24	10508-10512	1900	_	
53-25	10513-10515	ms	_	
53-26	10515-10516	/	_	
53-27	10516-10520	2.34	_	
53-28	10521-10523	ms	_	
53-29	10523-10524	;	_	
53-30	10525-10530	field	_	
53-31	10531-10533	of	_	
53-32	10534-10538	view	_	
53-33	10539-10540	=	_	
53-34	10541-10544	220	_	
53-35	10545-10547	mm	_	
53-36	10547-10548	;	_	
53-37	10549-10555	matrix	_	
53-38	10556-10557	=	_	
53-39	10558-10561	256	_	
53-40	10562-10563	×	_	
53-41	10564-10567	256	_	
53-42	10568-10574	voxels	_	
53-43	10574-10575	;	_	
53-44	10576-10579	192	_	
53-45	10580-10586	slices	_	
53-46	10586-10587	;	_	
53-47	10588-10593	slice	_	
53-48	10594-10603	thickness	_	
53-49	10604-10605	=	_	
53-50	10606-10609	1.0	_	
53-51	10610-10612	mm	_	
53-52	10613-10617	with	_	
53-53	10618-10620	no	_	
53-54	10621-10624	gap	_	
53-55	10624-10625	;	_	
53-56	10626-10631	final	_	
53-57	10632-10642	resolution	_	
53-58	10643-10644	=	_	
53-59	10645-10646	1	_	
53-60	10646-10647	-	_	
53-61	10647-10650	mm3	_	
53-62	10651-10657	voxels	_	
53-63	10657-10658	)	_	
53-64	10658-10659	.	_	

#Text=Functional images were acquired with a multislice gradient-echo echo-planar imaging (EPI) sequence (repetition time/echo time = 2200 ms/35 ms; field of view = 192 mm; matrix = 64 × 64 voxels; 36 slices; slice thickness = 3 mm with no gap; final resolution = 3 mm3 voxels).
54-1	10660-10670	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-2	10671-10677	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-3	10678-10682	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-4	10683-10691	acquired	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-5	10692-10696	with	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-6	10697-10698	a	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-7	10699-10709	multislice	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-8	10710-10723	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-9	10724-10735	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-10	10736-10743	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-11	10744-10745	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-12	10745-10748	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-13	10748-10749	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-14	10750-10758	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
54-15	10759-10760	(	_	
54-16	10760-10770	repetition	_	
54-17	10771-10775	time	_	
54-18	10775-10776	/	_	
54-19	10776-10780	echo	_	
54-20	10781-10785	time	_	
54-21	10786-10787	=	_	
54-22	10788-10792	2200	_	
54-23	10793-10795	ms	_	
54-24	10795-10796	/	_	
54-25	10796-10798	35	_	
54-26	10799-10801	ms	_	
54-27	10801-10802	;	_	
54-28	10803-10808	field	_	
54-29	10809-10811	of	_	
54-30	10812-10816	view	_	
54-31	10817-10818	=	_	
54-32	10819-10822	192	_	
54-33	10823-10825	mm	_	
54-34	10825-10826	;	_	
54-35	10827-10833	matrix	_	
54-36	10834-10835	=	_	
54-37	10836-10838	64	_	
54-38	10839-10840	×	_	
54-39	10841-10843	64	_	
54-40	10844-10850	voxels	_	
54-41	10850-10851	;	_	
54-42	10852-10854	36	_	
54-43	10855-10861	slices	_	
54-44	10861-10862	;	_	
54-45	10863-10868	slice	_	
54-46	10869-10878	thickness	_	
54-47	10879-10880	=	_	
54-48	10881-10882	3	_	
54-49	10883-10885	mm	_	
54-50	10886-10890	with	_	
54-51	10891-10893	no	_	
54-52	10894-10897	gap	_	
54-53	10897-10898	;	_	
54-54	10899-10904	final	_	
54-55	10905-10915	resolution	_	
54-56	10916-10917	=	_	
54-57	10918-10919	3	_	
54-58	10920-10923	mm3	_	
54-59	10924-10930	voxels	_	
54-60	10930-10931	)	_	
54-61	10931-10932	.	_	

#Text=Each functional run consisted of 328 time points.
55-1	10933-10937	Each	_	
55-2	10938-10948	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
55-3	10949-10952	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
55-4	10953-10962	consisted	_	
55-5	10963-10965	of	_	
55-6	10966-10969	328	_	
55-7	10970-10974	time	_	
55-8	10975-10981	points	_	
55-9	10981-10982	.	_	

#Text=Procedures: cTBS Protocol—Real and Sham cTBS.
56-1	10983-10993	Procedures	_	
56-2	10993-10994	:	_	
56-3	10995-10999	cTBS	_	
56-4	11000-11013	Protocol—Real	_	
56-5	11014-11017	and	_	
56-6	11018-11022	Sham	_	
56-7	11023-11027	cTBS	_	
56-8	11027-11028	.	_	

#Text=Coil position was determined using standardized coordinates from the International 10–20 system (with Fp1 corresponding to the left VMPFC stimulation target).
57-1	11029-11033	Coil	_	
57-2	11034-11042	position	_	
57-3	11043-11046	was	_	
57-4	11047-11057	determined	_	
57-5	11058-11063	using	_	
57-6	11064-11076	standardized	_	
57-7	11077-11088	coordinates	_	
57-8	11089-11093	from	_	
57-9	11094-11097	the	_	
57-10	11098-11111	International	_	
57-11	11112-11114	10	_	
57-12	11114-11115	–	_	
57-13	11115-11117	20	_	
57-14	11118-11124	system	_	
57-15	11125-11126	(	_	
57-16	11126-11130	with	_	
57-17	11131-11134	Fp1	_	
57-18	11135-11148	corresponding	_	
57-19	11149-11151	to	_	
57-20	11152-11155	the	_	
57-21	11156-11160	left	_	
57-22	11161-11166	VMPFC	_	
57-23	11167-11178	stimulation	_	
57-24	11179-11185	target	_	
57-25	11185-11186	)	_	
57-26	11186-11187	.	_	

#Text=The location and orientation of each participant’s coil placement was indicated on a nylon cap that participants wore throughout visit 1 and both MRI/rTMS sessions.
58-1	11188-11191	The	_	
58-2	11192-11200	location	_	
58-3	11201-11204	and	_	
58-4	11205-11216	orientation	_	
58-5	11217-11219	of	_	
58-6	11220-11224	each	_	
58-7	11225-11236	participant	_	
58-8	11236-11237	’	_	
58-9	11237-11238	s	_	
58-10	11239-11243	coil	_	
58-11	11244-11253	placement	_	
58-12	11254-11257	was	_	
58-13	11258-11267	indicated	_	
58-14	11268-11270	on	_	
58-15	11271-11272	a	_	
58-16	11273-11278	nylon	_	
58-17	11279-11282	cap	_	
58-18	11283-11287	that	_	
58-19	11288-11300	participants	_	
58-20	11301-11305	wore	_	
58-21	11306-11316	throughout	_	
58-22	11317-11322	visit	_	
58-23	11323-11324	1	_	
58-24	11325-11328	and	_	
58-25	11329-11333	both	_	
58-26	11334-11337	MRI	_	
58-27	11337-11338	/	_	
58-28	11338-11342	rTMS	_	
58-29	11343-11351	sessions	_	
58-30	11351-11352	.	_	

#Text=Participants’ rMT was identified via the standardized Parametric Estimation by Sequential Testing procedure.
59-1	11353-11365	Participants	_	
59-2	11365-11366	’	_	
59-3	11367-11370	rMT	_	
59-4	11371-11374	was	_	
59-5	11375-11385	identified	_	
59-6	11386-11389	via	_	
59-7	11390-11393	the	_	
59-8	11394-11406	standardized	_	
59-9	11407-11417	Parametric	_	
59-10	11418-11428	Estimation	_	
59-11	11429-11431	by	_	
59-12	11432-11442	Sequential	_	
59-13	11443-11450	Testing	_	
59-14	11451-11460	procedure	_	
59-15	11460-11461	.	_	

#Text=The cTBS was administered with a figure-of-eight Cool-B65 A/P coil (MagVenture, Farum, Denmark).
60-1	11462-11465	The	_	
60-2	11466-11470	cTBS	_	
60-3	11471-11474	was	_	
60-4	11475-11487	administered	_	
60-5	11488-11492	with	_	
60-6	11493-11494	a	_	
60-7	11495-11510	figure-of-eight	_	
60-8	11511-11519	Cool-B65	_	
60-9	11520-11521	A	_	
60-10	11521-11522	/	_	
60-11	11522-11523	P	_	
60-12	11524-11528	coil	_	
60-13	11529-11530	(	_	
60-14	11530-11540	MagVenture	_	
60-15	11540-11541	,	_	
60-16	11542-11547	Farum	_	
60-17	11547-11548	,	_	
60-18	11549-11556	Denmark	_	
60-19	11556-11557	)	_	
60-20	11557-11558	.	_	

#Text=Participants received two 2-minute trains of cTBS over Fp1 (one train = 120 seconds; three pulse bursts at 5 Hz; 15 pulses/s; 1800 pulses/train; 60-second intertrain interval; 110% rMT) (see Supplemental Methods for details of rigorous active sham).
61-1	11559-11571	Participants	_	
61-2	11572-11580	received	_	
61-3	11581-11584	two	_	
61-4	11585-11586	2	_	
61-5	11586-11587	-	_	
61-6	11587-11593	minute	_	
61-7	11594-11600	trains	_	
61-8	11601-11603	of	_	
61-9	11604-11608	cTBS	_	
61-10	11609-11613	over	_	
61-11	11614-11617	Fp1	_	
61-12	11618-11619	(	_	
61-13	11619-11622	one	_	
61-14	11623-11628	train	_	
61-15	11629-11630	=	_	
61-16	11631-11634	120	_	
61-17	11635-11642	seconds	_	
61-18	11642-11643	;	_	
61-19	11644-11649	three	_	
61-20	11650-11655	pulse	_	
61-21	11656-11662	bursts	_	
61-22	11663-11665	at	_	
61-23	11666-11667	5	_	
61-24	11668-11670	Hz	_	
61-25	11670-11671	;	_	
61-26	11672-11674	15	_	
61-27	11675-11681	pulses	_	
61-28	11681-11682	/	_	
61-29	11682-11683	s	_	
61-30	11683-11684	;	_	
61-31	11685-11689	1800	_	
61-32	11690-11696	pulses	_	
61-33	11696-11697	/	_	
61-34	11697-11702	train	_	
61-35	11702-11703	;	_	
61-36	11704-11706	60	_	
61-37	11706-11707	-	_	
61-38	11707-11713	second	_	
61-39	11714-11724	intertrain	_	
61-40	11725-11733	interval	_	
61-41	11733-11734	;	_	
61-42	11735-11739	110%	_	
61-43	11740-11743	rMT	_	
61-44	11743-11744	)	_	
61-45	11745-11746	(	_	
61-46	11746-11749	see	_	
61-47	11750-11762	Supplemental	_	
61-48	11763-11770	Methods	_	
61-49	11771-11774	for	_	
61-50	11775-11782	details	_	
61-51	11783-11785	of	_	
61-52	11786-11794	rigorous	_	
61-53	11795-11801	active	_	
61-54	11802-11806	sham	_	
61-55	11806-11807	)	_	
61-56	11807-11808	.	_	

#Text=To enhance tolerability, stimulation intensity was gradually escalated in 5% increments (from 80% to 110% rMT) over the first 30 seconds of each train.
62-1	11809-11811	To	_	
62-2	11812-11819	enhance	_	
62-3	11820-11832	tolerability	_	
62-4	11832-11833	,	_	
62-5	11834-11845	stimulation	_	
62-6	11846-11855	intensity	_	
62-7	11856-11859	was	_	
62-8	11860-11869	gradually	_	
62-9	11870-11879	escalated	_	
62-10	11880-11882	in	_	
62-11	11883-11885	5%	_	
62-12	11886-11896	increments	_	
62-13	11897-11898	(	_	
62-14	11898-11902	from	_	
62-15	11903-11906	80%	_	
62-16	11907-11909	to	_	
62-17	11910-11914	110%	_	
62-18	11915-11918	rMT	_	
62-19	11918-11919	)	_	
62-20	11920-11924	over	_	
62-21	11925-11928	the	_	
62-22	11929-11934	first	_	
62-23	11935-11937	30	_	
62-24	11938-11945	seconds	_	
62-25	11946-11948	of	_	
62-26	11949-11953	each	_	
62-27	11954-11959	train	_	
62-28	11959-11960	.	_	

#Text=Procedures: Cue Recollection During cTBS Administration.
63-1	11961-11971	Procedures	_	
63-2	11971-11972	:	_	
63-3	11973-11976	Cue	_	
63-4	11977-11989	Recollection	_	
63-5	11990-11996	During	_	
63-6	11997-12001	cTBS	_	
63-7	12002-12016	Administration	_	
63-8	12016-12017	.	_	

#Text=Before cTBS administration, participants were asked to recall the last time they used cocaine or alcohol (respectively) and, using a series of standardized questions from traditional Narrative Exposure Therapy practice, they were asked to describe the place they were using, a visual description of the scene, and a description of the sensory properties of the drug including taste, smell, and sensation.
64-1	12018-12024	Before	_	
64-2	12025-12029	cTBS	_	
64-3	12030-12044	administration	_	
64-4	12044-12045	,	_	
64-5	12046-12058	participants	_	
64-6	12059-12063	were	_	
64-7	12064-12069	asked	_	
64-8	12070-12072	to	_	
64-9	12073-12079	recall	_	
64-10	12080-12083	the	_	
64-11	12084-12088	last	_	
64-12	12089-12093	time	_	
64-13	12094-12098	they	_	
64-14	12099-12103	used	_	
64-15	12104-12111	cocaine	_	
64-16	12112-12114	or	_	
64-17	12115-12122	alcohol	_	
64-18	12123-12124	(	_	
64-19	12124-12136	respectively	_	
64-20	12136-12137	)	_	
64-21	12138-12141	and	_	
64-22	12141-12142	,	_	
64-23	12143-12148	using	_	
64-24	12149-12150	a	_	
64-25	12151-12157	series	_	
64-26	12158-12160	of	_	
64-27	12161-12173	standardized	_	
64-28	12174-12183	questions	_	
64-29	12184-12188	from	_	
64-30	12189-12200	traditional	_	
64-31	12201-12210	Narrative	_	
64-32	12211-12219	Exposure	_	
64-33	12220-12227	Therapy	_	
64-34	12228-12236	practice	_	
64-35	12236-12237	,	_	
64-36	12238-12242	they	_	
64-37	12243-12247	were	_	
64-38	12248-12253	asked	_	
64-39	12254-12256	to	_	
64-40	12257-12265	describe	_	
64-41	12266-12269	the	_	
64-42	12270-12275	place	_	
64-43	12276-12280	they	_	
64-44	12281-12285	were	_	
64-45	12286-12291	using	_	
64-46	12291-12292	,	_	
64-47	12293-12294	a	_	
64-48	12295-12301	visual	_	
64-49	12302-12313	description	_	
64-50	12314-12316	of	_	
64-51	12317-12320	the	_	
64-52	12321-12326	scene	_	
64-53	12326-12327	,	_	
64-54	12328-12331	and	_	
64-55	12332-12333	a	_	
64-56	12334-12345	description	_	
64-57	12346-12348	of	_	
64-58	12349-12352	the	_	
64-59	12353-12360	sensory	_	
64-60	12361-12371	properties	_	
64-61	12372-12374	of	_	
64-62	12375-12378	the	_	
64-63	12379-12383	drug	_	
64-64	12384-12393	including	_	
64-65	12394-12399	taste	_	
64-66	12399-12400	,	_	
64-67	12401-12406	smell	_	
64-68	12406-12407	,	_	
64-69	12408-12411	and	_	
64-70	12412-12421	sensation	_	
64-71	12421-12422	.	_	

#Text=During cTBS administration, the participants were primed every 20 seconds to “Think about that scene you described wherein you were last using cocaine/alcohol” (paraphrased so as to be tailored to the participant’s description).
65-1	12423-12429	During	_	
65-2	12430-12434	cTBS	_	
65-3	12435-12449	administration	_	
65-4	12449-12450	,	_	
65-5	12451-12454	the	_	
65-6	12455-12467	participants	_	
65-7	12468-12472	were	_	
65-8	12473-12479	primed	_	
65-9	12480-12485	every	_	
65-10	12486-12488	20	_	
65-11	12489-12496	seconds	_	
65-12	12497-12499	to	_	
65-13	12500-12501	“	_	
65-14	12501-12506	Think	_	
65-15	12507-12512	about	_	
65-16	12513-12517	that	_	
65-17	12518-12523	scene	_	
65-18	12524-12527	you	_	
65-19	12528-12537	described	_	
65-20	12538-12545	wherein	_	
65-21	12546-12549	you	_	
65-22	12550-12554	were	_	
65-23	12555-12559	last	_	
65-24	12560-12565	using	_	
65-25	12566-12573	cocaine	_	
65-26	12573-12574	/	_	
65-27	12574-12581	alcohol	_	
65-28	12581-12582	”	_	
65-29	12583-12584	(	_	
65-30	12584-12595	paraphrased	_	
65-31	12596-12598	so	_	
65-32	12599-12601	as	_	
65-33	12602-12604	to	_	
65-34	12605-12607	be	_	
65-35	12608-12616	tailored	_	
65-36	12617-12619	to	_	
65-37	12620-12623	the	_	
65-38	12624-12635	participant	_	
65-39	12635-12636	’	_	
65-40	12636-12637	s	_	
65-41	12638-12649	description	_	
65-42	12649-12650	)	_	
65-43	12650-12651	.	_	

#Text=Data Analysis
#Text=Self-reported Craving.
66-1	12652-12656	Data	_	
66-2	12657-12665	Analysis	_	
66-3	12666-12679	Self-reported	_	
66-4	12680-12687	Craving	_	
66-5	12687-12688	.	_	

#Text=Self-reported craving scores were entered into a two-way analysis of variance (ANOVA) (treatment type [real/sham] × time [pre/post]) and subsequent t tests to determine the effect of treatment on changes in craving.
67-1	12689-12702	Self-reported	_	
67-2	12703-12710	craving	_	
67-3	12711-12717	scores	_	
67-4	12718-12722	were	_	
67-5	12723-12730	entered	_	
67-6	12731-12735	into	_	
67-7	12736-12737	a	_	
67-8	12738-12745	two-way	_	
67-9	12746-12754	analysis	_	
67-10	12755-12757	of	_	
67-11	12758-12766	variance	_	
67-12	12767-12768	(	_	
67-13	12768-12773	ANOVA	_	
67-14	12773-12774	)	_	
67-15	12775-12776	(	_	
67-16	12776-12785	treatment	_	
67-17	12786-12790	type	_	
67-18	12791-12792	[	_	
67-19	12792-12796	real	_	
67-20	12796-12797	/	_	
67-21	12797-12801	sham	_	
67-22	12801-12802	]	_	
67-23	12803-12804	×	_	
67-24	12805-12809	time	_	
67-25	12810-12811	[	_	
67-26	12811-12814	pre	_	
67-27	12814-12815	/	_	
67-28	12815-12819	post	_	
67-29	12819-12820	]	_	
67-30	12820-12821	)	_	
67-31	12822-12825	and	_	
67-32	12826-12836	subsequent	_	
67-33	12837-12838	t	_	
67-34	12839-12844	tests	_	
67-35	12845-12847	to	_	
67-36	12848-12857	determine	_	
67-37	12858-12861	the	_	
67-38	12862-12868	effect	_	
67-39	12869-12871	of	_	
67-40	12872-12881	treatment	_	
67-41	12882-12884	on	_	
67-42	12885-12892	changes	_	
67-43	12893-12895	in	_	
67-44	12896-12903	craving	_	
67-45	12903-12904	.	_	

#Text=Neuroimaging Preprocessing.
68-1	12905-12917	Neuroimaging	_	
68-2	12918-12931	Preprocessing	_	
68-3	12931-12932	.	_	

#Text=MRI data were preprocessed using standard protocols via SPM12 (Wellcome Department of Cognitive Neurology, London, United Kingdom) implemented in MATLAB 7.14 (The MathWorks, Inc., Natick, MA) (see Supplemental Methods for preprocessing details).
69-1	12933-12936	MRI	_	
69-2	12937-12941	data	_	
69-3	12942-12946	were	_	
69-4	12947-12959	preprocessed	_	
69-5	12960-12965	using	_	
69-6	12966-12974	standard	_	
69-7	12975-12984	protocols	_	
69-8	12985-12988	via	_	
69-9	12989-12994	SPM12	_	
69-10	12995-12996	(	_	
69-11	12996-13004	Wellcome	_	
69-12	13005-13015	Department	_	
69-13	13016-13018	of	_	
69-14	13019-13028	Cognitive	_	
69-15	13029-13038	Neurology	_	
69-16	13038-13039	,	_	
69-17	13040-13046	London	_	
69-18	13046-13047	,	_	
69-19	13048-13054	United	_	
69-20	13055-13062	Kingdom	_	
69-21	13062-13063	)	_	
69-22	13064-13075	implemented	_	
69-23	13076-13078	in	_	
69-24	13079-13085	MATLAB	_	
69-25	13086-13090	7.14	_	
69-26	13091-13092	(	_	
69-27	13092-13095	The	_	
69-28	13096-13105	MathWorks	_	
69-29	13105-13106	,	_	
69-30	13107-13110	Inc	_	
69-31	13110-13111	.	_	
69-32	13111-13112	,	_	
69-33	13113-13119	Natick	_	
69-34	13119-13120	,	_	
69-35	13121-13123	MA	_	
69-36	13123-13124	)	_	
69-37	13125-13126	(	_	
69-38	13126-13129	see	_	
69-39	13130-13142	Supplemental	_	
69-40	13143-13150	Methods	_	
69-41	13151-13154	for	_	
69-42	13155-13168	preprocessing	_	
69-43	13169-13176	details	_	
69-44	13176-13177	)	_	
69-45	13177-13178	.	_	

#Text=Data analyses were conducted on a total of 49 participants (30 men; mean age = 34 ± 11 years; age range = 21–54 years) (see Table 1 for detailed demographics).
70-1	13179-13183	Data	_	
70-2	13184-13192	analyses	_	
70-3	13193-13197	were	_	
70-4	13198-13207	conducted	_	
70-5	13208-13210	on	_	
70-6	13211-13212	a	_	
70-7	13213-13218	total	_	
70-8	13219-13221	of	_	
70-9	13222-13224	49	_	
70-10	13225-13237	participants	_	
70-11	13238-13239	(	_	
70-12	13239-13241	30	_	
70-13	13242-13245	men	_	
70-14	13245-13246	;	_	
70-15	13247-13251	mean	_	
70-16	13252-13255	age	_	
70-17	13256-13257	=	_	
70-18	13258-13260	34	_	
70-19	13261-13262	±	_	
70-20	13263-13265	11	_	
70-21	13266-13271	years	_	
70-22	13271-13272	;	_	
70-23	13273-13276	age	_	
70-24	13277-13282	range	_	
70-25	13283-13284	=	_	
70-26	13285-13287	21	_	
70-27	13287-13288	–	_	
70-28	13288-13290	54	_	
70-29	13291-13296	years	_	
70-30	13296-13297	)	_	
70-31	13298-13299	(	_	
70-32	13299-13302	see	_	
70-33	13303-13308	Table	_	
70-34	13309-13310	1	_	
70-35	13311-13314	for	_	
70-36	13315-13323	detailed	_	
70-37	13324-13336	demographics	_	
70-38	13336-13337	)	_	
70-39	13337-13338	.	_	

#Text=Generalized Psychophysiological Interaction.
71-1	13339-13350	Generalized	_	
71-2	13351-13370	Psychophysiological	_	
71-3	13371-13382	Interaction	_	
71-4	13382-13383	.	_	

#Text=Generalized psychophysiological interaction (gPPI) was used to investigate task-modulated patterns of FC between the VMPFC and eight regions of interest (ROIs) during the drug/alcohol cue reactivity task. gPPI was conducted as described by McLaren et al.
72-1	13384-13395	Generalized	_	
72-2	13396-13415	psychophysiological	_	
72-3	13416-13427	interaction	_	
72-4	13428-13429	(	_	
72-5	13429-13433	gPPI	_	
72-6	13433-13434	)	_	
72-7	13435-13438	was	_	
72-8	13439-13443	used	_	
72-9	13444-13446	to	_	
72-10	13447-13458	investigate	_	
72-11	13459-13473	task-modulated	_	
72-12	13474-13482	patterns	_	
72-13	13483-13485	of	_	
72-14	13486-13488	FC	_	
72-15	13489-13496	between	_	
72-16	13497-13500	the	_	
72-17	13501-13506	VMPFC	_	
72-18	13507-13510	and	_	
72-19	13511-13516	eight	_	
72-20	13517-13524	regions	_	
72-21	13525-13527	of	_	
72-22	13528-13536	interest	_	
72-23	13537-13538	(	_	
72-24	13538-13542	ROIs	_	
72-25	13542-13543	)	_	
72-26	13544-13550	during	_	
72-27	13551-13554	the	_	
72-28	13555-13559	drug	_	
72-29	13559-13560	/	_	
72-30	13560-13567	alcohol	_	
72-31	13568-13571	cue	_	
72-32	13572-13582	reactivity	_	
72-33	13583-13587	task	_	
72-34	13587-13588	.	_	
72-35	13589-13593	gPPI	_	
72-36	13594-13597	was	_	
72-37	13598-13607	conducted	_	
72-38	13608-13610	as	_	
72-39	13611-13620	described	_	
72-40	13621-13623	by	_	
72-41	13624-13631	McLaren	_	
72-42	13632-13634	et	_	
72-43	13635-13637	al	_	
72-44	13637-13638	.	_	

#Text=(see Supplemental Methods for gPPI analysis details).
73-1	13639-13640	(	_	
73-2	13640-13643	see	_	
73-3	13644-13656	Supplemental	_	
73-4	13657-13664	Methods	_	
73-5	13665-13668	for	_	
73-6	13669-13673	gPPI	_	
73-7	13674-13682	analysis	_	
73-8	13683-13690	details	_	
73-9	13690-13691	)	_	
73-10	13691-13692	.	_	

#Text=We computed drug/alcohol cue minus neutral cue “contrast betas” indicating the relative FC during drug versus neutral conditions.
74-1	13693-13695	We	_	
74-2	13696-13704	computed	_	
74-3	13705-13709	drug	_	
74-4	13709-13710	/	_	
74-5	13710-13717	alcohol	_	
74-6	13718-13721	cue	_	
74-7	13722-13727	minus	_	
74-8	13728-13735	neutral	_	
74-9	13736-13739	cue	_	
74-10	13740-13741	“	_	
74-11	13741-13749	contrast	_	
74-12	13750-13755	betas	_	
74-13	13755-13756	”	_	
74-14	13757-13767	indicating	_	
74-15	13768-13771	the	_	
74-16	13772-13780	relative	_	
74-17	13781-13783	FC	_	
74-18	13784-13790	during	_	
74-19	13791-13795	drug	_	
74-20	13796-13802	versus	_	
74-21	13803-13810	neutral	_	
74-22	13811-13821	conditions	_	
74-23	13821-13822	.	_	

#Text=Four contrast betas were computed: prereal cTBS, postreal cTBS, presham, and postsham.
75-1	13823-13827	Four	_	
75-2	13828-13836	contrast	_	
75-3	13837-13842	betas	_	
75-4	13843-13847	were	_	
75-5	13848-13856	computed	_	
75-6	13856-13857	:	_	
75-7	13858-13865	prereal	_	
75-8	13866-13870	cTBS	_	
75-9	13870-13871	,	_	
75-10	13872-13880	postreal	_	
75-11	13881-13885	cTBS	_	
75-12	13885-13886	,	_	
75-13	13887-13894	presham	_	
75-14	13894-13895	,	_	
75-15	13896-13899	and	_	
75-16	13900-13908	postsham	_	
75-17	13908-13909	.	_	

#Text=We aimed to show that FC between the VMPFC and several striatal and salience regions would decrease during drug/alcohol cue versus neutral cue exposure following real but not sham VMPFC cTBS.
76-1	13910-13912	We	_	
76-2	13913-13918	aimed	_	
76-3	13919-13921	to	_	
76-4	13922-13926	show	_	
76-5	13927-13931	that	_	
76-6	13932-13934	FC	_	
76-7	13935-13942	between	_	
76-8	13943-13946	the	_	
76-9	13947-13952	VMPFC	_	
76-10	13953-13956	and	_	
76-11	13957-13964	several	_	
76-12	13965-13973	striatal	_	
76-13	13974-13977	and	_	
76-14	13978-13986	salience	_	
76-15	13987-13994	regions	_	
76-16	13995-14000	would	_	
76-17	14001-14009	decrease	_	
76-18	14010-14016	during	_	
76-19	14017-14021	drug	_	
76-20	14021-14022	/	_	
76-21	14022-14029	alcohol	_	
76-22	14030-14033	cue	_	
76-23	14034-14040	versus	_	
76-24	14041-14048	neutral	_	
76-25	14049-14052	cue	_	
76-26	14053-14061	exposure	_	
76-27	14062-14071	following	_	
76-28	14072-14076	real	_	
76-29	14077-14080	but	_	
76-30	14081-14084	not	_	
76-31	14085-14089	sham	_	
76-32	14090-14095	VMPFC	_	
76-33	14096-14100	cTBS	_	
76-34	14100-14101	.	_	

#Text=To do this, we conducted a three-way repeated-measures ANOVA involving treatment type (real vs. sham), time (pre vs. post), and ROI as independent variables and drug/alcohol versus neutral contrast betas as the dependent variable.
77-1	14102-14104	To	_	
77-2	14105-14107	do	_	
77-3	14108-14112	this	_	
77-4	14112-14113	,	_	
77-5	14114-14116	we	_	
77-6	14117-14126	conducted	_	
77-7	14127-14128	a	_	
77-8	14129-14138	three-way	_	
77-9	14139-14156	repeated-measures	_	
77-10	14157-14162	ANOVA	_	
77-11	14163-14172	involving	_	
77-12	14173-14182	treatment	_	
77-13	14183-14187	type	_	
77-14	14188-14189	(	_	
77-15	14189-14193	real	_	
77-16	14194-14196	vs	_	
77-17	14196-14197	.	_	
77-18	14198-14202	sham	_	
77-19	14202-14203	)	_	
77-20	14203-14204	,	_	
77-21	14205-14209	time	_	
77-22	14210-14211	(	_	
77-23	14211-14214	pre	_	
77-24	14215-14217	vs	_	
77-25	14217-14218	.	_	
77-26	14219-14223	post	_	
77-27	14223-14224	)	_	
77-28	14224-14225	,	_	
77-29	14226-14229	and	_	
77-30	14230-14233	ROI	_	
77-31	14234-14236	as	_	
77-32	14237-14248	independent	_	
77-33	14249-14258	variables	_	
77-34	14259-14262	and	_	
77-35	14263-14267	drug	_	
77-36	14267-14268	/	_	
77-37	14268-14275	alcohol	_	
77-38	14276-14282	versus	_	
77-39	14283-14290	neutral	_	
77-40	14291-14299	contrast	_	
77-41	14300-14305	betas	_	
77-42	14306-14308	as	_	
77-43	14309-14312	the	_	
77-44	14313-14322	dependent	_	
77-45	14323-14331	variable	_	
77-46	14331-14332	.	_	

#Text=Subsequent t tests were then used to determine the effect of treatment on changes in drug/alcohol cue–evoked FC across regions.
78-1	14333-14343	Subsequent	_	
78-2	14344-14345	t	_	
78-3	14346-14351	tests	_	
78-4	14352-14356	were	_	
78-5	14357-14361	then	_	
78-6	14362-14366	used	_	
78-7	14367-14369	to	_	
78-8	14370-14379	determine	_	
78-9	14380-14383	the	_	
78-10	14384-14390	effect	_	
78-11	14391-14393	of	_	
78-12	14394-14403	treatment	_	
78-13	14404-14406	on	_	
78-14	14407-14414	changes	_	
78-15	14415-14417	in	_	
78-16	14418-14422	drug	_	
78-17	14422-14423	/	_	
78-18	14423-14430	alcohol	_	
78-19	14431-14441	cue–evoked	_	
78-20	14442-14444	FC	_	
78-21	14445-14451	across	_	
78-22	14452-14459	regions	_	
78-23	14459-14460	.	_	

#Text=The focus on FC analysis in the present study, rather than traditional general linear model analysis, was due to the nature of TMS effects on the brain.
79-1	14461-14464	The	_	
79-2	14465-14470	focus	_	
79-3	14471-14473	on	_	
79-4	14474-14476	FC	_	
79-5	14477-14485	analysis	_	
79-6	14486-14488	in	_	
79-7	14489-14492	the	_	
79-8	14493-14500	present	_	
79-9	14501-14506	study	_	
79-10	14506-14507	,	_	
79-11	14508-14514	rather	_	
79-12	14515-14519	than	_	
79-13	14520-14531	traditional	_	
79-14	14532-14539	general	_	
79-15	14540-14546	linear	_	
79-16	14547-14552	model	_	
79-17	14553-14561	analysis	_	
79-18	14561-14562	,	_	
79-19	14563-14566	was	_	
79-20	14567-14570	due	_	
79-21	14571-14573	to	_	
79-22	14574-14577	the	_	
79-23	14578-14584	nature	_	
79-24	14585-14587	of	_	
79-25	14588-14591	TMS	_	
79-26	14592-14599	effects	_	
79-27	14600-14602	on	_	
79-28	14603-14606	the	_	
79-29	14607-14612	brain	_	
79-30	14612-14613	.	_	

#Text=To influence subcortical brain regions (such as the striatum), we applied TMS to cortical targets (such as the VMPFC) and took advantage of the monosynaptic functional connections between cortical and subcortical regions.
80-1	14614-14616	To	_	
80-2	14617-14626	influence	_	
80-3	14627-14638	subcortical	_	
80-4	14639-14644	brain	_	
80-5	14645-14652	regions	_	
80-6	14653-14654	(	_	
80-7	14654-14658	such	_	
80-8	14659-14661	as	_	
80-9	14662-14665	the	_	
80-10	14666-14674	striatum	_	
80-11	14674-14675	)	_	
80-12	14675-14676	,	_	
80-13	14677-14679	we	_	
80-14	14680-14687	applied	_	
80-15	14688-14691	TMS	_	
80-16	14692-14694	to	_	
80-17	14695-14703	cortical	_	
80-18	14704-14711	targets	_	
80-19	14712-14713	(	_	
80-20	14713-14717	such	_	
80-21	14718-14720	as	_	
80-22	14721-14724	the	_	
80-23	14725-14730	VMPFC	_	
80-24	14730-14731	)	_	
80-25	14732-14735	and	_	
80-26	14736-14740	took	_	
80-27	14741-14750	advantage	_	
80-28	14751-14753	of	_	
80-29	14754-14757	the	_	
80-30	14758-14770	monosynaptic	_	
80-31	14771-14781	functional	_	
80-32	14782-14793	connections	_	
80-33	14794-14801	between	_	
80-34	14802-14810	cortical	_	
80-35	14811-14814	and	_	
80-36	14815-14826	subcortical	_	
80-37	14827-14834	regions	_	
80-38	14834-14835	.	_	

#Text=As such, we felt that measuring the efficacy of the cTBS-induced changes in frontostriatolimbic circuits should be conducted at the level of these functional connections.
81-1	14836-14838	As	_	
81-2	14839-14843	such	_	
81-3	14843-14844	,	_	
81-4	14845-14847	we	_	
81-5	14848-14852	felt	_	
81-6	14853-14857	that	_	
81-7	14858-14867	measuring	_	
81-8	14868-14871	the	_	
81-9	14872-14880	efficacy	_	
81-10	14881-14883	of	_	
81-11	14884-14887	the	_	
81-12	14888-14900	cTBS-induced	_	
81-13	14901-14908	changes	_	
81-14	14909-14911	in	_	
81-15	14912-14931	frontostriatolimbic	_	
81-16	14932-14940	circuits	_	
81-17	14941-14947	should	_	
81-18	14948-14950	be	_	
81-19	14951-14960	conducted	_	
81-20	14961-14963	at	_	
81-21	14964-14967	the	_	
81-22	14968-14973	level	_	
81-23	14974-14976	of	_	
81-24	14977-14982	these	_	
81-25	14983-14993	functional	_	
81-26	14994-15005	connections	_	
81-27	15005-15006	.	_	

#Text=Relationship Between Clinical/Demographic Variables and FC Changes.
82-1	15007-15019	Relationship	_	
82-2	15020-15027	Between	_	
82-3	15028-15036	Clinical	_	
82-4	15036-15037	/	_	
82-5	15037-15048	Demographic	_	
82-6	15049-15058	Variables	_	
82-7	15059-15062	and	_	
82-8	15063-15065	FC	_	
82-9	15066-15073	Changes	_	
82-10	15073-15074	.	_	

#Text=To determine whether clinical and demographic variables influenced or predicted cTBS treatment outcomes, hierarchical multiple linear regressions were conducted with clinical and demographic variables of interest as the predictors and covariate predictors and changes in VMPFC FC after real versus sham cTBS as the outcome variable.
83-1	15075-15077	To	_	
83-2	15078-15087	determine	_	
83-3	15088-15095	whether	_	
83-4	15096-15104	clinical	_	
83-5	15105-15108	and	_	
83-6	15109-15120	demographic	_	
83-7	15121-15130	variables	_	
83-8	15131-15141	influenced	_	
83-9	15142-15144	or	_	
83-10	15145-15154	predicted	_	
83-11	15155-15159	cTBS	_	
83-12	15160-15169	treatment	_	
83-13	15170-15178	outcomes	_	
83-14	15178-15179	,	_	
83-15	15180-15192	hierarchical	_	
83-16	15193-15201	multiple	_	
83-17	15202-15208	linear	_	
83-18	15209-15220	regressions	_	
83-19	15221-15225	were	_	
83-20	15226-15235	conducted	_	
83-21	15236-15240	with	_	
83-22	15241-15249	clinical	_	
83-23	15250-15253	and	_	
83-24	15254-15265	demographic	_	
83-25	15266-15275	variables	_	
83-26	15276-15278	of	_	
83-27	15279-15287	interest	_	
83-28	15288-15290	as	_	
83-29	15291-15294	the	_	
83-30	15295-15305	predictors	_	
83-31	15306-15309	and	_	
83-32	15310-15319	covariate	_	
83-33	15320-15330	predictors	_	
83-34	15331-15334	and	_	
83-35	15335-15342	changes	_	
83-36	15343-15345	in	_	
83-37	15346-15351	VMPFC	_	
83-38	15352-15354	FC	_	
83-39	15355-15360	after	_	
83-40	15361-15365	real	_	
83-41	15366-15372	versus	_	
83-42	15373-15377	sham	_	
83-43	15378-15382	cTBS	_	
83-44	15383-15385	as	_	
83-45	15386-15389	the	_	
83-46	15390-15397	outcome	_	
83-47	15398-15406	variable	_	
83-48	15406-15407	.	_	

#Text=Scalp-to-Cortex Distance Measurement.
84-1	15408-15423	Scalp-to-Cortex	_	
84-2	15424-15432	Distance	_	
84-3	15433-15444	Measurement	_	
84-4	15444-15445	.	_	

#Text=Given that the effects of TMS on cortical depolarization are proportional to the distance between the skull and cortex, we calculated the distance from the scalp to cortex on the transverse plane of magnetization prepared rapid acquisition gradient-echo images for each participant using BrainRuler software, a dedicated tool for scalp-to-cortex distance measurements.
85-1	15446-15451	Given	_	
85-2	15452-15456	that	_	
85-3	15457-15460	the	_	
85-4	15461-15468	effects	_	
85-5	15469-15471	of	_	
85-6	15472-15475	TMS	_	
85-7	15476-15478	on	_	
85-8	15479-15487	cortical	_	
85-9	15488-15502	depolarization	_	
85-10	15503-15506	are	_	
85-11	15507-15519	proportional	_	
85-12	15520-15522	to	_	
85-13	15523-15526	the	_	
85-14	15527-15535	distance	_	
85-15	15536-15543	between	_	
85-16	15544-15547	the	_	
85-17	15548-15553	skull	_	
85-18	15554-15557	and	_	
85-19	15558-15564	cortex	_	
85-20	15564-15565	,	_	
85-21	15566-15568	we	_	
85-22	15569-15579	calculated	_	
85-23	15580-15583	the	_	
85-24	15584-15592	distance	_	
85-25	15593-15597	from	_	
85-26	15598-15601	the	_	
85-27	15602-15607	scalp	_	
85-28	15608-15610	to	_	
85-29	15611-15617	cortex	_	
85-30	15618-15620	on	_	
85-31	15621-15624	the	_	
85-32	15625-15635	transverse	_	
85-33	15636-15641	plane	_	
85-34	15642-15644	of	_	
85-35	15645-15658	magnetization	_	
85-36	15659-15667	prepared	_	
85-37	15668-15673	rapid	_	
85-38	15674-15685	acquisition	_	
85-39	15686-15699	gradient-echo	_	
85-40	15700-15706	images	_	
85-41	15707-15710	for	_	
85-42	15711-15715	each	_	
85-43	15716-15727	participant	_	
85-44	15728-15733	using	_	
85-45	15734-15744	BrainRuler	_	
85-46	15745-15753	software	_	
85-47	15753-15754	,	_	
85-48	15755-15756	a	_	
85-49	15757-15766	dedicated	_	
85-50	15767-15771	tool	_	
85-51	15772-15775	for	_	
85-52	15776-15791	scalp-to-cortex	_	
85-53	15792-15800	distance	_	
85-54	15801-15813	measurements	_	
85-55	15813-15814	.	_	

#Text=The average distance from participant-specific placement of Fp1 to the cortex was 17.4 ± 3.7 mm for cocaine users and 16.4 ± 3.2 mm for alcohol users.
86-1	15815-15818	The	_	
86-2	15819-15826	average	_	
86-3	15827-15835	distance	_	
86-4	15836-15840	from	_	
86-5	15841-15861	participant-specific	_	
86-6	15862-15871	placement	_	
86-7	15872-15874	of	_	
86-8	15875-15878	Fp1	_	
86-9	15879-15881	to	_	
86-10	15882-15885	the	_	
86-11	15886-15892	cortex	_	
86-12	15893-15896	was	_	
86-13	15897-15901	17.4	_	
86-14	15902-15903	±	_	
86-15	15904-15907	3.7	_	
86-16	15908-15910	mm	_	
86-17	15911-15914	for	_	
86-18	15915-15922	cocaine	_	
86-19	15923-15928	users	_	
86-20	15929-15932	and	_	
86-21	15933-15937	16.4	_	
86-22	15938-15939	±	_	
86-23	15940-15943	3.2	_	
86-24	15944-15946	mm	_	
86-25	15947-15950	for	_	
86-26	15951-15958	alcohol	_	
86-27	15959-15964	users	_	
86-28	15964-15965	.	_	

#Text=These distances were incorporated into the analyses as covariates.
87-1	15966-15971	These	_	
87-2	15972-15981	distances	_	
87-3	15982-15986	were	_	
87-4	15987-15999	incorporated	_	
87-5	16000-16004	into	_	
87-6	16005-16008	the	_	
87-7	16009-16017	analyses	_	
87-8	16018-16020	as	_	
87-9	16021-16031	covariates	_	
87-10	16031-16032	.	_	

#Text=RESULTS
#Text=Experiment 1 Results (Cocaine Users)
#Text=A three-way repeated-measures ANOVA (treatment [real/sham] × time [pre/post] × ROI) revealed a significant interaction between treatment and time (F1,768 = 27.1, p < .00001).
88-1	16033-16040	RESULTS	_	
88-2	16041-16051	Experiment	_	
88-3	16052-16053	1	_	
88-4	16054-16061	Results	_	
88-5	16062-16063	(	_	
88-6	16063-16070	Cocaine	_	
88-7	16071-16076	Users	_	
88-8	16076-16077	)	_	
88-9	16078-16079	A	_	
88-10	16080-16089	three-way	_	
88-11	16090-16107	repeated-measures	_	
88-12	16108-16113	ANOVA	_	
88-13	16114-16115	(	_	
88-14	16115-16124	treatment	_	
88-15	16125-16126	[	_	
88-16	16126-16130	real	_	
88-17	16130-16131	/	_	
88-18	16131-16135	sham	_	
88-19	16135-16136	]	_	
88-20	16137-16138	×	_	
88-21	16139-16143	time	_	
88-22	16144-16145	[	_	
88-23	16145-16148	pre	_	
88-24	16148-16149	/	_	
88-25	16149-16153	post	_	
88-26	16153-16154	]	_	
88-27	16155-16156	×	_	
88-28	16157-16160	ROI	_	
88-29	16160-16161	)	_	
88-30	16162-16170	revealed	_	
88-31	16171-16172	a	_	
88-32	16173-16184	significant	_	
88-33	16185-16196	interaction	_	
88-34	16197-16204	between	_	
88-35	16205-16214	treatment	_	
88-36	16215-16218	and	_	
88-37	16219-16223	time	_	
88-38	16224-16225	(	_	
88-39	16225-16231	F1,768	_	
88-40	16232-16233	=	_	
88-41	16234-16238	27.1	_	
88-42	16238-16239	,	_	
88-43	16240-16241	p	_	
88-44	16242-16243	<	_	
88-45	16244-16250	.00001	_	
88-46	16250-16251	)	_	
88-47	16251-16252	.	_	

#Text=There was neither a main effect nor an interaction with ROI, indicating a general effect of treatment × time across all ROIs (Figure 2A).
89-1	16253-16258	There	_	
89-2	16259-16262	was	_	
89-3	16263-16270	neither	_	
89-4	16271-16272	a	_	
89-5	16273-16277	main	_	
89-6	16278-16284	effect	_	
89-7	16285-16288	nor	_	
89-8	16289-16291	an	_	
89-9	16292-16303	interaction	_	
89-10	16304-16308	with	_	
89-11	16309-16312	ROI	_	
89-12	16312-16313	,	_	
89-13	16314-16324	indicating	_	
89-14	16325-16326	a	_	
89-15	16327-16334	general	_	
89-16	16335-16341	effect	_	
89-17	16342-16344	of	_	
89-18	16345-16354	treatment	_	
89-19	16355-16356	×	_	
89-20	16357-16361	time	_	
89-21	16362-16368	across	_	
89-22	16369-16372	all	_	
89-23	16373-16377	ROIs	_	
89-24	16378-16379	(	_	
89-25	16379-16385	Figure	_	
89-26	16386-16388	2A	_	
89-27	16388-16389	)	_	
89-28	16389-16390	.	_	

#Text=A post hoc t test of the interaction revealed that FC for drug versus neutral cues was significantly attenuated following real versus sham cTBS (t24 = −5.25, p < .00001).
90-1	16391-16392	A	_	
90-2	16393-16397	post	_	
90-3	16398-16401	hoc	_	
90-4	16402-16403	t	_	
90-5	16404-16408	test	_	
90-6	16409-16411	of	_	
90-7	16412-16415	the	_	
90-8	16416-16427	interaction	_	
90-9	16428-16436	revealed	_	
90-10	16437-16441	that	_	
90-11	16442-16444	FC	_	
90-12	16445-16448	for	_	
90-13	16449-16453	drug	_	
90-14	16454-16460	versus	_	
90-15	16461-16468	neutral	_	
90-16	16469-16473	cues	_	
90-17	16474-16477	was	_	
90-18	16478-16491	significantly	_	
90-19	16492-16502	attenuated	_	
90-20	16503-16512	following	_	
90-21	16513-16517	real	_	
90-22	16518-16524	versus	_	
90-23	16525-16529	sham	_	
90-24	16530-16534	cTBS	_	
90-25	16535-16536	(	_	
90-26	16536-16539	t24	_	
90-27	16540-16541	=	_	
90-28	16542-16543	−	_	
90-29	16543-16547	5.25	_	
90-30	16547-16548	,	_	
90-31	16549-16550	p	_	
90-32	16551-16552	<	_	
90-33	16553-16559	.00001	_	
90-34	16559-16560	)	_	
90-35	16560-16561	.	_	

#Text=This significant difference was driven by significant attenuations following real cTBS (t24 = −4.74, p <.00001) as well as significant increases following sham cTBS (t24 = 3.37, p < .001).
91-1	16562-16566	This	_	
91-2	16567-16578	significant	_	
91-3	16579-16589	difference	_	
91-4	16590-16593	was	_	
91-5	16594-16600	driven	_	
91-6	16601-16603	by	_	
91-7	16604-16615	significant	_	
91-8	16616-16628	attenuations	_	
91-9	16629-16638	following	_	
91-10	16639-16643	real	_	
91-11	16644-16648	cTBS	_	
91-12	16649-16650	(	_	
91-13	16650-16653	t24	_	
91-14	16654-16655	=	_	
91-15	16656-16657	−	_	
91-16	16657-16661	4.74	_	
91-17	16661-16662	,	_	
91-18	16663-16664	p	_	
91-19	16665-16666	<	_	
91-20	16666-16672	.00001	_	
91-21	16672-16673	)	_	
91-22	16674-16676	as	_	
91-23	16677-16681	well	_	
91-24	16682-16684	as	_	
91-25	16685-16696	significant	_	
91-26	16697-16706	increases	_	
91-27	16707-16716	following	_	
91-28	16717-16721	sham	_	
91-29	16722-16726	cTBS	_	
91-30	16727-16728	(	_	
91-31	16728-16731	t24	_	
91-32	16732-16733	=	_	
91-33	16734-16738	3.37	_	
91-34	16738-16739	,	_	
91-35	16740-16741	p	_	
91-36	16742-16743	<	_	
91-37	16744-16748	.001	_	
91-38	16748-16749	)	_	
91-39	16749-16750	.	_	

#Text=Although there was no significant effect of ROI, the largest attenuating effects were between the VMPFC and left caudate (effect size: Cohen’s d = −0.50) and left insula (d = −0.70).
92-1	16751-16759	Although	_	
92-2	16760-16765	there	_	
92-3	16766-16769	was	_	
92-4	16770-16772	no	_	
92-5	16773-16784	significant	_	
92-6	16785-16791	effect	_	
92-7	16792-16794	of	_	
92-8	16795-16798	ROI	_	
92-9	16798-16799	,	_	
92-10	16800-16803	the	_	
92-11	16804-16811	largest	_	
92-12	16812-16823	attenuating	_	
92-13	16824-16831	effects	_	
92-14	16832-16836	were	_	
92-15	16837-16844	between	_	
92-16	16845-16848	the	_	
92-17	16849-16854	VMPFC	_	
92-18	16855-16858	and	_	
92-19	16859-16863	left	_	
92-20	16864-16871	caudate	_	
92-21	16872-16873	(	_	
92-22	16873-16879	effect	_	
92-23	16880-16884	size	_	
92-24	16884-16885	:	_	
92-25	16886-16891	Cohen	_	
92-26	16891-16892	’	_	
92-27	16892-16893	s	_	
92-28	16894-16895	d	_	
92-29	16896-16897	=	_	
92-30	16898-16899	−	_	
92-31	16899-16903	0.50	_	
92-32	16903-16904	)	_	
92-33	16905-16908	and	_	
92-34	16909-16913	left	_	
92-35	16914-16920	insula	_	
92-36	16921-16922	(	_	
92-37	16922-16923	d	_	
92-38	16924-16925	=	_	
92-39	16926-16927	−	_	
92-40	16927-16931	0.70	_	
92-41	16931-16932	)	_	
92-42	16932-16933	.	_	

#Text=There were also smaller decreases between the VMPFC and right caudate (d = −0.35), left putamen (d = −0.48), right putamen (d = −0.37), ACC (d = −0.23), and ventral striatum (d = −0.46) (Figure 3A; see Supplemental Figure S1 for interaction plots).
93-1	16934-16939	There	_	
93-2	16940-16944	were	_	
93-3	16945-16949	also	_	
93-4	16950-16957	smaller	_	
93-5	16958-16967	decreases	_	
93-6	16968-16975	between	_	
93-7	16976-16979	the	_	
93-8	16980-16985	VMPFC	_	
93-9	16986-16989	and	_	
93-10	16990-16995	right	_	
93-11	16996-17003	caudate	_	
93-12	17004-17005	(	_	
93-13	17005-17006	d	_	
93-14	17007-17008	=	_	
93-15	17009-17010	−	_	
93-16	17010-17014	0.35	_	
93-17	17014-17015	)	_	
93-18	17015-17016	,	_	
93-19	17017-17021	left	_	
93-20	17022-17029	putamen	_	
93-21	17030-17031	(	_	
93-22	17031-17032	d	_	
93-23	17033-17034	=	_	
93-24	17035-17036	−	_	
93-25	17036-17040	0.48	_	
93-26	17040-17041	)	_	
93-27	17041-17042	,	_	
93-28	17043-17048	right	_	
93-29	17049-17056	putamen	_	
93-30	17057-17058	(	_	
93-31	17058-17059	d	_	
93-32	17060-17061	=	_	
93-33	17062-17063	−	_	
93-34	17063-17067	0.37	_	
93-35	17067-17068	)	_	
93-36	17068-17069	,	_	
93-37	17070-17073	ACC	_	
93-38	17074-17075	(	_	
93-39	17075-17076	d	_	
93-40	17077-17078	=	_	
93-41	17079-17080	−	_	
93-42	17080-17084	0.23	_	
93-43	17084-17085	)	_	
93-44	17085-17086	,	_	
93-45	17087-17090	and	_	
93-46	17091-17098	ventral	_	
93-47	17099-17107	striatum	_	
93-48	17108-17109	(	_	
93-49	17109-17110	d	_	
93-50	17111-17112	=	_	
93-51	17113-17114	−	_	
93-52	17114-17118	0.46	_	
93-53	17118-17119	)	_	
93-54	17120-17121	(	_	
93-55	17121-17127	Figure	_	
93-56	17128-17130	3A	_	
93-57	17130-17131	;	_	
93-58	17132-17135	see	_	
93-59	17136-17148	Supplemental	_	
93-60	17149-17155	Figure	_	
93-61	17156-17158	S1	_	
93-62	17159-17162	for	_	
93-63	17163-17174	interaction	_	
93-64	17175-17180	plots	_	
93-65	17180-17181	)	_	
93-66	17181-17182	.	_	

#Text=In accordance with the generally accepted system for interpreting effect sizes, small effect sizes were classified as those with Cohen’s d ≥ 0.20, moderate effect sizes with Cohen’s d ≥ 0.50, and large effect sizes with Cohen’s d ≥ 0.80.
94-1	17183-17185	In	_	
94-2	17186-17196	accordance	_	
94-3	17197-17201	with	_	
94-4	17202-17205	the	_	
94-5	17206-17215	generally	_	
94-6	17216-17224	accepted	_	
94-7	17225-17231	system	_	
94-8	17232-17235	for	_	
94-9	17236-17248	interpreting	_	
94-10	17249-17255	effect	_	
94-11	17256-17261	sizes	_	
94-12	17261-17262	,	_	
94-13	17263-17268	small	_	
94-14	17269-17275	effect	_	
94-15	17276-17281	sizes	_	
94-16	17282-17286	were	_	
94-17	17287-17297	classified	_	
94-18	17298-17300	as	_	
94-19	17301-17306	those	_	
94-20	17307-17311	with	_	
94-21	17312-17317	Cohen	_	
94-22	17317-17318	’	_	
94-23	17318-17319	s	_	
94-24	17320-17321	d	_	
94-25	17322-17323	≥	_	
94-26	17324-17328	0.20	_	
94-27	17328-17329	,	_	
94-28	17330-17338	moderate	_	
94-29	17339-17345	effect	_	
94-30	17346-17351	sizes	_	
94-31	17352-17356	with	_	
94-32	17357-17362	Cohen	_	
94-33	17362-17363	’	_	
94-34	17363-17364	s	_	
94-35	17365-17366	d	_	
94-36	17367-17368	≥	_	
94-37	17369-17373	0.50	_	
94-38	17373-17374	,	_	
94-39	17375-17378	and	_	
94-40	17379-17384	large	_	
94-41	17385-17391	effect	_	
94-42	17392-17397	sizes	_	
94-43	17398-17402	with	_	
94-44	17403-17408	Cohen	_	
94-45	17408-17409	’	_	
94-46	17409-17410	s	_	
94-47	17411-17412	d	_	
94-48	17413-17414	≥	_	
94-49	17415-17419	0.80	_	
94-50	17419-17420	.	_	

#Text=At baseline, cocaine users showed significantly elevated FC for drug versus neutral cues across all striatal and salience connections with VMPFC (t199 = 4.25, p < .0001, d = 0.30).
95-1	17421-17423	At	_	
95-2	17424-17432	baseline	_	
95-3	17432-17433	,	_	
95-4	17434-17441	cocaine	_	
95-5	17442-17447	users	_	
95-6	17448-17454	showed	_	
95-7	17455-17468	significantly	_	
95-8	17469-17477	elevated	_	
95-9	17478-17480	FC	_	
95-10	17481-17484	for	_	
95-11	17485-17489	drug	_	
95-12	17490-17496	versus	_	
95-13	17497-17504	neutral	_	
95-14	17505-17509	cues	_	
95-15	17510-17516	across	_	
95-16	17517-17520	all	_	
95-17	17521-17529	striatal	_	
95-18	17530-17533	and	_	
95-19	17534-17542	salience	_	
95-20	17543-17554	connections	_	
95-21	17555-17559	with	_	
95-22	17560-17565	VMPFC	_	
95-23	17566-17567	(	_	
95-24	17567-17571	t199	_	
95-25	17572-17573	=	_	
95-26	17574-17578	4.25	_	
95-27	17578-17579	,	_	
95-28	17580-17581	p	_	
95-29	17582-17583	<	_	
95-30	17584-17589	.0001	_	
95-31	17589-17590	,	_	
95-32	17591-17592	d	_	
95-33	17593-17594	=	_	
95-34	17595-17599	0.30	_	
95-35	17599-17600	)	_	
95-36	17600-17601	.	_	

#Text=Although individual connections were not statistically significant after correcting for multiple comparisons, the effect size of elevated baseline FC was largest between the VMPFC and left putamen (d = 0.55).
96-1	17602-17610	Although	_	
96-2	17611-17621	individual	_	
96-3	17622-17633	connections	_	
96-4	17634-17638	were	_	
96-5	17639-17642	not	_	
96-6	17643-17656	statistically	_	
96-7	17657-17668	significant	_	
96-8	17669-17674	after	_	
96-9	17675-17685	correcting	_	
96-10	17686-17689	for	_	
96-11	17690-17698	multiple	_	
96-12	17699-17710	comparisons	_	
96-13	17710-17711	,	_	
96-14	17712-17715	the	_	
96-15	17716-17722	effect	_	
96-16	17723-17727	size	_	
96-17	17728-17730	of	_	
96-18	17731-17739	elevated	_	
96-19	17740-17748	baseline	_	
96-20	17749-17751	FC	_	
96-21	17752-17755	was	_	
96-22	17756-17763	largest	_	
96-23	17764-17771	between	_	
96-24	17772-17775	the	_	
96-25	17776-17781	VMPFC	_	
96-26	17782-17785	and	_	
96-27	17786-17790	left	_	
96-28	17791-17798	putamen	_	
96-29	17799-17800	(	_	
96-30	17800-17801	d	_	
96-31	17802-17803	=	_	
96-32	17804-17808	0.55	_	
96-33	17808-17809	)	_	
96-34	17809-17810	.	_	

#Text=There were also smaller effect sizes between the VMPFC and left caudate (d = 0.37), right caudate (d = 0.26), right putamen (d = 0.30), left insula (d = 0.42), right insula (d = 0.25), ACC (d = 0.21), and ventral striatum (d = 0.33) (Figure 3A).
97-1	17811-17816	There	_	
97-2	17817-17821	were	_	
97-3	17822-17826	also	_	
97-4	17827-17834	smaller	_	
97-5	17835-17841	effect	_	
97-6	17842-17847	sizes	_	
97-7	17848-17855	between	_	
97-8	17856-17859	the	_	
97-9	17860-17865	VMPFC	_	
97-10	17866-17869	and	_	
97-11	17870-17874	left	_	
97-12	17875-17882	caudate	_	
97-13	17883-17884	(	_	
97-14	17884-17885	d	_	
97-15	17886-17887	=	_	
97-16	17888-17892	0.37	_	
97-17	17892-17893	)	_	
97-18	17893-17894	,	_	
97-19	17895-17900	right	_	
97-20	17901-17908	caudate	_	
97-21	17909-17910	(	_	
97-22	17910-17911	d	_	
97-23	17912-17913	=	_	
97-24	17914-17918	0.26	_	
97-25	17918-17919	)	_	
97-26	17919-17920	,	_	
97-27	17921-17926	right	_	
97-28	17927-17934	putamen	_	
97-29	17935-17936	(	_	
97-30	17936-17937	d	_	
97-31	17938-17939	=	_	
97-32	17940-17944	0.30	_	
97-33	17944-17945	)	_	
97-34	17945-17946	,	_	
97-35	17947-17951	left	_	
97-36	17952-17958	insula	_	
97-37	17959-17960	(	_	
97-38	17960-17961	d	_	
97-39	17962-17963	=	_	
97-40	17964-17968	0.42	_	
97-41	17968-17969	)	_	
97-42	17969-17970	,	_	
97-43	17971-17976	right	_	
97-44	17977-17983	insula	_	
97-45	17984-17985	(	_	
97-46	17985-17986	d	_	
97-47	17987-17988	=	_	
97-48	17989-17993	0.25	_	
97-49	17993-17994	)	_	
97-50	17994-17995	,	_	
97-51	17996-17999	ACC	_	
97-52	18000-18001	(	_	
97-53	18001-18002	d	_	
97-54	18003-18004	=	_	
97-55	18005-18009	0.21	_	
97-56	18009-18010	)	_	
97-57	18010-18011	,	_	
97-58	18012-18015	and	_	
97-59	18016-18023	ventral	_	
97-60	18024-18032	striatum	_	
97-61	18033-18034	(	_	
97-62	18034-18035	d	_	
97-63	18036-18037	=	_	
97-64	18038-18042	0.33	_	
97-65	18042-18043	)	_	
97-66	18044-18045	(	_	
97-67	18045-18051	Figure	_	
97-68	18052-18054	3A	_	
97-69	18054-18055	)	_	
97-70	18055-18056	.	_	

#Text=Changes in cue-evoked FC for real versus sham cTBS was related to several clinical and demographic variables.
98-1	18057-18064	Changes	_	
98-2	18065-18067	in	_	
98-3	18068-18078	cue-evoked	_	
98-4	18079-18081	FC	_	
98-5	18082-18085	for	_	
98-6	18086-18090	real	_	
98-7	18091-18097	versus	_	
98-8	18098-18102	sham	_	
98-9	18103-18107	cTBS	_	
98-10	18108-18111	was	_	
98-11	18112-18119	related	_	
98-12	18120-18122	to	_	
98-13	18123-18130	several	_	
98-14	18131-18139	clinical	_	
98-15	18140-18143	and	_	
98-16	18144-18155	demographic	_	
98-17	18156-18165	variables	_	
98-18	18165-18166	.	_	

#Text=Change in cue-evoked FC was related to years of cocaine use (for VMPFC-left caudate [r = .63, p < .001]), baseline craving score (for VMPFC-left putamen [r = .58, p < .01]), and trait anxiety score (for VMPFC-left insula [r = .65, p < .001], while controlling for age and scalp-to-cortex distance) (Supplemental Figure S2).
99-1	18167-18173	Change	_	
99-2	18174-18176	in	_	
99-3	18177-18187	cue-evoked	_	
99-4	18188-18190	FC	_	
99-5	18191-18194	was	_	
99-6	18195-18202	related	_	
99-7	18203-18205	to	_	
99-8	18206-18211	years	_	
99-9	18212-18214	of	_	
99-10	18215-18222	cocaine	_	
99-11	18223-18226	use	_	
99-12	18227-18228	(	_	
99-13	18228-18231	for	_	
99-14	18232-18242	VMPFC-left	_	
99-15	18243-18250	caudate	_	
99-16	18251-18252	[	_	
99-17	18252-18253	r	_	
99-18	18254-18255	=	_	
99-19	18256-18259	.63	_	
99-20	18259-18260	,	_	
99-21	18261-18262	p	_	
99-22	18263-18264	<	_	
99-23	18265-18269	.001	_	
99-24	18269-18270	]	_	
99-25	18270-18271	)	_	
99-26	18271-18272	,	_	
99-27	18273-18281	baseline	_	
99-28	18282-18289	craving	_	
99-29	18290-18295	score	_	
99-30	18296-18297	(	_	
99-31	18297-18300	for	_	
99-32	18301-18311	VMPFC-left	_	
99-33	18312-18319	putamen	_	
99-34	18320-18321	[	_	
99-35	18321-18322	r	_	
99-36	18323-18324	=	_	
99-37	18325-18328	.58	_	
99-38	18328-18329	,	_	
99-39	18330-18331	p	_	
99-40	18332-18333	<	_	
99-41	18334-18337	.01	_	
99-42	18337-18338	]	_	
99-43	18338-18339	)	_	
99-44	18339-18340	,	_	
99-45	18341-18344	and	_	
99-46	18345-18350	trait	_	
99-47	18351-18358	anxiety	_	
99-48	18359-18364	score	_	
99-49	18365-18366	(	_	
99-50	18366-18369	for	_	
99-51	18370-18380	VMPFC-left	_	
99-52	18381-18387	insula	_	
99-53	18388-18389	[	_	
99-54	18389-18390	r	_	
99-55	18391-18392	=	_	
99-56	18393-18396	.65	_	
99-57	18396-18397	,	_	
99-58	18398-18399	p	_	
99-59	18400-18401	<	_	
99-60	18402-18406	.001	_	
99-61	18406-18407	]	_	
99-62	18407-18408	,	_	
99-63	18409-18414	while	_	
99-64	18415-18426	controlling	_	
99-65	18427-18430	for	_	
99-66	18431-18434	age	_	
99-67	18435-18438	and	_	
99-68	18439-18454	scalp-to-cortex	_	
99-69	18455-18463	distance	_	
99-70	18463-18464	)	_	
99-71	18465-18466	(	_	
99-72	18466-18478	Supplemental	_	
99-73	18479-18485	Figure	_	
99-74	18486-18488	S2	_	
99-75	18488-18489	)	_	
99-76	18489-18490	.	_	

#Text=A two-way ANOVA revealed a significant main effect of time (pre/post) on self-reported cocaine craving (F1,96 = 5.65, p = .02), but a nonsignificant effect of treatment or treatment × time (both p ≥ .05).
100-1	18491-18492	A	_	
100-2	18493-18500	two-way	_	
100-3	18501-18506	ANOVA	_	
100-4	18507-18515	revealed	_	
100-5	18516-18517	a	_	
100-6	18518-18529	significant	_	
100-7	18530-18534	main	_	
100-8	18535-18541	effect	_	
100-9	18542-18544	of	_	
100-10	18545-18549	time	_	
100-11	18550-18551	(	_	
100-12	18551-18554	pre	_	
100-13	18554-18555	/	_	
100-14	18555-18559	post	_	
100-15	18559-18560	)	_	
100-16	18561-18563	on	_	
100-17	18564-18577	self-reported	_	
100-18	18578-18585	cocaine	_	
100-19	18586-18593	craving	_	
100-20	18594-18595	(	_	
100-21	18595-18600	F1,96	_	
100-22	18601-18602	=	_	
100-23	18603-18607	5.65	_	
100-24	18607-18608	,	_	
100-25	18609-18610	p	_	
100-26	18611-18612	=	_	
100-27	18613-18616	.02	_	
100-28	18616-18617	)	_	
100-29	18617-18618	,	_	
100-30	18619-18622	but	_	
100-31	18623-18624	a	_	
100-32	18625-18639	nonsignificant	_	
100-33	18640-18646	effect	_	
100-34	18647-18649	of	_	
100-35	18650-18659	treatment	_	
100-36	18660-18662	or	_	
100-37	18663-18672	treatment	_	
100-38	18673-18674	×	_	
100-39	18675-18679	time	_	
100-40	18680-18681	(	_	
100-41	18681-18685	both	_	
100-42	18686-18687	p	_	
100-43	18688-18689	≥	_	
100-44	18690-18693	.05	_	
100-45	18693-18694	)	_	
100-46	18694-18695	.	_	

#Text=Post hoc paired t tests revealed that self-reported cocaine craving was significantly lower than baseline following real cTBS (t24 = −3.18, p = .004), but not following sham (t24 = −2.07, p ≥ .05).
101-1	18696-18700	Post	_	
101-2	18701-18704	hoc	_	
101-3	18705-18711	paired	_	
101-4	18712-18713	t	_	
101-5	18714-18719	tests	_	
101-6	18720-18728	revealed	_	
101-7	18729-18733	that	_	
101-8	18734-18747	self-reported	_	
101-9	18748-18755	cocaine	_	
101-10	18756-18763	craving	_	
101-11	18764-18767	was	_	
101-12	18768-18781	significantly	_	
101-13	18782-18787	lower	_	
101-14	18788-18792	than	_	
101-15	18793-18801	baseline	_	
101-16	18802-18811	following	_	
101-17	18812-18816	real	_	
101-18	18817-18821	cTBS	_	
101-19	18822-18823	(	_	
101-20	18823-18826	t24	_	
101-21	18827-18828	=	_	
101-22	18829-18830	−	_	
101-23	18830-18834	3.18	_	
101-24	18834-18835	,	_	
101-25	18836-18837	p	_	
101-26	18838-18839	=	_	
101-27	18840-18844	.004	_	
101-28	18844-18845	)	_	
101-29	18845-18846	,	_	
101-30	18847-18850	but	_	
101-31	18851-18854	not	_	
101-32	18855-18864	following	_	
101-33	18865-18869	sham	_	
101-34	18870-18871	(	_	
101-35	18871-18874	t24	_	
101-36	18875-18876	=	_	
101-37	18877-18878	−	_	
101-38	18878-18882	2.07	_	
101-39	18882-18883	,	_	
101-40	18884-18885	p	_	
101-41	18886-18887	≥	_	
101-42	18888-18891	.05	_	
101-43	18891-18892	)	_	
101-44	18892-18893	.	_	

#Text=Changes in craving did not correspond to changes in FC.
102-1	18894-18901	Changes	_	
102-2	18902-18904	in	_	
102-3	18905-18912	craving	_	
102-4	18913-18916	did	_	
102-5	18917-18920	not	_	
102-6	18921-18931	correspond	_	
102-7	18932-18934	to	_	
102-8	18935-18942	changes	_	
102-9	18943-18945	in	_	
102-10	18946-18948	FC	_	
102-11	18948-18949	.	_	

#Text=Experiment 2 Results (Heavy Alcohol Users)
#Text=As in experiment 1, a three-way repeated-measures ANOVA (treatment [real/sham] × time [pre/post] × ROI) revealed a significant interaction between treatment and time (F1,736 = 24.6, p < .00001), but no effect or interaction with ROI.
103-1	18950-18960	Experiment	_	
103-2	18961-18962	2	_	
103-3	18963-18970	Results	_	
103-4	18971-18972	(	_	
103-5	18972-18977	Heavy	_	
103-6	18978-18985	Alcohol	_	
103-7	18986-18991	Users	_	
103-8	18991-18992	)	_	
103-9	18993-18995	As	_	
103-10	18996-18998	in	_	
103-11	18999-19009	experiment	_	
103-12	19010-19011	1	_	
103-13	19011-19012	,	_	
103-14	19013-19014	a	_	
103-15	19015-19024	three-way	_	
103-16	19025-19042	repeated-measures	_	
103-17	19043-19048	ANOVA	_	
103-18	19049-19050	(	_	
103-19	19050-19059	treatment	_	
103-20	19060-19061	[	_	
103-21	19061-19065	real	_	
103-22	19065-19066	/	_	
103-23	19066-19070	sham	_	
103-24	19070-19071	]	_	
103-25	19072-19073	×	_	
103-26	19074-19078	time	_	
103-27	19079-19080	[	_	
103-28	19080-19083	pre	_	
103-29	19083-19084	/	_	
103-30	19084-19088	post	_	
103-31	19088-19089	]	_	
103-32	19090-19091	×	_	
103-33	19092-19095	ROI	_	
103-34	19095-19096	)	_	
103-35	19097-19105	revealed	_	
103-36	19106-19107	a	_	
103-37	19108-19119	significant	_	
103-38	19120-19131	interaction	_	
103-39	19132-19139	between	_	
103-40	19140-19149	treatment	_	
103-41	19150-19153	and	_	
103-42	19154-19158	time	_	
103-43	19159-19160	(	_	
103-44	19160-19166	F1,736	_	
103-45	19167-19168	=	_	
103-46	19169-19173	24.6	_	
103-47	19173-19174	,	_	
103-48	19175-19176	p	_	
103-49	19177-19178	<	_	
103-50	19179-19185	.00001	_	
103-51	19185-19186	)	_	
103-52	19186-19187	,	_	
103-53	19188-19191	but	_	
103-54	19192-19194	no	_	
103-55	19195-19201	effect	_	
103-56	19202-19204	or	_	
103-57	19205-19216	interaction	_	
103-58	19217-19221	with	_	
103-59	19222-19225	ROI	_	
103-60	19225-19226	.	_	

#Text=This indicates a general effect of treatment × time across all ROIs (Figure 2B).
104-1	19227-19231	This	_	
104-2	19232-19241	indicates	_	
104-3	19242-19243	a	_	
104-4	19244-19251	general	_	
104-5	19252-19258	effect	_	
104-6	19259-19261	of	_	
104-7	19262-19271	treatment	_	
104-8	19272-19273	×	_	
104-9	19274-19278	time	_	
104-10	19279-19285	across	_	
104-11	19286-19289	all	_	
104-12	19290-19294	ROIs	_	
104-13	19295-19296	(	_	
104-14	19296-19302	Figure	_	
104-15	19303-19305	2B	_	
104-16	19305-19306	)	_	
104-17	19306-19307	.	_	

#Text=A post hoc t test of the interaction revealed that FC for alcohol versus neutral cues was significantly attenuated following real versus sham cTBS (t23 = −5.91, false discovery rate [FDR] p < .00001).
105-1	19308-19309	A	_	
105-2	19310-19314	post	_	
105-3	19315-19318	hoc	_	
105-4	19319-19320	t	_	
105-5	19321-19325	test	_	
105-6	19326-19328	of	_	
105-7	19329-19332	the	_	
105-8	19333-19344	interaction	_	
105-9	19345-19353	revealed	_	
105-10	19354-19358	that	_	
105-11	19359-19361	FC	_	
105-12	19362-19365	for	_	
105-13	19366-19373	alcohol	_	
105-14	19374-19380	versus	_	
105-15	19381-19388	neutral	_	
105-16	19389-19393	cues	_	
105-17	19394-19397	was	_	
105-18	19398-19411	significantly	_	
105-19	19412-19422	attenuated	_	
105-20	19423-19432	following	_	
105-21	19433-19437	real	_	
105-22	19438-19444	versus	_	
105-23	19445-19449	sham	_	
105-24	19450-19454	cTBS	_	
105-25	19455-19456	(	_	
105-26	19456-19459	t23	_	
105-27	19460-19461	=	_	
105-28	19462-19463	−	_	
105-29	19463-19467	5.91	_	
105-30	19467-19468	,	_	
105-31	19469-19474	false	_	
105-32	19475-19484	discovery	_	
105-33	19485-19489	rate	_	
105-34	19490-19491	[	_	
105-35	19491-19494	FDR	_	
105-36	19494-19495	]	_	
105-37	19496-19497	p	_	
105-38	19498-19499	<	_	
105-39	19500-19506	.00001	_	
105-40	19506-19507	)	_	
105-41	19507-19508	.	_	

#Text=This significant difference was driven by significant attenuations following real cTBS (t23 = −4.70, FDR p < .00001), as well as significant increases following sham cTBS (t23 = 2.81, FDR p < .01).
106-1	19509-19513	This	_	
106-2	19514-19525	significant	_	
106-3	19526-19536	difference	_	
106-4	19537-19540	was	_	
106-5	19541-19547	driven	_	
106-6	19548-19550	by	_	
106-7	19551-19562	significant	_	
106-8	19563-19575	attenuations	_	
106-9	19576-19585	following	_	
106-10	19586-19590	real	_	
106-11	19591-19595	cTBS	_	
106-12	19596-19597	(	_	
106-13	19597-19600	t23	_	
106-14	19601-19602	=	_	
106-15	19603-19604	−	_	
106-16	19604-19608	4.70	_	
106-17	19608-19609	,	_	
106-18	19610-19613	FDR	_	
106-19	19614-19615	p	_	
106-20	19616-19617	<	_	
106-21	19618-19624	.00001	_	
106-22	19624-19625	)	_	
106-23	19625-19626	,	_	
106-24	19627-19629	as	_	
106-25	19630-19634	well	_	
106-26	19635-19637	as	_	
106-27	19638-19649	significant	_	
106-28	19650-19659	increases	_	
106-29	19660-19669	following	_	
106-30	19670-19674	sham	_	
106-31	19675-19679	cTBS	_	
106-32	19680-19681	(	_	
106-33	19681-19684	t23	_	
106-34	19685-19686	=	_	
106-35	19687-19691	2.81	_	
106-36	19691-19692	,	_	
106-37	19693-19696	FDR	_	
106-38	19697-19698	p	_	
106-39	19699-19700	<	_	
106-40	19701-19704	.01	_	
106-41	19704-19705	)	_	
106-42	19705-19706	.	_	

#Text=Although there was no significant main effect or interaction with ROI, the largest decreases in alcohol cue-evoked FC following real versus sham cTBS were between VMPFC and left caudate (d = −0.50), right caudate (d = −0.60), left putamen (d = −0.65), left insula (d = −0.51), ACC (d = −0.51), and ventral striatum (d = −0.54).
107-1	19707-19715	Although	_	
107-2	19716-19721	there	_	
107-3	19722-19725	was	_	
107-4	19726-19728	no	_	
107-5	19729-19740	significant	_	
107-6	19741-19745	main	_	
107-7	19746-19752	effect	_	
107-8	19753-19755	or	_	
107-9	19756-19767	interaction	_	
107-10	19768-19772	with	_	
107-11	19773-19776	ROI	_	
107-12	19776-19777	,	_	
107-13	19778-19781	the	_	
107-14	19782-19789	largest	_	
107-15	19790-19799	decreases	_	
107-16	19800-19802	in	_	
107-17	19803-19810	alcohol	_	
107-18	19811-19821	cue-evoked	_	
107-19	19822-19824	FC	_	
107-20	19825-19834	following	_	
107-21	19835-19839	real	_	
107-22	19840-19846	versus	_	
107-23	19847-19851	sham	_	
107-24	19852-19856	cTBS	_	
107-25	19857-19861	were	_	
107-26	19862-19869	between	_	
107-27	19870-19875	VMPFC	_	
107-28	19876-19879	and	_	
107-29	19880-19884	left	_	
107-30	19885-19892	caudate	_	
107-31	19893-19894	(	_	
107-32	19894-19895	d	_	
107-33	19896-19897	=	_	
107-34	19898-19899	−	_	
107-35	19899-19903	0.50	_	
107-36	19903-19904	)	_	
107-37	19904-19905	,	_	
107-38	19906-19911	right	_	
107-39	19912-19919	caudate	_	
107-40	19920-19921	(	_	
107-41	19921-19922	d	_	
107-42	19923-19924	=	_	
107-43	19925-19926	−	_	
107-44	19926-19930	0.60	_	
107-45	19930-19931	)	_	
107-46	19931-19932	,	_	
107-47	19933-19937	left	_	
107-48	19938-19945	putamen	_	
107-49	19946-19947	(	_	
107-50	19947-19948	d	_	
107-51	19949-19950	=	_	
107-52	19951-19952	−	_	
107-53	19952-19956	0.65	_	
107-54	19956-19957	)	_	
107-55	19957-19958	,	_	
107-56	19959-19963	left	_	
107-57	19964-19970	insula	_	
107-58	19971-19972	(	_	
107-59	19972-19973	d	_	
107-60	19974-19975	=	_	
107-61	19976-19977	−	_	
107-62	19977-19981	0.51	_	
107-63	19981-19982	)	_	
107-64	19982-19983	,	_	
107-65	19984-19987	ACC	_	
107-66	19988-19989	(	_	
107-67	19989-19990	d	_	
107-68	19991-19992	=	_	
107-69	19993-19994	−	_	
107-70	19994-19998	0.51	_	
107-71	19998-19999	)	_	
107-72	19999-20000	,	_	
107-73	20001-20004	and	_	
107-74	20005-20012	ventral	_	
107-75	20013-20021	striatum	_	
107-76	20022-20023	(	_	
107-77	20023-20024	d	_	
107-78	20025-20026	=	_	
107-79	20027-20028	−	_	
107-80	20028-20032	0.54	_	
107-81	20032-20033	)	_	
107-82	20033-20034	.	_	

#Text=There was also a smaller decrease between the VMPFC and right putamen (d = −0.29) (Figure 3B; see Supplemental Figure S3 for interaction plots).
108-1	20035-20040	There	_	
108-2	20041-20044	was	_	
108-3	20045-20049	also	_	
108-4	20050-20051	a	_	
108-5	20052-20059	smaller	_	
108-6	20060-20068	decrease	_	
108-7	20069-20076	between	_	
108-8	20077-20080	the	_	
108-9	20081-20086	VMPFC	_	
108-10	20087-20090	and	_	
108-11	20091-20096	right	_	
108-12	20097-20104	putamen	_	
108-13	20105-20106	(	_	
108-14	20106-20107	d	_	
108-15	20108-20109	=	_	
108-16	20110-20111	−	_	
108-17	20111-20115	0.29	_	
108-18	20115-20116	)	_	
108-19	20117-20118	(	_	
108-20	20118-20124	Figure	_	
108-21	20125-20127	3B	_	
108-22	20127-20128	;	_	
108-23	20129-20132	see	_	
108-24	20133-20145	Supplemental	_	
108-25	20146-20152	Figure	_	
108-26	20153-20155	S3	_	
108-27	20156-20159	for	_	
108-28	20160-20171	interaction	_	
108-29	20172-20177	plots	_	
108-30	20177-20178	)	_	
108-31	20178-20179	.	_	

#Text=At baseline, alcohol users showed significantly elevated FC for alcohol versus neutral cues across striatal and salience connections with VMPFC (t192 = 5.38, p < .00001, d = 0.39).
109-1	20180-20182	At	_	
109-2	20183-20191	baseline	_	
109-3	20191-20192	,	_	
109-4	20193-20200	alcohol	_	
109-5	20201-20206	users	_	
109-6	20207-20213	showed	_	
109-7	20214-20227	significantly	_	
109-8	20228-20236	elevated	_	
109-9	20237-20239	FC	_	
109-10	20240-20243	for	_	
109-11	20244-20251	alcohol	_	
109-12	20252-20258	versus	_	
109-13	20259-20266	neutral	_	
109-14	20267-20271	cues	_	
109-15	20272-20278	across	_	
109-16	20279-20287	striatal	_	
109-17	20288-20291	and	_	
109-18	20292-20300	salience	_	
109-19	20301-20312	connections	_	
109-20	20313-20317	with	_	
109-21	20318-20323	VMPFC	_	
109-22	20324-20325	(	_	
109-23	20325-20329	t192	_	
109-24	20330-20331	=	_	
109-25	20332-20336	5.38	_	
109-26	20336-20337	,	_	
109-27	20338-20339	p	_	
109-28	20340-20341	<	_	
109-29	20342-20348	.00001	_	
109-30	20348-20349	,	_	
109-31	20350-20351	d	_	
109-32	20352-20353	=	_	
109-33	20354-20358	0.39	_	
109-34	20358-20359	)	_	
109-35	20359-20360	.	_	

#Text=Baseline functional connections that were significantly elevated for alcohol versus neutral cues included the VMPFC to right caudate (t23 = 2.51, FDR p ≤ .05), left putamen (t23 = 2.43, FDR p ≤ .05), and left insula (t23 = 3.04, FDR p ≤ .05).
110-1	20361-20369	Baseline	_	
110-2	20370-20380	functional	_	
110-3	20381-20392	connections	_	
110-4	20393-20397	that	_	
110-5	20398-20402	were	_	
110-6	20403-20416	significantly	_	
110-7	20417-20425	elevated	_	
110-8	20426-20429	for	_	
110-9	20430-20437	alcohol	_	
110-10	20438-20444	versus	_	
110-11	20445-20452	neutral	_	
110-12	20453-20457	cues	_	
110-13	20458-20466	included	_	
110-14	20467-20470	the	_	
110-15	20471-20476	VMPFC	_	
110-16	20477-20479	to	_	
110-17	20480-20485	right	_	
110-18	20486-20493	caudate	_	
110-19	20494-20495	(	_	
110-20	20495-20498	t23	_	
110-21	20499-20500	=	_	
110-22	20501-20505	2.51	_	
110-23	20505-20506	,	_	
110-24	20507-20510	FDR	_	
110-25	20511-20512	p	_	
110-26	20513-20514	≤	_	
110-27	20515-20518	.05	_	
110-28	20518-20519	)	_	
110-29	20519-20520	,	_	
110-30	20521-20525	left	_	
110-31	20526-20533	putamen	_	
110-32	20534-20535	(	_	
110-33	20535-20538	t23	_	
110-34	20539-20540	=	_	
110-35	20541-20545	2.43	_	
110-36	20545-20546	,	_	
110-37	20547-20550	FDR	_	
110-38	20551-20552	p	_	
110-39	20553-20554	≤	_	
110-40	20555-20558	.05	_	
110-41	20558-20559	)	_	
110-42	20559-20560	,	_	
110-43	20561-20564	and	_	
110-44	20565-20569	left	_	
110-45	20570-20576	insula	_	
110-46	20577-20578	(	_	
110-47	20578-20581	t23	_	
110-48	20582-20583	=	_	
110-49	20584-20588	3.04	_	
110-50	20588-20589	,	_	
110-51	20590-20593	FDR	_	
110-52	20594-20595	p	_	
110-53	20596-20597	≤	_	
110-54	20598-20601	.05	_	
110-55	20601-20602	)	_	
110-56	20602-20603	.	_	

#Text=Effect sizes of elevated baseline FC were largest between the VMPFC and right caudate (d = 0.51), left putamen (d = 0.50), and left insula (d = 0.62), and smaller between the VMPFC and left caudate (d = 0.47), right putamen (d = 0.28), and ventral striatum (d = 0.35) (Figure 3B).
111-1	20604-20610	Effect	_	
111-2	20611-20616	sizes	_	
111-3	20617-20619	of	_	
111-4	20620-20628	elevated	_	
111-5	20629-20637	baseline	_	
111-6	20638-20640	FC	_	
111-7	20641-20645	were	_	
111-8	20646-20653	largest	_	
111-9	20654-20661	between	_	
111-10	20662-20665	the	_	
111-11	20666-20671	VMPFC	_	
111-12	20672-20675	and	_	
111-13	20676-20681	right	_	
111-14	20682-20689	caudate	_	
111-15	20690-20691	(	_	
111-16	20691-20692	d	_	
111-17	20693-20694	=	_	
111-18	20695-20699	0.51	_	
111-19	20699-20700	)	_	
111-20	20700-20701	,	_	
111-21	20702-20706	left	_	
111-22	20707-20714	putamen	_	
111-23	20715-20716	(	_	
111-24	20716-20717	d	_	
111-25	20718-20719	=	_	
111-26	20720-20724	0.50	_	
111-27	20724-20725	)	_	
111-28	20725-20726	,	_	
111-29	20727-20730	and	_	
111-30	20731-20735	left	_	
111-31	20736-20742	insula	_	
111-32	20743-20744	(	_	
111-33	20744-20745	d	_	
111-34	20746-20747	=	_	
111-35	20748-20752	0.62	_	
111-36	20752-20753	)	_	
111-37	20753-20754	,	_	
111-38	20755-20758	and	_	
111-39	20759-20766	smaller	_	
111-40	20767-20774	between	_	
111-41	20775-20778	the	_	
111-42	20779-20784	VMPFC	_	
111-43	20785-20788	and	_	
111-44	20789-20793	left	_	
111-45	20794-20801	caudate	_	
111-46	20802-20803	(	_	
111-47	20803-20804	d	_	
111-48	20805-20806	=	_	
111-49	20807-20811	0.47	_	
111-50	20811-20812	)	_	
111-51	20812-20813	,	_	
111-52	20814-20819	right	_	
111-53	20820-20827	putamen	_	
111-54	20828-20829	(	_	
111-55	20829-20830	d	_	
111-56	20831-20832	=	_	
111-57	20833-20837	0.28	_	
111-58	20837-20838	)	_	
111-59	20838-20839	,	_	
111-60	20840-20843	and	_	
111-61	20844-20851	ventral	_	
111-62	20852-20860	striatum	_	
111-63	20861-20862	(	_	
111-64	20862-20863	d	_	
111-65	20864-20865	=	_	
111-66	20866-20870	0.35	_	
111-67	20870-20871	)	_	
111-68	20872-20873	(	_	
111-69	20873-20879	Figure	_	
111-70	20880-20882	3B	_	
111-71	20882-20883	)	_	
111-72	20883-20884	.	_	

#Text=Change in cue-evoked FC for real versus sham cTBS was significantly related to cTBS dose (for VMPFC-left caudate [r = .59, p < .01], VMPFC-right caudate [r = .64, p < .001], and VMPFC-left putamen [r = .48, p < .05], while controlling for age and scalp-to-cortex distance) and scalp-to-cortex distance (for VMPFC-ACC [r = .52, p < .01], while controlling for age) (Supplemental Figure S4).
112-1	20885-20891	Change	_	
112-2	20892-20894	in	_	
112-3	20895-20905	cue-evoked	_	
112-4	20906-20908	FC	_	
112-5	20909-20912	for	_	
112-6	20913-20917	real	_	
112-7	20918-20924	versus	_	
112-8	20925-20929	sham	_	
112-9	20930-20934	cTBS	_	
112-10	20935-20938	was	_	
112-11	20939-20952	significantly	_	
112-12	20953-20960	related	_	
112-13	20961-20963	to	_	
112-14	20964-20968	cTBS	_	
112-15	20969-20973	dose	_	
112-16	20974-20975	(	_	
112-17	20975-20978	for	_	
112-18	20979-20989	VMPFC-left	_	
112-19	20990-20997	caudate	_	
112-20	20998-20999	[	_	
112-21	20999-21000	r	_	
112-22	21001-21002	=	_	
112-23	21003-21006	.59	_	
112-24	21006-21007	,	_	
112-25	21008-21009	p	_	
112-26	21010-21011	<	_	
112-27	21012-21015	.01	_	
112-28	21015-21016	]	_	
112-29	21016-21017	,	_	
112-30	21018-21029	VMPFC-right	_	
112-31	21030-21037	caudate	_	
112-32	21038-21039	[	_	
112-33	21039-21040	r	_	
112-34	21041-21042	=	_	
112-35	21043-21046	.64	_	
112-36	21046-21047	,	_	
112-37	21048-21049	p	_	
112-38	21050-21051	<	_	
112-39	21052-21056	.001	_	
112-40	21056-21057	]	_	
112-41	21057-21058	,	_	
112-42	21059-21062	and	_	
112-43	21063-21073	VMPFC-left	_	
112-44	21074-21081	putamen	_	
112-45	21082-21083	[	_	
112-46	21083-21084	r	_	
112-47	21085-21086	=	_	
112-48	21087-21090	.48	_	
112-49	21090-21091	,	_	
112-50	21092-21093	p	_	
112-51	21094-21095	<	_	
112-52	21096-21099	.05	_	
112-53	21099-21100	]	_	
112-54	21100-21101	,	_	
112-55	21102-21107	while	_	
112-56	21108-21119	controlling	_	
112-57	21120-21123	for	_	
112-58	21124-21127	age	_	
112-59	21128-21131	and	_	
112-60	21132-21147	scalp-to-cortex	_	
112-61	21148-21156	distance	_	
112-62	21156-21157	)	_	
112-63	21158-21161	and	_	
112-64	21162-21177	scalp-to-cortex	_	
112-65	21178-21186	distance	_	
112-66	21187-21188	(	_	
112-67	21188-21191	for	_	
112-68	21192-21201	VMPFC-ACC	_	
112-69	21202-21203	[	_	
112-70	21203-21204	r	_	
112-71	21205-21206	=	_	
112-72	21207-21210	.52	_	
112-73	21210-21211	,	_	
112-74	21212-21213	p	_	
112-75	21214-21215	<	_	
112-76	21216-21219	.01	_	
112-77	21219-21220	]	_	
112-78	21220-21221	,	_	
112-79	21222-21227	while	_	
112-80	21228-21239	controlling	_	
112-81	21240-21243	for	_	
112-82	21244-21247	age	_	
112-83	21247-21248	)	_	
112-84	21249-21250	(	_	
112-85	21250-21262	Supplemental	_	
112-86	21263-21269	Figure	_	
112-87	21270-21272	S4	_	
112-88	21272-21273	)	_	
112-89	21273-21274	.	_	

#Text=A two-way ANOVA revealed no significant main or interaction effects of time (pre/post) or treatment (real/sham) on self-reported alcohol craving (all p ≥ .05).
113-1	21275-21276	A	_	
113-2	21277-21284	two-way	_	
113-3	21285-21290	ANOVA	_	
113-4	21291-21299	revealed	_	
113-5	21300-21302	no	_	
113-6	21303-21314	significant	_	
113-7	21315-21319	main	_	
113-8	21320-21322	or	_	
113-9	21323-21334	interaction	_	
113-10	21335-21342	effects	_	
113-11	21343-21345	of	_	
113-12	21346-21350	time	_	
113-13	21351-21352	(	_	
113-14	21352-21355	pre	_	
113-15	21355-21356	/	_	
113-16	21356-21360	post	_	
113-17	21360-21361	)	_	
113-18	21362-21364	or	_	
113-19	21365-21374	treatment	_	
113-20	21375-21376	(	_	
113-21	21376-21380	real	_	
113-22	21380-21381	/	_	
113-23	21381-21385	sham	_	
113-24	21385-21386	)	_	
113-25	21387-21389	on	_	
113-26	21390-21403	self-reported	_	
113-27	21404-21411	alcohol	_	
113-28	21412-21419	craving	_	
113-29	21420-21421	(	_	
113-30	21421-21424	all	_	
113-31	21425-21426	p	_	
113-32	21427-21428	≥	_	
113-33	21429-21432	.05	_	
113-34	21432-21433	)	_	
113-35	21433-21434	.	_	

#Text=Changes in craving did not correspond to changes in FC.
114-1	21435-21442	Changes	_	
114-2	21443-21445	in	_	
114-3	21446-21453	craving	_	
114-4	21454-21457	did	_	
114-5	21458-21461	not	_	
114-6	21462-21472	correspond	_	
114-7	21473-21475	to	_	
114-8	21476-21483	changes	_	
114-9	21484-21486	in	_	
114-10	21487-21489	FC	_	
114-11	21489-21490	.	_	

#Text=Integration of Data From Experiments 1 and 2
#Text=When assessing cocaine and heavy alcohol users together (N = 49), baseline FC for drug versus neutral cues was significantly elevated across all striatal and salience connections with the VMPFC (t391 = 6.59, p < .00001, d = 0.33).
115-1	21491-21502	Integration	_	
115-2	21503-21505	of	_	
115-3	21506-21510	Data	_	
115-4	21511-21515	From	_	
115-5	21516-21527	Experiments	_	
115-6	21528-21529	1	_	
115-7	21530-21533	and	_	
115-8	21534-21535	2	_	
115-9	21536-21540	When	_	
115-10	21541-21550	assessing	_	
115-11	21551-21558	cocaine	_	
115-12	21559-21562	and	_	
115-13	21563-21568	heavy	_	
115-14	21569-21576	alcohol	_	
115-15	21577-21582	users	_	
115-16	21583-21591	together	_	
115-17	21592-21593	(	_	
115-18	21593-21594	N	_	
115-19	21595-21596	=	_	
115-20	21597-21599	49	_	
115-21	21599-21600	)	_	
115-22	21600-21601	,	_	
115-23	21602-21610	baseline	_	
115-24	21611-21613	FC	_	
115-25	21614-21617	for	_	
115-26	21618-21622	drug	_	
115-27	21623-21629	versus	_	
115-28	21630-21637	neutral	_	
115-29	21638-21642	cues	_	
115-30	21643-21646	was	_	
115-31	21647-21660	significantly	_	
115-32	21661-21669	elevated	_	
115-33	21670-21676	across	_	
115-34	21677-21680	all	_	
115-35	21681-21689	striatal	_	
115-36	21690-21693	and	_	
115-37	21694-21702	salience	_	
115-38	21703-21714	connections	_	
115-39	21715-21719	with	_	
115-40	21720-21723	the	_	
115-41	21724-21729	VMPFC	_	
115-42	21730-21731	(	_	
115-43	21731-21735	t391	_	
115-44	21736-21737	=	_	
115-45	21738-21742	6.59	_	
115-46	21742-21743	,	_	
115-47	21744-21745	p	_	
115-48	21746-21747	<	_	
115-49	21748-21754	.00001	_	
115-50	21754-21755	,	_	
115-51	21756-21757	d	_	
115-52	21758-21759	=	_	
115-53	21760-21764	0.33	_	
115-54	21764-21765	)	_	
115-55	21765-21766	.	_	

#Text=Specifically, there was significantly elevated FC between the VMPFC and left caudate, right caudate, left putamen, right putamen, left insula, and ventral striatum (all FDR-corrected p ≤ .05; effect sizes: d = 0.42, 0.37, 0.53, 0.30, 0.53, 0.21, and 0.31, respectively) (Figure 4).
116-1	21767-21779	Specifically	_	
116-2	21779-21780	,	_	
116-3	21781-21786	there	_	
116-4	21787-21790	was	_	
116-5	21791-21804	significantly	_	
116-6	21805-21813	elevated	_	
116-7	21814-21816	FC	_	
116-8	21817-21824	between	_	
116-9	21825-21828	the	_	
116-10	21829-21834	VMPFC	_	
116-11	21835-21838	and	_	
116-12	21839-21843	left	_	
116-13	21844-21851	caudate	_	
116-14	21851-21852	,	_	
116-15	21853-21858	right	_	
116-16	21859-21866	caudate	_	
116-17	21866-21867	,	_	
116-18	21868-21872	left	_	
116-19	21873-21880	putamen	_	
116-20	21880-21881	,	_	
116-21	21882-21887	right	_	
116-22	21888-21895	putamen	_	
116-23	21895-21896	,	_	
116-24	21897-21901	left	_	
116-25	21902-21908	insula	_	
116-26	21908-21909	,	_	
116-27	21910-21913	and	_	
116-28	21914-21921	ventral	_	
116-29	21922-21930	striatum	_	
116-30	21931-21932	(	_	
116-31	21932-21935	all	_	
116-32	21936-21949	FDR-corrected	_	
116-33	21950-21951	p	_	
116-34	21952-21953	≤	_	
116-35	21954-21957	.05	_	
116-36	21957-21958	;	_	
116-37	21959-21965	effect	_	
116-38	21966-21971	sizes	_	
116-39	21971-21972	:	_	
116-40	21973-21974	d	_	
116-41	21975-21976	=	_	
116-42	21977-21981	0.42	_	
116-43	21981-21982	,	_	
116-44	21983-21987	0.37	_	
116-45	21987-21988	,	_	
116-46	21989-21993	0.53	_	
116-47	21993-21994	,	_	
116-48	21995-21999	0.30	_	
116-49	21999-22000	,	_	
116-50	22001-22005	0.53	_	
116-51	22005-22006	,	_	
116-52	22007-22011	0.21	_	
116-53	22011-22012	,	_	
116-54	22013-22016	and	_	
116-55	22017-22021	0.31	_	
116-56	22021-22022	,	_	
116-57	22023-22035	respectively	_	
116-58	22035-22036	)	_	
116-59	22037-22038	(	_	
116-60	22038-22044	Figure	_	
116-61	22045-22046	4	_	
116-62	22046-22047	)	_	
116-63	22047-22048	.	_	

#Text=A three-way repeated-measures ANOVA (treatment [real/sham] × time [pre/post] × ROI) revealed a significant interaction between treatment and time (F1,1536 = 50.8, p < .00001), but no main effect or interaction with ROI, indicating a general effect of treatment × time across all ROIs (Figure 4).
117-1	22049-22050	A	_	
117-2	22051-22060	three-way	_	
117-3	22061-22078	repeated-measures	_	
117-4	22079-22084	ANOVA	_	
117-5	22085-22086	(	_	
117-6	22086-22095	treatment	_	
117-7	22096-22097	[	_	
117-8	22097-22101	real	_	
117-9	22101-22102	/	_	
117-10	22102-22106	sham	_	
117-11	22106-22107	]	_	
117-12	22108-22109	×	_	
117-13	22110-22114	time	_	
117-14	22115-22116	[	_	
117-15	22116-22119	pre	_	
117-16	22119-22120	/	_	
117-17	22120-22124	post	_	
117-18	22124-22125	]	_	
117-19	22126-22127	×	_	
117-20	22128-22131	ROI	_	
117-21	22131-22132	)	_	
117-22	22133-22141	revealed	_	
117-23	22142-22143	a	_	
117-24	22144-22155	significant	_	
117-25	22156-22167	interaction	_	
117-26	22168-22175	between	_	
117-27	22176-22185	treatment	_	
117-28	22186-22189	and	_	
117-29	22190-22194	time	_	
117-30	22195-22196	(	_	
117-31	22196-22203	F1,1536	_	
117-32	22204-22205	=	_	
117-33	22206-22210	50.8	_	
117-34	22210-22211	,	_	
117-35	22212-22213	p	_	
117-36	22214-22215	<	_	
117-37	22216-22222	.00001	_	
117-38	22222-22223	)	_	
117-39	22223-22224	,	_	
117-40	22225-22228	but	_	
117-41	22229-22231	no	_	
117-42	22232-22236	main	_	
117-43	22237-22243	effect	_	
117-44	22244-22246	or	_	
117-45	22247-22258	interaction	_	
117-46	22259-22263	with	_	
117-47	22264-22267	ROI	_	
117-48	22267-22268	,	_	
117-49	22269-22279	indicating	_	
117-50	22280-22281	a	_	
117-51	22282-22289	general	_	
117-52	22290-22296	effect	_	
117-53	22297-22299	of	_	
117-54	22300-22309	treatment	_	
117-55	22310-22311	×	_	
117-56	22312-22316	time	_	
117-57	22317-22323	across	_	
117-58	22324-22327	all	_	
117-59	22328-22332	ROIs	_	
117-60	22333-22334	(	_	
117-61	22334-22340	Figure	_	
117-62	22341-22342	4	_	
117-63	22342-22343	)	_	
117-64	22343-22344	.	_	

#Text=A post hoc t test of the interaction revealed that FC for drug versus neutral cues was significantly attenuated following real versus sham cTBS (t391 = −7.47, FDR p < .00001).
118-1	22345-22346	A	_	
118-2	22347-22351	post	_	
118-3	22352-22355	hoc	_	
118-4	22356-22357	t	_	
118-5	22358-22362	test	_	
118-6	22363-22365	of	_	
118-7	22366-22369	the	_	
118-8	22370-22381	interaction	_	
118-9	22382-22390	revealed	_	
118-10	22391-22395	that	_	
118-11	22396-22398	FC	_	
118-12	22399-22402	for	_	
118-13	22403-22407	drug	_	
118-14	22408-22414	versus	_	
118-15	22415-22422	neutral	_	
118-16	22423-22427	cues	_	
118-17	22428-22431	was	_	
118-18	22432-22445	significantly	_	
118-19	22446-22456	attenuated	_	
118-20	22457-22466	following	_	
118-21	22467-22471	real	_	
118-22	22472-22478	versus	_	
118-23	22479-22483	sham	_	
118-24	22484-22488	cTBS	_	
118-25	22489-22490	(	_	
118-26	22490-22494	t391	_	
118-27	22495-22496	=	_	
118-28	22497-22498	−	_	
118-29	22498-22502	7.47	_	
118-30	22502-22503	,	_	
118-31	22504-22507	FDR	_	
118-32	22508-22509	p	_	
118-33	22510-22511	<	_	
118-34	22512-22518	.00001	_	
118-35	22518-22519	)	_	
118-36	22519-22520	.	_	

#Text=This significant difference was driven by significant attenuations following real cTBS (t391 = −6.67, FDR p < .00001), as well as significant increases following sham cTBS (t391 = 4.26, FDR p < .0001).
119-1	22521-22525	This	_	
119-2	22526-22537	significant	_	
119-3	22538-22548	difference	_	
119-4	22549-22552	was	_	
119-5	22553-22559	driven	_	
119-6	22560-22562	by	_	
119-7	22563-22574	significant	_	
119-8	22575-22587	attenuations	_	
119-9	22588-22597	following	_	
119-10	22598-22602	real	_	
119-11	22603-22607	cTBS	_	
119-12	22608-22609	(	_	
119-13	22609-22613	t391	_	
119-14	22614-22615	=	_	
119-15	22616-22617	−	_	
119-16	22617-22621	6.67	_	
119-17	22621-22622	,	_	
119-18	22623-22626	FDR	_	
119-19	22627-22628	p	_	
119-20	22629-22630	<	_	
119-21	22631-22637	.00001	_	
119-22	22637-22638	)	_	
119-23	22638-22639	,	_	
119-24	22640-22642	as	_	
119-25	22643-22647	well	_	
119-26	22648-22650	as	_	
119-27	22651-22662	significant	_	
119-28	22663-22672	increases	_	
119-29	22673-22682	following	_	
119-30	22683-22687	sham	_	
119-31	22688-22692	cTBS	_	
119-32	22693-22694	(	_	
119-33	22694-22698	t391	_	
119-34	22699-22700	=	_	
119-35	22701-22705	4.26	_	
119-36	22705-22706	,	_	
119-37	22707-22710	FDR	_	
119-38	22711-22712	p	_	
119-39	22713-22714	<	_	
119-40	22715-22720	.0001	_	
119-41	22720-22721	)	_	
119-42	22721-22722	.	_	

#Text=Although there was no significant main effect or interaction with ROI, effect sizes of the attenuations in alcohol cue–evoked FC following real versus sham cTBS were largest between the VMPFC and left putamen (d = −0.52) and left insula (d = −0.60), and smaller between the VMPFC and left caudate (d = −0.48), right caudate (d = −0.42), right putamen (d = −0.32), ACC (d = −0.30), and ventral striatum (d = −0.42) (Figure 4).
120-1	22723-22731	Although	_	
120-2	22732-22737	there	_	
120-3	22738-22741	was	_	
120-4	22742-22744	no	_	
120-5	22745-22756	significant	_	
120-6	22757-22761	main	_	
120-7	22762-22768	effect	_	
120-8	22769-22771	or	_	
120-9	22772-22783	interaction	_	
120-10	22784-22788	with	_	
120-11	22789-22792	ROI	_	
120-12	22792-22793	,	_	
120-13	22794-22800	effect	_	
120-14	22801-22806	sizes	_	
120-15	22807-22809	of	_	
120-16	22810-22813	the	_	
120-17	22814-22826	attenuations	_	
120-18	22827-22829	in	_	
120-19	22830-22837	alcohol	_	
120-20	22838-22848	cue–evoked	_	
120-21	22849-22851	FC	_	
120-22	22852-22861	following	_	
120-23	22862-22866	real	_	
120-24	22867-22873	versus	_	
120-25	22874-22878	sham	_	
120-26	22879-22883	cTBS	_	
120-27	22884-22888	were	_	
120-28	22889-22896	largest	_	
120-29	22897-22904	between	_	
120-30	22905-22908	the	_	
120-31	22909-22914	VMPFC	_	
120-32	22915-22918	and	_	
120-33	22919-22923	left	_	
120-34	22924-22931	putamen	_	
120-35	22932-22933	(	_	
120-36	22933-22934	d	_	
120-37	22935-22936	=	_	
120-38	22937-22938	−	_	
120-39	22938-22942	0.52	_	
120-40	22942-22943	)	_	
120-41	22944-22947	and	_	
120-42	22948-22952	left	_	
120-43	22953-22959	insula	_	
120-44	22960-22961	(	_	
120-45	22961-22962	d	_	
120-46	22963-22964	=	_	
120-47	22965-22966	−	_	
120-48	22966-22970	0.60	_	
120-49	22970-22971	)	_	
120-50	22971-22972	,	_	
120-51	22973-22976	and	_	
120-52	22977-22984	smaller	_	
120-53	22985-22992	between	_	
120-54	22993-22996	the	_	
120-55	22997-23002	VMPFC	_	
120-56	23003-23006	and	_	
120-57	23007-23011	left	_	
120-58	23012-23019	caudate	_	
120-59	23020-23021	(	_	
120-60	23021-23022	d	_	
120-61	23023-23024	=	_	
120-62	23025-23026	−	_	
120-63	23026-23030	0.48	_	
120-64	23030-23031	)	_	
120-65	23031-23032	,	_	
120-66	23033-23038	right	_	
120-67	23039-23046	caudate	_	
120-68	23047-23048	(	_	
120-69	23048-23049	d	_	
120-70	23050-23051	=	_	
120-71	23052-23053	−	_	
120-72	23053-23057	0.42	_	
120-73	23057-23058	)	_	
120-74	23058-23059	,	_	
120-75	23060-23065	right	_	
120-76	23066-23073	putamen	_	
120-77	23074-23075	(	_	
120-78	23075-23076	d	_	
120-79	23077-23078	=	_	
120-80	23079-23080	−	_	
120-81	23080-23084	0.32	_	
120-82	23084-23085	)	_	
120-83	23085-23086	,	_	
120-84	23087-23090	ACC	_	
120-85	23091-23092	(	_	
120-86	23092-23093	d	_	
120-87	23094-23095	=	_	
120-88	23096-23097	−	_	
120-89	23097-23101	0.30	_	
120-90	23101-23102	)	_	
120-91	23102-23103	,	_	
120-92	23104-23107	and	_	
120-93	23108-23115	ventral	_	
120-94	23116-23124	striatum	_	
120-95	23125-23126	(	_	
120-96	23126-23127	d	_	
120-97	23128-23129	=	_	
120-98	23130-23131	−	_	
120-99	23131-23135	0.42	_	
120-100	23135-23136	)	_	
120-101	23137-23138	(	_	
120-102	23138-23144	Figure	_	
120-103	23145-23146	4	_	
120-104	23146-23147	)	_	
120-105	23147-23148	.	_	

#Text=For the group, a two-way ANOVA revealed a significant main effect of time (pre/post) on self-reported cocaine craving (F1,184 = 6.56, p = .01), but a nonsignificant effect of treatment or treatment × time (both p ≥ .05).
121-1	23149-23152	For	_	
121-2	23153-23156	the	_	
121-3	23157-23162	group	_	
121-4	23162-23163	,	_	
121-5	23164-23165	a	_	
121-6	23166-23173	two-way	_	
121-7	23174-23179	ANOVA	_	
121-8	23180-23188	revealed	_	
121-9	23189-23190	a	_	
121-10	23191-23202	significant	_	
121-11	23203-23207	main	_	
121-12	23208-23214	effect	_	
121-13	23215-23217	of	_	
121-14	23218-23222	time	_	
121-15	23223-23224	(	_	
121-16	23224-23227	pre	_	
121-17	23227-23228	/	_	
121-18	23228-23232	post	_	
121-19	23232-23233	)	_	
121-20	23234-23236	on	_	
121-21	23237-23250	self-reported	_	
121-22	23251-23258	cocaine	_	
121-23	23259-23266	craving	_	
121-24	23267-23268	(	_	
121-25	23268-23274	F1,184	_	
121-26	23275-23276	=	_	
121-27	23277-23281	6.56	_	
121-28	23281-23282	,	_	
121-29	23283-23284	p	_	
121-30	23285-23286	=	_	
121-31	23287-23290	.01	_	
121-32	23290-23291	)	_	
121-33	23291-23292	,	_	
121-34	23293-23296	but	_	
121-35	23297-23298	a	_	
121-36	23299-23313	nonsignificant	_	
121-37	23314-23320	effect	_	
121-38	23321-23323	of	_	
121-39	23324-23333	treatment	_	
121-40	23334-23336	or	_	
121-41	23337-23346	treatment	_	
121-42	23347-23348	×	_	
121-43	23349-23353	time	_	
121-44	23354-23355	(	_	
121-45	23355-23359	both	_	
121-46	23360-23361	p	_	
121-47	23362-23363	≥	_	
121-48	23364-23367	.05	_	
121-49	23367-23368	)	_	
121-50	23368-23369	.	_	

#Text=Post hoc paired t tests revealed that self-reported craving was significantly lower than baseline following real cTBS (t48 = −3.32, p = .002), and also following sham cTBS (t46 = −2.97, p = .005).
122-1	23370-23374	Post	_	
122-2	23375-23378	hoc	_	
122-3	23379-23385	paired	_	
122-4	23386-23387	t	_	
122-5	23388-23393	tests	_	
122-6	23394-23402	revealed	_	
122-7	23403-23407	that	_	
122-8	23408-23421	self-reported	_	
122-9	23422-23429	craving	_	
122-10	23430-23433	was	_	
122-11	23434-23447	significantly	_	
122-12	23448-23453	lower	_	
122-13	23454-23458	than	_	
122-14	23459-23467	baseline	_	
122-15	23468-23477	following	_	
122-16	23478-23482	real	_	
122-17	23483-23487	cTBS	_	
122-18	23488-23489	(	_	
122-19	23489-23492	t48	_	
122-20	23493-23494	=	_	
122-21	23495-23496	−	_	
122-22	23496-23500	3.32	_	
122-23	23500-23501	,	_	
122-24	23502-23503	p	_	
122-25	23504-23505	=	_	
122-26	23506-23510	.002	_	
122-27	23510-23511	)	_	
122-28	23511-23512	,	_	
122-29	23513-23516	and	_	
122-30	23517-23521	also	_	
122-31	23522-23531	following	_	
122-32	23532-23536	sham	_	
122-33	23537-23541	cTBS	_	
122-34	23542-23543	(	_	
122-35	23543-23546	t46	_	
122-36	23547-23548	=	_	
122-37	23549-23550	−	_	
122-38	23550-23554	2.97	_	
122-39	23554-23555	,	_	
122-40	23556-23557	p	_	
122-41	23558-23559	=	_	
122-42	23560-23564	.005	_	
122-43	23564-23565	)	_	
122-44	23565-23566	.	_	

#Text=Thus, changes in craving after real cTBS did not significantly differ from sham (t46 = −0.29, p ≥ .05).
123-1	23567-23571	Thus	_	
123-2	23571-23572	,	_	
123-3	23573-23580	changes	_	
123-4	23581-23583	in	_	
123-5	23584-23591	craving	_	
123-6	23592-23597	after	_	
123-7	23598-23602	real	_	
123-8	23603-23607	cTBS	_	
123-9	23608-23611	did	_	
123-10	23612-23615	not	_	
123-11	23616-23629	significantly	_	
123-12	23630-23636	differ	_	
123-13	23637-23641	from	_	
123-14	23642-23646	sham	_	
123-15	23647-23648	(	_	
123-16	23648-23651	t46	_	
123-17	23652-23653	=	_	
123-18	23654-23655	−	_	
123-19	23655-23659	0.29	_	
123-20	23659-23660	,	_	
123-21	23661-23662	p	_	
123-22	23663-23664	≥	_	
123-23	23665-23668	.05	_	
123-24	23668-23669	)	_	
123-25	23669-23670	.	_	

#Text=Furthermore, changes in craving did not correspond to changes in FC.
124-1	23671-23682	Furthermore	_	
124-2	23682-23683	,	_	
124-3	23684-23691	changes	_	
124-4	23692-23694	in	_	
124-5	23695-23702	craving	_	
124-6	23703-23706	did	_	
124-7	23707-23710	not	_	
124-8	23711-23721	correspond	_	
124-9	23722-23724	to	_	
124-10	23725-23732	changes	_	
124-11	23733-23735	in	_	
124-12	23736-23738	FC	_	
124-13	23738-23739	.	_	

#Text=DISCUSSION
#Text=In the last 20 years, both basic and clinical research has demonstrated that frontostriatal circuitry is critical to drug-taking behaviors.
125-1	23740-23750	DISCUSSION	_	
125-2	23751-23753	In	_	
125-3	23754-23757	the	_	
125-4	23758-23762	last	_	
125-5	23763-23765	20	_	
125-6	23766-23771	years	_	
125-7	23771-23772	,	_	
125-8	23773-23777	both	_	
125-9	23778-23783	basic	_	
125-10	23784-23787	and	_	
125-11	23788-23796	clinical	_	
125-12	23797-23805	research	_	
125-13	23806-23809	has	_	
125-14	23810-23822	demonstrated	_	
125-15	23823-23827	that	_	
125-16	23828-23842	frontostriatal	_	
125-17	23843-23852	circuitry	_	
125-18	23853-23855	is	_	
125-19	23856-23864	critical	_	
125-20	23865-23867	to	_	
125-21	23868-23879	drug-taking	_	
125-22	23880-23889	behaviors	_	
125-23	23889-23890	.	_	

#Text=With advances in human brain stimulation research, for the first time it is now possible to determine if stimulation of these circuits can change drug cue reactivity.
126-1	23891-23895	With	_	
126-2	23896-23904	advances	_	
126-3	23905-23907	in	_	
126-4	23908-23913	human	_	
126-5	23914-23919	brain	_	
126-6	23920-23931	stimulation	_	
126-7	23932-23940	research	_	
126-8	23940-23941	,	_	
126-9	23942-23945	for	_	
126-10	23946-23949	the	_	
126-11	23950-23955	first	_	
126-12	23956-23960	time	_	
126-13	23961-23963	it	_	
126-14	23964-23966	is	_	
126-15	23967-23970	now	_	
126-16	23971-23979	possible	_	
126-17	23980-23982	to	_	
126-18	23983-23992	determine	_	
126-19	23993-23995	if	_	
126-20	23996-24007	stimulation	_	
126-21	24008-24010	of	_	
126-22	24011-24016	these	_	
126-23	24017-24025	circuits	_	
126-24	24026-24029	can	_	
126-25	24030-24036	change	_	
126-26	24037-24041	drug	_	
126-27	24042-24045	cue	_	
126-28	24046-24056	reactivity	_	
126-29	24056-24057	.	_	

#Text=In this paper, we describe two experiments in humans suggesting that noninvasive modulation of the VMPFC can dampen drug cue reactivity in multiple classes of substance-dependent individuals.
127-1	24058-24060	In	_	
127-2	24061-24065	this	_	
127-3	24066-24071	paper	_	
127-4	24071-24072	,	_	
127-5	24073-24075	we	_	
127-6	24076-24084	describe	_	
127-7	24085-24088	two	_	
127-8	24089-24100	experiments	_	
127-9	24101-24103	in	_	
127-10	24104-24110	humans	_	
127-11	24111-24121	suggesting	_	
127-12	24122-24126	that	_	
127-13	24127-24138	noninvasive	_	
127-14	24139-24149	modulation	_	
127-15	24150-24152	of	_	
127-16	24153-24156	the	_	
127-17	24157-24162	VMPFC	_	
127-18	24163-24166	can	_	
127-19	24167-24173	dampen	_	
127-20	24174-24178	drug	_	
127-21	24179-24182	cue	_	
127-22	24183-24193	reactivity	_	
127-23	24194-24196	in	_	
127-24	24197-24205	multiple	_	
127-25	24206-24213	classes	_	
127-26	24214-24216	of	_	
127-27	24217-24236	substance-dependent	_	
127-28	24237-24248	individuals	_	
127-29	24248-24249	.	_	

#Text=The data from experiments 1 and 2 demonstrate that a single session of 3600 pulses of cTBS has significant effects on drug cue reactivity in both cocaine users and heavy alcohol users.
128-1	24250-24253	The	_	
128-2	24254-24258	data	_	
128-3	24259-24263	from	_	
128-4	24264-24275	experiments	_	
128-5	24276-24277	1	_	
128-6	24278-24281	and	_	
128-7	24282-24283	2	_	
128-8	24284-24295	demonstrate	_	
128-9	24296-24300	that	_	
128-10	24301-24302	a	_	
128-11	24303-24309	single	_	
128-12	24310-24317	session	_	
128-13	24318-24320	of	_	
128-14	24321-24325	3600	_	
128-15	24326-24332	pulses	_	
128-16	24333-24335	of	_	
128-17	24336-24340	cTBS	_	
128-18	24341-24344	has	_	
128-19	24345-24356	significant	_	
128-20	24357-24364	effects	_	
128-21	24365-24367	on	_	
128-22	24368-24372	drug	_	
128-23	24373-24376	cue	_	
128-24	24377-24387	reactivity	_	
128-25	24388-24390	in	_	
128-26	24391-24395	both	_	
128-27	24396-24403	cocaine	_	
128-28	24404-24409	users	_	
128-29	24410-24413	and	_	
128-30	24414-24419	heavy	_	
128-31	24420-24427	alcohol	_	
128-32	24428-24433	users	_	
128-33	24433-24434	.	_	

#Text=Additionally, the attenuating effects are greatest in cocaine users with shorter substance use histories and lower levels of craving.
129-1	24435-24447	Additionally	_	
129-2	24447-24448	,	_	
129-3	24449-24452	the	_	
129-4	24453-24464	attenuating	_	
129-5	24465-24472	effects	_	
129-6	24473-24476	are	_	
129-7	24477-24485	greatest	_	
129-8	24486-24488	in	_	
129-9	24489-24496	cocaine	_	
129-10	24497-24502	users	_	
129-11	24503-24507	with	_	
129-12	24508-24515	shorter	_	
129-13	24516-24525	substance	_	
129-14	24526-24529	use	_	
129-15	24530-24539	histories	_	
129-16	24540-24543	and	_	
129-17	24544-24549	lower	_	
129-18	24550-24556	levels	_	
129-19	24557-24559	of	_	
129-20	24560-24567	craving	_	
129-21	24567-24568	.	_	

#Text=Together, these results represent the first set of empirical data demonstrating that it is possible to attenuate drug cue–related neural reactivity through noninvasive attenuation of the VMPFC.
130-1	24569-24577	Together	_	
130-2	24577-24578	,	_	
130-3	24579-24584	these	_	
130-4	24585-24592	results	_	
130-5	24593-24602	represent	_	
130-6	24603-24606	the	_	
130-7	24607-24612	first	_	
130-8	24613-24616	set	_	
130-9	24617-24619	of	_	
130-10	24620-24629	empirical	_	
130-11	24630-24634	data	_	
130-12	24635-24648	demonstrating	_	
130-13	24649-24653	that	_	
130-14	24654-24656	it	_	
130-15	24657-24659	is	_	
130-16	24660-24668	possible	_	
130-17	24669-24671	to	_	
130-18	24672-24681	attenuate	_	
130-19	24682-24686	drug	_	
130-20	24687-24698	cue–related	_	
130-21	24699-24705	neural	_	
130-22	24706-24716	reactivity	_	
130-23	24717-24724	through	_	
130-24	24725-24736	noninvasive	_	
130-25	24737-24748	attenuation	_	
130-26	24749-24751	of	_	
130-27	24752-24755	the	_	
130-28	24756-24761	VMPFC	_	
130-29	24761-24762	.	_	

#Text=Although the effects of a single session of cTBS are likely temporary, these results provide initial proof-of-principle data regarding treatment target engagement.
131-1	24763-24771	Although	_	
131-2	24772-24775	the	_	
131-3	24776-24783	effects	_	
131-4	24784-24786	of	_	
131-5	24787-24788	a	_	
131-6	24789-24795	single	_	
131-7	24796-24803	session	_	
131-8	24804-24806	of	_	
131-9	24807-24811	cTBS	_	
131-10	24812-24815	are	_	
131-11	24816-24822	likely	_	
131-12	24823-24832	temporary	_	
131-13	24832-24833	,	_	
131-14	24834-24839	these	_	
131-15	24840-24847	results	_	
131-16	24848-24855	provide	_	
131-17	24856-24863	initial	_	
131-18	24864-24882	proof-of-principle	_	
131-19	24883-24887	data	_	
131-20	24888-24897	regarding	_	
131-21	24898-24907	treatment	_	
131-22	24908-24914	target	_	
131-23	24915-24925	engagement	_	
131-24	24925-24926	.	_	

#Text=They serve as a foundation for future clinical trials that may evaluate the efficacy, durability, and clinical implications of VMPFC cTBS in cocaine-dependent and alcohol-dependent individuals.
132-1	24927-24931	They	_	
132-2	24932-24937	serve	_	
132-3	24938-24940	as	_	
132-4	24941-24942	a	_	
132-5	24943-24953	foundation	_	
132-6	24954-24957	for	_	
132-7	24958-24964	future	_	
132-8	24965-24973	clinical	_	
132-9	24974-24980	trials	_	
132-10	24981-24985	that	_	
132-11	24986-24989	may	_	
132-12	24990-24998	evaluate	_	
132-13	24999-25002	the	_	
132-14	25003-25011	efficacy	_	
132-15	25011-25012	,	_	
132-16	25013-25023	durability	_	
132-17	25023-25024	,	_	
132-18	25025-25028	and	_	
132-19	25029-25037	clinical	_	
132-20	25038-25050	implications	_	
132-21	25051-25053	of	_	
132-22	25054-25059	VMPFC	_	
132-23	25060-25064	cTBS	_	
132-24	25065-25067	in	_	
132-25	25068-25085	cocaine-dependent	_	
132-26	25086-25089	and	_	
132-27	25090-25107	alcohol-dependent	_	
132-28	25108-25119	individuals	_	
132-29	25119-25120	.	_	

#Text=Importance of the Brain as a Biomarker in SUD Treatment Research
#Text=The present study is the first to demonstrate that noninvasive brain stimulation can alter drug/alcohol cue–related neural reactivity in humans.
133-1	25121-25131	Importance	_	
133-2	25132-25134	of	_	
133-3	25135-25138	the	_	
133-4	25139-25144	Brain	_	
133-5	25145-25147	as	_	
133-6	25148-25149	a	_	
133-7	25150-25159	Biomarker	_	
133-8	25160-25162	in	_	
133-9	25163-25166	SUD	_	
133-10	25167-25176	Treatment	_	
133-11	25177-25185	Research	_	
133-12	25186-25189	The	_	
133-13	25190-25197	present	_	
133-14	25198-25203	study	_	
133-15	25204-25206	is	_	
133-16	25207-25210	the	_	
133-17	25211-25216	first	_	
133-18	25217-25219	to	_	
133-19	25220-25231	demonstrate	_	
133-20	25232-25236	that	_	
133-21	25237-25248	noninvasive	_	
133-22	25249-25254	brain	_	
133-23	25255-25266	stimulation	_	
133-24	25267-25270	can	_	
133-25	25271-25276	alter	_	
133-26	25277-25281	drug	_	
133-27	25281-25282	/	_	
133-28	25282-25289	alcohol	_	
133-29	25290-25301	cue–related	_	
133-30	25302-25308	neural	_	
133-31	25309-25319	reactivity	_	
133-32	25320-25322	in	_	
133-33	25323-25329	humans	_	
133-34	25329-25330	.	_	

#Text=Although previous rTMS treatment studies have demonstrated that rTMS to the dorsolateral PFC (DLPFC), and the VMPFC can reduce subjective craving, the neural reactivity to drug cues may provide an even more robust and objective marker of relapse risk.
134-1	25331-25339	Although	_	
134-2	25340-25348	previous	_	
134-3	25349-25353	rTMS	_	
134-4	25354-25363	treatment	_	
134-5	25364-25371	studies	_	
134-6	25372-25376	have	_	
134-7	25377-25389	demonstrated	_	
134-8	25390-25394	that	_	
134-9	25395-25399	rTMS	_	
134-10	25400-25402	to	_	
134-11	25403-25406	the	_	
134-12	25407-25419	dorsolateral	_	
134-13	25420-25423	PFC	_	
134-14	25424-25425	(	_	
134-15	25425-25430	DLPFC	_	
134-16	25430-25431	)	_	
134-17	25431-25432	,	_	
134-18	25433-25436	and	_	
134-19	25437-25440	the	_	
134-20	25441-25446	VMPFC	_	
134-21	25447-25450	can	_	
134-22	25451-25457	reduce	_	
134-23	25458-25468	subjective	_	
134-24	25469-25476	craving	_	
134-25	25476-25477	,	_	
134-26	25478-25481	the	_	
134-27	25482-25488	neural	_	
134-28	25489-25499	reactivity	_	
134-29	25500-25502	to	_	
134-30	25503-25507	drug	_	
134-31	25508-25512	cues	_	
134-32	25513-25516	may	_	
134-33	25517-25524	provide	_	
134-34	25525-25527	an	_	
134-35	25528-25532	even	_	
134-36	25533-25537	more	_	
134-37	25538-25544	robust	_	
134-38	25545-25548	and	_	
134-39	25549-25558	objective	_	
134-40	25559-25565	marker	_	
134-41	25566-25568	of	_	
134-42	25569-25576	relapse	_	
134-43	25577-25581	risk	_	
134-44	25581-25582	.	_	

#Text=This cue reactivity is of particular importance in the development of treatment for addiction because it has been shown to predict relapse in cocaine, alcohol, nicotine, and opioid users.
135-1	25583-25587	This	_	
135-2	25588-25591	cue	_	
135-3	25592-25602	reactivity	_	
135-4	25603-25605	is	_	
135-5	25606-25608	of	_	
135-6	25609-25619	particular	_	
135-7	25620-25630	importance	_	
135-8	25631-25633	in	_	
135-9	25634-25637	the	_	
135-10	25638-25649	development	_	
135-11	25650-25652	of	_	
135-12	25653-25662	treatment	_	
135-13	25663-25666	for	_	
135-14	25667-25676	addiction	_	
135-15	25677-25684	because	_	
135-16	25685-25687	it	_	
135-17	25688-25691	has	_	
135-18	25692-25696	been	_	
135-19	25697-25702	shown	_	
135-20	25703-25705	to	_	
135-21	25706-25713	predict	_	
135-22	25714-25721	relapse	_	
135-23	25722-25724	in	_	
135-24	25725-25732	cocaine	_	
135-25	25732-25733	,	_	
135-26	25734-25741	alcohol	_	
135-27	25741-25742	,	_	
135-28	25743-25751	nicotine	_	
135-29	25751-25752	,	_	
135-30	25753-25756	and	_	
135-31	25757-25763	opioid	_	
135-32	25764-25769	users	_	
135-33	25769-25770	.	_	

#Text=These studies have demonstrated that cue-related reactivity in frontostriatolimbic circuitry is a transdiagnostic endophenotype of relapse vulnerability.
136-1	25771-25776	These	_	
136-2	25777-25784	studies	_	
136-3	25785-25789	have	_	
136-4	25790-25802	demonstrated	_	
136-5	25803-25807	that	_	
136-6	25808-25819	cue-related	_	
136-7	25820-25830	reactivity	_	
136-8	25831-25833	in	_	
136-9	25834-25853	frontostriatolimbic	_	
136-10	25854-25863	circuitry	_	
136-11	25864-25866	is	_	
136-12	25867-25868	a	_	
136-13	25869-25884	transdiagnostic	_	
136-14	25885-25898	endophenotype	_	
136-15	25899-25901	of	_	
136-16	25902-25909	relapse	_	
136-17	25910-25923	vulnerability	_	
136-18	25923-25924	.	_	

#Text=Hence, neurobiological treatment approaches targeting the neural circuitry related to cue reactivity, such as cTBS to the VMPFC, may provide a direct influence on subsequent cue-induced craving and relapse.
137-1	25925-25930	Hence	_	
137-2	25930-25931	,	_	
137-3	25932-25947	neurobiological	_	
137-4	25948-25957	treatment	_	
137-5	25958-25968	approaches	_	
137-6	25969-25978	targeting	_	
137-7	25979-25982	the	_	
137-8	25983-25989	neural	_	
137-9	25990-25999	circuitry	_	
137-10	26000-26007	related	_	
137-11	26008-26010	to	_	
137-12	26011-26014	cue	_	
137-13	26015-26025	reactivity	_	
137-14	26025-26026	,	_	
137-15	26027-26031	such	_	
137-16	26032-26034	as	_	
137-17	26035-26039	cTBS	_	
137-18	26040-26042	to	_	
137-19	26043-26046	the	_	
137-20	26047-26052	VMPFC	_	
137-21	26052-26053	,	_	
137-22	26054-26057	may	_	
137-23	26058-26065	provide	_	
137-24	26066-26067	a	_	
137-25	26068-26074	direct	_	
137-26	26075-26084	influence	_	
137-27	26085-26087	on	_	
137-28	26088-26098	subsequent	_	
137-29	26099-26110	cue-induced	_	
137-30	26111-26118	craving	_	
137-31	26119-26122	and	_	
137-32	26123-26130	relapse	_	
137-33	26130-26131	.	_	

#Text=Furthermore, neural biomarkers serve as objective and quantifiable measures for evaluating changes associated with treatment beyond what can be gathered from self-report or behavior alone.
138-1	26132-26143	Furthermore	_	
138-2	26143-26144	,	_	
138-3	26145-26151	neural	_	
138-4	26152-26162	biomarkers	_	
138-5	26163-26168	serve	_	
138-6	26169-26171	as	_	
138-7	26172-26181	objective	_	
138-8	26182-26185	and	_	
138-9	26186-26198	quantifiable	_	
138-10	26199-26207	measures	_	
138-11	26208-26211	for	_	
138-12	26212-26222	evaluating	_	
138-13	26223-26230	changes	_	
138-14	26231-26241	associated	_	
138-15	26242-26246	with	_	
138-16	26247-26256	treatment	_	
138-17	26257-26263	beyond	_	
138-18	26264-26268	what	_	
138-19	26269-26272	can	_	
138-20	26273-26275	be	_	
138-21	26276-26284	gathered	_	
138-22	26285-26289	from	_	
138-23	26290-26301	self-report	_	
138-24	26302-26304	or	_	
138-25	26305-26313	behavior	_	
138-26	26314-26319	alone	_	
138-27	26319-26320	.	_	

#Text=In the present study, we demonstrated for the first time that is possible to decrease frontostriatolimbic receptivity to drug cues.
139-1	26321-26323	In	_	
139-2	26324-26327	the	_	
139-3	26328-26335	present	_	
139-4	26336-26341	study	_	
139-5	26341-26342	,	_	
139-6	26343-26345	we	_	
139-7	26346-26358	demonstrated	_	
139-8	26359-26362	for	_	
139-9	26363-26366	the	_	
139-10	26367-26372	first	_	
139-11	26373-26377	time	_	
139-12	26378-26382	that	_	
139-13	26383-26385	is	_	
139-14	26386-26394	possible	_	
139-15	26395-26397	to	_	
139-16	26398-26406	decrease	_	
139-17	26407-26426	frontostriatolimbic	_	
139-18	26427-26438	receptivity	_	
139-19	26439-26441	to	_	
139-20	26442-26446	drug	_	
139-21	26447-26451	cues	_	
139-22	26451-26452	.	_	

#Text=Further research is necessary to determine if multiple sessions of this intervention will produce a sustainable decrease in cue reactivity and craving and lower relapse risk.
140-1	26453-26460	Further	_	
140-2	26461-26469	research	_	
140-3	26470-26472	is	_	
140-4	26473-26482	necessary	_	
140-5	26483-26485	to	_	
140-6	26486-26495	determine	_	
140-7	26496-26498	if	_	
140-8	26499-26507	multiple	_	
140-9	26508-26516	sessions	_	
140-10	26517-26519	of	_	
140-11	26520-26524	this	_	
140-12	26525-26537	intervention	_	
140-13	26538-26542	will	_	
140-14	26543-26550	produce	_	
140-15	26551-26552	a	_	
140-16	26553-26564	sustainable	_	
140-17	26565-26573	decrease	_	
140-18	26574-26576	in	_	
140-19	26577-26580	cue	_	
140-20	26581-26591	reactivity	_	
140-21	26592-26595	and	_	
140-22	26596-26603	craving	_	
140-23	26604-26607	and	_	
140-24	26608-26613	lower	_	
140-25	26614-26621	relapse	_	
140-26	26622-26626	risk	_	
140-27	26626-26627	.	_	

#Text=Drug Cue Exposure During cTBS Delivery: Priming the Circuit for Plasticity
#Text=Owing to the involvement of frontostriatolimbic regions in processing natural rewards, such as food, sex, and social interaction, it is important to consider the context in which brain stimulation treatment is used to alter this circuit.
141-1	26628-26632	Drug	_	
141-2	26633-26636	Cue	_	
141-3	26637-26645	Exposure	_	
141-4	26646-26652	During	_	
141-5	26653-26657	cTBS	_	
141-6	26658-26666	Delivery	_	
141-7	26666-26667	:	_	
141-8	26668-26675	Priming	_	
141-9	26676-26679	the	_	
141-10	26680-26687	Circuit	_	
141-11	26688-26691	for	_	
141-12	26692-26702	Plasticity	_	
141-13	26703-26708	Owing	_	
141-14	26709-26711	to	_	
141-15	26712-26715	the	_	
141-16	26716-26727	involvement	_	
141-17	26728-26730	of	_	
141-18	26731-26750	frontostriatolimbic	_	
141-19	26751-26758	regions	_	
141-20	26759-26761	in	_	
141-21	26762-26772	processing	_	
141-22	26773-26780	natural	_	
141-23	26781-26788	rewards	_	
141-24	26788-26789	,	_	
141-25	26790-26794	such	_	
141-26	26795-26797	as	_	
141-27	26798-26802	food	_	
141-28	26802-26803	,	_	
141-29	26804-26807	sex	_	
141-30	26807-26808	,	_	
141-31	26809-26812	and	_	
141-32	26813-26819	social	_	
141-33	26820-26831	interaction	_	
141-34	26831-26832	,	_	
141-35	26833-26835	it	_	
141-36	26836-26838	is	_	
141-37	26839-26848	important	_	
141-38	26849-26851	to	_	
141-39	26852-26860	consider	_	
141-40	26861-26864	the	_	
141-41	26865-26872	context	_	
141-42	26873-26875	in	_	
141-43	26876-26881	which	_	
141-44	26882-26887	brain	_	
141-45	26888-26899	stimulation	_	
141-46	26900-26909	treatment	_	
141-47	26910-26912	is	_	
141-48	26913-26917	used	_	
141-49	26918-26920	to	_	
141-50	26921-26926	alter	_	
141-51	26927-26931	this	_	
141-52	26932-26939	circuit	_	
141-53	26939-26940	.	_	

#Text=To target drug/alcohol cue reactivity, we employed a drug cue induction paradigm during TMS sessions as part of the treatment.
142-1	26941-26943	To	_	
142-2	26944-26950	target	_	
142-3	26951-26955	drug	_	
142-4	26955-26956	/	_	
142-5	26956-26963	alcohol	_	
142-6	26964-26967	cue	_	
142-7	26968-26978	reactivity	_	
142-8	26978-26979	,	_	
142-9	26980-26982	we	_	
142-10	26983-26991	employed	_	
142-11	26992-26993	a	_	
142-12	26994-26998	drug	_	
142-13	26999-27002	cue	_	
142-14	27003-27012	induction	_	
142-15	27013-27021	paradigm	_	
142-16	27022-27028	during	_	
142-17	27029-27032	TMS	_	
142-18	27033-27041	sessions	_	
142-19	27042-27044	as	_	
142-20	27045-27049	part	_	
142-21	27050-27052	of	_	
142-22	27053-27056	the	_	
142-23	27057-27066	treatment	_	
142-24	27066-27067	.	_	

#Text=This enabled us to “mobilize” or prime the circuit before modulation.
143-1	27068-27072	This	_	
143-2	27073-27080	enabled	_	
143-3	27081-27083	us	_	
143-4	27084-27086	to	_	
143-5	27087-27088	“	_	
143-6	27088-27096	mobilize	_	
143-7	27096-27097	”	_	
143-8	27098-27100	or	_	
143-9	27101-27106	prime	_	
143-10	27107-27110	the	_	
143-11	27111-27118	circuit	_	
143-12	27119-27125	before	_	
143-13	27126-27136	modulation	_	
143-14	27136-27137	.	_	

#Text=The use of cues to amplify the neural response to TMS was first demonstrated by Dinur-Klein et al..
144-1	27138-27141	The	_	
144-2	27142-27145	use	_	
144-3	27146-27148	of	_	
144-4	27149-27153	cues	_	
144-5	27154-27156	to	_	
144-6	27157-27164	amplify	_	
144-7	27165-27168	the	_	
144-8	27169-27175	neural	_	
144-9	27176-27184	response	_	
144-10	27185-27187	to	_	
144-11	27188-27191	TMS	_	
144-12	27192-27195	was	_	
144-13	27196-27201	first	_	
144-14	27202-27214	demonstrated	_	
144-15	27215-27217	by	_	
144-16	27218-27229	Dinur-Klein	_	
144-17	27230-27232	et	_	
144-18	27233-27235	al	_	
144-19	27235-27236	.	_	
144-20	27236-27237	.	_	

#Text=In their large, parametric study, they demonstrated that rTMS delivered in the presence of a smoking cue produced significantly larger reductions in cigarette use and craving than rTMS delivered without a cue prime.
145-1	27238-27240	In	_	
145-2	27241-27246	their	_	
145-3	27247-27252	large	_	
145-4	27252-27253	,	_	
145-5	27254-27264	parametric	_	
145-6	27265-27270	study	_	
145-7	27270-27271	,	_	
145-8	27272-27276	they	_	
145-9	27277-27289	demonstrated	_	
145-10	27290-27294	that	_	
145-11	27295-27299	rTMS	_	
145-12	27300-27309	delivered	_	
145-13	27310-27312	in	_	
145-14	27313-27316	the	_	
145-15	27317-27325	presence	_	
145-16	27326-27328	of	_	
145-17	27329-27330	a	_	
145-18	27331-27338	smoking	_	
145-19	27339-27342	cue	_	
145-20	27343-27351	produced	_	
145-21	27352-27365	significantly	_	
145-22	27366-27372	larger	_	
145-23	27373-27383	reductions	_	
145-24	27384-27386	in	_	
145-25	27387-27396	cigarette	_	
145-26	27397-27400	use	_	
145-27	27401-27404	and	_	
145-28	27405-27412	craving	_	
145-29	27413-27417	than	_	
145-30	27418-27422	rTMS	_	
145-31	27423-27432	delivered	_	
145-32	27433-27440	without	_	
145-33	27441-27442	a	_	
145-34	27443-27446	cue	_	
145-35	27447-27452	prime	_	
145-36	27452-27453	.	_	

#Text=Although the mechanisms through which this priming-associated plasticity occurs are not fully understood, preclinical and clinical research supports the notion that changes in excitability induced by brain stimulation are state dependent, or depend on the history of activation.
146-1	27454-27462	Although	_	
146-2	27463-27466	the	_	
146-3	27467-27477	mechanisms	_	
146-4	27478-27485	through	_	
146-5	27486-27491	which	_	
146-6	27492-27496	this	_	
146-7	27497-27515	priming-associated	_	
146-8	27516-27526	plasticity	_	
146-9	27527-27533	occurs	_	
146-10	27534-27537	are	_	
146-11	27538-27541	not	_	
146-12	27542-27547	fully	_	
146-13	27548-27558	understood	_	
146-14	27558-27559	,	_	
146-15	27560-27571	preclinical	_	
146-16	27572-27575	and	_	
146-17	27576-27584	clinical	_	
146-18	27585-27593	research	_	
146-19	27594-27602	supports	_	
146-20	27603-27606	the	_	
146-21	27607-27613	notion	_	
146-22	27614-27618	that	_	
146-23	27619-27626	changes	_	
146-24	27627-27629	in	_	
146-25	27630-27642	excitability	_	
146-26	27643-27650	induced	_	
146-27	27651-27653	by	_	
146-28	27654-27659	brain	_	
146-29	27660-27671	stimulation	_	
146-30	27672-27675	are	_	
146-31	27676-27681	state	_	
146-32	27682-27691	dependent	_	
146-33	27691-27692	,	_	
146-34	27693-27695	or	_	
146-35	27696-27702	depend	_	
146-36	27703-27705	on	_	
146-37	27706-27709	the	_	
146-38	27710-27717	history	_	
146-39	27718-27720	of	_	
146-40	27721-27731	activation	_	
146-41	27731-27732	.	_	

#Text=For instance, Muellbacher et al. found that inhibitory rTMS applied directly after motor learning inhibited the expression and maintenance of long-term potentiation in the primary motor cortex.
147-1	27733-27736	For	_	
147-2	27737-27745	instance	_	
147-3	27745-27746	,	_	
147-4	27747-27758	Muellbacher	_	
147-5	27759-27761	et	_	
147-6	27762-27764	al	_	
147-7	27764-27765	.	_	
147-8	27766-27771	found	_	
147-9	27772-27776	that	_	
147-10	27777-27787	inhibitory	_	
147-11	27788-27792	rTMS	_	
147-12	27793-27800	applied	_	
147-13	27801-27809	directly	_	
147-14	27810-27815	after	_	
147-15	27816-27821	motor	_	
147-16	27822-27830	learning	_	
147-17	27831-27840	inhibited	_	
147-18	27841-27844	the	_	
147-19	27845-27855	expression	_	
147-20	27856-27859	and	_	
147-21	27860-27871	maintenance	_	
147-22	27872-27874	of	_	
147-23	27875-27884	long-term	_	
147-24	27885-27897	potentiation	_	
147-25	27898-27900	in	_	
147-26	27901-27904	the	_	
147-27	27905-27912	primary	_	
147-28	27913-27918	motor	_	
147-29	27919-27925	cortex	_	
147-30	27925-27926	.	_	

#Text=In contrast, a study by Rioult-Pedotti et al. found that inhibitory rTMS given before motor learning produced facilitation in the primary motor cortex.
148-1	27927-27929	In	_	
148-2	27930-27938	contrast	_	
148-3	27938-27939	,	_	
148-4	27940-27941	a	_	
148-5	27942-27947	study	_	
148-6	27948-27950	by	_	
148-7	27951-27965	Rioult-Pedotti	_	
148-8	27966-27968	et	_	
148-9	27969-27971	al	_	
148-10	27971-27972	.	_	
148-11	27973-27978	found	_	
148-12	27979-27983	that	_	
148-13	27984-27994	inhibitory	_	
148-14	27995-27999	rTMS	_	
148-15	28000-28005	given	_	
148-16	28006-28012	before	_	
148-17	28013-28018	motor	_	
148-18	28019-28027	learning	_	
148-19	28028-28036	produced	_	
148-20	28037-28049	facilitation	_	
148-21	28050-28052	in	_	
148-22	28053-28056	the	_	
148-23	28057-28064	primary	_	
148-24	28065-28070	motor	_	
148-25	28071-28077	cortex	_	
148-26	28077-28078	.	_	

#Text=These and other studies suggest that there is an interaction between the neural state and stimulation protocol that is of crucial importance to determining the magnitude and direction of the aftereffects.
149-1	28079-28084	These	_	
149-2	28085-28088	and	_	
149-3	28089-28094	other	_	
149-4	28095-28102	studies	_	
149-5	28103-28110	suggest	_	
149-6	28111-28115	that	_	
149-7	28116-28121	there	_	
149-8	28122-28124	is	_	
149-9	28125-28127	an	_	
149-10	28128-28139	interaction	_	
149-11	28140-28147	between	_	
149-12	28148-28151	the	_	
149-13	28152-28158	neural	_	
149-14	28159-28164	state	_	
149-15	28165-28168	and	_	
149-16	28169-28180	stimulation	_	
149-17	28181-28189	protocol	_	
149-18	28190-28194	that	_	
149-19	28195-28197	is	_	
149-20	28198-28200	of	_	
149-21	28201-28208	crucial	_	
149-22	28209-28219	importance	_	
149-23	28220-28222	to	_	
149-24	28223-28234	determining	_	
149-25	28235-28238	the	_	
149-26	28239-28248	magnitude	_	
149-27	28249-28252	and	_	
149-28	28253-28262	direction	_	
149-29	28263-28265	of	_	
149-30	28266-28269	the	_	
149-31	28270-28282	aftereffects	_	
149-32	28282-28283	.	_	

#Text=Therefore, further research is needed to investigate the optimal contextual parameters needed to gain specificity of TMS treatment outcomes in addiction.
150-1	28284-28293	Therefore	_	
150-2	28293-28294	,	_	
150-3	28295-28302	further	_	
150-4	28303-28311	research	_	
150-5	28312-28314	is	_	
150-6	28315-28321	needed	_	
150-7	28322-28324	to	_	
150-8	28325-28336	investigate	_	
150-9	28337-28340	the	_	
150-10	28341-28348	optimal	_	
150-11	28349-28359	contextual	_	
150-12	28360-28370	parameters	_	
150-13	28371-28377	needed	_	
150-14	28378-28380	to	_	
150-15	28381-28385	gain	_	
150-16	28386-28397	specificity	_	
150-17	28398-28400	of	_	
150-18	28401-28404	TMS	_	
150-19	28405-28414	treatment	_	
150-20	28415-28423	outcomes	_	
150-21	28424-28426	in	_	
150-22	28427-28436	addiction	_	
150-23	28436-28437	.	_	

#Text=Importance of VMPFC as a Translationally Relevant Treatment Target
#Text=Another important contribution of the present study is that it is the first to investigate the VMPFC as a TMS treatment target for addiction.
151-1	28438-28448	Importance	_	
151-2	28449-28451	of	_	
151-3	28452-28457	VMPFC	_	
151-4	28458-28460	as	_	
151-5	28461-28462	a	_	
151-6	28463-28478	Translationally	_	
151-7	28479-28487	Relevant	_	
151-8	28488-28497	Treatment	_	
151-9	28498-28504	Target	_	
151-10	28505-28512	Another	_	
151-11	28513-28522	important	_	
151-12	28523-28535	contribution	_	
151-13	28536-28538	of	_	
151-14	28539-28542	the	_	
151-15	28543-28550	present	_	
151-16	28551-28556	study	_	
151-17	28557-28559	is	_	
151-18	28560-28564	that	_	
151-19	28565-28567	it	_	
151-20	28568-28570	is	_	
151-21	28571-28574	the	_	
151-22	28575-28580	first	_	
151-23	28581-28583	to	_	
151-24	28584-28595	investigate	_	
151-25	28596-28599	the	_	
151-26	28600-28605	VMPFC	_	
151-27	28606-28608	as	_	
151-28	28609-28610	a	_	
151-29	28611-28614	TMS	_	
151-30	28615-28624	treatment	_	
151-31	28625-28631	target	_	
151-32	28632-28635	for	_	
151-33	28636-28645	addiction	_	
151-34	28645-28646	.	_	

#Text=Most prior studies have focused on stimulating the DLPFC, a hub of the cognitive control circuit that is also dysfunctional in substance-dependent individuals.
152-1	28647-28651	Most	_	
152-2	28652-28657	prior	_	
152-3	28658-28665	studies	_	
152-4	28666-28670	have	_	
152-5	28671-28678	focused	_	
152-6	28679-28681	on	_	
152-7	28682-28693	stimulating	_	
152-8	28694-28697	the	_	
152-9	28698-28703	DLPFC	_	
152-10	28703-28704	,	_	
152-11	28705-28706	a	_	
152-12	28707-28710	hub	_	
152-13	28711-28713	of	_	
152-14	28714-28717	the	_	
152-15	28718-28727	cognitive	_	
152-16	28728-28735	control	_	
152-17	28736-28743	circuit	_	
152-18	28744-28748	that	_	
152-19	28749-28751	is	_	
152-20	28752-28756	also	_	
152-21	28757-28770	dysfunctional	_	
152-22	28771-28773	in	_	
152-23	28774-28793	substance-dependent	_	
152-24	28794-28805	individuals	_	
152-25	28805-28806	.	_	

#Text=These studies have revealed reductions in craving through either enhancement of the left DLPFC or inhibition of the right DLPFC.
153-1	28807-28812	These	_	
153-2	28813-28820	studies	_	
153-3	28821-28825	have	_	
153-4	28826-28834	revealed	_	
153-5	28835-28845	reductions	_	
153-6	28846-28848	in	_	
153-7	28849-28856	craving	_	
153-8	28857-28864	through	_	
153-9	28865-28871	either	_	
153-10	28872-28883	enhancement	_	
153-11	28884-28886	of	_	
153-12	28887-28890	the	_	
153-13	28891-28895	left	_	
153-14	28896-28901	DLPFC	_	
153-15	28902-28904	or	_	
153-16	28905-28915	inhibition	_	
153-17	28916-28918	of	_	
153-18	28919-28922	the	_	
153-19	28923-28928	right	_	
153-20	28929-28934	DLPFC	_	
153-21	28934-28935	.	_	

#Text=However, it is not clear that the DLPFC is the only target for TMS treatment development in addiction.
154-1	28936-28943	However	_	
154-2	28943-28944	,	_	
154-3	28945-28947	it	_	
154-4	28948-28950	is	_	
154-5	28951-28954	not	_	
154-6	28955-28960	clear	_	
154-7	28961-28965	that	_	
154-8	28966-28969	the	_	
154-9	28970-28975	DLPFC	_	
154-10	28976-28978	is	_	
154-11	28979-28982	the	_	
154-12	28983-28987	only	_	
154-13	28988-28994	target	_	
154-14	28995-28998	for	_	
154-15	28999-29002	TMS	_	
154-16	29003-29012	treatment	_	
154-17	29013-29024	development	_	
154-18	29025-29027	in	_	
154-19	29028-29037	addiction	_	
154-20	29037-29038	.	_	

#Text=In fact, the VMPFC may provide a more direct target, given its functional and structural connectivity with striatal and limbic regions and known involvement in drug cue reactivity.
155-1	29039-29041	In	_	
155-2	29042-29046	fact	_	
155-3	29046-29047	,	_	
155-4	29048-29051	the	_	
155-5	29052-29057	VMPFC	_	
155-6	29058-29061	may	_	
155-7	29062-29069	provide	_	
155-8	29070-29071	a	_	
155-9	29072-29076	more	_	
155-10	29077-29083	direct	_	
155-11	29084-29090	target	_	
155-12	29090-29091	,	_	
155-13	29092-29097	given	_	
155-14	29098-29101	its	_	
155-15	29102-29112	functional	_	
155-16	29113-29116	and	_	
155-17	29117-29127	structural	_	
155-18	29128-29140	connectivity	_	
155-19	29141-29145	with	_	
155-20	29146-29154	striatal	_	
155-21	29155-29158	and	_	
155-22	29159-29165	limbic	_	
155-23	29166-29173	regions	_	
155-24	29174-29177	and	_	
155-25	29178-29183	known	_	
155-26	29184-29195	involvement	_	
155-27	29196-29198	in	_	
155-28	29199-29203	drug	_	
155-29	29204-29207	cue	_	
155-30	29208-29218	reactivity	_	
155-31	29218-29219	.	_	

#Text=Preclinical research provides ample evidence for targeting ventral frontostriatal circuitry as a way to modulate drug self-administration.
156-1	29220-29231	Preclinical	_	
156-2	29232-29240	research	_	
156-3	29241-29249	provides	_	
156-4	29250-29255	ample	_	
156-5	29256-29264	evidence	_	
156-6	29265-29268	for	_	
156-7	29269-29278	targeting	_	
156-8	29279-29286	ventral	_	
156-9	29287-29301	frontostriatal	_	
156-10	29302-29311	circuitry	_	
156-11	29312-29314	as	_	
156-12	29315-29316	a	_	
156-13	29317-29320	way	_	
156-14	29321-29323	to	_	
156-15	29324-29332	modulate	_	
156-16	29333-29337	drug	_	
156-17	29338-29357	self-administration	_	
156-18	29357-29358	.	_	

#Text=It is possible to increase or decrease cocaine, methamphetamine, and heroin seeking in rats through stimulation or inhibition of the infralimbic cortex, a cortical region in the VMPFC.
157-1	29359-29361	It	_	
157-2	29362-29364	is	_	
157-3	29365-29373	possible	_	
157-4	29374-29376	to	_	
157-5	29377-29385	increase	_	
157-6	29386-29388	or	_	
157-7	29389-29397	decrease	_	
157-8	29398-29405	cocaine	_	
157-9	29405-29406	,	_	
157-10	29407-29422	methamphetamine	_	
157-11	29422-29423	,	_	
157-12	29424-29427	and	_	
157-13	29428-29434	heroin	_	
157-14	29435-29442	seeking	_	
157-15	29443-29445	in	_	
157-16	29446-29450	rats	_	
157-17	29451-29458	through	_	
157-18	29459-29470	stimulation	_	
157-19	29471-29473	or	_	
157-20	29474-29484	inhibition	_	
157-21	29485-29487	of	_	
157-22	29488-29491	the	_	
157-23	29492-29503	infralimbic	_	
157-24	29504-29510	cortex	_	
157-25	29510-29511	,	_	
157-26	29512-29513	a	_	
157-27	29514-29522	cortical	_	
157-28	29523-29529	region	_	
157-29	29530-29532	in	_	
157-30	29533-29536	the	_	
157-31	29537-29542	VMPFC	_	
157-32	29542-29543	.	_	

#Text=Additionally, it is possible to increase or decrease cocaine self-administration via stimulation or inhibition of the nucleus accumbens, a brain region in the ventral striatum that facilitates reinforced behavior and reward saliency.
158-1	29544-29556	Additionally	_	
158-2	29556-29557	,	_	
158-3	29558-29560	it	_	
158-4	29561-29563	is	_	
158-5	29564-29572	possible	_	
158-6	29573-29575	to	_	
158-7	29576-29584	increase	_	
158-8	29585-29587	or	_	
158-9	29588-29596	decrease	_	
158-10	29597-29604	cocaine	_	
158-11	29605-29624	self-administration	_	
158-12	29625-29628	via	_	
158-13	29629-29640	stimulation	_	
158-14	29641-29643	or	_	
158-15	29644-29654	inhibition	_	
158-16	29655-29657	of	_	
158-17	29658-29661	the	_	
158-18	29662-29669	nucleus	_	
158-19	29670-29679	accumbens	_	
158-20	29679-29680	,	_	
158-21	29681-29682	a	_	
158-22	29683-29688	brain	_	
158-23	29689-29695	region	_	
158-24	29696-29698	in	_	
158-25	29699-29702	the	_	
158-26	29703-29710	ventral	_	
158-27	29711-29719	striatum	_	
158-28	29720-29724	that	_	
158-29	29725-29736	facilitates	_	
158-30	29737-29747	reinforced	_	
158-31	29748-29756	behavior	_	
158-32	29757-29760	and	_	
158-33	29761-29767	reward	_	
158-34	29768-29776	saliency	_	
158-35	29776-29777	.	_	

#Text=This has been achieved through optogenetics and designer receptors exclusively activated by designer drugs.
159-1	29778-29782	This	_	
159-2	29783-29786	has	_	
159-3	29787-29791	been	_	
159-4	29792-29800	achieved	_	
159-5	29801-29808	through	_	
159-6	29809-29821	optogenetics	_	
159-7	29822-29825	and	_	
159-8	29826-29834	designer	_	
159-9	29835-29844	receptors	_	
159-10	29845-29856	exclusively	_	
159-11	29857-29866	activated	_	
159-12	29867-29869	by	_	
159-13	29870-29878	designer	_	
159-14	29879-29884	drugs	_	
159-15	29884-29885	.	_	

#Text=These promising preclinical data on ventral frontostriatal stimulation highlight the translational relevance of the VMPFC as a TMS treatment target for addiction.
160-1	29886-29891	These	_	
160-2	29892-29901	promising	_	
160-3	29902-29913	preclinical	_	
160-4	29914-29918	data	_	
160-5	29919-29921	on	_	
160-6	29922-29929	ventral	_	
160-7	29930-29944	frontostriatal	_	
160-8	29945-29956	stimulation	_	
160-9	29957-29966	highlight	_	
160-10	29967-29970	the	_	
160-11	29971-29984	translational	_	
160-12	29985-29994	relevance	_	
160-13	29995-29997	of	_	
160-14	29998-30001	the	_	
160-15	30002-30007	VMPFC	_	
160-16	30008-30010	as	_	
160-17	30011-30012	a	_	
160-18	30013-30016	TMS	_	
160-19	30017-30026	treatment	_	
160-20	30027-30033	target	_	
160-21	30034-30037	for	_	
160-22	30038-30047	addiction	_	
160-23	30047-30048	.	_	

#Text=Differences Across Drug Classes
#Text=While these data from two independent experiments point to a common mechanism of response to VMPFC cTBS, we also find that there are differences in predictors of treatment response across the drug classes.
161-1	30049-30060	Differences	_	
161-2	30061-30067	Across	_	
161-3	30068-30072	Drug	_	
161-4	30073-30080	Classes	_	
161-5	30081-30086	While	_	
161-6	30087-30092	these	_	
161-7	30093-30097	data	_	
161-8	30098-30102	from	_	
161-9	30103-30106	two	_	
161-10	30107-30118	independent	_	
161-11	30119-30130	experiments	_	
161-12	30131-30136	point	_	
161-13	30137-30139	to	_	
161-14	30140-30141	a	_	
161-15	30142-30148	common	_	
161-16	30149-30158	mechanism	_	
161-17	30159-30161	of	_	
161-18	30162-30170	response	_	
161-19	30171-30173	to	_	
161-20	30174-30179	VMPFC	_	
161-21	30180-30184	cTBS	_	
161-22	30184-30185	,	_	
161-23	30186-30188	we	_	
161-24	30189-30193	also	_	
161-25	30194-30198	find	_	
161-26	30199-30203	that	_	
161-27	30204-30209	there	_	
161-28	30210-30213	are	_	
161-29	30214-30225	differences	_	
161-30	30226-30228	in	_	
161-31	30229-30239	predictors	_	
161-32	30240-30242	of	_	
161-33	30243-30252	treatment	_	
161-34	30253-30261	response	_	
161-35	30262-30268	across	_	
161-36	30269-30272	the	_	
161-37	30273-30277	drug	_	
161-38	30278-30285	classes	_	
161-39	30285-30286	.	_	

#Text=While exploratory and in need of replication, we show that in cocaine users TMS treatment response in frontostriatolimbic circuitry is positively related to years of cocaine use, baseline craving, and trait anxiety.
162-1	30287-30292	While	_	
162-2	30293-30304	exploratory	_	
162-3	30305-30308	and	_	
162-4	30309-30311	in	_	
162-5	30312-30316	need	_	
162-6	30317-30319	of	_	
162-7	30320-30331	replication	_	
162-8	30331-30332	,	_	
162-9	30333-30335	we	_	
162-10	30336-30340	show	_	
162-11	30341-30345	that	_	
162-12	30346-30348	in	_	
162-13	30349-30356	cocaine	_	
162-14	30357-30362	users	_	
162-15	30363-30366	TMS	_	
162-16	30367-30376	treatment	_	
162-17	30377-30385	response	_	
162-18	30386-30388	in	_	
162-19	30389-30408	frontostriatolimbic	_	
162-20	30409-30418	circuitry	_	
162-21	30419-30421	is	_	
162-22	30422-30432	positively	_	
162-23	30433-30440	related	_	
162-24	30441-30443	to	_	
162-25	30444-30449	years	_	
162-26	30450-30452	of	_	
162-27	30453-30460	cocaine	_	
162-28	30461-30464	use	_	
162-29	30464-30465	,	_	
162-30	30466-30474	baseline	_	
162-31	30475-30482	craving	_	
162-32	30482-30483	,	_	
162-33	30484-30487	and	_	
162-34	30488-30493	trait	_	
162-35	30494-30501	anxiety	_	
162-36	30501-30502	.	_	

#Text=In other words, individuals with shorter-term cocaine dependence, lower baseline subjective craving, and lower trait anxiety experience more of a treatment-related attenuation in cue-evoked FC.
163-1	30503-30505	In	_	
163-2	30506-30511	other	_	
163-3	30512-30517	words	_	
163-4	30517-30518	,	_	
163-5	30519-30530	individuals	_	
163-6	30531-30535	with	_	
163-7	30536-30548	shorter-term	_	
163-8	30549-30556	cocaine	_	
163-9	30557-30567	dependence	_	
163-10	30567-30568	,	_	
163-11	30569-30574	lower	_	
163-12	30575-30583	baseline	_	
163-13	30584-30594	subjective	_	
163-14	30595-30602	craving	_	
163-15	30602-30603	,	_	
163-16	30604-30607	and	_	
163-17	30608-30613	lower	_	
163-18	30614-30619	trait	_	
163-19	30620-30627	anxiety	_	
163-20	30628-30638	experience	_	
163-21	30639-30643	more	_	
163-22	30644-30646	of	_	
163-23	30647-30648	a	_	
163-24	30649-30666	treatment-related	_	
163-25	30667-30678	attenuation	_	
163-26	30679-30681	in	_	
163-27	30682-30692	cue-evoked	_	
163-28	30693-30695	FC	_	
163-29	30695-30696	.	_	

#Text=Therefore, it is possible that individuals with mild-to-moderate clinical symptoms may respond best to the TMS treatment.
164-1	30697-30706	Therefore	_	
164-2	30706-30707	,	_	
164-3	30708-30710	it	_	
164-4	30711-30713	is	_	
164-5	30714-30722	possible	_	
164-6	30723-30727	that	_	
164-7	30728-30739	individuals	_	
164-8	30740-30744	with	_	
164-9	30745-30761	mild-to-moderate	_	
164-10	30762-30770	clinical	_	
164-11	30771-30779	symptoms	_	
164-12	30780-30783	may	_	
164-13	30784-30791	respond	_	
164-14	30792-30796	best	_	
164-15	30797-30799	to	_	
164-16	30800-30803	the	_	
164-17	30804-30807	TMS	_	
164-18	30808-30817	treatment	_	
164-19	30817-30818	.	_	

#Text=For alcohol users, TMS treatment response is related to absolute cTBS dose, a measure of the extent of stimulation reaching cortical tissue.
165-1	30819-30822	For	_	
165-2	30823-30830	alcohol	_	
165-3	30831-30836	users	_	
165-4	30836-30837	,	_	
165-5	30838-30841	TMS	_	
165-6	30842-30851	treatment	_	
165-7	30852-30860	response	_	
165-8	30861-30863	is	_	
165-9	30864-30871	related	_	
165-10	30872-30874	to	_	
165-11	30875-30883	absolute	_	
165-12	30884-30888	cTBS	_	
165-13	30889-30893	dose	_	
165-14	30893-30894	,	_	
165-15	30895-30896	a	_	
165-16	30897-30904	measure	_	
165-17	30905-30907	of	_	
165-18	30908-30911	the	_	
165-19	30912-30918	extent	_	
165-20	30919-30921	of	_	
165-21	30922-30933	stimulation	_	
165-22	30934-30942	reaching	_	
165-23	30943-30951	cortical	_	
165-24	30952-30958	tissue	_	
165-25	30958-30959	.	_	

#Text=Also, while speculative, this could suggest that physical measures relevant to treatment efficacy are greater indicators of treatment response in alcohol users.
166-1	30960-30964	Also	_	
166-2	30964-30965	,	_	
166-3	30966-30971	while	_	
166-4	30972-30983	speculative	_	
166-5	30983-30984	,	_	
166-6	30985-30989	this	_	
166-7	30990-30995	could	_	
166-8	30996-31003	suggest	_	
166-9	31004-31008	that	_	
166-10	31009-31017	physical	_	
166-11	31018-31026	measures	_	
166-12	31027-31035	relevant	_	
166-13	31036-31038	to	_	
166-14	31039-31048	treatment	_	
166-15	31049-31057	efficacy	_	
166-16	31058-31061	are	_	
166-17	31062-31069	greater	_	
166-18	31070-31080	indicators	_	
166-19	31081-31083	of	_	
166-20	31084-31093	treatment	_	
166-21	31094-31102	response	_	
166-22	31103-31105	in	_	
166-23	31106-31113	alcohol	_	
166-24	31114-31119	users	_	
166-25	31119-31120	.	_	

#Text=Future Directions and Limitations
#Text=Despite the strong evidence these data provide in support of being able to temporarily modulate VMPFC with cTBS in patients with substance abuse, these results do not provide direct evidence of clinical effects.
167-1	31121-31127	Future	_	
167-2	31128-31138	Directions	_	
167-3	31139-31142	and	_	
167-4	31143-31154	Limitations	_	
167-5	31155-31162	Despite	_	
167-6	31163-31166	the	_	
167-7	31167-31173	strong	_	
167-8	31174-31182	evidence	_	
167-9	31183-31188	these	_	
167-10	31189-31193	data	_	
167-11	31194-31201	provide	_	
167-12	31202-31204	in	_	
167-13	31205-31212	support	_	
167-14	31213-31215	of	_	
167-15	31216-31221	being	_	
167-16	31222-31226	able	_	
167-17	31227-31229	to	_	
167-18	31230-31241	temporarily	_	
167-19	31242-31250	modulate	_	
167-20	31251-31256	VMPFC	_	
167-21	31257-31261	with	_	
167-22	31262-31266	cTBS	_	
167-23	31267-31269	in	_	
167-24	31270-31278	patients	_	
167-25	31279-31283	with	_	
167-26	31284-31293	substance	_	
167-27	31294-31299	abuse	_	
167-28	31299-31300	,	_	
167-29	31301-31306	these	_	
167-30	31307-31314	results	_	
167-31	31315-31317	do	_	
167-32	31318-31321	not	_	
167-33	31322-31329	provide	_	
167-34	31330-31336	direct	_	
167-35	31337-31345	evidence	_	
167-36	31346-31348	of	_	
167-37	31349-31357	clinical	_	
167-38	31358-31365	effects	_	
167-39	31365-31366	.	_	

#Text=Specifically, these experiments were designed to gather data on the basic proof of principle that cTBS to the VMPFC could induce specific decreases in drug/alcohol cue reactivity when rigorously compared with a sham condition in a single-blinded manner.
168-1	31367-31379	Specifically	_	
168-2	31379-31380	,	_	
168-3	31381-31386	these	_	
168-4	31387-31398	experiments	_	
168-5	31399-31403	were	_	
168-6	31404-31412	designed	_	
168-7	31413-31415	to	_	
168-8	31416-31422	gather	_	
168-9	31423-31427	data	_	
168-10	31428-31430	on	_	
168-11	31431-31434	the	_	
168-12	31435-31440	basic	_	
168-13	31441-31446	proof	_	
168-14	31447-31449	of	_	
168-15	31450-31459	principle	_	
168-16	31460-31464	that	_	
168-17	31465-31469	cTBS	_	
168-18	31470-31472	to	_	
168-19	31473-31476	the	_	
168-20	31477-31482	VMPFC	_	
168-21	31483-31488	could	_	
168-22	31489-31495	induce	_	
168-23	31496-31504	specific	_	
168-24	31505-31514	decreases	_	
168-25	31515-31517	in	_	
168-26	31518-31522	drug	_	
168-27	31522-31523	/	_	
168-28	31523-31530	alcohol	_	
168-29	31531-31534	cue	_	
168-30	31535-31545	reactivity	_	
168-31	31546-31550	when	_	
168-32	31551-31561	rigorously	_	
168-33	31562-31570	compared	_	
168-34	31571-31575	with	_	
168-35	31576-31577	a	_	
168-36	31578-31582	sham	_	
168-37	31583-31592	condition	_	
168-38	31593-31595	in	_	
168-39	31596-31597	a	_	
168-40	31598-31612	single-blinded	_	
168-41	31613-31619	manner	_	
168-42	31619-31620	.	_	

#Text=While several clinical parameters were associated with greater efficacy on FC, we did not observe an effect of cTBS on drug/alcohol-induced craving.
169-1	31621-31626	While	_	
169-2	31627-31634	several	_	
169-3	31635-31643	clinical	_	
169-4	31644-31654	parameters	_	
169-5	31655-31659	were	_	
169-6	31660-31670	associated	_	
169-7	31671-31675	with	_	
169-8	31676-31683	greater	_	
169-9	31684-31692	efficacy	_	
169-10	31693-31695	on	_	
169-11	31696-31698	FC	_	
169-12	31698-31699	,	_	
169-13	31700-31702	we	_	
169-14	31703-31706	did	_	
169-15	31707-31710	not	_	
169-16	31711-31718	observe	_	
169-17	31719-31721	an	_	
169-18	31722-31728	effect	_	
169-19	31729-31731	of	_	
169-20	31732-31736	cTBS	_	
169-21	31737-31739	on	_	
169-22	31740-31744	drug	_	
169-23	31744-31745	/	_	
169-24	31745-31760	alcohol-induced	_	
169-25	31761-31768	craving	_	
169-26	31768-31769	.	_	

#Text=While craving is endorsed as a key feature of SUDs (as noted by its inclusion in the DSM-5), in human behavioral experiments it is an outcome measure that is often highly variable and as such does not in itself indicate lack of potential clinical utility.
170-1	31770-31775	While	_	
170-2	31776-31783	craving	_	
170-3	31784-31786	is	_	
170-4	31787-31795	endorsed	_	
170-5	31796-31798	as	_	
170-6	31799-31800	a	_	
170-7	31801-31804	key	_	
170-8	31805-31812	feature	_	
170-9	31813-31815	of	_	
170-10	31816-31820	SUDs	_	
170-11	31821-31822	(	_	
170-12	31822-31824	as	_	
170-13	31825-31830	noted	_	
170-14	31831-31833	by	_	
170-15	31834-31837	its	_	
170-16	31838-31847	inclusion	_	
170-17	31848-31850	in	_	
170-18	31851-31854	the	_	
170-19	31855-31858	DSM	_	
170-20	31858-31859	-	_	
170-21	31859-31860	5	_	
170-22	31860-31861	)	_	
170-23	31861-31862	,	_	
170-24	31863-31865	in	_	
170-25	31866-31871	human	_	
170-26	31872-31882	behavioral	_	
170-27	31883-31894	experiments	_	
170-28	31895-31897	it	_	
170-29	31898-31900	is	_	
170-30	31901-31903	an	_	
170-31	31904-31911	outcome	_	
170-32	31912-31919	measure	_	
170-33	31920-31924	that	_	
170-34	31925-31927	is	_	
170-35	31928-31933	often	_	
170-36	31934-31940	highly	_	
170-37	31941-31949	variable	_	
170-38	31950-31953	and	_	
170-39	31954-31956	as	_	
170-40	31957-31961	such	_	
170-41	31962-31966	does	_	
170-42	31967-31970	not	_	
170-43	31971-31973	in	_	
170-44	31974-31980	itself	_	
170-45	31981-31989	indicate	_	
170-46	31990-31994	lack	_	
170-47	31995-31997	of	_	
170-48	31998-32007	potential	_	
170-49	32008-32016	clinical	_	
170-50	32017-32024	utility	_	
170-51	32024-32025	.	_	

#Text=Given this, the data relevant to a larger clinical trial (including the durability of clinical effects, if they exist) is still unknown.
171-1	32026-32031	Given	_	
171-2	32032-32036	this	_	
171-3	32036-32037	,	_	
171-4	32038-32041	the	_	
171-5	32042-32046	data	_	
171-6	32047-32055	relevant	_	
171-7	32056-32058	to	_	
171-8	32059-32060	a	_	
171-9	32061-32067	larger	_	
171-10	32068-32076	clinical	_	
171-11	32077-32082	trial	_	
171-12	32083-32084	(	_	
171-13	32084-32093	including	_	
171-14	32094-32097	the	_	
171-15	32098-32108	durability	_	
171-16	32109-32111	of	_	
171-17	32112-32120	clinical	_	
171-18	32121-32128	effects	_	
171-19	32128-32129	,	_	
171-20	32130-32132	if	_	
171-21	32133-32137	they	_	
171-22	32138-32143	exist	_	
171-23	32143-32144	)	_	
171-24	32145-32147	is	_	
171-25	32148-32153	still	_	
171-26	32154-32161	unknown	_	
171-27	32161-32162	.	_	

#Text=For these same reasons, it is not yet clear if cTBS-related changes in drug/alcohol cue reactivity correspond to real-world changes in drug/alcohol intake.
172-1	32163-32166	For	_	
172-2	32167-32172	these	_	
172-3	32173-32177	same	_	
172-4	32178-32185	reasons	_	
172-5	32185-32186	,	_	
172-6	32187-32189	it	_	
172-7	32190-32192	is	_	
172-8	32193-32196	not	_	
172-9	32197-32200	yet	_	
172-10	32201-32206	clear	_	
172-11	32207-32209	if	_	
172-12	32210-32222	cTBS-related	_	
172-13	32223-32230	changes	_	
172-14	32231-32233	in	_	
172-15	32234-32238	drug	_	
172-16	32238-32239	/	_	
172-17	32239-32246	alcohol	_	
172-18	32247-32250	cue	_	
172-19	32251-32261	reactivity	_	
172-20	32262-32272	correspond	_	
172-21	32273-32275	to	_	
172-22	32276-32286	real-world	_	
172-23	32287-32294	changes	_	
172-24	32295-32297	in	_	
172-25	32298-32302	drug	_	
172-26	32302-32303	/	_	
172-27	32303-32310	alcohol	_	
172-28	32311-32317	intake	_	
172-29	32317-32318	.	_	

#Text=Although there are some studies in nicotine and cocaine users that have shown changes in use patterns following excitatory DLPFC TMS, a considerable amount of work needs to be done in this area.
173-1	32319-32327	Although	_	
173-2	32328-32333	there	_	
173-3	32334-32337	are	_	
173-4	32338-32342	some	_	
173-5	32343-32350	studies	_	
173-6	32351-32353	in	_	
173-7	32354-32362	nicotine	_	
173-8	32363-32366	and	_	
173-9	32367-32374	cocaine	_	
173-10	32375-32380	users	_	
173-11	32381-32385	that	_	
173-12	32386-32390	have	_	
173-13	32391-32396	shown	_	
173-14	32397-32404	changes	_	
173-15	32405-32407	in	_	
173-16	32408-32411	use	_	
173-17	32412-32420	patterns	_	
173-18	32421-32430	following	_	
173-19	32431-32441	excitatory	_	
173-20	32442-32447	DLPFC	_	
173-21	32448-32451	TMS	_	
173-22	32451-32452	,	_	
173-23	32453-32454	a	_	
173-24	32455-32467	considerable	_	
173-25	32468-32474	amount	_	
173-26	32475-32477	of	_	
173-27	32478-32482	work	_	
173-28	32483-32488	needs	_	
173-29	32489-32491	to	_	
173-30	32492-32494	be	_	
173-31	32495-32499	done	_	
173-32	32500-32502	in	_	
173-33	32503-32507	this	_	
173-34	32508-32512	area	_	
173-35	32512-32513	.	_	

#Text=For instance, although the duration of neural effects of 3600 pulses of cTBS has not yet been assessed in an imaging study, Chistyakov et al. found that in medication-stabilized depressed patients, 10 sessions of 3600 pulses cTBS to the right DLPFC resulted in a significantly greater reduction of Hamilton depression scores as compared with sham cTBS.
174-1	32514-32517	For	_	
174-2	32518-32526	instance	_	
174-3	32526-32527	,	_	
174-4	32528-32536	although	_	
174-5	32537-32540	the	_	
174-6	32541-32549	duration	_	
174-7	32550-32552	of	_	
174-8	32553-32559	neural	_	
174-9	32560-32567	effects	_	
174-10	32568-32570	of	_	
174-11	32571-32575	3600	_	
174-12	32576-32582	pulses	_	
174-13	32583-32585	of	_	
174-14	32586-32590	cTBS	_	
174-15	32591-32594	has	_	
174-16	32595-32598	not	_	
174-17	32599-32602	yet	_	
174-18	32603-32607	been	_	
174-19	32608-32616	assessed	_	
174-20	32617-32619	in	_	
174-21	32620-32622	an	_	
174-22	32623-32630	imaging	_	
174-23	32631-32636	study	_	
174-24	32636-32637	,	_	
174-25	32638-32648	Chistyakov	_	
174-26	32649-32651	et	_	
174-27	32652-32654	al	_	
174-28	32654-32655	.	_	
174-29	32656-32661	found	_	
174-30	32662-32666	that	_	
174-31	32667-32669	in	_	
174-32	32670-32691	medication-stabilized	_	
174-33	32692-32701	depressed	_	
174-34	32702-32710	patients	_	
174-35	32710-32711	,	_	
174-36	32712-32714	10	_	
174-37	32715-32723	sessions	_	
174-38	32724-32726	of	_	
174-39	32727-32731	3600	_	
174-40	32732-32738	pulses	_	
174-41	32739-32743	cTBS	_	
174-42	32744-32746	to	_	
174-43	32747-32750	the	_	
174-44	32751-32756	right	_	
174-45	32757-32762	DLPFC	_	
174-46	32763-32771	resulted	_	
174-47	32772-32774	in	_	
174-48	32775-32776	a	_	
174-49	32777-32790	significantly	_	
174-50	32791-32798	greater	_	
174-51	32799-32808	reduction	_	
174-52	32809-32811	of	_	
174-53	32812-32820	Hamilton	_	
174-54	32821-32831	depression	_	
174-55	32832-32838	scores	_	
174-56	32839-32841	as	_	
174-57	32842-32850	compared	_	
174-58	32851-32855	with	_	
174-59	32856-32860	sham	_	
174-60	32861-32865	cTBS	_	
174-61	32865-32866	.	_	

#Text=Therefore, 3600 pulses of cTBS likely produces long-term depression–like effects on neural circuitry, and the corresponding behavioral effects of cTBS last beyond the time of stimulation.
175-1	32867-32876	Therefore	_	
175-2	32876-32877	,	_	
175-3	32878-32882	3600	_	
175-4	32883-32889	pulses	_	
175-5	32890-32892	of	_	
175-6	32893-32897	cTBS	_	
175-7	32898-32904	likely	_	
175-8	32905-32913	produces	_	
175-9	32914-32923	long-term	_	
175-10	32924-32939	depression–like	_	
175-11	32940-32947	effects	_	
175-12	32948-32950	on	_	
175-13	32951-32957	neural	_	
175-14	32958-32967	circuitry	_	
175-15	32967-32968	,	_	
175-16	32969-32972	and	_	
175-17	32973-32976	the	_	
175-18	32977-32990	corresponding	_	
175-19	32991-33001	behavioral	_	
175-20	33002-33009	effects	_	
175-21	33010-33012	of	_	
175-22	33013-33017	cTBS	_	
175-23	33018-33022	last	_	
175-24	33023-33029	beyond	_	
175-25	33030-33033	the	_	
175-26	33034-33038	time	_	
175-27	33039-33041	of	_	
175-28	33042-33053	stimulation	_	
175-29	33053-33054	.	_	

#Text=To further address these unknowns, our group is presently conducting the first double-blind, active sham–controlled clinical trial of TMS in treatment-engaged cocaine users, which involves cTBS to the VMPFC over the course of 10 days.
176-1	33055-33057	To	_	
176-2	33058-33065	further	_	
176-3	33066-33073	address	_	
176-4	33074-33079	these	_	
176-5	33080-33088	unknowns	_	
176-6	33088-33089	,	_	
176-7	33090-33093	our	_	
176-8	33094-33099	group	_	
176-9	33100-33102	is	_	
176-10	33103-33112	presently	_	
176-11	33113-33123	conducting	_	
176-12	33124-33127	the	_	
176-13	33128-33133	first	_	
176-14	33134-33146	double-blind	_	
176-15	33146-33147	,	_	
176-16	33148-33154	active	_	
176-17	33155-33170	sham–controlled	_	
176-18	33171-33179	clinical	_	
176-19	33180-33185	trial	_	
176-20	33186-33188	of	_	
176-21	33189-33192	TMS	_	
176-22	33193-33195	in	_	
176-23	33196-33213	treatment-engaged	_	
176-24	33214-33221	cocaine	_	
176-25	33222-33227	users	_	
176-26	33227-33228	,	_	
176-27	33229-33234	which	_	
176-28	33235-33243	involves	_	
176-29	33244-33248	cTBS	_	
176-30	33249-33251	to	_	
176-31	33252-33255	the	_	
176-32	33256-33261	VMPFC	_	
176-33	33262-33266	over	_	
176-34	33267-33270	the	_	
176-35	33271-33277	course	_	
176-36	33278-33280	of	_	
176-37	33281-33283	10	_	
176-38	33284-33288	days	_	
176-39	33288-33289	.	_	

#Text=Neuroimaging data are collected to evaluate changes in neural circuitry over time, while outcome measures such as urine drug screens are used to evaluate the clinical efficacy on relapse.
177-1	33290-33302	Neuroimaging	_	
177-2	33303-33307	data	_	
177-3	33308-33311	are	_	
177-4	33312-33321	collected	_	
177-5	33322-33324	to	_	
177-6	33325-33333	evaluate	_	
177-7	33334-33341	changes	_	
177-8	33342-33344	in	_	
177-9	33345-33351	neural	_	
177-10	33352-33361	circuitry	_	
177-11	33362-33366	over	_	
177-12	33367-33371	time	_	
177-13	33371-33372	,	_	
177-14	33373-33378	while	_	
177-15	33379-33386	outcome	_	
177-16	33387-33395	measures	_	
177-17	33396-33400	such	_	
177-18	33401-33403	as	_	
177-19	33404-33409	urine	_	
177-20	33410-33414	drug	_	
177-21	33415-33422	screens	_	
177-22	33423-33426	are	_	
177-23	33427-33431	used	_	
177-24	33432-33434	to	_	
177-25	33435-33443	evaluate	_	
177-26	33444-33447	the	_	
177-27	33448-33456	clinical	_	
177-28	33457-33465	efficacy	_	
177-29	33466-33468	on	_	
177-30	33469-33476	relapse	_	
177-31	33476-33477	.	_	

#Text=The present paper provides the initial proof-of-principle data that our current and future clinical trials will use as an empirical foundation.
178-1	33478-33481	The	_	
178-2	33482-33489	present	_	
178-3	33490-33495	paper	_	
178-4	33496-33504	provides	_	
178-5	33505-33508	the	_	
178-6	33509-33516	initial	_	
178-7	33517-33535	proof-of-principle	_	
178-8	33536-33540	data	_	
178-9	33541-33545	that	_	
178-10	33546-33549	our	_	
178-11	33550-33557	current	_	
178-12	33558-33561	and	_	
178-13	33562-33568	future	_	
178-14	33569-33577	clinical	_	
178-15	33578-33584	trials	_	
178-16	33585-33589	will	_	
178-17	33590-33593	use	_	
178-18	33594-33596	as	_	
178-19	33597-33599	an	_	
178-20	33600-33609	empirical	_	
178-21	33610-33620	foundation	_	
178-22	33620-33621	.	_	

#Text=The lack of effects on subjective ratings of drug/alcohol craving in this study is not altogether unexpected given the resistance of some complex human behaviors to change.
179-1	33622-33625	The	_	
179-2	33626-33630	lack	_	
179-3	33631-33633	of	_	
179-4	33634-33641	effects	_	
179-5	33642-33644	on	_	
179-6	33645-33655	subjective	_	
179-7	33656-33663	ratings	_	
179-8	33664-33666	of	_	
179-9	33667-33671	drug	_	
179-10	33671-33672	/	_	
179-11	33672-33679	alcohol	_	
179-12	33680-33687	craving	_	
179-13	33688-33690	in	_	
179-14	33691-33695	this	_	
179-15	33696-33701	study	_	
179-16	33702-33704	is	_	
179-17	33705-33708	not	_	
179-18	33709-33719	altogether	_	
179-19	33720-33730	unexpected	_	
179-20	33731-33736	given	_	
179-21	33737-33740	the	_	
179-22	33741-33751	resistance	_	
179-23	33752-33754	of	_	
179-24	33755-33759	some	_	
179-25	33760-33767	complex	_	
179-26	33768-33773	human	_	
179-27	33774-33783	behaviors	_	
179-28	33784-33786	to	_	
179-29	33787-33793	change	_	
179-30	33793-33794	.	_	

#Text=All of the studies leading to Food and Drug Administration approval of TMS for treatment-resistant depression involved several weeks of treatment across multiple sessions, with effects on depression emerging only after several sessions [for reviews, see ].
180-1	33795-33798	All	_	
180-2	33799-33801	of	_	
180-3	33802-33805	the	_	
180-4	33806-33813	studies	_	
180-5	33814-33821	leading	_	
180-6	33822-33824	to	_	
180-7	33825-33829	Food	_	
180-8	33830-33833	and	_	
180-9	33834-33838	Drug	_	
180-10	33839-33853	Administration	_	
180-11	33854-33862	approval	_	
180-12	33863-33865	of	_	
180-13	33866-33869	TMS	_	
180-14	33870-33873	for	_	
180-15	33874-33893	treatment-resistant	_	
180-16	33894-33904	depression	_	
180-17	33905-33913	involved	_	
180-18	33914-33921	several	_	
180-19	33922-33927	weeks	_	
180-20	33928-33930	of	_	
180-21	33931-33940	treatment	_	
180-22	33941-33947	across	_	
180-23	33948-33956	multiple	_	
180-24	33957-33965	sessions	_	
180-25	33965-33966	,	_	
180-26	33967-33971	with	_	
180-27	33972-33979	effects	_	
180-28	33980-33982	on	_	
180-29	33983-33993	depression	_	
180-30	33994-34002	emerging	_	
180-31	34003-34007	only	_	
180-32	34008-34013	after	_	
180-33	34014-34021	several	_	
180-34	34022-34030	sessions	_	
180-35	34031-34032	[	_	
180-36	34032-34035	for	_	
180-37	34036-34043	reviews	_	
180-38	34043-34044	,	_	
180-39	34045-34048	see	_	
180-40	34049-34050	]	_	
180-41	34050-34051	.	_	

#Text=Studies showing TMS effects on craving in SUDs have also involved multiple treatment sessions.
181-1	34052-34059	Studies	_	
181-2	34060-34067	showing	_	
181-3	34068-34071	TMS	_	
181-4	34072-34079	effects	_	
181-5	34080-34082	on	_	
181-6	34083-34090	craving	_	
181-7	34091-34093	in	_	
181-8	34094-34098	SUDs	_	
181-9	34099-34103	have	_	
181-10	34104-34108	also	_	
181-11	34109-34117	involved	_	
181-12	34118-34126	multiple	_	
181-13	34127-34136	treatment	_	
181-14	34137-34145	sessions	_	
181-15	34145-34146	.	_	

#Text=This suggests that the effects of TMS on complex behaviors such as craving are likely cumulative.
182-1	34147-34151	This	_	
182-2	34152-34160	suggests	_	
182-3	34161-34165	that	_	
182-4	34166-34169	the	_	
182-5	34170-34177	effects	_	
182-6	34178-34180	of	_	
182-7	34181-34184	TMS	_	
182-8	34185-34187	on	_	
182-9	34188-34195	complex	_	
182-10	34196-34205	behaviors	_	
182-11	34206-34210	such	_	
182-12	34211-34213	as	_	
182-13	34214-34221	craving	_	
182-14	34222-34225	are	_	
182-15	34226-34232	likely	_	
182-16	34233-34243	cumulative	_	
182-17	34243-34244	.	_	

#Text=Therefore, while we do not show changes in craving after a single session, it is possible that after a multisession VMPFC cTBS intervention the effects on self-reported craving may emerge—a possibility that will be addressed by our lab’s ongoing multisession clinical trial in cocaine users.
183-1	34245-34254	Therefore	_	
183-2	34254-34255	,	_	
183-3	34256-34261	while	_	
183-4	34262-34264	we	_	
183-5	34265-34267	do	_	
183-6	34268-34271	not	_	
183-7	34272-34276	show	_	
183-8	34277-34284	changes	_	
183-9	34285-34287	in	_	
183-10	34288-34295	craving	_	
183-11	34296-34301	after	_	
183-12	34302-34303	a	_	
183-13	34304-34310	single	_	
183-14	34311-34318	session	_	
183-15	34318-34319	,	_	
183-16	34320-34322	it	_	
183-17	34323-34325	is	_	
183-18	34326-34334	possible	_	
183-19	34335-34339	that	_	
183-20	34340-34345	after	_	
183-21	34346-34347	a	_	
183-22	34348-34360	multisession	_	
183-23	34361-34366	VMPFC	_	
183-24	34367-34371	cTBS	_	
183-25	34372-34384	intervention	_	
183-26	34385-34388	the	_	
183-27	34389-34396	effects	_	
183-28	34397-34399	on	_	
183-29	34400-34413	self-reported	_	
183-30	34414-34421	craving	_	
183-31	34422-34425	may	_	
183-32	34426-34434	emerge—a	_	
183-33	34435-34446	possibility	_	
183-34	34447-34451	that	_	
183-35	34452-34456	will	_	
183-36	34457-34459	be	_	
183-37	34460-34469	addressed	_	
183-38	34470-34472	by	_	
183-39	34473-34476	our	_	
183-40	34477-34480	lab	_	
183-41	34480-34481	’	_	
183-42	34481-34482	s	_	
183-43	34483-34490	ongoing	_	
183-44	34491-34503	multisession	_	
183-45	34504-34512	clinical	_	
183-46	34513-34518	trial	_	
183-47	34519-34521	in	_	
183-48	34522-34529	cocaine	_	
183-49	34530-34535	users	_	
183-50	34535-34536	.	_	

#Text=Furthermore, there is some criticism of self-report measures, namely of craving, as being less reliable outcome measures when used on their own because they rely on the individual’s definition of cravings/urges as a construct, as well as individuals’ ability to accurately and truthfully verbally convey their internal states.
184-1	34537-34548	Furthermore	_	
184-2	34548-34549	,	_	
184-3	34550-34555	there	_	
184-4	34556-34558	is	_	
184-5	34559-34563	some	_	
184-6	34564-34573	criticism	_	
184-7	34574-34576	of	_	
184-8	34577-34588	self-report	_	
184-9	34589-34597	measures	_	
184-10	34597-34598	,	_	
184-11	34599-34605	namely	_	
184-12	34606-34608	of	_	
184-13	34609-34616	craving	_	
184-14	34616-34617	,	_	
184-15	34618-34620	as	_	
184-16	34621-34626	being	_	
184-17	34627-34631	less	_	
184-18	34632-34640	reliable	_	
184-19	34641-34648	outcome	_	
184-20	34649-34657	measures	_	
184-21	34658-34662	when	_	
184-22	34663-34667	used	_	
184-23	34668-34670	on	_	
184-24	34671-34676	their	_	
184-25	34677-34680	own	_	
184-26	34681-34688	because	_	
184-27	34689-34693	they	_	
184-28	34694-34698	rely	_	
184-29	34699-34701	on	_	
184-30	34702-34705	the	_	
184-31	34706-34716	individual	_	
184-32	34716-34717	’	_	
184-33	34717-34718	s	_	
184-34	34719-34729	definition	_	
184-35	34730-34732	of	_	
184-36	34733-34741	cravings	_	
184-37	34741-34742	/	_	
184-38	34742-34747	urges	_	
184-39	34748-34750	as	_	
184-40	34751-34752	a	_	
184-41	34753-34762	construct	_	
184-42	34762-34763	,	_	
184-43	34764-34766	as	_	
184-44	34767-34771	well	_	
184-45	34772-34774	as	_	
184-46	34775-34786	individuals	_	
184-47	34786-34787	’	_	
184-48	34788-34795	ability	_	
184-49	34796-34798	to	_	
184-50	34799-34809	accurately	_	
184-51	34810-34813	and	_	
184-52	34814-34824	truthfully	_	
184-53	34825-34833	verbally	_	
184-54	34834-34840	convey	_	
184-55	34841-34846	their	_	
184-56	34847-34855	internal	_	
184-57	34856-34862	states	_	
184-58	34862-34863	.	_	

#Text=Instead, biomarkers serve as objective and quantifiable measures of use or relapse risk.
185-1	34864-34871	Instead	_	
185-2	34871-34872	,	_	
185-3	34873-34883	biomarkers	_	
185-4	34884-34889	serve	_	
185-5	34890-34892	as	_	
185-6	34893-34902	objective	_	
185-7	34903-34906	and	_	
185-8	34907-34919	quantifiable	_	
185-9	34920-34928	measures	_	
185-10	34929-34931	of	_	
185-11	34932-34935	use	_	
185-12	34936-34938	or	_	
185-13	34939-34946	relapse	_	
185-14	34947-34951	risk	_	
185-15	34951-34952	.	_	

#Text=As such, in addition to self-report outcome measures, studies should aim to incorporate objective markers that are sensitive to change, such as urine drug screens, as we are now doing in our ongoing clinical trial.
186-1	34953-34955	As	_	
186-2	34956-34960	such	_	
186-3	34960-34961	,	_	
186-4	34962-34964	in	_	
186-5	34965-34973	addition	_	
186-6	34974-34976	to	_	
186-7	34977-34988	self-report	_	
186-8	34989-34996	outcome	_	
186-9	34997-35005	measures	_	
186-10	35005-35006	,	_	
186-11	35007-35014	studies	_	
186-12	35015-35021	should	_	
186-13	35022-35025	aim	_	
186-14	35026-35028	to	_	
186-15	35029-35040	incorporate	_	
186-16	35041-35050	objective	_	
186-17	35051-35058	markers	_	
186-18	35059-35063	that	_	
186-19	35064-35067	are	_	
186-20	35068-35077	sensitive	_	
186-21	35078-35080	to	_	
186-22	35081-35087	change	_	
186-23	35087-35088	,	_	
186-24	35089-35093	such	_	
186-25	35094-35096	as	_	
186-26	35097-35102	urine	_	
186-27	35103-35107	drug	_	
186-28	35108-35115	screens	_	
186-29	35115-35116	,	_	
186-30	35117-35119	as	_	
186-31	35120-35122	we	_	
186-32	35123-35126	are	_	
186-33	35127-35130	now	_	
186-34	35131-35136	doing	_	
186-35	35137-35139	in	_	
186-36	35140-35143	our	_	
186-37	35144-35151	ongoing	_	
186-38	35152-35160	clinical	_	
186-39	35161-35166	trial	_	
186-40	35166-35167	.	_	

#Text=Another limitation of the present study is that despite the diverse samples recruited, exclusion criteria regarding comorbid DSM-IV Axis I psychiatric disorders and other substance dependence limited the ability of our samples to fully portray the incidence of comorbid disorders in typical substance-dependent individuals, namely cocaine users who tend to also drink heavily, smoke cigarettes at higher rates, and be depressed.
187-1	35168-35175	Another	_	
187-2	35176-35186	limitation	_	
187-3	35187-35189	of	_	
187-4	35190-35193	the	_	
187-5	35194-35201	present	_	
187-6	35202-35207	study	_	
187-7	35208-35210	is	_	
187-8	35211-35215	that	_	
187-9	35216-35223	despite	_	
187-10	35224-35227	the	_	
187-11	35228-35235	diverse	_	
187-12	35236-35243	samples	_	
187-13	35244-35253	recruited	_	
187-14	35253-35254	,	_	
187-15	35255-35264	exclusion	_	
187-16	35265-35273	criteria	_	
187-17	35274-35283	regarding	_	
187-18	35284-35292	comorbid	_	
187-19	35293-35299	DSM-IV	_	
187-20	35300-35304	Axis	_	
187-21	35305-35306	I	_	
187-22	35307-35318	psychiatric	_	
187-23	35319-35328	disorders	_	
187-24	35329-35332	and	_	
187-25	35333-35338	other	_	
187-26	35339-35348	substance	_	
187-27	35349-35359	dependence	_	
187-28	35360-35367	limited	_	
187-29	35368-35371	the	_	
187-30	35372-35379	ability	_	
187-31	35380-35382	of	_	
187-32	35383-35386	our	_	
187-33	35387-35394	samples	_	
187-34	35395-35397	to	_	
187-35	35398-35403	fully	_	
187-36	35404-35411	portray	_	
187-37	35412-35415	the	_	
187-38	35416-35425	incidence	_	
187-39	35426-35428	of	_	
187-40	35429-35437	comorbid	_	
187-41	35438-35447	disorders	_	
187-42	35448-35450	in	_	
187-43	35451-35458	typical	_	
187-44	35459-35478	substance-dependent	_	
187-45	35479-35490	individuals	_	
187-46	35490-35491	,	_	
187-47	35492-35498	namely	_	
187-48	35499-35506	cocaine	_	
187-49	35507-35512	users	_	
187-50	35513-35516	who	_	
187-51	35517-35521	tend	_	
187-52	35522-35524	to	_	
187-53	35525-35529	also	_	
187-54	35530-35535	drink	_	
187-55	35536-35543	heavily	_	
187-56	35543-35544	,	_	
187-57	35545-35550	smoke	_	
187-58	35551-35561	cigarettes	_	
187-59	35562-35564	at	_	
187-60	35565-35571	higher	_	
187-61	35572-35577	rates	_	
187-62	35577-35578	,	_	
187-63	35579-35582	and	_	
187-64	35583-35585	be	_	
187-65	35586-35595	depressed	_	
187-66	35595-35596	.	_	

#Text=However, the consistency of our findings between the substance-using groups increases our confidence that the neural response to VMPFC cTBS translates beyond the characteristics of any single drug use class and will generalize to larger populations of drug users.
188-1	35597-35604	However	_	
188-2	35604-35605	,	_	
188-3	35606-35609	the	_	
188-4	35610-35621	consistency	_	
188-5	35622-35624	of	_	
188-6	35625-35628	our	_	
188-7	35629-35637	findings	_	
188-8	35638-35645	between	_	
188-9	35646-35649	the	_	
188-10	35650-35665	substance-using	_	
188-11	35666-35672	groups	_	
188-12	35673-35682	increases	_	
188-13	35683-35686	our	_	
188-14	35687-35697	confidence	_	
188-15	35698-35702	that	_	
188-16	35703-35706	the	_	
188-17	35707-35713	neural	_	
188-18	35714-35722	response	_	
188-19	35723-35725	to	_	
188-20	35726-35731	VMPFC	_	
188-21	35732-35736	cTBS	_	
188-22	35737-35747	translates	_	
188-23	35748-35754	beyond	_	
188-24	35755-35758	the	_	
188-25	35759-35774	characteristics	_	
188-26	35775-35777	of	_	
188-27	35778-35781	any	_	
188-28	35782-35788	single	_	
188-29	35789-35793	drug	_	
188-30	35794-35797	use	_	
188-31	35798-35803	class	_	
188-32	35804-35807	and	_	
188-33	35808-35812	will	_	
188-34	35813-35823	generalize	_	
188-35	35824-35826	to	_	
188-36	35827-35833	larger	_	
188-37	35834-35845	populations	_	
188-38	35846-35848	of	_	
188-39	35849-35853	drug	_	
188-40	35854-35859	users	_	
188-41	35859-35860	.	_	

#Text=In this study, we provide the first clear demonstration of the transdiagnostic efficacy of VMPFC TMS to modulate both frontostriatal and salience network circuitry often associated with drug/alcohol craving and relapse.
189-1	35861-35863	In	_	
189-2	35864-35868	this	_	
189-3	35869-35874	study	_	
189-4	35874-35875	,	_	
189-5	35876-35878	we	_	
189-6	35879-35886	provide	_	
189-7	35887-35890	the	_	
189-8	35891-35896	first	_	
189-9	35897-35902	clear	_	
189-10	35903-35916	demonstration	_	
189-11	35917-35919	of	_	
189-12	35920-35923	the	_	
189-13	35924-35939	transdiagnostic	_	
189-14	35940-35948	efficacy	_	
189-15	35949-35951	of	_	
189-16	35952-35957	VMPFC	_	
189-17	35958-35961	TMS	_	
189-18	35962-35964	to	_	
189-19	35965-35973	modulate	_	
189-20	35974-35978	both	_	
189-21	35979-35993	frontostriatal	_	
189-22	35994-35997	and	_	
189-23	35998-36006	salience	_	
189-24	36007-36014	network	_	
189-25	36015-36024	circuitry	_	
189-26	36025-36030	often	_	
189-27	36031-36041	associated	_	
189-28	36042-36046	with	_	
189-29	36047-36051	drug	_	
189-30	36051-36052	/	_	
189-31	36052-36059	alcohol	_	
189-32	36060-36067	craving	_	
189-33	36068-36071	and	_	
189-34	36072-36079	relapse	_	
189-35	36079-36080	.	_	

#Text=We thus corroborate prior evidence from our lab indicating the VMPFC as a viable TMS (cTBS) treatment target.
190-1	36081-36083	We	_	
190-2	36084-36088	thus	_	
190-3	36089-36100	corroborate	_	
190-4	36101-36106	prior	_	
190-5	36107-36115	evidence	_	
190-6	36116-36120	from	_	
190-7	36121-36124	our	_	
190-8	36125-36128	lab	_	
190-9	36129-36139	indicating	_	
190-10	36140-36143	the	_	
190-11	36144-36149	VMPFC	_	
190-12	36150-36152	as	_	
190-13	36153-36154	a	_	
190-14	36155-36161	viable	_	
190-15	36162-36165	TMS	_	
190-16	36166-36167	(	_	
190-17	36167-36171	cTBS	_	
190-18	36171-36172	)	_	
190-19	36173-36182	treatment	_	
190-20	36183-36189	target	_	
190-21	36189-36190	.	_	

#Text=These findings facilitate the next critical steps in developing inhibitory VMPFC TMS as an innovative, noninvasive neurobiologically targeted intervention in SUDs.
191-1	36191-36196	These	_	
191-2	36197-36205	findings	_	
191-3	36206-36216	facilitate	_	
191-4	36217-36220	the	_	
191-5	36221-36225	next	_	
191-6	36226-36234	critical	_	
191-7	36235-36240	steps	_	
191-8	36241-36243	in	_	
191-9	36244-36254	developing	_	
191-10	36255-36265	inhibitory	_	
191-11	36266-36271	VMPFC	_	
191-12	36272-36275	TMS	_	
191-13	36276-36278	as	_	
191-14	36279-36281	an	_	
191-15	36282-36292	innovative	_	
191-16	36292-36293	,	_	
191-17	36294-36305	noninvasive	_	
191-18	36306-36323	neurobiologically	_	
191-19	36324-36332	targeted	_	
191-20	36333-36345	intervention	_	
191-21	36346-36348	in	_	
191-22	36349-36353	SUDs	_	
191-23	36353-36354	.	_	

#Text=Supplementary Material
#Text=Supplementary material cited in this article is available online at https://doi.org/10.1016/j.bpsc.2018.03.016.
192-1	36355-36368	Supplementary	_	
192-2	36369-36377	Material	_	
192-3	36378-36391	Supplementary	_	
192-4	36392-36400	material	_	
192-5	36401-36406	cited	_	
192-6	36407-36409	in	_	
192-7	36410-36414	this	_	
192-8	36415-36422	article	_	
192-9	36423-36425	is	_	
192-10	36426-36435	available	_	
192-11	36436-36442	online	_	
192-12	36443-36445	at	_	
192-13	36446-36451	https	_	
192-14	36451-36452	:	_	
192-15	36452-36453	/	_	
192-16	36453-36454	/	_	
192-17	36454-36461	doi.org	_	
192-18	36461-36462	/	_	
192-19	36462-36469	10.1016	_	
192-20	36469-36470	/	_	
192-21	36470-36476	j.bpsc	_	
192-22	36476-36488	.2018.03.016	_	
192-23	36488-36489	.	_	

#Text=DISCLOSURES
#Text=The authors report no biomedical financial interests or potential conflicts of interest.
193-1	36490-36501	DISCLOSURES	_	
193-2	36502-36505	The	_	
193-3	36506-36513	authors	_	
193-4	36514-36520	report	_	
193-5	36521-36523	no	_	
193-6	36524-36534	biomedical	_	
193-7	36535-36544	financial	_	
193-8	36545-36554	interests	_	
193-9	36555-36557	or	_	
193-10	36558-36567	potential	_	
193-11	36568-36577	conflicts	_	
193-12	36578-36580	of	_	
193-13	36581-36589	interest	_	
193-14	36589-36590	.	_	

#Text=REFERENCES
#Text=New findings on biological factors predicting addiction relapse vulnerability.
194-1	36591-36601	REFERENCES	_	
194-2	36602-36605	New	_	
194-3	36606-36614	findings	_	
194-4	36615-36617	on	_	
194-5	36618-36628	biological	_	
194-6	36629-36636	factors	_	
194-7	36637-36647	predicting	_	
194-8	36648-36657	addiction	_	
194-9	36658-36665	relapse	_	
194-10	36666-36679	vulnerability	_	
194-11	36679-36680	.	_	

#Text=Neural activity related to drug craving in cocaine addiction.
195-1	36681-36687	Neural	_	
195-2	36688-36696	activity	_	
195-3	36697-36704	related	_	
195-4	36705-36707	to	_	
195-5	36708-36712	drug	_	
195-6	36713-36720	craving	_	
195-7	36721-36723	in	_	
195-8	36724-36731	cocaine	_	
195-9	36732-36741	addiction	_	
195-10	36741-36742	.	_	

#Text=Functional neuroimaging studies of alcohol cue reactivity: A quantitative meta-analysis and systematic review.
196-1	36743-36753	Functional	_	
196-2	36754-36766	neuroimaging	_	
196-3	36767-36774	studies	_	
196-4	36775-36777	of	_	
196-5	36778-36785	alcohol	_	
196-6	36786-36789	cue	_	
196-7	36790-36800	reactivity	_	
196-8	36800-36801	:	_	
196-9	36802-36803	A	_	
196-10	36804-36816	quantitative	_	
196-11	36817-36830	meta-analysis	_	
196-12	36831-36834	and	_	
196-13	36835-36845	systematic	_	
196-14	36846-36852	review	_	
196-15	36852-36853	.	_	

#Text=Neural substrates of smoking cue reactivity: A meta-analysis of fMRI studies.
197-1	36854-36860	Neural	_	
197-2	36861-36871	substrates	_	
197-3	36872-36874	of	_	
197-4	36875-36882	smoking	_	
197-5	36883-36886	cue	_	
197-6	36887-36897	reactivity	_	
197-7	36897-36898	:	_	
197-8	36899-36900	A	_	
197-9	36901-36914	meta-analysis	_	
197-10	36915-36917	of	_	
197-11	36918-36922	fMRI	_	
197-12	36923-36930	studies	_	
197-13	36930-36931	.	_	

#Text=Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry.
198-1	36932-36940	Exposure	_	
198-2	36941-36943	to	_	
198-3	36944-36947	the	_	
198-4	36948-36953	taste	_	
198-5	36954-36956	of	_	
198-6	36957-36964	alcohol	_	
198-7	36965-36972	elicits	_	
198-8	36973-36983	activation	_	
198-9	36984-36986	of	_	
198-10	36987-36990	the	_	
198-11	36991-37008	mesocorticolimbic	_	
198-12	37009-37023	neurocircuitry	_	
198-13	37023-37024	.	_	

#Text=Predicting subsequent relapse by drug-related cue-induced brain activation in heroin addiction: An event-related functional magnetic resonance imaging study.
199-1	37025-37035	Predicting	_	
199-2	37036-37046	subsequent	_	
199-3	37047-37054	relapse	_	
199-4	37055-37057	by	_	
199-5	37058-37070	drug-related	_	
199-6	37071-37082	cue-induced	_	
199-7	37083-37088	brain	_	
199-8	37089-37099	activation	_	
199-9	37100-37102	in	_	
199-10	37103-37109	heroin	_	
199-11	37110-37119	addiction	_	
199-12	37119-37120	:	_	
199-13	37121-37123	An	_	
199-14	37124-37137	event-related	_	
199-15	37138-37148	functional	_	
199-16	37149-37157	magnetic	_	
199-17	37158-37167	resonance	_	
199-18	37168-37175	imaging	_	
199-19	37176-37181	study	_	
199-20	37181-37182	.	_	

#Text=Physiology of repetitive transcranial magnetic stimulation of the human brain.
200-1	37183-37193	Physiology	_	
200-2	37194-37196	of	_	
200-3	37197-37207	repetitive	_	
200-4	37208-37220	transcranial	_	
200-5	37221-37229	magnetic	_	
200-6	37230-37241	stimulation	_	
200-7	37242-37244	of	_	
200-8	37245-37248	the	_	
200-9	37249-37254	human	_	
200-10	37255-37260	brain	_	
200-11	37260-37261	.	_	

#Text=Theta burst stimulation of the human motor cortex.
201-1	37262-37267	Theta	_	
201-2	37268-37273	burst	_	
201-3	37274-37285	stimulation	_	
201-4	37286-37288	of	_	
201-5	37289-37292	the	_	
201-6	37293-37298	human	_	
201-7	37299-37304	motor	_	
201-8	37305-37311	cortex	_	
201-9	37311-37312	.	_	

#Text=Consensus: New methodologies for brain stimulation.
202-1	37313-37322	Consensus	_	
202-2	37322-37323	:	_	
202-3	37324-37327	New	_	
202-4	37328-37341	methodologies	_	
202-5	37342-37345	for	_	
202-6	37346-37351	brain	_	
202-7	37352-37363	stimulation	_	
202-8	37363-37364	.	_	

#Text=Noninvasive brain stimulation treatments for addiction and major depression.
203-1	37365-37376	Noninvasive	_	
203-2	37377-37382	brain	_	
203-3	37383-37394	stimulation	_	
203-4	37395-37405	treatments	_	
203-5	37406-37409	for	_	
203-6	37410-37419	addiction	_	
203-7	37420-37423	and	_	
203-8	37424-37429	major	_	
203-9	37430-37440	depression	_	
203-10	37440-37441	.	_	

#Text=Probing the frontostriatal loops involved in executive and limbic processing via interleaved TMS and functional MRI at two prefrontal locations: A pilot study.
204-1	37442-37449	Probing	_	
204-2	37450-37453	the	_	
204-3	37454-37468	frontostriatal	_	
204-4	37469-37474	loops	_	
204-5	37475-37483	involved	_	
204-6	37484-37486	in	_	
204-7	37487-37496	executive	_	
204-8	37497-37500	and	_	
204-9	37501-37507	limbic	_	
204-10	37508-37518	processing	_	
204-11	37519-37522	via	_	
204-12	37523-37534	interleaved	_	
204-13	37535-37538	TMS	_	
204-14	37539-37542	and	_	
204-15	37543-37553	functional	_	
204-16	37554-37557	MRI	_	
204-17	37558-37560	at	_	
204-18	37561-37564	two	_	
204-19	37565-37575	prefrontal	_	
204-20	37576-37585	locations	_	
204-21	37585-37586	:	_	
204-22	37587-37588	A	_	
204-23	37589-37594	pilot	_	
204-24	37595-37600	study	_	
204-25	37600-37601	.	_	

#Text=Recovering from cocaine: Insights from clinical and preclinical investigations.
205-1	37602-37612	Recovering	_	
205-2	37613-37617	from	_	
205-3	37618-37625	cocaine	_	
205-4	37625-37626	:	_	
205-5	37627-37635	Insights	_	
205-6	37636-37640	from	_	
205-7	37641-37649	clinical	_	
205-8	37650-37653	and	_	
205-9	37654-37665	preclinical	_	
205-10	37666-37680	investigations	_	
205-11	37680-37681	.	_	

#Text=Left frontal pole theta burst stimulation decreases orbitofrontal and insula activity in cocaine users and alcohol users.
206-1	37682-37686	Left	_	
206-2	37687-37694	frontal	_	
206-3	37695-37699	pole	_	
206-4	37700-37705	theta	_	
206-5	37706-37711	burst	_	
206-6	37712-37723	stimulation	_	
206-7	37724-37733	decreases	_	
206-8	37734-37747	orbitofrontal	_	
206-9	37748-37751	and	_	
206-10	37752-37758	insula	_	
206-11	37759-37767	activity	_	
206-12	37768-37770	in	_	
206-13	37771-37778	cocaine	_	
206-14	37779-37784	users	_	
206-15	37785-37788	and	_	
206-16	37789-37796	alcohol	_	
206-17	37797-37802	users	_	
206-18	37802-37803	.	_	

#Text=Mobilization of Medial and lateral frontal-striatal circuits in cocaine users and controls: An interleaved TMS/BOLD functional connectivity study.
207-1	37804-37816	Mobilization	_	
207-2	37817-37819	of	_	
207-3	37820-37826	Medial	_	
207-4	37827-37830	and	_	
207-5	37831-37838	lateral	_	
207-6	37839-37855	frontal-striatal	_	
207-7	37856-37864	circuits	_	
207-8	37865-37867	in	_	
207-9	37868-37875	cocaine	_	
207-10	37876-37881	users	_	
207-11	37882-37885	and	_	
207-12	37886-37894	controls	_	
207-13	37894-37895	:	_	
207-14	37896-37898	An	_	
207-15	37899-37910	interleaved	_	
207-16	37911-37914	TMS	_	
207-17	37914-37915	/	_	
207-18	37915-37919	BOLD	_	
207-19	37920-37930	functional	_	
207-20	37931-37943	connectivity	_	
207-21	37944-37949	study	_	
207-22	37949-37950	.	_	

#Text=What goes up, can come down: Novel brain stimulation paradigms may attenuate craving and craving-related neural circuitry in substance dependent individuals.
208-1	37951-37955	What	_	
208-2	37956-37960	goes	_	
208-3	37961-37963	up	_	
208-4	37963-37964	,	_	
208-5	37965-37968	can	_	
208-6	37969-37973	come	_	
208-7	37974-37978	down	_	
208-8	37978-37979	:	_	
208-9	37980-37985	Novel	_	
208-10	37986-37991	brain	_	
208-11	37992-38003	stimulation	_	
208-12	38004-38013	paradigms	_	
208-13	38014-38017	may	_	
208-14	38018-38027	attenuate	_	
208-15	38028-38035	craving	_	
208-16	38036-38039	and	_	
208-17	38040-38055	craving-related	_	
208-18	38056-38062	neural	_	
208-19	38063-38072	circuitry	_	
208-20	38073-38075	in	_	
208-21	38076-38085	substance	_	
208-22	38086-38095	dependent	_	
208-23	38096-38107	individuals	_	
208-24	38107-38108	.	_	

#Text=Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial.
209-1	38109-38117	Efficacy	_	
209-2	38118-38121	and	_	
209-3	38122-38128	safety	_	
209-4	38129-38131	of	_	
209-5	38132-38144	transcranial	_	
209-6	38145-38153	magnetic	_	
209-7	38154-38165	stimulation	_	
209-8	38166-38168	in	_	
209-9	38169-38172	the	_	
209-10	38173-38178	acute	_	
209-11	38179-38188	treatment	_	
209-12	38189-38191	of	_	
209-13	38192-38197	major	_	
209-14	38198-38208	depression	_	
209-15	38208-38209	:	_	
209-16	38210-38211	A	_	
209-17	38212-38221	multisite	_	
209-18	38222-38232	randomized	_	
209-19	38233-38243	controlled	_	
209-20	38244-38249	trial	_	
209-21	38249-38250	.	_	

#Text=The Fagerström Test for Nicotine Dependence: A Revision of the Fagerström Tolerance Questionnaire.
210-1	38254-38257	The	_	
210-2	38258-38268	Fagerström	_	
210-3	38269-38273	Test	_	
210-4	38274-38277	for	_	
210-5	38278-38286	Nicotine	_	
210-6	38287-38297	Dependence	_	
210-7	38297-38298	:	_	
210-8	38299-38300	A	_	
210-9	38301-38309	Revision	_	
210-10	38310-38312	of	_	
210-11	38313-38316	the	_	
210-12	38317-38327	Fagerström	_	
210-13	38328-38337	Tolerance	_	
210-14	38338-38351	Questionnaire	_	
210-15	38351-38352	.	_	

#Text=Brain activation to cocaine cues and motivation/treatment status.
211-1	38355-38360	Brain	_	
211-2	38361-38371	activation	_	
211-3	38372-38374	to	_	
211-4	38375-38382	cocaine	_	
211-5	38383-38387	cues	_	
211-6	38388-38391	and	_	
211-7	38392-38402	motivation	_	
211-8	38402-38403	/	_	
211-9	38403-38412	treatment	_	
211-10	38413-38419	status	_	
211-11	38419-38420	.	_	

#Text=Stability of fMRI striatal response to alcohol cues: A hierarchical linear modeling approach.
212-1	38421-38430	Stability	_	
212-2	38431-38433	of	_	
212-3	38434-38438	fMRI	_	
212-4	38439-38447	striatal	_	
212-5	38448-38456	response	_	
212-6	38457-38459	to	_	
212-7	38460-38467	alcohol	_	
212-8	38468-38472	cues	_	
212-9	38472-38473	:	_	
212-10	38474-38475	A	_	
212-11	38476-38488	hierarchical	_	
212-12	38489-38495	linear	_	
212-13	38496-38504	modeling	_	
212-14	38505-38513	approach	_	
212-15	38513-38514	.	_	

#Text=Estimating resting motor thresholds in transcranial magnetic stimulation research and practice: A computer simulation evaluation of best methods.
213-1	38515-38525	Estimating	_	
213-2	38526-38533	resting	_	
213-3	38534-38539	motor	_	
213-4	38540-38550	thresholds	_	
213-5	38551-38553	in	_	
213-6	38554-38566	transcranial	_	
213-7	38567-38575	magnetic	_	
213-8	38576-38587	stimulation	_	
213-9	38588-38596	research	_	
213-10	38597-38600	and	_	
213-11	38601-38609	practice	_	
213-12	38609-38610	:	_	
213-13	38611-38612	A	_	
213-14	38613-38621	computer	_	
213-15	38622-38632	simulation	_	
213-16	38633-38643	evaluation	_	
213-17	38644-38646	of	_	
213-18	38647-38651	best	_	
213-19	38652-38659	methods	_	
213-20	38659-38660	.	_	

#Text=The emerging evidence for Narrative Exposure Therapy: A review.
214-1	38661-38664	The	_	
214-2	38665-38673	emerging	_	
214-3	38674-38682	evidence	_	
214-4	38683-38686	for	_	
214-5	38687-38696	Narrative	_	
214-6	38697-38705	Exposure	_	
214-7	38706-38713	Therapy	_	
214-8	38713-38714	:	_	
214-9	38715-38716	A	_	
214-10	38717-38723	review	_	
214-11	38723-38724	.	_	

#Text=A generalized form of context-dependent psychophysiological interactions (gPPI): A comparison to standard approaches.
215-1	38725-38726	A	_	
215-2	38727-38738	generalized	_	
215-3	38739-38743	form	_	
215-4	38744-38746	of	_	
215-5	38747-38764	context-dependent	_	
215-6	38765-38784	psychophysiological	_	
215-7	38785-38797	interactions	_	
215-8	38798-38799	(	_	
215-9	38799-38803	gPPI	_	
215-10	38803-38804	)	_	
215-11	38804-38805	:	_	
215-12	38806-38807	A	_	
215-13	38808-38818	comparison	_	
215-14	38819-38821	to	_	
215-15	38822-38830	standard	_	
215-16	38831-38841	approaches	_	
215-17	38841-38842	.	_	

#Text=How coil-cortex distance relates to age, motor threshold, and antidepressant response to repetitive transcranial magnetic stimulation.
216-1	38843-38846	How	_	
216-2	38847-38858	coil-cortex	_	
216-3	38859-38867	distance	_	
216-4	38868-38875	relates	_	
216-5	38876-38878	to	_	
216-6	38879-38882	age	_	
216-7	38882-38883	,	_	
216-8	38884-38889	motor	_	
216-9	38890-38899	threshold	_	
216-10	38899-38900	,	_	
216-11	38901-38904	and	_	
216-12	38905-38919	antidepressant	_	
216-13	38920-38928	response	_	
216-14	38929-38931	to	_	
216-15	38932-38942	repetitive	_	
216-16	38943-38955	transcranial	_	
216-17	38956-38964	magnetic	_	
216-18	38965-38976	stimulation	_	
216-19	38976-38977	.	_	

#Text=Biophysical determinants of transcranial magnetic stimulation: Effects of excitability and depth of targeted area.
217-1	38978-38989	Biophysical	_	
217-2	38990-39002	determinants	_	
217-3	39003-39005	of	_	
217-4	39006-39018	transcranial	_	
217-5	39019-39027	magnetic	_	
217-6	39028-39039	stimulation	_	
217-7	39039-39040	:	_	
217-8	39041-39048	Effects	_	
217-9	39049-39051	of	_	
217-10	39052-39064	excitability	_	
217-11	39065-39068	and	_	
217-12	39069-39074	depth	_	
217-13	39075-39077	of	_	
217-14	39078-39086	targeted	_	
217-15	39087-39091	area	_	
217-16	39091-39092	.	_	

#Text=BrainRuler-A free, open-access tool for calculating scalp to cortex distance.
218-1	39093-39105	BrainRuler-A	_	
218-2	39106-39110	free	_	
218-3	39110-39111	,	_	
218-4	39112-39123	open-access	_	
218-5	39124-39128	tool	_	
218-6	39129-39132	for	_	
218-7	39133-39144	calculating	_	
218-8	39145-39150	scalp	_	
218-9	39151-39153	to	_	
218-10	39154-39160	cortex	_	
218-11	39161-39169	distance	_	
218-12	39169-39170	.	_	

#Text=Daily sessions of transcranial magnetic stimulation to the left prefrontal cortex gradually reduce cocaine craving.
219-1	39172-39177	Daily	_	
219-2	39178-39186	sessions	_	
219-3	39187-39189	of	_	
219-4	39190-39202	transcranial	_	
219-5	39203-39211	magnetic	_	
219-6	39212-39223	stimulation	_	
219-7	39224-39226	to	_	
219-8	39227-39230	the	_	
219-9	39231-39235	left	_	
219-10	39236-39246	prefrontal	_	
219-11	39247-39253	cortex	_	
219-12	39254-39263	gradually	_	
219-13	39264-39270	reduce	_	
219-14	39271-39278	cocaine	_	
219-15	39279-39286	craving	_	
219-16	39286-39287	.	_	

#Text=Neural substrates of cue reactivity: association with treatment outcomes and relapse.
220-1	39288-39294	Neural	_	
220-2	39295-39305	substrates	_	
220-3	39306-39308	of	_	
220-4	39309-39312	cue	_	
220-5	39313-39323	reactivity	_	
220-6	39323-39324	:	_	
220-7	39325-39336	association	_	
220-8	39337-39341	with	_	
220-9	39342-39351	treatment	_	
220-10	39352-39360	outcomes	_	
220-11	39361-39364	and	_	
220-12	39365-39372	relapse	_	
220-13	39372-39373	.	_	

#Text=Predictors of naltrexone response in a randomized trial: Reward-related brain activation, OPRM1 genotype, and smoking status.
221-1	39374-39384	Predictors	_	
221-2	39385-39387	of	_	
221-3	39388-39398	naltrexone	_	
221-4	39399-39407	response	_	
221-5	39408-39410	in	_	
221-6	39411-39412	a	_	
221-7	39413-39423	randomized	_	
221-8	39424-39429	trial	_	
221-9	39429-39430	:	_	
221-10	39431-39445	Reward-related	_	
221-11	39446-39451	brain	_	
221-12	39452-39462	activation	_	
221-13	39462-39463	,	_	
221-14	39464-39469	OPRM1	_	
221-15	39470-39478	genotype	_	
221-16	39478-39479	,	_	
221-17	39480-39483	and	_	
221-18	39484-39491	smoking	_	
221-19	39492-39498	status	_	
221-20	39498-39499	.	_	

#Text=Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics.
222-1	39500-39511	Cue-induced	_	
222-2	39512-39522	activation	_	
222-3	39523-39525	of	_	
222-4	39526-39529	the	_	
222-5	39530-39538	striatum	_	
222-6	39539-39542	and	_	
222-7	39543-39549	medial	_	
222-8	39550-39560	prefrontal	_	
222-9	39561-39567	cortex	_	
222-10	39568-39570	is	_	
222-11	39571-39581	associated	_	
222-12	39582-39586	with	_	
222-13	39587-39597	subsequent	_	
222-14	39598-39605	relapse	_	
222-15	39606-39608	in	_	
222-16	39609-39618	abstinent	_	
222-17	39619-39629	alcoholics	_	
222-18	39629-39630	.	_	

#Text=Identifying the neural circuitry of alcohol craving and relapse vulnerability.
223-1	39631-39642	Identifying	_	
223-2	39643-39646	the	_	
223-3	39647-39653	neural	_	
223-4	39654-39663	circuitry	_	
223-5	39664-39666	of	_	
223-6	39667-39674	alcohol	_	
223-7	39675-39682	craving	_	
223-8	39683-39686	and	_	
223-9	39687-39694	relapse	_	
223-10	39695-39708	vulnerability	_	
223-11	39708-39709	.	_	

#Text=Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence.
224-1	39710-39715	Brain	_	
224-2	39716-39726	reactivity	_	
224-3	39727-39729	to	_	
224-4	39730-39737	smoking	_	
224-5	39738-39742	cues	_	
224-6	39743-39748	prior	_	
224-7	39749-39751	to	_	
224-8	39752-39759	smoking	_	
224-9	39760-39769	cessation	_	
224-10	39770-39778	predicts	_	
224-11	39779-39786	ability	_	
224-12	39787-39789	to	_	
224-13	39790-39798	maintain	_	
224-14	39799-39806	tobacco	_	
224-15	39807-39817	abstinence	_	
224-16	39817-39818	.	_	

#Text=Prequit fMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome.
225-1	39819-39826	Prequit	_	
225-2	39827-39831	fMRI	_	
225-3	39832-39841	responses	_	
225-4	39842-39844	to	_	
225-5	39845-39853	pleasant	_	
225-6	39854-39858	cues	_	
225-7	39859-39862	and	_	
225-8	39863-39880	cigarette-related	_	
225-9	39881-39885	cues	_	
225-10	39886-39893	predict	_	
225-11	39894-39901	smoking	_	
225-12	39902-39911	cessation	_	
225-13	39912-39919	outcome	_	
225-14	39919-39920	.	_	

#Text=Neural bases of pharmacological treatment of nicotine dependence - insights from functional brain imaging: A systematic review.
226-1	39921-39927	Neural	_	
226-2	39928-39933	bases	_	
226-3	39934-39936	of	_	
226-4	39937-39952	pharmacological	_	
226-5	39953-39962	treatment	_	
226-6	39963-39965	of	_	
226-7	39966-39974	nicotine	_	
226-8	39975-39985	dependence	_	
226-9	39986-39987	-	_	
226-10	39988-39996	insights	_	
226-11	39997-40001	from	_	
226-12	40002-40012	functional	_	
226-13	40013-40018	brain	_	
226-14	40019-40026	imaging	_	
226-15	40026-40027	:	_	
226-16	40028-40029	A	_	
226-17	40030-40040	systematic	_	
226-18	40041-40047	review	_	
226-19	40047-40048	.	_	

#Text=Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: A prospective, randomized controlled trial.
227-1	40049-40056	Smoking	_	
227-2	40057-40066	cessation	_	
227-3	40067-40074	induced	_	
227-4	40075-40077	by	_	
227-5	40078-40082	deep	_	
227-6	40083-40093	repetitive	_	
227-7	40094-40106	transcranial	_	
227-8	40107-40115	magnetic	_	
227-9	40116-40127	stimulation	_	
227-10	40128-40130	of	_	
227-11	40131-40134	the	_	
227-12	40135-40145	prefrontal	_	
227-13	40146-40149	and	_	
227-14	40150-40157	insular	_	
227-15	40158-40166	cortices	_	
227-16	40166-40167	:	_	
227-17	40168-40169	A	_	
227-18	40170-40181	prospective	_	
227-19	40181-40182	,	_	
227-20	40183-40193	randomized	_	
227-21	40194-40204	controlled	_	
227-22	40205-40210	trial	_	
227-23	40210-40211	.	_	

#Text=Role of the human motor cortex in rapid motor learning.
228-1	40212-40216	Role	_	
228-2	40217-40219	of	_	
228-3	40220-40223	the	_	
228-4	40224-40229	human	_	
228-5	40230-40235	motor	_	
228-6	40236-40242	cortex	_	
228-7	40243-40245	in	_	
228-8	40246-40251	rapid	_	
228-9	40252-40257	motor	_	
228-10	40258-40266	learning	_	
228-11	40266-40267	.	_	

#Text=Learning-induced LTP in neocortex.
229-1	40268-40284	Learning-induced	_	
229-2	40285-40288	LTP	_	
229-3	40289-40291	in	_	
229-4	40292-40301	neocortex	_	
229-5	40301-40302	.	_	

#Text=Transcranial magnetic stimulation in the treatment of substance addiction.
230-1	40303-40315	Transcranial	_	
230-2	40316-40324	magnetic	_	
230-3	40325-40336	stimulation	_	
230-4	40337-40339	in	_	
230-5	40340-40343	the	_	
230-6	40344-40353	treatment	_	
230-7	40354-40356	of	_	
230-8	40357-40366	substance	_	
230-9	40367-40376	addiction	_	
230-10	40376-40377	.	_	

#Text=Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving.
231-1	40378-40388	Repetitive	_	
231-2	40389-40401	transcranial	_	
231-3	40402-40410	magnetic	_	
231-4	40411-40422	stimulation	_	
231-5	40423-40425	of	_	
231-6	40426-40429	the	_	
231-7	40430-40442	dorsolateral	_	
231-8	40443-40453	prefrontal	_	
231-9	40454-40460	cortex	_	
231-10	40461-40468	reduces	_	
231-11	40469-40477	nicotine	_	
231-12	40478-40481	cue	_	
231-13	40482-40489	craving	_	
231-14	40489-40490	.	_	

#Text=One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving.
232-1	40491-40494	One	_	
232-2	40495-40502	session	_	
232-3	40503-40505	of	_	
232-4	40506-40510	high	_	
232-5	40511-40520	frequency	_	
232-6	40521-40531	repetitive	_	
232-7	40532-40544	transcranial	_	
232-8	40545-40553	magnetic	_	
232-9	40554-40565	stimulation	_	
232-10	40566-40567	(	_	
232-11	40567-40571	rTMS	_	
232-12	40571-40572	)	_	
232-13	40573-40575	to	_	
232-14	40576-40579	the	_	
232-15	40580-40585	right	_	
232-16	40586-40596	prefrontal	_	
232-17	40597-40603	cortex	_	
232-18	40604-40615	transiently	_	
232-19	40616-40623	reduces	_	
232-20	40624-40631	cocaine	_	
232-21	40632-40639	craving	_	
232-22	40639-40640	.	_	

#Text=Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: A sham-controlled study.
233-1	40641-40649	Efficacy	_	
233-2	40650-40652	of	_	
233-3	40653-40663	repetitive	_	
233-4	40664-40676	transcranial	_	
233-5	40677-40685	magnetic	_	
233-6	40686-40697	stimulation	_	
233-7	40698-40700	in	_	
233-8	40701-40708	alcohol	_	
233-9	40709-40719	dependence	_	
233-10	40719-40720	:	_	
233-11	40721-40722	A	_	
233-12	40723-40738	sham-controlled	_	
233-13	40739-40744	study	_	
233-14	40744-40745	.	_	

#Text=Infralimbic prefrontal cortex is responsible for inhibiting cocaine seeking in extinguished rats.
234-1	40746-40757	Infralimbic	_	
234-2	40758-40768	prefrontal	_	
234-3	40769-40775	cortex	_	
234-4	40776-40778	is	_	
234-5	40779-40790	responsible	_	
234-6	40791-40794	for	_	
234-7	40795-40805	inhibiting	_	
234-8	40806-40813	cocaine	_	
234-9	40814-40821	seeking	_	
234-10	40822-40824	in	_	
234-11	40825-40837	extinguished	_	
234-12	40838-40842	rats	_	
234-13	40842-40843	.	_	

#Text=Role of the prefrontal cortex and nucleus accumbens in reinstating methamphetamine seeking.
235-1	40844-40848	Role	_	
235-2	40849-40851	of	_	
235-3	40852-40855	the	_	
235-4	40856-40866	prefrontal	_	
235-5	40867-40873	cortex	_	
235-6	40874-40877	and	_	
235-7	40878-40885	nucleus	_	
235-8	40886-40895	accumbens	_	
235-9	40896-40898	in	_	
235-10	40899-40910	reinstating	_	
235-11	40911-40926	methamphetamine	_	
235-12	40927-40934	seeking	_	
235-13	40934-40935	.	_	

#Text=Ventral medial prefrontal cortex neuronal ensembles mediate context-induced relapse to heroin.
236-1	40936-40943	Ventral	_	
236-2	40944-40950	medial	_	
236-3	40951-40961	prefrontal	_	
236-4	40962-40968	cortex	_	
236-5	40969-40977	neuronal	_	
236-6	40978-40987	ensembles	_	
236-7	40988-40995	mediate	_	
236-8	40996-41011	context-induced	_	
236-9	41012-41019	relapse	_	
236-10	41020-41022	to	_	
236-11	41023-41029	heroin	_	
236-12	41029-41030	.	_	

#Text=Optogenetics: Potentials for addiction research.
237-1	41031-41043	Optogenetics	_	
237-2	41043-41044	:	_	
237-3	41045-41055	Potentials	_	
237-4	41056-41059	for	_	
237-5	41060-41069	addiction	_	
237-6	41070-41078	research	_	
237-7	41078-41079	.	_	

#Text=Rescuing cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking.
238-1	41080-41088	Rescuing	_	
238-2	41089-41104	cocaine-induced	_	
238-3	41105-41115	prefrontal	_	
238-4	41116-41122	cortex	_	
238-5	41123-41135	hypoactivity	_	
238-6	41136-41144	prevents	_	
238-7	41145-41155	compulsive	_	
238-8	41156-41163	cocaine	_	
238-9	41164-41171	seeking	_	
238-10	41171-41172	.	_	

#Text=Optogenetic inhibition of cocaine seeking in rats.
239-1	41173-41184	Optogenetic	_	
239-2	41185-41195	inhibition	_	
239-3	41196-41198	of	_	
239-4	41199-41206	cocaine	_	
239-5	41207-41214	seeking	_	
239-6	41215-41217	in	_	
239-7	41218-41222	rats	_	
239-8	41222-41223	.	_	

#Text=Terminal effects of optogenetic stimulation on dopamine dynamics in rat striatum.
240-1	41224-41232	Terminal	_	
240-2	41233-41240	effects	_	
240-3	41241-41243	of	_	
240-4	41244-41255	optogenetic	_	
240-5	41256-41267	stimulation	_	
240-6	41268-41270	on	_	
240-7	41271-41279	dopamine	_	
240-8	41280-41288	dynamics	_	
240-9	41289-41291	in	_	
240-10	41292-41295	rat	_	
240-11	41296-41304	striatum	_	
240-12	41304-41305	.	_	

#Text=Reverse pharmacogenetic modulation of the nucleus accumbens reduces ethanol consumption in a limited access paradigm.
241-1	41306-41313	Reverse	_	
241-2	41314-41329	pharmacogenetic	_	
241-3	41330-41340	modulation	_	
241-4	41341-41343	of	_	
241-5	41344-41347	the	_	
241-6	41348-41355	nucleus	_	
241-7	41356-41365	accumbens	_	
241-8	41366-41373	reduces	_	
241-9	41374-41381	ethanol	_	
241-10	41382-41393	consumption	_	
241-11	41394-41396	in	_	
241-12	41397-41398	a	_	
241-13	41399-41406	limited	_	
241-14	41407-41413	access	_	
241-15	41414-41422	paradigm	_	
241-16	41422-41423	.	_	

#Text=The measurement of drug craving.
242-1	41424-41427	The	_	
242-2	41428-41439	measurement	_	
242-3	41440-41442	of	_	
242-4	41443-41447	drug	_	
242-5	41448-41455	craving	_	
242-6	41455-41456	.	_	

#Text=Self-reports: How the questions shape the answers.
243-1	41457-41469	Self-reports	_	
243-2	41469-41470	:	_	
243-3	41471-41474	How	_	
243-4	41475-41478	the	_	
243-5	41479-41488	questions	_	
243-6	41489-41494	shape	_	
243-7	41495-41498	the	_	
243-8	41499-41506	answers	_	
243-9	41506-41507	.	_	

#Text=Craving research: Future directions.
244-1	41508-41515	Craving	_	
244-2	41516-41524	research	_	
244-3	41524-41525	:	_	
244-4	41526-41532	Future	_	
244-5	41533-41543	directions	_	
244-6	41543-41544	.	_	

#Text=Does smoking cue-induced craving tell us anything important about nicotine dependence?
245-1	41545-41549	Does	_	
245-2	41550-41557	smoking	_	
245-3	41558-41569	cue-induced	_	
245-4	41570-41577	craving	_	
245-5	41578-41582	tell	_	
245-6	41583-41585	us	_	
245-7	41586-41594	anything	_	
245-8	41595-41604	important	_	
245-9	41605-41610	about	_	
245-10	41611-41619	nicotine	_	
245-11	41620-41630	dependence	_	
245-12	41630-41631	?	_	

#Text=Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption.
246-1	41632-41640	Repeated	_	
246-2	41641-41655	high-frequency	_	
246-3	41656-41668	transcranial	_	
246-4	41669-41677	magnetic	_	
246-5	41678-41689	stimulation	_	
246-6	41690-41694	over	_	
246-7	41695-41698	the	_	
246-8	41699-41711	dorsolateral	_	
246-9	41712-41722	prefrontal	_	
246-10	41723-41729	cortex	_	
246-11	41730-41737	reduces	_	
246-12	41738-41747	cigarette	_	
246-13	41748-41755	craving	_	
246-14	41756-41759	and	_	
246-15	41760-41771	consumption	_	
246-16	41771-41772	.	_	

#Text=Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study.
247-1	41773-41785	Transcranial	_	
247-2	41786-41794	magnetic	_	
247-3	41795-41806	stimulation	_	
247-4	41807-41809	of	_	
247-5	41810-41822	dorsolateral	_	
247-6	41823-41833	prefrontal	_	
247-7	41834-41840	cortex	_	
247-8	41841-41848	reduces	_	
247-9	41849-41856	cocaine	_	
247-10	41857-41860	use	_	
247-11	41860-41861	:	_	
247-12	41862-41863	A	_	
247-13	41864-41869	pilot	_	
247-14	41870-41875	study	_	
247-15	41875-41876	.	_	

#Text=Preliminary assessment of the therapeutic efficacy of continuous theta-burst magnetic stimulation (cTBS) in major depression: A double-blind sham-controlled study.
248-1	41877-41888	Preliminary	_	
248-2	41889-41899	assessment	_	
248-3	41900-41902	of	_	
248-4	41903-41906	the	_	
248-5	41907-41918	therapeutic	_	
248-6	41919-41927	efficacy	_	
248-7	41928-41930	of	_	
248-8	41931-41941	continuous	_	
248-9	41942-41953	theta-burst	_	
248-10	41954-41962	magnetic	_	
248-11	41963-41974	stimulation	_	
248-12	41975-41976	(	_	
248-13	41976-41980	cTBS	_	
248-14	41980-41981	)	_	
248-15	41982-41984	in	_	
248-16	41985-41990	major	_	
248-17	41991-42001	depression	_	
248-18	42001-42002	:	_	
248-19	42003-42004	A	_	
248-20	42005-42017	double-blind	_	
248-21	42018-42033	sham-controlled	_	
248-22	42034-42039	study	_	
248-23	42039-42040	.	_	

#Text=Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: A systematic review and meta-analysis of randomized, double-blind and sham-controlled trials.
249-1	42041-42049	Response	_	
249-2	42049-42050	,	_	
249-3	42051-42060	remission	_	
249-4	42061-42064	and	_	
249-5	42065-42073	drop-out	_	
249-6	42074-42079	rates	_	
249-7	42080-42089	following	_	
249-8	42090-42104	high-frequency	_	
249-9	42105-42115	repetitive	_	
249-10	42116-42128	transcranial	_	
249-11	42129-42137	magnetic	_	
249-12	42138-42149	stimulation	_	
249-13	42150-42151	(	_	
249-14	42151-42155	rTMS	_	
249-15	42155-42156	)	_	
249-16	42157-42160	for	_	
249-17	42161-42169	treating	_	
249-18	42170-42175	major	_	
249-19	42176-42186	depression	_	
249-20	42186-42187	:	_	
249-21	42188-42189	A	_	
249-22	42190-42200	systematic	_	
249-23	42201-42207	review	_	
249-24	42208-42211	and	_	
249-25	42212-42225	meta-analysis	_	
249-26	42226-42228	of	_	
249-27	42229-42239	randomized	_	
249-28	42239-42240	,	_	
249-29	42241-42253	double-blind	_	
249-30	42254-42257	and	_	
249-31	42258-42273	sham-controlled	_	
249-32	42274-42280	trials	_	
249-33	42280-42281	.	_	

#Text=Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis.
250-1	42282-42292	Repetitive	_	
250-2	42293-42305	transcranial	_	
250-3	42306-42314	magnetic	_	
250-4	42315-42326	stimulation	_	
250-5	42327-42330	for	_	
250-6	42331-42350	treatment-resistant	_	
250-7	42351-42361	depression	_	
250-8	42361-42362	:	_	
250-9	42363-42364	A	_	
250-10	42365-42375	systematic	_	
250-11	42376-42382	review	_	
250-12	42383-42386	and	_	
250-13	42387-42400	meta-analysis	_	
250-14	42400-42401	.	_	

#Text=Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic significance.
251-1	42402-42412	Alcoholism	_	
251-2	42413-42415	in	_	
251-3	42416-42433	treatment-seeking	_	
251-4	42434-42441	cocaine	_	
251-5	42442-42449	abusers	_	
251-6	42449-42450	:	_	
251-7	42451-42459	clinical	_	
251-8	42460-42463	and	_	
251-9	42464-42474	prognostic	_	
251-10	42475-42487	significance	_	
251-11	42487-42488	.	_	

#Text=Nicotine and caffeine use in cocaine-dependent individuals.
252-1	42489-42497	Nicotine	_	
252-2	42498-42501	and	_	
252-3	42502-42510	caffeine	_	
252-4	42511-42514	use	_	
252-5	42515-42517	in	_	
252-6	42518-42535	cocaine-dependent	_	
252-7	42536-42547	individuals	_	
252-8	42547-42548	.	_	

#Text=Treatment of cocaine dependence and depression.
253-1	42549-42558	Treatment	_	
253-2	42559-42561	of	_	
253-3	42562-42569	cocaine	_	
253-4	42570-42580	dependence	_	
253-5	42581-42584	and	_	
253-6	42585-42595	depression	_	
253-7	42595-42596	.	_	

#Text=Magnetic resonance imaging (MRI)/repetitive transcranial magnetic stimulation visit.
254-1	42597-42605	Magnetic	_	
254-2	42606-42615	resonance	_	
254-3	42616-42623	imaging	_	
254-4	42624-42625	(	_	
254-5	42625-42628	MRI	_	
254-6	42628-42629	)	_	
254-7	42629-42630	/	_	
254-8	42630-42640	repetitive	_	
254-9	42641-42653	transcranial	_	
254-10	42654-42662	magnetic	_	
254-11	42663-42674	stimulation	_	
254-12	42675-42680	visit	_	
254-13	42680-42681	.	_	

#Text=All participants received both real and sham ventromedial prefrontal cortex (VMPFC) continuous theta burst stimulation (cTBS) (one type per MRI/repetitive transcranial magnetic stimulation visit) and were counter-balanced for the order in which they received stimulation (Fp1 landmark based on the International 10–20 system; 110% resting motor threshold; six sessions of cTBS for each visit; 3600 pulses total, with 60-second break after first 1800 pulses).
255-1	42682-42685	All	_	
255-2	42686-42698	participants	_	
255-3	42699-42707	received	_	
255-4	42708-42712	both	_	
255-5	42713-42717	real	_	
255-6	42718-42721	and	_	
255-7	42722-42726	sham	_	
255-8	42727-42739	ventromedial	_	
255-9	42740-42750	prefrontal	_	
255-10	42751-42757	cortex	_	
255-11	42758-42759	(	_	
255-12	42759-42764	VMPFC	_	
255-13	42764-42765	)	_	
255-14	42766-42776	continuous	_	
255-15	42777-42782	theta	_	
255-16	42783-42788	burst	_	
255-17	42789-42800	stimulation	_	
255-18	42801-42802	(	_	
255-19	42802-42806	cTBS	_	
255-20	42806-42807	)	_	
255-21	42808-42809	(	_	
255-22	42809-42812	one	_	
255-23	42813-42817	type	_	
255-24	42818-42821	per	_	
255-25	42822-42825	MRI	_	
255-26	42825-42826	/	_	
255-27	42826-42836	repetitive	_	
255-28	42837-42849	transcranial	_	
255-29	42850-42858	magnetic	_	
255-30	42859-42870	stimulation	_	
255-31	42871-42876	visit	_	
255-32	42876-42877	)	_	
255-33	42878-42881	and	_	
255-34	42882-42886	were	_	
255-35	42887-42903	counter-balanced	_	
255-36	42904-42907	for	_	
255-37	42908-42911	the	_	
255-38	42912-42917	order	_	
255-39	42918-42920	in	_	
255-40	42921-42926	which	_	
255-41	42927-42931	they	_	
255-42	42932-42940	received	_	
255-43	42941-42952	stimulation	_	
255-44	42953-42954	(	_	
255-45	42954-42957	Fp1	_	
255-46	42958-42966	landmark	_	
255-47	42967-42972	based	_	
255-48	42973-42975	on	_	
255-49	42976-42979	the	_	
255-50	42980-42993	International	_	
255-51	42994-42996	10	_	
255-52	42996-42997	–	_	
255-53	42997-42999	20	_	
255-54	43000-43006	system	_	
255-55	43006-43007	;	_	
255-56	43008-43012	110%	_	
255-57	43013-43020	resting	_	
255-58	43021-43026	motor	_	
255-59	43027-43036	threshold	_	
255-60	43036-43037	;	_	
255-61	43038-43041	six	_	
255-62	43042-43050	sessions	_	
255-63	43051-43053	of	_	
255-64	43054-43058	cTBS	_	
255-65	43059-43062	for	_	
255-66	43063-43067	each	_	
255-67	43068-43073	visit	_	
255-68	43073-43074	;	_	
255-69	43075-43079	3600	_	
255-70	43080-43086	pulses	_	
255-71	43087-43092	total	_	
255-72	43092-43093	,	_	
255-73	43094-43098	with	_	
255-74	43099-43101	60	_	
255-75	43101-43102	-	_	
255-76	43102-43108	second	_	
255-77	43109-43114	break	_	
255-78	43115-43120	after	_	
255-79	43121-43126	first	_	
255-80	43127-43131	1800	_	
255-81	43132-43138	pulses	_	
255-82	43138-43139	)	_	
255-83	43139-43140	.	_	

#Text=The drug cue reactivity functional MRI task was administered before and after VMPFC cTBS to evaluate cTBS effects on drug-related neural reactivity (functional connectivity) in non–treatment-seeking cocaine users and heavy alcohol users.
256-1	43141-43144	The	_	
256-2	43145-43149	drug	_	
256-3	43150-43153	cue	_	
256-4	43154-43164	reactivity	_	
256-5	43165-43175	functional	_	
256-6	43176-43179	MRI	_	
256-7	43180-43184	task	_	
256-8	43185-43188	was	_	
256-9	43189-43201	administered	_	
256-10	43202-43208	before	_	
256-11	43209-43212	and	_	
256-12	43213-43218	after	_	
256-13	43219-43224	VMPFC	_	
256-14	43225-43229	cTBS	_	
256-15	43230-43232	to	_	
256-16	43233-43241	evaluate	_	
256-17	43242-43246	cTBS	_	
256-18	43247-43254	effects	_	
256-19	43255-43257	on	_	
256-20	43258-43270	drug-related	_	
256-21	43271-43277	neural	_	
256-22	43278-43288	reactivity	_	
256-23	43289-43290	(	_	
256-24	43290-43300	functional	_	
256-25	43301-43313	connectivity	_	
256-26	43313-43314	)	_	
256-27	43315-43317	in	_	
256-28	43318-43339	non–treatment-seeking	_	
256-29	43340-43347	cocaine	_	
256-30	43348-43353	users	_	
256-31	43354-43357	and	_	
256-32	43358-43363	heavy	_	
256-33	43364-43371	alcohol	_	
256-34	43372-43377	users	_	
256-35	43377-43378	.	_	

#Text=Self-reported craving was reported at five time points (asterisk) throughout the study visit.
257-1	43379-43392	Self-reported	_	
257-2	43393-43400	craving	_	
257-3	43401-43404	was	_	
257-4	43405-43413	reported	_	
257-5	43414-43416	at	_	
257-6	43417-43421	five	_	
257-7	43422-43426	time	_	
257-8	43427-43433	points	_	
257-9	43434-43435	(	_	
257-10	43435-43443	asterisk	_	
257-11	43443-43444	)	_	
257-12	43445-43455	throughout	_	
257-13	43456-43459	the	_	
257-14	43460-43465	study	_	
257-15	43466-43471	visit	_	
257-16	43471-43472	.	_	

#Text=L, left.
258-1	43473-43474	L	_	
258-2	43474-43475	,	_	
258-3	43476-43480	left	_	
258-4	43480-43481	.	_	

#Text=Significant interaction between treatment type and time.
259-1	43482-43493	Significant	_	
259-2	43494-43505	interaction	_	
259-3	43506-43513	between	_	
259-4	43514-43523	treatment	_	
259-5	43524-43528	type	_	
259-6	43529-43532	and	_	
259-7	43533-43537	time	_	
259-8	43537-43538	.	_	

#Text=All participants were exposed to a standardized drug cue paradigm customized to their primary drug of abuse (cocaine, alcohol).
260-1	43539-43542	All	_	
260-2	43543-43555	participants	_	
260-3	43556-43560	were	_	
260-4	43561-43568	exposed	_	
260-5	43569-43571	to	_	
260-6	43572-43573	a	_	
260-7	43574-43586	standardized	_	
260-8	43587-43591	drug	_	
260-9	43592-43595	cue	_	
260-10	43596-43604	paradigm	_	
260-11	43605-43615	customized	_	
260-12	43616-43618	to	_	
260-13	43619-43624	their	_	
260-14	43625-43632	primary	_	
260-15	43633-43637	drug	_	
260-16	43638-43640	of	_	
260-17	43641-43646	abuse	_	
260-18	43647-43648	(	_	
260-19	43648-43655	cocaine	_	
260-20	43655-43656	,	_	
260-21	43657-43664	alcohol	_	
260-22	43664-43665	)	_	
260-23	43665-43666	.	_	

#Text=(A) In experiment 1, cocaine-dependent individuals performed a drug cue reactivity task immediately before and after six sessions (3600 pulses) of real or sham continuous theta burst stimulation (cTBS) directed at the ventromedial prefrontal cortex (see Methods and Materials).
261-1	43667-43668	(	_	
261-2	43668-43669	A	_	
261-3	43669-43670	)	_	
261-4	43671-43673	In	_	
261-5	43674-43684	experiment	_	
261-6	43685-43686	1	_	
261-7	43686-43687	,	_	
261-8	43688-43705	cocaine-dependent	_	
261-9	43706-43717	individuals	_	
261-10	43718-43727	performed	_	
261-11	43728-43729	a	_	
261-12	43730-43734	drug	_	
261-13	43735-43738	cue	_	
261-14	43739-43749	reactivity	_	
261-15	43750-43754	task	_	
261-16	43755-43766	immediately	_	
261-17	43767-43773	before	_	
261-18	43774-43777	and	_	
261-19	43778-43783	after	_	
261-20	43784-43787	six	_	
261-21	43788-43796	sessions	_	
261-22	43797-43798	(	_	
261-23	43798-43802	3600	_	
261-24	43803-43809	pulses	_	
261-25	43809-43810	)	_	
261-26	43811-43813	of	_	
261-27	43814-43818	real	_	
261-28	43819-43821	or	_	
261-29	43822-43826	sham	_	
261-30	43827-43837	continuous	_	
261-31	43838-43843	theta	_	
261-32	43844-43849	burst	_	
261-33	43850-43861	stimulation	_	
261-34	43862-43863	(	_	
261-35	43863-43867	cTBS	_	
261-36	43867-43868	)	_	
261-37	43869-43877	directed	_	
261-38	43878-43880	at	_	
261-39	43881-43884	the	_	
261-40	43885-43897	ventromedial	_	
261-41	43898-43908	prefrontal	_	
261-42	43909-43915	cortex	_	
261-43	43916-43917	(	_	
261-44	43917-43920	see	_	
261-45	43921-43928	Methods	_	
261-46	43929-43932	and	_	
261-47	43933-43942	Materials	_	
261-48	43942-43943	)	_	
261-49	43943-43944	.	_	

#Text=All participants received both real and sham cTBS.
262-1	43945-43948	All	_	
262-2	43949-43961	participants	_	
262-3	43962-43970	received	_	
262-4	43971-43975	both	_	
262-5	43976-43980	real	_	
262-6	43981-43984	and	_	
262-7	43985-43989	sham	_	
262-8	43990-43994	cTBS	_	
262-9	43994-43995	.	_	

#Text=(A) For cocaine users, a three-way repeated-measures analysis of variance (treatment [real/sham] × time [pre/post] × region of interest [ROI]) revealed a significant interaction between treatment and time (F1,768 = 27.1, p < .00001), but no main effect or interaction with ROI, indicating a general effect of treatment × time across all frontostriatal and frontolimbic ROIs.
263-1	43996-43997	(	_	
263-2	43997-43998	A	_	
263-3	43998-43999	)	_	
263-4	44000-44003	For	_	
263-5	44004-44011	cocaine	_	
263-6	44012-44017	users	_	
263-7	44017-44018	,	_	
263-8	44019-44020	a	_	
263-9	44021-44030	three-way	_	
263-10	44031-44048	repeated-measures	_	
263-11	44049-44057	analysis	_	
263-12	44058-44060	of	_	
263-13	44061-44069	variance	_	
263-14	44070-44071	(	_	
263-15	44071-44080	treatment	_	
263-16	44081-44082	[	_	
263-17	44082-44086	real	_	
263-18	44086-44087	/	_	
263-19	44087-44091	sham	_	
263-20	44091-44092	]	_	
263-21	44093-44094	×	_	
263-22	44095-44099	time	_	
263-23	44100-44101	[	_	
263-24	44101-44104	pre	_	
263-25	44104-44105	/	_	
263-26	44105-44109	post	_	
263-27	44109-44110	]	_	
263-28	44111-44112	×	_	
263-29	44113-44119	region	_	
263-30	44120-44122	of	_	
263-31	44123-44131	interest	_	
263-32	44132-44133	[	_	
263-33	44133-44136	ROI	_	
263-34	44136-44137	]	_	
263-35	44137-44138	)	_	
263-36	44139-44147	revealed	_	
263-37	44148-44149	a	_	
263-38	44150-44161	significant	_	
263-39	44162-44173	interaction	_	
263-40	44174-44181	between	_	
263-41	44182-44191	treatment	_	
263-42	44192-44195	and	_	
263-43	44196-44200	time	_	
263-44	44201-44202	(	_	
263-45	44202-44208	F1,768	_	
263-46	44209-44210	=	_	
263-47	44211-44215	27.1	_	
263-48	44215-44216	,	_	
263-49	44217-44218	p	_	
263-50	44219-44220	<	_	
263-51	44221-44227	.00001	_	
263-52	44227-44228	)	_	
263-53	44228-44229	,	_	
263-54	44230-44233	but	_	
263-55	44234-44236	no	_	
263-56	44237-44241	main	_	
263-57	44242-44248	effect	_	
263-58	44249-44251	or	_	
263-59	44252-44263	interaction	_	
263-60	44264-44268	with	_	
263-61	44269-44272	ROI	_	
263-62	44272-44273	,	_	
263-63	44274-44284	indicating	_	
263-64	44285-44286	a	_	
263-65	44287-44294	general	_	
263-66	44295-44301	effect	_	
263-67	44302-44304	of	_	
263-68	44305-44314	treatment	_	
263-69	44315-44316	×	_	
263-70	44317-44321	time	_	
263-71	44322-44328	across	_	
263-72	44329-44332	all	_	
263-73	44333-44347	frontostriatal	_	
263-74	44348-44351	and	_	
263-75	44352-44364	frontolimbic	_	
263-76	44365-44369	ROIs	_	
263-77	44369-44370	.	_	

#Text=A post hoc t test of the interaction revealed that functional connectivity (FC) for drug vs. neutral cues was significantly attenuated following real vs. sham cTBS (t24 = −5.25, p < .00001).
264-1	44371-44372	A	_	
264-2	44373-44377	post	_	
264-3	44378-44381	hoc	_	
264-4	44382-44383	t	_	
264-5	44384-44388	test	_	
264-6	44389-44391	of	_	
264-7	44392-44395	the	_	
264-8	44396-44407	interaction	_	
264-9	44408-44416	revealed	_	
264-10	44417-44421	that	_	
264-11	44422-44432	functional	_	
264-12	44433-44445	connectivity	_	
264-13	44446-44447	(	_	
264-14	44447-44449	FC	_	
264-15	44449-44450	)	_	
264-16	44451-44454	for	_	
264-17	44455-44459	drug	_	
264-18	44460-44462	vs	_	
264-19	44462-44463	.	_	
264-20	44464-44471	neutral	_	
264-21	44472-44476	cues	_	
264-22	44477-44480	was	_	
264-23	44481-44494	significantly	_	
264-24	44495-44505	attenuated	_	
264-25	44506-44515	following	_	
264-26	44516-44520	real	_	
264-27	44521-44523	vs	_	
264-28	44523-44524	.	_	
264-29	44525-44529	sham	_	
264-30	44530-44534	cTBS	_	
264-31	44535-44536	(	_	
264-32	44536-44539	t24	_	
264-33	44540-44541	=	_	
264-34	44542-44543	−	_	
264-35	44543-44547	5.25	_	
264-36	44547-44548	,	_	
264-37	44549-44550	p	_	
264-38	44551-44552	<	_	
264-39	44553-44559	.00001	_	
264-40	44559-44560	)	_	
264-41	44560-44561	.	_	

#Text=This significant difference was driven by significant attenuations following real cTBS (t24 = −4.74, p < .00001), as well as significant increases following sham cTBS (t24 = 3.37, p < .001).
265-1	44562-44566	This	_	
265-2	44567-44578	significant	_	
265-3	44579-44589	difference	_	
265-4	44590-44593	was	_	
265-5	44594-44600	driven	_	
265-6	44601-44603	by	_	
265-7	44604-44615	significant	_	
265-8	44616-44628	attenuations	_	
265-9	44629-44638	following	_	
265-10	44639-44643	real	_	
265-11	44644-44648	cTBS	_	
265-12	44649-44650	(	_	
265-13	44650-44653	t24	_	
265-14	44654-44655	=	_	
265-15	44656-44657	−	_	
265-16	44657-44661	4.74	_	
265-17	44661-44662	,	_	
265-18	44663-44664	p	_	
265-19	44665-44666	<	_	
265-20	44667-44673	.00001	_	
265-21	44673-44674	)	_	
265-22	44674-44675	,	_	
265-23	44676-44678	as	_	
265-24	44679-44683	well	_	
265-25	44684-44686	as	_	
265-26	44687-44698	significant	_	
265-27	44699-44708	increases	_	
265-28	44709-44718	following	_	
265-29	44719-44723	sham	_	
265-30	44724-44728	cTBS	_	
265-31	44729-44730	(	_	
265-32	44730-44733	t24	_	
265-33	44734-44735	=	_	
265-34	44736-44740	3.37	_	
265-35	44740-44741	,	_	
265-36	44742-44743	p	_	
265-37	44744-44745	<	_	
265-38	44746-44750	.001	_	
265-39	44750-44751	)	_	
265-40	44751-44752	.	_	

#Text=Panel (A) illustrates FC change from baseline for real (−0.14; blue line) vs. sham (0.17; orange line) cTBS for the frontostriatolimbic circuit.
266-1	44753-44758	Panel	_	
266-2	44759-44760	(	_	
266-3	44760-44761	A	_	
266-4	44761-44762	)	_	
266-5	44763-44774	illustrates	_	
266-6	44775-44777	FC	_	
266-7	44778-44784	change	_	
266-8	44785-44789	from	_	
266-9	44790-44798	baseline	_	
266-10	44799-44802	for	_	
266-11	44803-44807	real	_	
266-12	44808-44809	(	_	
266-13	44809-44810	−	_	
266-14	44810-44814	0.14	_	
266-15	44814-44815	;	_	
266-16	44816-44820	blue	_	
266-17	44821-44825	line	_	
266-18	44825-44826	)	_	
266-19	44827-44829	vs	_	
266-20	44829-44830	.	_	
266-21	44831-44835	sham	_	
266-22	44836-44837	(	_	
266-23	44837-44841	0.17	_	
266-24	44841-44842	;	_	
266-25	44843-44849	orange	_	
266-26	44850-44854	line	_	
266-27	44854-44855	)	_	
266-28	44856-44860	cTBS	_	
266-29	44861-44864	for	_	
266-30	44865-44868	the	_	
266-31	44869-44888	frontostriatolimbic	_	
266-32	44889-44896	circuit	_	
266-33	44896-44897	.	_	

#Text=(B) For alcohol users, a three-way repeated-measures analysis of variance (treatment [real/sham] × time [pre/post] × ROI) also revealed a significant interaction between treatment and time (F1,736 = 24.6, p < .00001), but no main effect or interaction with ROI, indicating a general effect of treatment × time across all ROIs.
267-1	44898-44899	(	_	
267-2	44899-44900	B	_	
267-3	44900-44901	)	_	
267-4	44902-44905	For	_	
267-5	44906-44913	alcohol	_	
267-6	44914-44919	users	_	
267-7	44919-44920	,	_	
267-8	44921-44922	a	_	
267-9	44923-44932	three-way	_	
267-10	44933-44950	repeated-measures	_	
267-11	44951-44959	analysis	_	
267-12	44960-44962	of	_	
267-13	44963-44971	variance	_	
267-14	44972-44973	(	_	
267-15	44973-44982	treatment	_	
267-16	44983-44984	[	_	
267-17	44984-44988	real	_	
267-18	44988-44989	/	_	
267-19	44989-44993	sham	_	
267-20	44993-44994	]	_	
267-21	44995-44996	×	_	
267-22	44997-45001	time	_	
267-23	45002-45003	[	_	
267-24	45003-45006	pre	_	
267-25	45006-45007	/	_	
267-26	45007-45011	post	_	
267-27	45011-45012	]	_	
267-28	45013-45014	×	_	
267-29	45015-45018	ROI	_	
267-30	45018-45019	)	_	
267-31	45020-45024	also	_	
267-32	45025-45033	revealed	_	
267-33	45034-45035	a	_	
267-34	45036-45047	significant	_	
267-35	45048-45059	interaction	_	
267-36	45060-45067	between	_	
267-37	45068-45077	treatment	_	
267-38	45078-45081	and	_	
267-39	45082-45086	time	_	
267-40	45087-45088	(	_	
267-41	45088-45094	F1,736	_	
267-42	45095-45096	=	_	
267-43	45097-45101	24.6	_	
267-44	45101-45102	,	_	
267-45	45103-45104	p	_	
267-46	45105-45106	<	_	
267-47	45107-45113	.00001	_	
267-48	45113-45114	)	_	
267-49	45114-45115	,	_	
267-50	45116-45119	but	_	
267-51	45120-45122	no	_	
267-52	45123-45127	main	_	
267-53	45128-45134	effect	_	
267-54	45135-45137	or	_	
267-55	45138-45149	interaction	_	
267-56	45150-45154	with	_	
267-57	45155-45158	ROI	_	
267-58	45158-45159	,	_	
267-59	45160-45170	indicating	_	
267-60	45171-45172	a	_	
267-61	45173-45180	general	_	
267-62	45181-45187	effect	_	
267-63	45188-45190	of	_	
267-64	45191-45200	treatment	_	
267-65	45201-45202	×	_	
267-66	45203-45207	time	_	
267-67	45208-45214	across	_	
267-68	45215-45218	all	_	
267-69	45219-45223	ROIs	_	
267-70	45223-45224	.	_	

#Text=A post hoc t test of the interaction revealed that FC for alcohol vs. neutral cues was significantly attenuated following real vs. sham cTBS (t23 = −5.91, false discovery rate p < .00001).
268-1	45225-45226	A	_	
268-2	45227-45231	post	_	
268-3	45232-45235	hoc	_	
268-4	45236-45237	t	_	
268-5	45238-45242	test	_	
268-6	45243-45245	of	_	
268-7	45246-45249	the	_	
268-8	45250-45261	interaction	_	
268-9	45262-45270	revealed	_	
268-10	45271-45275	that	_	
268-11	45276-45278	FC	_	
268-12	45279-45282	for	_	
268-13	45283-45290	alcohol	_	
268-14	45291-45293	vs	_	
268-15	45293-45294	.	_	
268-16	45295-45302	neutral	_	
268-17	45303-45307	cues	_	
268-18	45308-45311	was	_	
268-19	45312-45325	significantly	_	
268-20	45326-45336	attenuated	_	
268-21	45337-45346	following	_	
268-22	45347-45351	real	_	
268-23	45352-45354	vs	_	
268-24	45354-45355	.	_	
268-25	45356-45360	sham	_	
268-26	45361-45365	cTBS	_	
268-27	45366-45367	(	_	
268-28	45367-45370	t23	_	
268-29	45371-45372	=	_	
268-30	45373-45374	−	_	
268-31	45374-45378	5.91	_	
268-32	45378-45379	,	_	
268-33	45380-45385	false	_	
268-34	45386-45395	discovery	_	
268-35	45396-45400	rate	_	
268-36	45401-45402	p	_	
268-37	45403-45404	<	_	
268-38	45405-45411	.00001	_	
268-39	45411-45412	)	_	
268-40	45412-45413	.	_	

#Text=This significant difference was driven by significant attenuaions following real cTBS (t23 = −4.70, false discovery rate p < .00001), as well as significant increases following sham cTBS (t23 = 2.81, false discovery rate p < .01).
269-1	45414-45418	This	_	
269-2	45419-45430	significant	_	
269-3	45431-45441	difference	_	
269-4	45442-45445	was	_	
269-5	45446-45452	driven	_	
269-6	45453-45455	by	_	
269-7	45456-45467	significant	_	
269-8	45468-45479	attenuaions	_	
269-9	45480-45489	following	_	
269-10	45490-45494	real	_	
269-11	45495-45499	cTBS	_	
269-12	45500-45501	(	_	
269-13	45501-45504	t23	_	
269-14	45505-45506	=	_	
269-15	45507-45508	−	_	
269-16	45508-45512	4.70	_	
269-17	45512-45513	,	_	
269-18	45514-45519	false	_	
269-19	45520-45529	discovery	_	
269-20	45530-45534	rate	_	
269-21	45535-45536	p	_	
269-22	45537-45538	<	_	
269-23	45539-45545	.00001	_	
269-24	45545-45546	)	_	
269-25	45546-45547	,	_	
269-26	45548-45550	as	_	
269-27	45551-45555	well	_	
269-28	45556-45558	as	_	
269-29	45559-45570	significant	_	
269-30	45571-45580	increases	_	
269-31	45581-45590	following	_	
269-32	45591-45595	sham	_	
269-33	45596-45600	cTBS	_	
269-34	45601-45602	(	_	
269-35	45602-45605	t23	_	
269-36	45606-45607	=	_	
269-37	45608-45612	2.81	_	
269-38	45612-45613	,	_	
269-39	45614-45619	false	_	
269-40	45620-45629	discovery	_	
269-41	45630-45634	rate	_	
269-42	45635-45636	p	_	
269-43	45637-45638	<	_	
269-44	45639-45642	.01	_	
269-45	45642-45643	)	_	
269-46	45643-45644	.	_	

#Text=Panel (B) illustrates FC change from baseline for real (−0.14; blue line) vs. sham (0.08; orange line) cTBS for the frontostriatolimbic circuit.
270-1	45645-45650	Panel	_	
270-2	45651-45652	(	_	
270-3	45652-45653	B	_	
270-4	45653-45654	)	_	
270-5	45655-45666	illustrates	_	
270-6	45667-45669	FC	_	
270-7	45670-45676	change	_	
270-8	45677-45681	from	_	
270-9	45682-45690	baseline	_	
270-10	45691-45694	for	_	
270-11	45695-45699	real	_	
270-12	45700-45701	(	_	
270-13	45701-45702	−	_	
270-14	45702-45706	0.14	_	
270-15	45706-45707	;	_	
270-16	45708-45712	blue	_	
270-17	45713-45717	line	_	
270-18	45717-45718	)	_	
270-19	45719-45721	vs	_	
270-20	45721-45722	.	_	
270-21	45723-45727	sham	_	
270-22	45728-45729	(	_	
270-23	45729-45733	0.08	_	
270-24	45733-45734	;	_	
270-25	45735-45741	orange	_	
270-26	45742-45746	line	_	
270-27	45746-45747	)	_	
270-28	45748-45752	cTBS	_	
270-29	45753-45756	for	_	
270-30	45757-45760	the	_	
270-31	45761-45780	frontostriatolimbic	_	
270-32	45781-45788	circuit	_	
270-33	45788-45789	.	_	

#Text=Drug class–specific treatment-related changes in cue-evoked functional connectivity.
271-1	45790-45794	Drug	_	
271-2	45795-45809	class–specific	_	
271-3	45810-45827	treatment-related	_	
271-4	45828-45835	changes	_	
271-5	45836-45838	in	_	
271-6	45839-45849	cue-evoked	_	
271-7	45850-45860	functional	_	
271-8	45861-45873	connectivity	_	
271-9	45873-45874	.	_	

#Text=(A) At baseline there was greater functional connectivity to drug vs. neutral cues between the ventromedial prefrontal cortex (MPFC) and multiple regions.
272-1	45875-45876	(	_	
272-2	45876-45877	A	_	
272-3	45877-45878	)	_	
272-4	45879-45881	At	_	
272-5	45882-45890	baseline	_	
272-6	45891-45896	there	_	
272-7	45897-45900	was	_	
272-8	45901-45908	greater	_	
272-9	45909-45919	functional	_	
272-10	45920-45932	connectivity	_	
272-11	45933-45935	to	_	
272-12	45936-45940	drug	_	
272-13	45941-45943	vs	_	
272-14	45943-45944	.	_	
272-15	45945-45952	neutral	_	
272-16	45953-45957	cues	_	
272-17	45958-45965	between	_	
272-18	45966-45969	the	_	
272-19	45970-45982	ventromedial	_	
272-20	45983-45993	prefrontal	_	
272-21	45994-46000	cortex	_	
272-22	46001-46002	(	_	
272-23	46002-46006	MPFC	_	
272-24	46006-46007	)	_	
272-25	46008-46011	and	_	
272-26	46012-46020	multiple	_	
272-27	46021-46028	regions	_	
272-28	46028-46029	.	_	

#Text=The largest effect size was between the MPFC and left putamen (L Put) (d = 0.55) (left image; bright red lines).
273-1	46030-46033	The	_	
273-2	46034-46041	largest	_	
273-3	46042-46048	effect	_	
273-4	46049-46053	size	_	
273-5	46054-46057	was	_	
273-6	46058-46065	between	_	
273-7	46066-46069	the	_	
273-8	46070-46074	MPFC	_	
273-9	46075-46078	and	_	
273-10	46079-46083	left	_	
273-11	46084-46091	putamen	_	
273-12	46092-46093	(	_	
273-13	46093-46094	L	_	
273-14	46095-46098	Put	_	
273-15	46098-46099	)	_	
273-16	46100-46101	(	_	
273-17	46101-46102	d	_	
273-18	46103-46104	=	_	
273-19	46105-46109	0.55	_	
273-20	46109-46110	)	_	
273-21	46111-46112	(	_	
273-22	46112-46116	left	_	
273-23	46117-46122	image	_	
273-24	46122-46123	;	_	
273-25	46124-46130	bright	_	
273-26	46131-46134	red	_	
273-27	46135-46140	lines	_	
273-28	46140-46141	)	_	
273-29	46141-46142	.	_	

#Text=There were also smaller effect sizes between the MPFC and left caudate (L Caud) (d = 0.37), right caudate (R Caud) (d = 0.26), right putamen (R Put) (d = 0.30), left insula (L Ins) (d = 0.42), right insula (R Ins) (d = 0.25), anterior cingulate cortex (ACC) (d = 0.21), and ventral striatum (VS) (d = 0.33) (left image; dark red lines).
274-1	46143-46148	There	_	
274-2	46149-46153	were	_	
274-3	46154-46158	also	_	
274-4	46159-46166	smaller	_	
274-5	46167-46173	effect	_	
274-6	46174-46179	sizes	_	
274-7	46180-46187	between	_	
274-8	46188-46191	the	_	
274-9	46192-46196	MPFC	_	
274-10	46197-46200	and	_	
274-11	46201-46205	left	_	
274-12	46206-46213	caudate	_	
274-13	46214-46215	(	_	
274-14	46215-46216	L	_	
274-15	46217-46221	Caud	_	
274-16	46221-46222	)	_	
274-17	46223-46224	(	_	
274-18	46224-46225	d	_	
274-19	46226-46227	=	_	
274-20	46228-46232	0.37	_	
274-21	46232-46233	)	_	
274-22	46233-46234	,	_	
274-23	46235-46240	right	_	
274-24	46241-46248	caudate	_	
274-25	46249-46250	(	_	
274-26	46250-46251	R	_	
274-27	46252-46256	Caud	_	
274-28	46256-46257	)	_	
274-29	46258-46259	(	_	
274-30	46259-46260	d	_	
274-31	46261-46262	=	_	
274-32	46263-46267	0.26	_	
274-33	46267-46268	)	_	
274-34	46268-46269	,	_	
274-35	46270-46275	right	_	
274-36	46276-46283	putamen	_	
274-37	46284-46285	(	_	
274-38	46285-46286	R	_	
274-39	46287-46290	Put	_	
274-40	46290-46291	)	_	
274-41	46292-46293	(	_	
274-42	46293-46294	d	_	
274-43	46295-46296	=	_	
274-44	46297-46301	0.30	_	
274-45	46301-46302	)	_	
274-46	46302-46303	,	_	
274-47	46304-46308	left	_	
274-48	46309-46315	insula	_	
274-49	46316-46317	(	_	
274-50	46317-46318	L	_	
274-51	46319-46322	Ins	_	
274-52	46322-46323	)	_	
274-53	46324-46325	(	_	
274-54	46325-46326	d	_	
274-55	46327-46328	=	_	
274-56	46329-46333	0.42	_	
274-57	46333-46334	)	_	
274-58	46334-46335	,	_	
274-59	46336-46341	right	_	
274-60	46342-46348	insula	_	
274-61	46349-46350	(	_	
274-62	46350-46351	R	_	
274-63	46352-46355	Ins	_	
274-64	46355-46356	)	_	
274-65	46357-46358	(	_	
274-66	46358-46359	d	_	
274-67	46360-46361	=	_	
274-68	46362-46366	0.25	_	
274-69	46366-46367	)	_	
274-70	46367-46368	,	_	
274-71	46369-46377	anterior	_	
274-72	46378-46387	cingulate	_	
274-73	46388-46394	cortex	_	
274-74	46395-46396	(	_	
274-75	46396-46399	ACC	_	
274-76	46399-46400	)	_	
274-77	46401-46402	(	_	
274-78	46402-46403	d	_	
274-79	46404-46405	=	_	
274-80	46406-46410	0.21	_	
274-81	46410-46411	)	_	
274-82	46411-46412	,	_	
274-83	46413-46416	and	_	
274-84	46417-46424	ventral	_	
274-85	46425-46433	striatum	_	
274-86	46434-46435	(	_	
274-87	46435-46437	VS	_	
274-88	46437-46438	)	_	
274-89	46439-46440	(	_	
274-90	46440-46441	d	_	
274-91	46442-46443	=	_	
274-92	46444-46448	0.33	_	
274-93	46448-46449	)	_	
274-94	46450-46451	(	_	
274-95	46451-46455	left	_	
274-96	46456-46461	image	_	
274-97	46461-46462	;	_	
274-98	46463-46467	dark	_	
274-99	46468-46471	red	_	
274-100	46472-46477	lines	_	
274-101	46477-46478	)	_	
274-102	46478-46479	.	_	

#Text=Following real vs. sham continuous theta burst stimulation (cTBS), there was a decrease in functional connectivity to drug vs. neutral cues between the MPFC and several regions.
275-1	46480-46489	Following	_	
275-2	46490-46494	real	_	
275-3	46495-46497	vs	_	
275-4	46497-46498	.	_	
275-5	46499-46503	sham	_	
275-6	46504-46514	continuous	_	
275-7	46515-46520	theta	_	
275-8	46521-46526	burst	_	
275-9	46527-46538	stimulation	_	
275-10	46539-46540	(	_	
275-11	46540-46544	cTBS	_	
275-12	46544-46545	)	_	
275-13	46545-46546	,	_	
275-14	46547-46552	there	_	
275-15	46553-46556	was	_	
275-16	46557-46558	a	_	
275-17	46559-46567	decrease	_	
275-18	46568-46570	in	_	
275-19	46571-46581	functional	_	
275-20	46582-46594	connectivity	_	
275-21	46595-46597	to	_	
275-22	46598-46602	drug	_	
275-23	46603-46605	vs	_	
275-24	46605-46606	.	_	
275-25	46607-46614	neutral	_	
275-26	46615-46619	cues	_	
275-27	46620-46627	between	_	
275-28	46628-46631	the	_	
275-29	46632-46636	MPFC	_	
275-30	46637-46640	and	_	
275-31	46641-46648	several	_	
275-32	46649-46656	regions	_	
275-33	46656-46657	.	_	

#Text=The largest decreases were between the MPFC and left caudate (d = −0.50) and left insula (d = −0.70) (right image; bright blue lines).
276-1	46658-46661	The	_	
276-2	46662-46669	largest	_	
276-3	46670-46679	decreases	_	
276-4	46680-46684	were	_	
276-5	46685-46692	between	_	
276-6	46693-46696	the	_	
276-7	46697-46701	MPFC	_	
276-8	46702-46705	and	_	
276-9	46706-46710	left	_	
276-10	46711-46718	caudate	_	
276-11	46719-46720	(	_	
276-12	46720-46721	d	_	
276-13	46722-46723	=	_	
276-14	46724-46725	−	_	
276-15	46725-46729	0.50	_	
276-16	46729-46730	)	_	
276-17	46731-46734	and	_	
276-18	46735-46739	left	_	
276-19	46740-46746	insula	_	
276-20	46747-46748	(	_	
276-21	46748-46749	d	_	
276-22	46750-46751	=	_	
276-23	46752-46753	−	_	
276-24	46753-46757	0.70	_	
276-25	46757-46758	)	_	
276-26	46759-46760	(	_	
276-27	46760-46765	right	_	
276-28	46766-46771	image	_	
276-29	46771-46772	;	_	
276-30	46773-46779	bright	_	
276-31	46780-46784	blue	_	
276-32	46785-46790	lines	_	
276-33	46790-46791	)	_	
276-34	46791-46792	.	_	

#Text=There were also smaller decreases between the MPFC and right caudate (d = −0.35), left putamen (d = −0.48), right putamen (d = −0.37), ACC (d = −0.23), and VS (d = −0.46) (right image; dark blue lines).
277-1	46793-46798	There	_	
277-2	46799-46803	were	_	
277-3	46804-46808	also	_	
277-4	46809-46816	smaller	_	
277-5	46817-46826	decreases	_	
277-6	46827-46834	between	_	
277-7	46835-46838	the	_	
277-8	46839-46843	MPFC	_	
277-9	46844-46847	and	_	
277-10	46848-46853	right	_	
277-11	46854-46861	caudate	_	
277-12	46862-46863	(	_	
277-13	46863-46864	d	_	
277-14	46865-46866	=	_	
277-15	46867-46868	−	_	
277-16	46868-46872	0.35	_	
277-17	46872-46873	)	_	
277-18	46873-46874	,	_	
277-19	46875-46879	left	_	
277-20	46880-46887	putamen	_	
277-21	46888-46889	(	_	
277-22	46889-46890	d	_	
277-23	46891-46892	=	_	
277-24	46893-46894	−	_	
277-25	46894-46898	0.48	_	
277-26	46898-46899	)	_	
277-27	46899-46900	,	_	
277-28	46901-46906	right	_	
277-29	46907-46914	putamen	_	
277-30	46915-46916	(	_	
277-31	46916-46917	d	_	
277-32	46918-46919	=	_	
277-33	46920-46921	−	_	
277-34	46921-46925	0.37	_	
277-35	46925-46926	)	_	
277-36	46926-46927	,	_	
277-37	46928-46931	ACC	_	
277-38	46932-46933	(	_	
277-39	46933-46934	d	_	
277-40	46935-46936	=	_	
277-41	46937-46938	−	_	
277-42	46938-46942	0.23	_	
277-43	46942-46943	)	_	
277-44	46943-46944	,	_	
277-45	46945-46948	and	_	
277-46	46949-46951	VS	_	
277-47	46952-46953	(	_	
277-48	46953-46954	d	_	
277-49	46955-46956	=	_	
277-50	46957-46958	−	_	
277-51	46958-46962	0.46	_	
277-52	46962-46963	)	_	
277-53	46964-46965	(	_	
277-54	46965-46970	right	_	
277-55	46971-46976	image	_	
277-56	46976-46977	;	_	
277-57	46978-46982	dark	_	
277-58	46983-46987	blue	_	
277-59	46988-46993	lines	_	
277-60	46993-46994	)	_	
277-61	46994-46995	.	_	

#Text=(B) In experiment 2, the procedures were replicated in a cohort of alcohol-dependent individuals.
278-1	46996-46997	(	_	
278-2	46997-46998	B	_	
278-3	46998-46999	)	_	
278-4	47000-47002	In	_	
278-5	47003-47013	experiment	_	
278-6	47014-47015	2	_	
278-7	47015-47016	,	_	
278-8	47017-47020	the	_	
278-9	47021-47031	procedures	_	
278-10	47032-47036	were	_	
278-11	47037-47047	replicated	_	
278-12	47048-47050	in	_	
278-13	47051-47052	a	_	
278-14	47053-47059	cohort	_	
278-15	47060-47062	of	_	
278-16	47063-47080	alcohol-dependent	_	
278-17	47081-47092	individuals	_	
278-18	47092-47093	.	_	

#Text=At baseline, there was greater functional connectivity to alcohol vs. neutral cues between the MPFC and multiple regions.
279-1	47094-47096	At	_	
279-2	47097-47105	baseline	_	
279-3	47105-47106	,	_	
279-4	47107-47112	there	_	
279-5	47113-47116	was	_	
279-6	47117-47124	greater	_	
279-7	47125-47135	functional	_	
279-8	47136-47148	connectivity	_	
279-9	47149-47151	to	_	
279-10	47152-47159	alcohol	_	
279-11	47160-47162	vs	_	
279-12	47162-47163	.	_	
279-13	47164-47171	neutral	_	
279-14	47172-47176	cues	_	
279-15	47177-47184	between	_	
279-16	47185-47188	the	_	
279-17	47189-47193	MPFC	_	
279-18	47194-47197	and	_	
279-19	47198-47206	multiple	_	
279-20	47207-47214	regions	_	
279-21	47214-47215	.	_	

#Text=The largest effect sizes were between the MPFC and right caudate (d = 0.51), left putamen (d = 0.50), and left insula (d = 0.62) (left image; bright red lines).
280-1	47216-47219	The	_	
280-2	47220-47227	largest	_	
280-3	47228-47234	effect	_	
280-4	47235-47240	sizes	_	
280-5	47241-47245	were	_	
280-6	47246-47253	between	_	
280-7	47254-47257	the	_	
280-8	47258-47262	MPFC	_	
280-9	47263-47266	and	_	
280-10	47267-47272	right	_	
280-11	47273-47280	caudate	_	
280-12	47281-47282	(	_	
280-13	47282-47283	d	_	
280-14	47284-47285	=	_	
280-15	47286-47290	0.51	_	
280-16	47290-47291	)	_	
280-17	47291-47292	,	_	
280-18	47293-47297	left	_	
280-19	47298-47305	putamen	_	
280-20	47306-47307	(	_	
280-21	47307-47308	d	_	
280-22	47309-47310	=	_	
280-23	47311-47315	0.50	_	
280-24	47315-47316	)	_	
280-25	47316-47317	,	_	
280-26	47318-47321	and	_	
280-27	47322-47326	left	_	
280-28	47327-47333	insula	_	
280-29	47334-47335	(	_	
280-30	47335-47336	d	_	
280-31	47337-47338	=	_	
280-32	47339-47343	0.62	_	
280-33	47343-47344	)	_	
280-34	47345-47346	(	_	
280-35	47346-47350	left	_	
280-36	47351-47356	image	_	
280-37	47356-47357	;	_	
280-38	47358-47364	bright	_	
280-39	47365-47368	red	_	
280-40	47369-47374	lines	_	
280-41	47374-47375	)	_	
280-42	47375-47376	.	_	

#Text=There were also smaller effect sizes between the MPFC and left caudate (d = 0.47), right putamen (d = 0.28), and VS (d = 0.35) (left image; dark red lines).
281-1	47377-47382	There	_	
281-2	47383-47387	were	_	
281-3	47388-47392	also	_	
281-4	47393-47400	smaller	_	
281-5	47401-47407	effect	_	
281-6	47408-47413	sizes	_	
281-7	47414-47421	between	_	
281-8	47422-47425	the	_	
281-9	47426-47430	MPFC	_	
281-10	47431-47434	and	_	
281-11	47435-47439	left	_	
281-12	47440-47447	caudate	_	
281-13	47448-47449	(	_	
281-14	47449-47450	d	_	
281-15	47451-47452	=	_	
281-16	47453-47457	0.47	_	
281-17	47457-47458	)	_	
281-18	47458-47459	,	_	
281-19	47460-47465	right	_	
281-20	47466-47473	putamen	_	
281-21	47474-47475	(	_	
281-22	47475-47476	d	_	
281-23	47477-47478	=	_	
281-24	47479-47483	0.28	_	
281-25	47483-47484	)	_	
281-26	47484-47485	,	_	
281-27	47486-47489	and	_	
281-28	47490-47492	VS	_	
281-29	47493-47494	(	_	
281-30	47494-47495	d	_	
281-31	47496-47497	=	_	
281-32	47498-47502	0.35	_	
281-33	47502-47503	)	_	
281-34	47504-47505	(	_	
281-35	47505-47509	left	_	
281-36	47510-47515	image	_	
281-37	47515-47516	;	_	
281-38	47517-47521	dark	_	
281-39	47522-47525	red	_	
281-40	47526-47531	lines	_	
281-41	47531-47532	)	_	
281-42	47532-47533	.	_	

#Text=Following real vs. sham cTBS, there was a decrease in functional connectivity to alcohol vs. neutral cues between the MPFC and several regions.
282-1	47534-47543	Following	_	
282-2	47544-47548	real	_	
282-3	47549-47551	vs	_	
282-4	47551-47552	.	_	
282-5	47553-47557	sham	_	
282-6	47558-47562	cTBS	_	
282-7	47562-47563	,	_	
282-8	47564-47569	there	_	
282-9	47570-47573	was	_	
282-10	47574-47575	a	_	
282-11	47576-47584	decrease	_	
282-12	47585-47587	in	_	
282-13	47588-47598	functional	_	
282-14	47599-47611	connectivity	_	
282-15	47612-47614	to	_	
282-16	47615-47622	alcohol	_	
282-17	47623-47625	vs	_	
282-18	47625-47626	.	_	
282-19	47627-47634	neutral	_	
282-20	47635-47639	cues	_	
282-21	47640-47647	between	_	
282-22	47648-47651	the	_	
282-23	47652-47656	MPFC	_	
282-24	47657-47660	and	_	
282-25	47661-47668	several	_	
282-26	47669-47676	regions	_	
282-27	47676-47677	.	_	

#Text=The largest decreases were between the MPFC and left caudate (d = −0.50), right caudate (d = −0.60), left putamen (d = −0.65), left insula (d = −0.51), ACC (d = −0.51), and VS (d = −0.54) (right image; bright blue lines).
283-1	47678-47681	The	_	
283-2	47682-47689	largest	_	
283-3	47690-47699	decreases	_	
283-4	47700-47704	were	_	
283-5	47705-47712	between	_	
283-6	47713-47716	the	_	
283-7	47717-47721	MPFC	_	
283-8	47722-47725	and	_	
283-9	47726-47730	left	_	
283-10	47731-47738	caudate	_	
283-11	47739-47740	(	_	
283-12	47740-47741	d	_	
283-13	47742-47743	=	_	
283-14	47744-47745	−	_	
283-15	47745-47749	0.50	_	
283-16	47749-47750	)	_	
283-17	47750-47751	,	_	
283-18	47752-47757	right	_	
283-19	47758-47765	caudate	_	
283-20	47766-47767	(	_	
283-21	47767-47768	d	_	
283-22	47769-47770	=	_	
283-23	47771-47772	−	_	
283-24	47772-47776	0.60	_	
283-25	47776-47777	)	_	
283-26	47777-47778	,	_	
283-27	47779-47783	left	_	
283-28	47784-47791	putamen	_	
283-29	47792-47793	(	_	
283-30	47793-47794	d	_	
283-31	47795-47796	=	_	
283-32	47797-47798	−	_	
283-33	47798-47802	0.65	_	
283-34	47802-47803	)	_	
283-35	47803-47804	,	_	
283-36	47805-47809	left	_	
283-37	47810-47816	insula	_	
283-38	47817-47818	(	_	
283-39	47818-47819	d	_	
283-40	47820-47821	=	_	
283-41	47822-47823	−	_	
283-42	47823-47827	0.51	_	
283-43	47827-47828	)	_	
283-44	47828-47829	,	_	
283-45	47830-47833	ACC	_	
283-46	47834-47835	(	_	
283-47	47835-47836	d	_	
283-48	47837-47838	=	_	
283-49	47839-47840	−	_	
283-50	47840-47844	0.51	_	
283-51	47844-47845	)	_	
283-52	47845-47846	,	_	
283-53	47847-47850	and	_	
283-54	47851-47853	VS	_	
283-55	47854-47855	(	_	
283-56	47855-47856	d	_	
283-57	47857-47858	=	_	
283-58	47859-47860	−	_	
283-59	47860-47864	0.54	_	
283-60	47864-47865	)	_	
283-61	47866-47867	(	_	
283-62	47867-47872	right	_	
283-63	47873-47878	image	_	
283-64	47878-47879	;	_	
283-65	47880-47886	bright	_	
283-66	47887-47891	blue	_	
283-67	47892-47897	lines	_	
283-68	47897-47898	)	_	
283-69	47898-47899	.	_	

#Text=There was also a smaller effect size between the MPFC and right putamen (d = −0.29) (right image; dark blue line).
284-1	47900-47905	There	_	
284-2	47906-47909	was	_	
284-3	47910-47914	also	_	
284-4	47915-47916	a	_	
284-5	47917-47924	smaller	_	
284-6	47925-47931	effect	_	
284-7	47932-47936	size	_	
284-8	47937-47944	between	_	
284-9	47945-47948	the	_	
284-10	47949-47953	MPFC	_	
284-11	47954-47957	and	_	
284-12	47958-47963	right	_	
284-13	47964-47971	putamen	_	
284-14	47972-47973	(	_	
284-15	47973-47974	d	_	
284-16	47975-47976	=	_	
284-17	47977-47978	−	_	
284-18	47978-47982	0.29	_	
284-19	47982-47983	)	_	
284-20	47984-47985	(	_	
284-21	47985-47990	right	_	
284-22	47991-47996	image	_	
284-23	47996-47997	;	_	
284-24	47998-48002	dark	_	
284-25	48003-48007	blue	_	
284-26	48008-48012	line	_	
284-27	48012-48013	)	_	
284-28	48013-48014	.	_	

#Text=Blue arrows convey overall direction of change in functional connectivity following real vs. sham cTBS.
285-1	48015-48019	Blue	_	
285-2	48020-48026	arrows	_	
285-3	48027-48033	convey	_	
285-4	48034-48041	overall	_	
285-5	48042-48051	direction	_	
285-6	48052-48054	of	_	
285-7	48055-48061	change	_	
285-8	48062-48064	in	_	
285-9	48065-48075	functional	_	
285-10	48076-48088	connectivity	_	
285-11	48089-48098	following	_	
285-12	48099-48103	real	_	
285-13	48104-48106	vs	_	
285-14	48106-48107	.	_	
285-15	48108-48112	sham	_	
285-16	48113-48117	cTBS	_	
285-17	48117-48118	.	_	

#Text=Treatment-related changes in cue-evoked functional connectivity for cocaine and alcohol users combined.
286-1	48119-48136	Treatment-related	_	
286-2	48137-48144	changes	_	
286-3	48145-48147	in	_	
286-4	48148-48158	cue-evoked	_	
286-5	48159-48169	functional	_	
286-6	48170-48182	connectivity	_	
286-7	48183-48186	for	_	
286-8	48187-48194	cocaine	_	
286-9	48195-48198	and	_	
286-10	48199-48206	alcohol	_	
286-11	48207-48212	users	_	
286-12	48213-48221	combined	_	
286-13	48221-48222	.	_	

#Text=At baseline for the group, drug cue vs. neutral cue exposure led to elevated functional connectivity between the ventromedial prefrontal cortex (MPFC) and several striatal and salience brain regions.
287-1	48223-48225	At	_	
287-2	48226-48234	baseline	_	
287-3	48235-48238	for	_	
287-4	48239-48242	the	_	
287-5	48243-48248	group	_	
287-6	48248-48249	,	_	
287-7	48250-48254	drug	_	
287-8	48255-48258	cue	_	
287-9	48259-48261	vs	_	
287-10	48261-48262	.	_	
287-11	48263-48270	neutral	_	
287-12	48271-48274	cue	_	
287-13	48275-48283	exposure	_	
287-14	48284-48287	led	_	
287-15	48288-48290	to	_	
287-16	48291-48299	elevated	_	
287-17	48300-48310	functional	_	
287-18	48311-48323	connectivity	_	
287-19	48324-48331	between	_	
287-20	48332-48335	the	_	
287-21	48336-48348	ventromedial	_	
287-22	48349-48359	prefrontal	_	
287-23	48360-48366	cortex	_	
287-24	48367-48368	(	_	
287-25	48368-48372	MPFC	_	
287-26	48372-48373	)	_	
287-27	48374-48377	and	_	
287-28	48378-48385	several	_	
287-29	48386-48394	striatal	_	
287-30	48395-48398	and	_	
287-31	48399-48407	salience	_	
287-32	48408-48413	brain	_	
287-33	48414-48421	regions	_	
287-34	48421-48422	.	_	

#Text=The largest effect sizes were between the MPFC and left putamen (L Put) (d = 0.53) and left insula (L Ins) (d = 0.53) (top right image; bright blue lines).
288-1	48423-48426	The	_	
288-2	48427-48434	largest	_	
288-3	48435-48441	effect	_	
288-4	48442-48447	sizes	_	
288-5	48448-48452	were	_	
288-6	48453-48460	between	_	
288-7	48461-48464	the	_	
288-8	48465-48469	MPFC	_	
288-9	48470-48473	and	_	
288-10	48474-48478	left	_	
288-11	48479-48486	putamen	_	
288-12	48487-48488	(	_	
288-13	48488-48489	L	_	
288-14	48490-48493	Put	_	
288-15	48493-48494	)	_	
288-16	48495-48496	(	_	
288-17	48496-48497	d	_	
288-18	48498-48499	=	_	
288-19	48500-48504	0.53	_	
288-20	48504-48505	)	_	
288-21	48506-48509	and	_	
288-22	48510-48514	left	_	
288-23	48515-48521	insula	_	
288-24	48522-48523	(	_	
288-25	48523-48524	L	_	
288-26	48525-48528	Ins	_	
288-27	48528-48529	)	_	
288-28	48530-48531	(	_	
288-29	48531-48532	d	_	
288-30	48533-48534	=	_	
288-31	48535-48539	0.53	_	
288-32	48539-48540	)	_	
288-33	48541-48542	(	_	
288-34	48542-48545	top	_	
288-35	48546-48551	right	_	
288-36	48552-48557	image	_	
288-37	48557-48558	;	_	
288-38	48559-48565	bright	_	
288-39	48566-48570	blue	_	
288-40	48571-48576	lines	_	
288-41	48576-48577	)	_	
288-42	48577-48578	.	_	

#Text=There were also smaller effect sizes between the MPFC and left caudate (L caud) (d = 0.42), right caudate (R Caud) (d = 0.37), right putamen (R Put) (d = 0.30), right insula (R Ins) (d = 0.21), anterior cingulate cortex (ACC) (d = 0.20), and ventral striatum (VS) (d = 0.31) (top right image; dark blue lines).
289-1	48579-48584	There	_	
289-2	48585-48589	were	_	
289-3	48590-48594	also	_	
289-4	48595-48602	smaller	_	
289-5	48603-48609	effect	_	
289-6	48610-48615	sizes	_	
289-7	48616-48623	between	_	
289-8	48624-48627	the	_	
289-9	48628-48632	MPFC	_	
289-10	48633-48636	and	_	
289-11	48637-48641	left	_	
289-12	48642-48649	caudate	_	
289-13	48650-48651	(	_	
289-14	48651-48652	L	_	
289-15	48653-48657	caud	_	
289-16	48657-48658	)	_	
289-17	48659-48660	(	_	
289-18	48660-48661	d	_	
289-19	48662-48663	=	_	
289-20	48664-48668	0.42	_	
289-21	48668-48669	)	_	
289-22	48669-48670	,	_	
289-23	48671-48676	right	_	
289-24	48677-48684	caudate	_	
289-25	48685-48686	(	_	
289-26	48686-48687	R	_	
289-27	48688-48692	Caud	_	
289-28	48692-48693	)	_	
289-29	48694-48695	(	_	
289-30	48695-48696	d	_	
289-31	48697-48698	=	_	
289-32	48699-48703	0.37	_	
289-33	48703-48704	)	_	
289-34	48704-48705	,	_	
289-35	48706-48711	right	_	
289-36	48712-48719	putamen	_	
289-37	48720-48721	(	_	
289-38	48721-48722	R	_	
289-39	48723-48726	Put	_	
289-40	48726-48727	)	_	
289-41	48728-48729	(	_	
289-42	48729-48730	d	_	
289-43	48731-48732	=	_	
289-44	48733-48737	0.30	_	
289-45	48737-48738	)	_	
289-46	48738-48739	,	_	
289-47	48740-48745	right	_	
289-48	48746-48752	insula	_	
289-49	48753-48754	(	_	
289-50	48754-48755	R	_	
289-51	48756-48759	Ins	_	
289-52	48759-48760	)	_	
289-53	48761-48762	(	_	
289-54	48762-48763	d	_	
289-55	48764-48765	=	_	
289-56	48766-48770	0.21	_	
289-57	48770-48771	)	_	
289-58	48771-48772	,	_	
289-59	48773-48781	anterior	_	
289-60	48782-48791	cingulate	_	
289-61	48792-48798	cortex	_	
289-62	48799-48800	(	_	
289-63	48800-48803	ACC	_	
289-64	48803-48804	)	_	
289-65	48805-48806	(	_	
289-66	48806-48807	d	_	
289-67	48808-48809	=	_	
289-68	48810-48814	0.20	_	
289-69	48814-48815	)	_	
289-70	48815-48816	,	_	
289-71	48817-48820	and	_	
289-72	48821-48828	ventral	_	
289-73	48829-48837	striatum	_	
289-74	48838-48839	(	_	
289-75	48839-48841	VS	_	
289-76	48841-48842	)	_	
289-77	48843-48844	(	_	
289-78	48844-48845	d	_	
289-79	48846-48847	=	_	
289-80	48848-48852	0.31	_	
289-81	48852-48853	)	_	
289-82	48854-48855	(	_	
289-83	48855-48858	top	_	
289-84	48859-48864	right	_	
289-85	48865-48870	image	_	
289-86	48870-48871	;	_	
289-87	48872-48876	dark	_	
289-88	48877-48881	blue	_	
289-89	48882-48887	lines	_	
289-90	48887-48888	)	_	
289-91	48888-48889	.	_	

#Text=Three-way repeated-measures analysis of variance (treatment [real/sham] × time [pre/post] × region of interest [ROI]) revealed a significant interaction between treatment and time (F1,1536 = 50.8, p < .00001), but no main effect or interaction with ROI, indicating a general effect of treatment × time across all ROIs (bottom image).
290-1	48890-48899	Three-way	_	
290-2	48900-48917	repeated-measures	_	
290-3	48918-48926	analysis	_	
290-4	48927-48929	of	_	
290-5	48930-48938	variance	_	
290-6	48939-48940	(	_	
290-7	48940-48949	treatment	_	
290-8	48950-48951	[	_	
290-9	48951-48955	real	_	
290-10	48955-48956	/	_	
290-11	48956-48960	sham	_	
290-12	48960-48961	]	_	
290-13	48962-48963	×	_	
290-14	48964-48968	time	_	
290-15	48969-48970	[	_	
290-16	48970-48973	pre	_	
290-17	48973-48974	/	_	
290-18	48974-48978	post	_	
290-19	48978-48979	]	_	
290-20	48980-48981	×	_	
290-21	48982-48988	region	_	
290-22	48989-48991	of	_	
290-23	48992-49000	interest	_	
290-24	49001-49002	[	_	
290-25	49002-49005	ROI	_	
290-26	49005-49006	]	_	
290-27	49006-49007	)	_	
290-28	49008-49016	revealed	_	
290-29	49017-49018	a	_	
290-30	49019-49030	significant	_	
290-31	49031-49042	interaction	_	
290-32	49043-49050	between	_	
290-33	49051-49060	treatment	_	
290-34	49061-49064	and	_	
290-35	49065-49069	time	_	
290-36	49070-49071	(	_	
290-37	49071-49078	F1,1536	_	
290-38	49079-49080	=	_	
290-39	49081-49085	50.8	_	
290-40	49085-49086	,	_	
290-41	49087-49088	p	_	
290-42	49089-49090	<	_	
290-43	49091-49097	.00001	_	
290-44	49097-49098	)	_	
290-45	49098-49099	,	_	
290-46	49100-49103	but	_	
290-47	49104-49106	no	_	
290-48	49107-49111	main	_	
290-49	49112-49118	effect	_	
290-50	49119-49121	or	_	
290-51	49122-49133	interaction	_	
290-52	49134-49138	with	_	
290-53	49139-49142	ROI	_	
290-54	49142-49143	,	_	
290-55	49144-49154	indicating	_	
290-56	49155-49156	a	_	
290-57	49157-49164	general	_	
290-58	49165-49171	effect	_	
290-59	49172-49174	of	_	
290-60	49175-49184	treatment	_	
290-61	49185-49186	×	_	
290-62	49187-49191	time	_	
290-63	49192-49198	across	_	
290-64	49199-49202	all	_	
290-65	49203-49207	ROIs	_	
290-66	49208-49209	(	_	
290-67	49209-49215	bottom	_	
290-68	49216-49221	image	_	
290-69	49221-49222	)	_	
290-70	49222-49223	.	_	

#Text=Although there was no significant main effect or interaction with ROI, effect sizes of the attenuations in drug cue–evoked functional connectivity following real vs. sham continuous theta burst stimulation (cTBS) were largest between the MPFC and left putamen (d = −0.52) and left insula (d = −0.60) (top left image; bright red lines), and smaller between the MPFC and left caudate (d = 20.48), right caudate (d = −0.42), right putamen (d = −0.32), ACC (d = −0.30), and VS (d = −0.42) (top left image; dark red lines).
291-1	49224-49232	Although	_	
291-2	49233-49238	there	_	
291-3	49239-49242	was	_	
291-4	49243-49245	no	_	
291-5	49246-49257	significant	_	
291-6	49258-49262	main	_	
291-7	49263-49269	effect	_	
291-8	49270-49272	or	_	
291-9	49273-49284	interaction	_	
291-10	49285-49289	with	_	
291-11	49290-49293	ROI	_	
291-12	49293-49294	,	_	
291-13	49295-49301	effect	_	
291-14	49302-49307	sizes	_	
291-15	49308-49310	of	_	
291-16	49311-49314	the	_	
291-17	49315-49327	attenuations	_	
291-18	49328-49330	in	_	
291-19	49331-49335	drug	_	
291-20	49336-49346	cue–evoked	_	
291-21	49347-49357	functional	_	
291-22	49358-49370	connectivity	_	
291-23	49371-49380	following	_	
291-24	49381-49385	real	_	
291-25	49386-49388	vs	_	
291-26	49388-49389	.	_	
291-27	49390-49394	sham	_	
291-28	49395-49405	continuous	_	
291-29	49406-49411	theta	_	
291-30	49412-49417	burst	_	
291-31	49418-49429	stimulation	_	
291-32	49430-49431	(	_	
291-33	49431-49435	cTBS	_	
291-34	49435-49436	)	_	
291-35	49437-49441	were	_	
291-36	49442-49449	largest	_	
291-37	49450-49457	between	_	
291-38	49458-49461	the	_	
291-39	49462-49466	MPFC	_	
291-40	49467-49470	and	_	
291-41	49471-49475	left	_	
291-42	49476-49483	putamen	_	
291-43	49484-49485	(	_	
291-44	49485-49486	d	_	
291-45	49487-49488	=	_	
291-46	49489-49490	−	_	
291-47	49490-49494	0.52	_	
291-48	49494-49495	)	_	
291-49	49496-49499	and	_	
291-50	49500-49504	left	_	
291-51	49505-49511	insula	_	
291-52	49512-49513	(	_	
291-53	49513-49514	d	_	
291-54	49515-49516	=	_	
291-55	49517-49518	−	_	
291-56	49518-49522	0.60	_	
291-57	49522-49523	)	_	
291-58	49524-49525	(	_	
291-59	49525-49528	top	_	
291-60	49529-49533	left	_	
291-61	49534-49539	image	_	
291-62	49539-49540	;	_	
291-63	49541-49547	bright	_	
291-64	49548-49551	red	_	
291-65	49552-49557	lines	_	
291-66	49557-49558	)	_	
291-67	49558-49559	,	_	
291-68	49560-49563	and	_	
291-69	49564-49571	smaller	_	
291-70	49572-49579	between	_	
291-71	49580-49583	the	_	
291-72	49584-49588	MPFC	_	
291-73	49589-49592	and	_	
291-74	49593-49597	left	_	
291-75	49598-49605	caudate	_	
291-76	49606-49607	(	_	
291-77	49607-49608	d	_	
291-78	49609-49610	=	_	
291-79	49611-49616	20.48	_	
291-80	49616-49617	)	_	
291-81	49617-49618	,	_	
291-82	49619-49624	right	_	
291-83	49625-49632	caudate	_	
291-84	49633-49634	(	_	
291-85	49634-49635	d	_	
291-86	49636-49637	=	_	
291-87	49638-49639	−	_	
291-88	49639-49643	0.42	_	
291-89	49643-49644	)	_	
291-90	49644-49645	,	_	
291-91	49646-49651	right	_	
291-92	49652-49659	putamen	_	
291-93	49660-49661	(	_	
291-94	49661-49662	d	_	
291-95	49663-49664	=	_	
291-96	49665-49666	−	_	
291-97	49666-49670	0.32	_	
291-98	49670-49671	)	_	
291-99	49671-49672	,	_	
291-100	49673-49676	ACC	_	
291-101	49677-49678	(	_	
291-102	49678-49679	d	_	
291-103	49680-49681	=	_	
291-104	49682-49683	−	_	
291-105	49683-49687	0.30	_	
291-106	49687-49688	)	_	
291-107	49688-49689	,	_	
291-108	49690-49693	and	_	
291-109	49694-49696	VS	_	
291-110	49697-49698	(	_	
291-111	49698-49699	d	_	
291-112	49700-49701	=	_	
291-113	49702-49703	−	_	
291-114	49703-49707	0.42	_	
291-115	49707-49708	)	_	
291-116	49709-49710	(	_	
291-117	49710-49713	top	_	
291-118	49714-49718	left	_	
291-119	49719-49724	image	_	
291-120	49724-49725	;	_	
291-121	49726-49730	dark	_	
291-122	49731-49734	red	_	
291-123	49735-49740	lines	_	
291-124	49740-49741	)	_	
291-125	49741-49742	.	_	

#Text=The blue arrow conveys overall direction of change in functional connectivity following real vs. sham cTBS.
292-1	49743-49746	The	_	
292-2	49747-49751	blue	_	
292-3	49752-49757	arrow	_	
292-4	49758-49765	conveys	_	
292-5	49766-49773	overall	_	
292-6	49774-49783	direction	_	
292-7	49784-49786	of	_	
292-8	49787-49793	change	_	
292-9	49794-49796	in	_	
292-10	49797-49807	functional	_	
292-11	49808-49820	connectivity	_	
292-12	49821-49830	following	_	
292-13	49831-49835	real	_	
292-14	49836-49838	vs	_	
292-15	49838-49839	.	_	
292-16	49840-49844	sham	_	
292-17	49845-49849	cTBS	_	
292-18	49849-49850	.	_	

#Text=Descriptive Demographic, Clinical, and Drug Use Statistics
#Text=\tTotal Sample (N = 49)\tCocaine Users (n = 25)\tAlcohol Users (n = 24)\t \tDemographics\t\t\t\t \t Sex\t30 M, 19 F\t13 M, 12 F\t17 M, 7 F\t \t Age, years\t34.3 ± 10.6\t41.6 ± 9.0\t26.8 ± 5.6\t \t Ethnicity\t29 AA, 20 C\t22 AA, 3 C\t17 C, 7 AA\t \t Education, years\t13.5 ± 2.3\t12.2 ± 1.8\t14.9 ± 2.0\t \tSubstance Use\t\t\t\t \t Age of first use, years\t19.7 ± 5.8\t22.6 ± 6.8\t16.7 ± 1.9\t \t Total duration of use, years\t14.6 ± 9.0\t19.0 ± 9.8\t10.0 ± 5.1\t \t Days used in last 30 days\t15.3 ± 7.6\t12.6 ± 7.5\t18.2 ± 6.5\t \t Time since last use (at visit), days\t2.5 ± 2.0\t2.3 ± 1.1\t2.8 ± 2.6\t \t Alcohol use severity (AUDIT)\t11.9 ± 5.6\t9.2 ± 5.3\t14.2 ± 4.8\t \tOther Substance Use\t\t\t\t \t Nicotine smoker\t27 (55)\t21 (84)\t6 (25)\t \t Nicotine severity (Fagerström)\t2.7 ± 2.4\t3.1 ± 2.3\t0.4 ± 0.8\t \t MJ smoker\t34 (69)\t18 (72)\t16 (67)\t \t Days used MJ in last 30 days\t2.0 ± 6.6\t6 ± 10.1\t0.4 ± 0.5\t \tMental Status\t\t\t\t \t Depressive symptoms (BDI)\t6.8 ± 8.3\t10.2 ± 9.7\t3.3 ± 4.3\t \t State anxiety (STAI-S)\t33.0 ± 12.9\t36.0 ± 13.3\t29.9 ± 11.6\t \t Trait anxiety (STAI-T)\t35.5 ± 12.5\t39.8 ± 12.5\t31.2 ± 10.9\t \tTreatment-Related Measures\t\t\t\t \t Scalp-to-cortex distance, mma\t16.9 ± 3.5\t17.4 ± 3.7\t16.4 ± 3.2\t \t TMS threshold, %b\t53.3 ± 8.7\t56.5 ± 9.1\t49.9 ± 6.7\t \t
#Text=Values represent mean ± SD or n (%) unless otherwise indicated.
293-1	49851-49862	Descriptive	_	
293-2	49863-49874	Demographic	_	
293-3	49874-49875	,	_	
293-4	49876-49884	Clinical	_	
293-5	49884-49885	,	_	
293-6	49886-49889	and	_	
293-7	49890-49894	Drug	_	
293-8	49895-49898	Use	_	
293-9	49899-49909	Statistics	_	
293-10	49911-49916	Total	_	
293-11	49917-49923	Sample	_	
293-12	49924-49925	(	_	
293-13	49925-49926	N	_	
293-14	49927-49928	=	_	
293-15	49929-49931	49	_	
293-16	49931-49932	)	_	
293-17	49933-49940	Cocaine	_	
293-18	49941-49946	Users	_	
293-19	49947-49948	(	_	
293-20	49948-49949	n	_	
293-21	49950-49951	=	_	
293-22	49952-49954	25	_	
293-23	49954-49955	)	_	
293-24	49956-49963	Alcohol	_	
293-25	49964-49969	Users	_	
293-26	49970-49971	(	_	
293-27	49971-49972	n	_	
293-28	49973-49974	=	_	
293-29	49975-49977	24	_	
293-30	49977-49978	)	_	
293-31	49981-49993	Demographics	_	
293-32	50000-50003	Sex	_	
293-33	50004-50006	30	_	
293-34	50007-50008	M	_	
293-35	50008-50009	,	_	
293-36	50010-50012	19	_	
293-37	50013-50014	F	_	
293-38	50015-50017	13	_	
293-39	50018-50019	M	_	
293-40	50019-50020	,	_	
293-41	50021-50023	12	_	
293-42	50024-50025	F	_	
293-43	50026-50028	17	_	
293-44	50029-50030	M	_	
293-45	50030-50031	,	_	
293-46	50032-50033	7	_	
293-47	50034-50035	F	_	
293-48	50039-50042	Age	_	
293-49	50042-50043	,	_	
293-50	50044-50049	years	_	
293-51	50050-50054	34.3	_	
293-52	50055-50056	±	_	
293-53	50057-50061	10.6	_	
293-54	50062-50066	41.6	_	
293-55	50067-50068	±	_	
293-56	50069-50072	9.0	_	
293-57	50073-50077	26.8	_	
293-58	50078-50079	±	_	
293-59	50080-50083	5.6	_	
293-60	50087-50096	Ethnicity	_	
293-61	50097-50099	29	_	
293-62	50100-50102	AA	_	
293-63	50102-50103	,	_	
293-64	50104-50106	20	_	
293-65	50107-50108	C	_	
293-66	50109-50111	22	_	
293-67	50112-50114	AA	_	
293-68	50114-50115	,	_	
293-69	50116-50117	3	_	
293-70	50118-50119	C	_	
293-71	50120-50122	17	_	
293-72	50123-50124	C	_	
293-73	50124-50125	,	_	
293-74	50126-50127	7	_	
293-75	50128-50130	AA	_	
293-76	50134-50143	Education	_	
293-77	50143-50144	,	_	
293-78	50145-50150	years	_	
293-79	50151-50155	13.5	_	
293-80	50156-50157	±	_	
293-81	50158-50161	2.3	_	
293-82	50162-50166	12.2	_	
293-83	50167-50168	±	_	
293-84	50169-50172	1.8	_	
293-85	50173-50177	14.9	_	
293-86	50178-50179	±	_	
293-87	50180-50183	2.0	_	
293-88	50186-50195	Substance	_	
293-89	50196-50199	Use	_	
293-90	50206-50209	Age	_	
293-91	50210-50212	of	_	
293-92	50213-50218	first	_	
293-93	50219-50222	use	_	
293-94	50222-50223	,	_	
293-95	50224-50229	years	_	
293-96	50230-50234	19.7	_	
293-97	50235-50236	±	_	
293-98	50237-50240	5.8	_	
293-99	50241-50245	22.6	_	
293-100	50246-50247	±	_	
293-101	50248-50251	6.8	_	
293-102	50252-50256	16.7	_	
293-103	50257-50258	±	_	
293-104	50259-50262	1.9	_	
293-105	50266-50271	Total	_	
293-106	50272-50280	duration	_	
293-107	50281-50283	of	_	
293-108	50284-50287	use	_	
293-109	50287-50288	,	_	
293-110	50289-50294	years	_	
293-111	50295-50299	14.6	_	
293-112	50300-50301	±	_	
293-113	50302-50305	9.0	_	
293-114	50306-50310	19.0	_	
293-115	50311-50312	±	_	
293-116	50313-50316	9.8	_	
293-117	50317-50321	10.0	_	
293-118	50322-50323	±	_	
293-119	50324-50327	5.1	_	
293-120	50331-50335	Days	_	
293-121	50336-50340	used	_	
293-122	50341-50343	in	_	
293-123	50344-50348	last	_	
293-124	50349-50351	30	_	
293-125	50352-50356	days	_	
293-126	50357-50361	15.3	_	
293-127	50362-50363	±	_	
293-128	50364-50367	7.6	_	
293-129	50368-50372	12.6	_	
293-130	50373-50374	±	_	
293-131	50375-50378	7.5	_	
293-132	50379-50383	18.2	_	
293-133	50384-50385	±	_	
293-134	50386-50389	6.5	_	
293-135	50393-50397	Time	_	
293-136	50398-50403	since	_	
293-137	50404-50408	last	_	
293-138	50409-50412	use	_	
293-139	50413-50414	(	_	
293-140	50414-50416	at	_	
293-141	50417-50422	visit	_	
293-142	50422-50423	)	_	
293-143	50423-50424	,	_	
293-144	50425-50429	days	_	
293-145	50430-50433	2.5	_	
293-146	50434-50435	±	_	
293-147	50436-50439	2.0	_	
293-148	50440-50443	2.3	_	
293-149	50444-50445	±	_	
293-150	50446-50449	1.1	_	
293-151	50450-50453	2.8	_	
293-152	50454-50455	±	_	
293-153	50456-50459	2.6	_	
293-154	50463-50470	Alcohol	_	
293-155	50471-50474	use	_	
293-156	50475-50483	severity	_	
293-157	50484-50485	(	_	
293-158	50485-50490	AUDIT	_	
293-159	50490-50491	)	_	
293-160	50492-50496	11.9	_	
293-161	50497-50498	±	_	
293-162	50499-50502	5.6	_	
293-163	50503-50506	9.2	_	
293-164	50507-50508	±	_	
293-165	50509-50512	5.3	_	
293-166	50513-50517	14.2	_	
293-167	50518-50519	±	_	
293-168	50520-50523	4.8	_	
293-169	50526-50531	Other	_	
293-170	50532-50541	Substance	_	
293-171	50542-50545	Use	_	
293-172	50552-50560	Nicotine	_	
293-173	50561-50567	smoker	_	
293-174	50568-50570	27	_	
293-175	50571-50572	(	_	
293-176	50572-50574	55	_	
293-177	50574-50575	)	_	
293-178	50576-50578	21	_	
293-179	50579-50580	(	_	
293-180	50580-50582	84	_	
293-181	50582-50583	)	_	
293-182	50584-50585	6	_	
293-183	50586-50587	(	_	
293-184	50587-50589	25	_	
293-185	50589-50590	)	_	
293-186	50594-50602	Nicotine	_	
293-187	50603-50611	severity	_	
293-188	50612-50613	(	_	
293-189	50613-50623	Fagerström	_	
293-190	50623-50624	)	_	
293-191	50625-50628	2.7	_	
293-192	50629-50630	±	_	
293-193	50631-50634	2.4	_	
293-194	50635-50638	3.1	_	
293-195	50639-50640	±	_	
293-196	50641-50644	2.3	_	
293-197	50645-50648	0.4	_	
293-198	50649-50650	±	_	
293-199	50651-50654	0.8	_	
293-200	50658-50660	MJ	_	
293-201	50661-50667	smoker	_	
293-202	50668-50670	34	_	
293-203	50671-50672	(	_	
293-204	50672-50674	69	_	
293-205	50674-50675	)	_	
293-206	50676-50678	18	_	
293-207	50679-50680	(	_	
293-208	50680-50682	72	_	
293-209	50682-50683	)	_	
293-210	50684-50686	16	_	
293-211	50687-50688	(	_	
293-212	50688-50690	67	_	
293-213	50690-50691	)	_	
293-214	50695-50699	Days	_	
293-215	50700-50704	used	_	
293-216	50705-50707	MJ	_	
293-217	50708-50710	in	_	
293-218	50711-50715	last	_	
293-219	50716-50718	30	_	
293-220	50719-50723	days	_	
293-221	50724-50727	2.0	_	
293-222	50728-50729	±	_	
293-223	50730-50733	6.6	_	
293-224	50734-50735	6	_	
293-225	50736-50737	±	_	
293-226	50738-50742	10.1	_	
293-227	50743-50746	0.4	_	
293-228	50747-50748	±	_	
293-229	50749-50752	0.5	_	
293-230	50755-50761	Mental	_	
293-231	50762-50768	Status	_	
293-232	50775-50785	Depressive	_	
293-233	50786-50794	symptoms	_	
293-234	50795-50796	(	_	
293-235	50796-50799	BDI	_	
293-236	50799-50800	)	_	
293-237	50801-50804	6.8	_	
293-238	50805-50806	±	_	
293-239	50807-50810	8.3	_	
293-240	50811-50815	10.2	_	
293-241	50816-50817	±	_	
293-242	50818-50821	9.7	_	
293-243	50822-50825	3.3	_	
293-244	50826-50827	±	_	
293-245	50828-50831	4.3	_	
293-246	50835-50840	State	_	
293-247	50841-50848	anxiety	_	
293-248	50849-50850	(	_	
293-249	50850-50856	STAI-S	_	
293-250	50856-50857	)	_	
293-251	50858-50862	33.0	_	
293-252	50863-50864	±	_	
293-253	50865-50869	12.9	_	
293-254	50870-50874	36.0	_	
293-255	50875-50876	±	_	
293-256	50877-50881	13.3	_	
293-257	50882-50886	29.9	_	
293-258	50887-50888	±	_	
293-259	50889-50893	11.6	_	
293-260	50897-50902	Trait	_	
293-261	50903-50910	anxiety	_	
293-262	50911-50912	(	_	
293-263	50912-50918	STAI-T	_	
293-264	50918-50919	)	_	
293-265	50920-50924	35.5	_	
293-266	50925-50926	±	_	
293-267	50927-50931	12.5	_	
293-268	50932-50936	39.8	_	
293-269	50937-50938	±	_	
293-270	50939-50943	12.5	_	
293-271	50944-50948	31.2	_	
293-272	50949-50950	±	_	
293-273	50951-50955	10.9	_	
293-274	50958-50975	Treatment-Related	_	
293-275	50976-50984	Measures	_	
293-276	50991-51006	Scalp-to-cortex	_	
293-277	51007-51015	distance	_	
293-278	51015-51016	,	_	
293-279	51017-51020	mma	_	
293-280	51021-51025	16.9	_	
293-281	51026-51027	±	_	
293-282	51028-51031	3.5	_	
293-283	51032-51036	17.4	_	
293-284	51037-51038	±	_	
293-285	51039-51042	3.7	_	
293-286	51043-51047	16.4	_	
293-287	51048-51049	±	_	
293-288	51050-51053	3.2	_	
293-289	51057-51060	TMS	_	
293-290	51061-51070	threshold	_	
293-291	51070-51071	,	_	
293-292	51072-51073	%	_	
293-293	51073-51074	b	_	
293-294	51075-51079	53.3	_	
293-295	51080-51081	±	_	
293-296	51082-51085	8.7	_	
293-297	51086-51090	56.5	_	
293-298	51091-51092	±	_	
293-299	51093-51096	9.1	_	
293-300	51097-51101	49.9	_	
293-301	51102-51103	±	_	
293-302	51104-51107	6.7	_	
293-303	51111-51117	Values	_	
293-304	51118-51127	represent	_	
293-305	51128-51132	mean	_	
293-306	51133-51134	±	_	
293-307	51135-51137	SD	_	
293-308	51138-51140	or	_	
293-309	51141-51142	n	_	
293-310	51143-51144	(	_	
293-311	51144-51145	%	_	
293-312	51145-51146	)	_	
293-313	51147-51153	unless	_	
293-314	51154-51163	otherwise	_	
293-315	51164-51173	indicated	_	
293-316	51173-51174	.	_	

#Text=AA, African American; AUDIT, Alcohol Use Disorders Identification Test; BDI, Beck Depression Inventory; C, Caucasian; F, female; M, male; MJ, marijuana; STAI, State-Trait Anxiety Inventory; TMS, transcranial magnetic stimulation.
294-1	51175-51177	AA	_	
294-2	51177-51178	,	_	
294-3	51179-51186	African	_	
294-4	51187-51195	American	_	
294-5	51195-51196	;	_	
294-6	51197-51202	AUDIT	_	
294-7	51202-51203	,	_	
294-8	51204-51211	Alcohol	_	
294-9	51212-51215	Use	_	
294-10	51216-51225	Disorders	_	
294-11	51226-51240	Identification	_	
294-12	51241-51245	Test	_	
294-13	51245-51246	;	_	
294-14	51247-51250	BDI	_	
294-15	51250-51251	,	_	
294-16	51252-51256	Beck	_	
294-17	51257-51267	Depression	_	
294-18	51268-51277	Inventory	_	
294-19	51277-51278	;	_	
294-20	51279-51280	C	_	
294-21	51280-51281	,	_	
294-22	51282-51291	Caucasian	_	
294-23	51291-51292	;	_	
294-24	51293-51294	F	_	
294-25	51294-51295	,	_	
294-26	51296-51302	female	_	
294-27	51302-51303	;	_	
294-28	51304-51305	M	_	
294-29	51305-51306	,	_	
294-30	51307-51311	male	_	
294-31	51311-51312	;	_	
294-32	51313-51315	MJ	_	
294-33	51315-51316	,	_	
294-34	51317-51326	marijuana	_	
294-35	51326-51327	;	_	
294-36	51328-51332	STAI	_	
294-37	51332-51333	,	_	
294-38	51334-51345	State-Trait	_	
294-39	51346-51353	Anxiety	_	
294-40	51354-51363	Inventory	_	
294-41	51363-51364	;	_	
294-42	51365-51368	TMS	_	
294-43	51368-51369	,	_	
294-44	51370-51382	transcranial	_	
294-45	51383-51391	magnetic	_	
294-46	51392-51403	stimulation	_	
294-47	51403-51404	.	_	

#Text=For ventromedial prefrontal cortex coil placement at International 10–20 system Fp1.
295-1	51405-51408	For	_	
295-2	51409-51421	ventromedial	_	
295-3	51422-51432	prefrontal	_	
295-4	51433-51439	cortex	_	
295-5	51440-51444	coil	_	
295-6	51445-51454	placement	_	
295-7	51455-51457	at	_	
295-8	51458-51471	International	_	
295-9	51472-51474	10	_	
295-10	51474-51475	–	_	
295-11	51475-51477	20	_	
295-12	51478-51484	system	_	
295-13	51485-51488	Fp1	_	
295-14	51488-51489	.	_	

#Text=Absolute continuous theta burst stimulation dose, percent machine output.
296-1	51490-51498	Absolute	_	
296-2	51499-51509	continuous	_	
296-3	51510-51515	theta	_	
296-4	51516-51521	burst	_	
296-5	51522-51533	stimulation	_	
296-6	51534-51538	dose	_	
296-7	51538-51539	,	_	
296-8	51540-51547	percent	_	
296-9	51548-51555	machine	_	
296-10	51556-51562	output	_	
296-11	51562-51563	.	_	
